

WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Tuesday, November 16, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L13	benzoquinone ansamycin	51
<input type="checkbox"/>	L12	benzoquinone ansamycine	0
<input type="checkbox"/>	L11	L10 AND HSP90	40
<input type="checkbox"/>	L10	FKBP12	649
<input type="checkbox"/>	L9	L8 AND FKBP12	64
<input type="checkbox"/>	L8	514/183,330,423,428,465,466.CCLS.	4646
<input type="checkbox"/>	L7	L6 AND FKBP12	4
<input type="checkbox"/>	L6	424/145.1.CCLS.	808
<input type="checkbox"/>	L5	Gold.IN.	3429
<input type="checkbox"/>	L4	Gold-B.IN.	9
<input type="checkbox"/>	L3	Gold-Bruce.IN.	2
<input type="checkbox"/>	L2	Gold-B-G.IN.	2
<input type="checkbox"/>	L1	(Gold-Bruce-G.IN.)	6

END OF SEARCH HISTORY

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 6 of 6 returned.

☐ 1. Document ID: US 20040063610 A1

Using default format because multiple data bases are involved.

L1: Entry 1 of 6

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063610

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040063610 A1

TITLE: Compositions and methods for promoting nerve regeneration

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gold, Bruce G.	West Linn	OR	US	

US-CL-CURRENT: [514/2](#); [424/143.1](#), [514/183](#), [514/291](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 2. Document ID: US 20020086015 A1

L1: Entry 2 of 6

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086015

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086015 A1

TITLE: Compositions and methods for promoting nerve regeneration

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gold, Bruce G.	West Linn	OR	US	

US-CL-CURRENT: [424/145.1](#); [514/2](#), [514/34](#)

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBPS52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 6734211 B1

L1: Entry 3 of 6

File: USPT

May 11, 2004

US-PAT-NO: 6734211

DOCUMENT-IDENTIFIER: US 6734211 B1

TITLE: Compositions and methods for promoting nerve regeneration

DATE-ISSUED: May 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 514/513

ABSTRACT:

Neurite outgrowth and nerve regeneration are promoted by disruption of the steroid receptor complex and stimulation of MAP kinase/kinase activity. This disruption can take the form of disruption of the physical assembly or function of the steroid receptor complex, such as the mature complex or a precursor of the mature complex that is required for assembly of the mature complex. Geldanamycin and its analogs, bastadin and members of the bastadin family, and radicicol and its analogs, as well as FKBP-52 antibody, are shown to disrupt the complex and promote nerve growth. Assays for finding neurotrophic compounds, as well as compounds found by these assays, pharmaceutical compositions into which they are incorporated, and methods of treating subjects having neuronal dysfunction caused by injury or disease are disclosed. Any of these compounds can be used in combination with a therapeutically effective amount of heat, such as heat applied locally to an area where nerve growth is desired, or systemically in an organism in which neurite growth is desired. Alternatively, these compounds can be used in association with a template, such as a tubular member that defines an anatomic pathway along which nerve regeneration is desired (particularly around a transected or partially transected nerve).

13 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 4. Document ID: US 6641810 B2

L1: Entry 4 of 6

File: USPT

Nov 4, 2003

US-PAT-NO: 6641810

DOCUMENT-IDENTIFIER: US 6641810 B2

**** See image for Certificate of Correction ****

TITLE: Methods of using geldanamycin and FK506 to treat peripheral nerve damage

DATE-ISSUED: November 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 424/145.1; 514/183, 514/330, 514/423, 514/428, 514/465, 514/466

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBPS52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

34 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMDC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 5. Document ID: US 6210974 B1

L1: Entry 5 of 6

File: USPT

Apr 3, 2001

US-PAT-NO: 6210974

DOCUMENT-IDENTIFIER: US 6210974 B1

**** See image for Certificate of Correction ****

TITLE: Compositions and methods for promoting nerve regeneration

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 436/501; 436/34, 436/63, 436/86, 436/91

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

17 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMDC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 6. Document ID: US 5968921 A

L1: Entry 6 of 6

File: USPT

Oct 19, 1999

US-PAT-NO: 5968921

DOCUMENT-IDENTIFIER: US 5968921 A

**** See image for Certificate of Correction ****

TITLE: Compositions and methods for promoting nerve regeneration

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 514/183; 514/330, 514/423, 514/428, 514/465, 514/466, 514/534,
514/547, 514/548, 514/549

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

36 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWMC	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
(Gold-Bruce-G.IN.)	6

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 6734211 B1, WO 200103692 A1, AU 200060748 A, EP 1200078 A1, JP 2003504330 W

Using default format because multiple data bases are involved.

L2: Entry 1 of 2

File: DWPI

May 11, 2004

DERWENT-ACC-NO: 2001-138247

DERWENT-WEEK: 200431

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Stimulating nerve cell growth in mammals, by administering an agent e.g. radicicol or bastadin which stimulates MAP kinase/kinase activity and/or an agent that disrupts assembly of steroid receptor complex

INVENTOR: GOLD, B G

PRIORITY-DATA: 1999US-143180P (July 9, 1999), 2002US-0030904 (April 29, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6734211 B1</u>	May 11, 2004		000	A61K031/21
<u>WO 200103692 A1</u>	January 18, 2001	E	080	A61K031/21
<u>AU 200060748 A</u>	January 30, 2001		000	A61K031/21
<u>EP 1200078 A1</u>	May 2, 2002	E	000	A61K031/21
<u>JP 2003504330 W</u>	February 4, 2003		096	A61K031/335

INT-CL (IPC): A61 K 31/165; A61 K 31/21; A61 K 31/335; A61 K 31/395; A61 K 38/00; A61 K 45/00; A61 P 25/00; A61 P 43/00; G01 N 33/15; G01 N 33/50

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 2. Document ID: US 20040063610 A1, WO 9921552 A1, AU 9896783 A, US 5968921 A, EP 1024806 A1, US 6210974 B1, JP 2001520995 W, US 20020086015 A1, AU 759011 B, US 6641810 B2

L2: Entry 2 of 2

File: DWPI

Apr 1, 2004

DERWENT-ACC-NO: 1999-312859

DERWENT-WEEK: 200425

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Stimulation of nerve cell growth to treat neurological conditions involving neuronal dysfunction

INVENTOR: GOLD, B G

PRIORITY-DATA: 1997US-0956691 (October 24, 1997), 1999US-0288061 (April 7, 1999),

<http://westbrs.9000/bin/gate.exe?f=TOC&state=1clt8p.3&ref=2&dbname=PGPB,USPT,USO...> 11/16/04

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 20040063610 A1</u>	April 1, 2004		000	A61K039/395
<u>WO 9921552 A1</u>	May 6, 1999	E	052	A61K031/395
<u>AU 9896783 A</u>	May 17, 1999		000	
<u>US 5968921 A</u>	October 19, 1999		000	A61K031/33
<u>EP 1024806 A1</u>	August 9, 2000	E	000	A61K031/395
<u>US 6210974 B1</u>	April 3, 2001		000	G01N033/566
<u>JP 2001520995 W</u>	November 6, 2001		070	A61K031/395
<u>US 20020086015 A1</u>	July 4, 2002		000	A61K039/395
<u>AU 759011 B</u>	April 3, 2003		000	A61K031/395
<u>US 6641810 B2</u>	November 4, 2003		000	A61K039/395

INT-CL (IPC): A01 N 43/30; A61 K 31/33; A61 K 31/36; A61 K 31/395; A61 K 31/40; A61 K 31/445; A61 K 31/4745; A61 K 31/704; A61 K 38/18; A61 K 39/395; A61 K 45/00; A61 P 25/00; A61 P 43/00; G01 N 24/00; G01 N 33/00; G01 N 33/48; G01 N 33/566

ABSTRACTED-PUB-NO: US 5968921A

BASIC-ABSTRACT:

NOVELTY - Method of stimulating nerve cell growth in subjects comprises administration of a compound that disrupts assembly of a steroid receptor complex, excluding estrogen, androgen or recognized compound that binds to immunophilin FKBP-12, without side effects such as immunosuppression, and cardiomyopathy, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) methods of screening for compound that stimulates nerve cell growth; and
- (2) pharmaceutical compositions containing nerve growth stimulating amount of an agent that binds to a poly peptide of a steroid receptor complex other than a steroid hormone binding portion of the complex.

ACTIVITY - Neurotrophic. Neuroblastoma SH-SY5Y cells were used to examine human neurite outgrowth in vitro. The results showed that FK506 increases neurite outgrowth in SH-SY5Y cells in a concentration-dependent manner. Cumulative histograms of neurite lengths showed that 10 pM-10 nM F506 significantly increased neurite outgrowth (Mann-Whitney U test ($\alpha = 0.05$)). However, 100 nM was less effective and, at 1000 nM or greeter concentrations, neurite outgrowth was inhibited.

MECHANISM OF ACTION - Steroid-receptor complex assembly disruption.

USE - Used to treat animals with neurological conditions associated with neuronal dysfunction caused by disease or injury to neurons, including animals with injury to a neuron of the central or peripheral nervous system (claimed). Used also in association with procedures such as surgical nerve grafts or other implantations of neurological tissue to promote healing of the graft or implant and promote incorporation of the graft or implant into neurological tissue.

Used to promote neuronal regeneration and functional recovery and to stimulate neurite outgrowth in the threatment of neuropathological states such as damage to peripheral nerves and the central nervous system caused by physical injury (e.g. spinal cord injury and trauma, sciatic or facial nerve lesion or injury, limb transplantation following amputation), disease (e.g. diabetic neuropathy), cancer chemotherapy (neuropathy induced by acrylamide, taxol, vinca alkaloids and doxorubicin), brain damaged associated with stroke and ischemia, and neurological disorders including peripheral neuropathic and neurological disorders related to

neurodegeneration including trigeminal neuralgia, glossopharyngeal neuralgia, Bell's palsy, myasthenia gravis, muscular dystrophy, amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar inherited muscular dystrophy, herniated, ruptured or prolapsed vertebral disc syndromes, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies caused by lead, acrylamides, gamma diketones (glue-sniffer's neuropathy), carbon disulfide, dapsone, ticks, porphyria, Gullain-Barre syndrome, Alzheimer's disease, Parkinson's disease and Huntington's chorea.

Also used in prevention and treatment of stroke and connective tissue disorders and as a male contraceptive.

ADVANTAGE - Compounds need not have significant calcineurin inhibition or rotamase inhibition. Avoids unwanted side-effects of prior-art methods e.g. immunosuppression and cardiomyopathy.

ABSTRACTED-PUB-NO:

US 6210974B EQUIVALENT-ABSTRACTS:

NOVELTY - Method of stimulating nerve cell growth in subjects comprises administration of a compound that disrupts assembly of a steroid receptor complex, excluding estrogen, androgen or recognized compound that binds to immunophilin FKBP-12, without side effects such as immunosuppression, and cardiomyopathy, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) methods of screening for compound that stimulates nerve cell growth; and
- (2) pharmaceutical compositions containing nerve growth stimulating amount of an agent that binds to a poly peptide of a steroid receptor complex other than a steroid hormone binding portion of the complex.

ACTIVITY - Neurotrophic. Neuroblastoma SH-SY5Y cells were used to examine human neurite outgrowth in vitro. The results showed that FK506 increases neurite outgrowth in SH-SY5Y cells in a concentration-dependent manner. Cumulative histograms of neurite lengths showed that 10 pM-10 nM F506 significantly increased neurite outgrowth (Mann-Whitney U test ($\alpha = 0.05$)). However, 100 nM was less effective and, at 1000 nM or greeter concentrations, neurite outgrowth was inhibited.

MECHANISM OF ACTION - Steroid-receptor complex assembly disruption.

USE - Used to treat animals with neurological conditions associated with neuronal dysfunction caused by disease or injury to neurons, including animals with injury to a neuron of the central or peripheral nervous system (claimed). Used also in association with procedures such as surgical nerve grafts or other implantations of neurological tissue to promote healing of the graft or implant and promote incorporation of the graft or implant into neurological tissue.

Used to promote neuronal regeneration and functional recovery and to stimulate neurite outgrowth in the threatement of neuropathological states such as damage to peripheral nerves and the central nervous system caused by physical injury (e.g. spinal cord injury and trauma, sciatic or facial nerve lesion or injury, limb transplantation following amputation), disease (e.g. diabetic neuropathy), cancer chemotherapy (neuropathy induced by acrylamide, taxol, vinca alkaloids and doxorubicin), brain damaged associated with stroke and ischemia, and neurological disorders including peripheral neuropathic and neurological disorders related to neurodegeneration including trigeminal neuralgia, glossopharyngeal neuralgia, Bell's palsy, myasthenia gravis, muscular dystrophy, amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar inherited muscular dystrophy, herniated, ruptured or prolapsed vertebral disc syndromes, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies caused by lead, acrylamides, gamma diketones (glue-sniffer's neuropathy), carbon disulfide, dapsone, ticks, porphyria, Gullain-Barre syndrome, Alzheimer's disease,

Parkinson's disease and Huntington's chorea.

Also used in prevention and treatment of stroke and connective tissue disorders and as a male contraceptive.

ADVANTAGE - Compounds need not have significant calcineurin inhibition or rotamase inhibition. Avoids unwanted side-effects of prior-art methods e.g. immunosuppression and cardiomyopathy.

NOVELTY - Method of stimulating nerve cell growth in subjects comprises administration of a compound that disrupts assembly of a steroid receptor complex, excluding estrogen, androgen or recognized compound that binds to immunophilin FKBP-12, without side effects such as immunosuppression, and cardiomyopathy, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) methods of screening for compound that stimulates nerve cell growth; and
- (2) pharmaceutical compositions containing nerve growth stimulating amount of an agent that binds to a poly peptide of a steroid receptor complex other than a steroid hormone binding portion of the complex.

ACTIVITY - Neurotrophic. Neuroblastoma SH-SY5Y cells were used to examine human neurite outgrowth in vitro. The results showed that FK506 increases neurite outgrowth in SH-SY5Y cells in a concentration-dependent manner. Cumulative histograms of neurite lengths showed that 10 pM-10 nM F506 significantly increased neurite outgrowth (Mann-Whitney U test ($\alpha = 0.05$)). However, 100 nM was less effective and, at 1000 nM or greater concentrations, neurite outgrowth was inhibited.

MECHANISM OF ACTION - Steroid-receptor complex assembly disruption.

USE - Used to treat animals with neurological conditions associated with neuronal dysfunction caused by disease or injury to neurons, including animals with injury to a neuron of the central or peripheral nervous system (claimed). Used also in association with procedures such as surgical nerve grafts or other implantations of neurological tissue to promote healing of the graft or implant and promote incorporation of the graft or implant into neurological tissue.

Used to promote neuronal regeneration and functional recovery and to stimulate neurite outgrowth in the threatment of neuropathological states such as damage to peripheral nerves and the central nervous system caused by physical injury (e.g. spinal cord injury and trauma, sciatic or facial nerve lesion or injury, limb transplantation following amputation), disease (e.g. diabetic neuropathy), cancer chemotherapy (neuropathy induced by acrylamide, taxol, vinca alkaloids and doxorubicin), brain damaged associated with stroke and ischemia, and neurological disorders including peripheral neuropathic and neurological disorders related to neurodegeneration including trigeminal neuralgia, glossopharyngeal neuralgia, Bell's palsy, myasthenia gravis, muscular dystrophy, amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar inherited muscular dystrophy, herniated, ruptured or prolapsed vertebral disc syndromes, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies caused by lead, acrylamides, gamma diketones (glue-sniffer's neuropathy), carbon disulfide, dapson, ticks, porphyria, Gullain-Barre syndrome, Alzheimer's disease, Parkinson's disease and Huntington's chorea.

Also used in prevention and treatment of stroke and connective tissue disorders and as a male contraceptive.

ADVANTAGE - Compounds need not have significant calcineurin inhibition or rotamase inhibition. Avoids unwanted side-effects of prior-art methods e.g. immunosuppression and cardiomyopathy.

US20020086015A

NOVELTY - Method of stimulating nerve cell growth in subjects comprises administration of a compound that disrupts assembly of a steroid receptor complex, excluding estrogen, androgen or recognized compound that binds to immunophilin FKBP-12, without side effects such as immunosuppression, and cardiomyopathy, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) methods of screening for compound that stimulates nerve cell growth; and
- (2) pharmaceutical compositions containing nerve growth stimulating amount of an agent that binds to a poly peptide of a steroid receptor complex other than a steroid hormone binding portion of the complex.

ACTIVITY - Neurotrophic. Neuroblastoma SH-SY5Y cells were used to examine human neurite outgrowth in vitro. The results showed that FK506 increases neurite outgrowth in SH0-SY5Y cells in a concentration-dependent manner. Cumulative histograms of neurite lengths showed that 10 pM-10 nM F506 significantly increased neurite outgrowth (Mann-Whitney U test ($\alpha = 0.05$)). However, 100 nM was less effective and, at 1000 nM or greeter concentrations, neurite outgrowth was inhibited.

MECHANISM OF ACTION - Steroid-receptor complex assembly disruption.

USE - Used to treat animals with neurological conditions associated with neuronal dysfunction caused by disease or injury to neurons, including animals with injury to a neuron of the central or peripheral nervous system (claimed). Used also in association with procedures such as surgical nerve grafts or other implantations of neurological tissue to promote healing of the graft or implant and promote incorporation of the graft or implant into neurological tissue.

Used to promote neuronal regeneration and functional recovery and to stimulate neurite outgrowth in the threathment of neuropathological states such as damage to peripheral nerves and the central nervous system caused by physical injury (e.g. spinal cord injury and trauma, sciatic or facial nerve lesion or injury, limb transplantation following amputation), disease (e.g. diabetic neuropathy), cancer chemotherapy (neuropathy induced by acrylamide, taxol, vinca alkaloids and doxorubicin), brain damaged associated with stroke and ischemia, and neurological disorders including peripheral neuropathic and neurological disorders related to neurodegeneration including trigeminal neuralgia, glossopharyngeal neuralgia, Bell's palsy, myasthenia gravis, muscular dystrophy, amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar inherited muscular dystrophy, herniated, ruptured or prolapsed vertebral disc syndromes, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies caused by lead, acrylamides, gamma diketones (glue-sniffer's neuropathy), carbon disulfide, dapsone, ticks, porphyria, Gullain-Barre syndrome, Alzheimer's disease, Parkinson's disease and Huntington's chorea.

Also used in prevention and treatment of stroke and connective tissue disorders and as a male contraceptive.

ADVANTAGE - Compounds need not have significant calcineurin inhibition or rotamase inhibition. Avoids unwanted side-effects of prior-art methods e.g. immunosuppression and cardiomyopathy.

WO 9921552A

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Gold-B-G.IN.	2

Display Format: **Change Format**

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 20040077676 A1

Using default format because multiple data bases are involved.

L3: Entry 1 of 2

File: PGPB

Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040077676

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040077676 A1

TITLE: Neurotrophic tacrolimus analogs

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Matsuoka, Nobuya	Osaka-shi	OR	JP	
Yamaji, Takayuki	Osaka-shi		JP	
Gold, Bruce	West Linn		US	

US-CL-CURRENT: 514/291

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 2. Document ID: WO 2053159 A1

L3: Entry 2 of 2

File: EPAB

Jul 11, 2002

PUB-NO: WO002053159A1

DOCUMENT-IDENTIFIER: WO 2053159 A1

TITLE: NEUROTROPHIC TACROLIMUS ANALOGS

PUBN-DATE: July 11, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
MATSUOKA, NOBUYA	JP
YAMAJI, TAKAYUKI	JP
GOLD, BRUCE	US

INT-CL (IPC): A61 K 31/44

EUR-CL (EPC): A61K031/44

ABSTRACT:

CHG DATE=20020802 STATUS=O>Tacrolimus derivatives having high levels of neurotrophic activity and low levels of immunosuppressive activity. These compounds are useful as

<http://westbrs.9000/bin/gate.exe?f=TOC&state=1clt8p.4&ref=3&dbname=PGPB,USPT,USO...> 11/16/04

neurotrophic agents, particularly, for preventing or treating neuronal injury/dysfunction.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWC	Draw Des				
<div>Clear Generate Collection Print Fwd Refs Bkwd Refs Generate OACS</div> <table border="1"><tr><td>Terms</td><td>Documents</td></tr><tr><td>Gold-Bruce.IN.</td><td>2</td></tr></table>													Terms	Documents	Gold-Bruce.IN.	2
Terms	Documents															
Gold-Bruce.IN.	2															

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 9 of 9 returned.

☐ 1. Document ID: US 6526973 B1

Using default format because multiple data bases are involved.

L4: Entry 1 of 9

File: DWPI

Mar 4, 2003

DERWENT-ACC-NO: 2003-310772

DERWENT-WEEK: 200469

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Increasing method for blood flow to the thorax by manipulating patient body where inflow valve prevents respiratory gases from entering lungs until negative intrathoracic pressure level range is exceeded

INVENTOR: GOLD, B ; LURIE, K G ; SWEENEY, M

PRIORITY-DATA: 1997US-0950702 (October 15, 1997), 1993US-0149204 (November 9, 1993), 1995US-0403009 (March 10, 1995), 2000US-0546252 (April 10, 2000)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

US 6526973 B1

March 4, 2003

024

A62B009/02

INT-CL (IPC): A62 B 9/02

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	RMIC	Draw. Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-----------

☐ 2. Document ID: JP 2004527472 W, WO 200253159 A1, EP 1353671 A1, HU 200302521 A2, AU 2002231277 A1, US 20040077676 A1, CZ 200302060 A3, KR 2004007431 A, BR 200116762 A

L4: Entry 2 of 9

File: DWPI

Sep 9, 2004

DERWENT-ACC-NO: 2002-599593

DERWENT-WEEK: 200459

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Use of tacrolimus derivatives for manufacturing neurotrophic agent useful for treating neuronal injury or dysfunction e.g. Alzheimer's disease, Huntington's disease, radiculopathy, diabetic neuropathy

INVENTOR: GOLD, B ; MATSUOKA, N ; YAMAJI, T

PRIORITY-DATA: 2000US-258500P (December 29, 2000), 2003US-0451361 (November 14, 2003)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

JP 2004527472 W

September 9, 2004

041

A61K031/70

WO 200253159 A1	July 11, 2002	E	024	A61K031/44
EP 1353671 A1	October 22, 2003	E	000	A61K031/44
HU 200302521 A2	November 28, 2003		000	A61K031/44
AU 2002231277 A1	July 16, 2002		000	A61K031/44
US 20040077676 A1	April 22, 2004		000	A61K031/4745
CZ 200302060 A3	January 14, 2004		000	A61K031/44
KR 2004007431 A	January 24, 2004		000	A61K031/44
BR 200116762 A	August 10, 2004		000	A61K031/44

INT-CL (IPC): A61 K 31/44; A61 K 31/4745; A61 K 31/70; A61 P 3/10; A61 P 21/00; A61 P 21/02; A61 P 25/00; A61 P 25/02; A61 P 25/14; A61 P 25/16; A61 P 25/18; A61 P 25/28; B65 D 77/00; B65 D 77/28

ABSTRACTED-PUB-NO: WO 200253159A
BASIC-ABSTRACT:

NOVELTY - Use of tacrolimus analog (1,14-dihydroxy-12-(2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl)-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxo-propyl)-11,28-dioxo-4-aza-tricyclo(22.3.1.0 asterisk 4,9 asterisk)octacos-18-ene-2,3,10,16-tetraone) (I) for manufacturing a neurotrophic agent (A).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a composition comprises (I);
- (2) a kit comprises:
 - (a) packaging material comprising a label or a written material which indicates that (I) can be used for preventing, ameliorating or treating neuronal injury/dysfunction, and
 - (b) compound of formula (I) inside packaging material;
- (3) a kit comprises a composition containing (I) and written matter associated in it;
- (4) a method for repairing a transected peripheral nerve or spinal cord in a subject (preferably mammal, especially human) involves administering a nerve growth stimulating amount of (I) and grafting to the peripheral nerve or spinal cord; and
- (5) a composition comprises a cell, tissue or graft treated with (I) and at least one nerve cell growth promoting agent.

ACTIVITY - Auditory; Nootropic; Neuroprotective; Antiparkinsonian; Anticonvulsant; Antidiabetic; Vulnerary; Vasotropic; Anti-HIV; Cytostatic; Tranquilizer; Hemostatic; Analgesic.

MECHANISM OF ACTION - FKBP12 binder.

An FKBP12 binding assay was performed according to Tamura, K., et al (Biochemical and Biophysical Research Communications, Vol. 202, No.1, 437 - 499, 1994) using 1,14-Dihydroxy-12-(2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-vinyl)-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxo-propyl)-11,28-dioxo-4-aza-tricyclo(22.3.1.0 asterisk 4,9 asterisk)octacos-18-ene-2,3,10,16-tetraone (Ia). The IC50 of compound (Ia) was found to be less than 5. The potent neurotrophic effects of compound (Ia) even at low concentrations increases neurite outgrowth. The systemic administration of compound (Ia) at low doses speed functional recovery following a nerve crush lesion by increasing the rate of axonal regeneration in the sciatic nerve and promotes functional recovery from spinal cord injury.

USE - (A) is used for preventing, ameliorating or treating neuronal

injury/dysfunction including polymyositis (multiple myositis), Guillain-Barre syndrome, Huntington's disease, radiculopathy, diabetic neuropathy (multiple neuritis), mononeuritis (solitary neuritis), Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, radiculopathy, diabetic neuropathy, chemotherapy-induced neuropathy, senile dementia, vascular dementia, multiple sclerosis, physical palsy or spinal cord injury of a subject (preferably mammal, especially human); for stimulating or promoting nerve cell growth or regeneration; for promoting functional recovery from a nerve injury including burn, traumatic injury, mechanical injury, surgical injury, physiological injury, pathological injury and immunological injury; increasing nerve cell growth in a tissue including brain tissue, spinal cord tissue or peripheral nerve tissue; for repairing a transected peripheral nerve or spinal cord (all claimed).

Also for treating damage, deterioration of dysfunction caused by physical injury, nutritional disorders, ischemia, degenerative diseases, malignant diseases, infectious diseases and by drug interactions, toxins or poisons; neurosurgery, peripheral nerve injury, burns, encephalomyelitis, HIV, herpes, cancer, radiation treatment, folic acid or Vitamin B-12 deficiency; and exposure to neurotoxins or chemicals such as lead; for treating damage of the central nervous system caused by physical injury including spinal cord injury, trauma, sciatic or facial nerve lesion or injury, limb transplantation following amputation; clouding of consciousness, dyskinesia, associated with cerebral infarction, hemorrhage infarct; trigeminal neuralgia, gloss pharyngeal neuralgia, Bell's palsy, myasthenia gravis, muscular dystrophy, progressive muscular atrophy, progressive bulbar inherited muscular atrophy, herniated, ruptured or prolapsed vertebral disk syndromes, cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies.

ADVANTAGE - (I) has excellent neurotrophic activity and a low level of immunosuppressive activity. Administration of (I) induces axonal regeneration and speedy recovery from nerve crush or spinal cord injuries.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 3. Document ID: US 6062219 A

L4: Entry 3 of 9

File: DWPI

May 16, 2000

DERWENT-ACC-NO: 2000-421466

DERWENT-WEEK: 200469

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Apparatus and methods for assisting cardiopulmonary resuscitation that incorporates a transition tube, which connects the endotracheal tube to the ventilation bag, the ventilation valve serves to introduce air into the device

INVENTOR: GOLD, B ; LURIE, K G ; SWEENEY, M

PRIORITY-DATA: 1997US-0950702 (October 15, 1997), 1993US-0149204 (November 9, 1993), 1995US-0403009 (March 10, 1995)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>US 6062219 A</u>	May 16, 2000		023	A62B009/02

INT-CL (IPC): A61 M 16/00; A62 B 7/10; A62 B 9/02

ABSTRACTED-PUB-NO: US 6062219A

BASIC-ABSTRACT:

NOVELTY - The device (35) for impeding airflow into a patients lungs. The device consists an endotracheal tube (36), which is placed into the patients trachea and provides a ventilation passageway. Connected is a transition tube (38), which connects the endotracheal tube to the ventilation bag (28). The ventilation valve (26) serves to introduce air into the device. Attached or connected to the transition tube is an airflow responsive valve (24). The inflow valve is biased so that it opens when the negative intrathoracic pressure in the patients chest reaches a threshold amount.

USE - External chest compression and decompression as part of the cardiopulmonary resuscitation procedures.

ADVANTAGE - Properly ventilate the patient with air, in a controlled manner.

DESCRIPTION OF DRAWING(S) - The figure shows a view of the device.

Responsive valve 24

Ventilation valve 26

Ventilation tube 28

Device 35

Endotracheal tube 36

Transition tube 38

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Drawn	Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	-------	-----

☐ 4. Document ID: WO 200011013 A1, AU 9955762 A

L4: Entry 4 of 9

File: DWPI

Mar 2, 2000

DERWENT-ACC-NO: 2000-246530

DERWENT-WEEK: 200021

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Modified nucleomonomers, used in physiologically stable, non-toxic oligomers used to inhibit expression of nucleic acids and in gene regulation, antisense technology and diagnostics

INVENTOR: GOLD, B

PRIORITY-DATA: 1998US-097712P (August 22, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 200011013 A1</u>	March 2, 2000	E	042	C07H021/04
<u>AU 9955762 A</u>	March 14, 2000		000	C07H021/04

INT-CL (IPC): A61 K 48/00; C07 H 21/02; C07 H 21/04

ABSTRACTED-PUB-NO: WO 200011013A

BASIC-ABSTRACT:

NOVELTY - Modified nucleomonomers and their pharmaceutically acceptable salts.

DETAILED DESCRIPTION - Modified nucleomonomers of formula (I) or (II) are new.

X = -CC(CH₂)_m-, -CH=CH(CH₂)_n- or (CH₂)_p;

m, n = 1-2;

p = 3-4;

R = OH, NH₂, SH, 1-4C alkoxy and 1-4C alkylthio.

dR is not formally defined.

An INDEPENDENT CLAIM is also included for inhibiting expression of nucleic acid molecules.

ACTIVITY - Gene regulation; antisense technology.

MECHANISM OF ACTION - Nucleic acid expression inhibitor; DNA expression inhibitor; RNA expression inhibitor.

USE - (I) and (II) are used as monomers in oligomers, which are used in pharmaceutical compositions to inhibit expression of nucleic acid molecules including DNA and RNA in cells such as bacterial, fungal, yeast, mammalian, cancer and virally-infected cells (claimed).

They are used in oligomers for gene regulation, antisense technology, diagnostic applications to detect target sequences in biological samples such as those containing pathogenic bacteria, fungi and viruses, oncogenes, growth hormones and enzymes, to target genes or encoded RNAs that encode enzymes, hormones, serum proteins, adhesion molecules, receptor molecules, cytokines, oncogenes, growth factors and interleukins associated with pathological conditions such as inflammatory conditions, cardiovascular disorders, immune reactions, cancer, viral infections and bacterial infections. The oligomers are suitable for use in both in vivo and ex vivo therapeutic applications including treatment of cells such as bone marrow or peripheral blood in conditions such as leukemia or viral infections, genes as target for cancer treatments including oncogenes such as ras, k-ras, bcl-2, c-myc, bcr, c-myc, c-abl or overexpressed sequences such as mdm2, oncostatin M, interleukin 6 (Kaposi's sarcoma), HER-2 and translocations such as bcr/abl or RNAs encoded by such genes, as well as viral gene sequences such as polymerase or reverse transcriptase genes of cytomegalovirus, herpes simplex virus-1 or -2, HTLV-1, human immunodeficiency virus-1 or -2, hepatitis B virus, human papilloma virus, varicella zoster virus, influenza virus or rhinovirus.

They can also be used to modulate inflammatory responses by modulating expression of genes such as IL-1 receptor, IL-1, ICAM-1 or E-selectin in mediating inflammation and modulation of cellular proliferation in conditions such as arterial occlusion (restenosis) after angioplasty by modulating the expression of growth or mitogenic factors such as non-muscle myosin, myc, fos, PCNA, platelet-derived growth factor or fibroblast growth factor or their receptors or cell proliferation factor such as c-myc, other extracellular proliferation factors such as transforming growth factor alpha, IL-6, approx. g-interferon, protein kinase C for treatment of psoriasis or other conditions, and epithelial growth factor, transforming growth factor or MHC alleles in autoimmune disease.

ADVANTAGE - Oligomers comprising (I) and (II) exhibit increased duplex DNA stability when hybridizing to target nucleic acid sequences, are physiologically stable, non-toxic and able to penetrate into cells while maintaining stringent base pair fidelity for target DNA sequences. The oligomers demonstrate significant single- or double-stranded target nucleic acid binding activity to form duplexes, triplexes or other forms of stable association. To demonstrate the potential of 5PNH₂-dU modified nucleotides to stabilize RNA-DNA complexes, a chimeric 14mer was synthesized and the stability of the duplexes with natural DNA (AGCGG-RNA adenosine-RNA adenosine-RNA adenosine-RNA adenosine-GCACC-3':3'-TCGCCTTTT- CGTCC-5'; ODN-11) and DNA containing

four of the 5PNH2-dU substitutions opposite the RNA bases (5'-AGCGG-RNA adenosine-RNA adenosine-RNA adenosine-RNA adenosine-GACACC-3' :3'-TCGCCXXXXCGTCC-5'; ODN-12) was measured. The TM data show that the 5PNH2-dU modification increased the melting point of ODN-12 by 10.2 deg. C in comparison to unmodified ODN-11.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 5. Document ID: DE 19849056 C1, IT 1306728 B, GB 2342953 A, FR 2785011 A1, GB 2342953 B

L4: Entry 5 of 9

File: DWPI

Jan 27, 2000

DERWENT-ACC-NO: 2000-107536

DERWENT-WEEK: 200231

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Adjustable hinge for motor vehicle door

INVENTOR: GOLD, B

PRIORITY-DATA: 1998DE-1049056 (October 24, 1998)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>DE 19849056 C1</u>	January 27, 2000		005	E05D007/04
<u>IT 1306728 B</u>	October 2, 2001		000	E05D000/00
<u>GB 2342953 A</u>	April 26, 2000		000	E05D007/00
<u>FR 2785011 A1</u>	April 28, 2000		000	E05D007/04
<u>GB 2342953 B</u>	August 23, 2000		000	E05D007/00

INT-CL (IPC): B60 J 5/00; B62 D 65/06; E05 D 0/00; E05 D 5/10; E05 D 5/12; E05 D 7/00; E05 D 7/04; F16 C 11/00

ABSTRACTED-PUB-NO: DE 19849056C

BASIC-ABSTRACT:

NOVELTY - The adjustable hinge (1) for a motor vehicle door has a hinge arm with an eccentric bearing bush (7) that is rotationally fixed to it. The bearing opening is threaded to cooperate with a bolt (4) having a conical surface to axially tension and clamp an opposing conical bearing on which the second arm is mounted.

USE - For motor vehicle door hinges.

ADVANTAGE - The hinge allows adjustment independently of the pivot position.

DESCRIPTION OF DRAWING(S) - Drawing shows cross-sectional view of the hinge.

Hinge assembly 1

Bolt 4

Eccentric bush 7

ABSTRACTED-PUB-NO:

GB 2342953B EQUIVALENT-ABSTRACTS:

NOVELTY - The adjustable hinge (1) for a motor vehicle door has a hinge arm with an eccentric bearing bush (7) that is rotationally fixed to it. The bearing opening is

threaded to cooperate with a bolt (4) having a conical surface to axially tension and clamp an opposing conical bearing on which the second arm is mounted.

USE - For motor vehicle door hinges.

ADVANTAGE - The hinge allows adjustment independently of the pivot position.

DESCRIPTION OF DRAWING(S) - Drawing shows cross-sectional view of the hinge.

Hinge assembly 1

Bolt 4

Eccentric bush 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 6. Document ID: WO 9628215 A1, AU 9649257 A, US 5692498 A, EP 898485 A1, CN 1183731 A, EP 898485 B1, DE 69627898 E

L4: Entry 6 of 9

File: DWPI

Sep 19, 1996

DERWENT-ACC-NO: 1996-433571

DERWENT-WEEK: 200469

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Cardio-pulmonary resuscitation device - has airflow impeding structure in form of restrictive orifice or pressure responsive valve placed within or in series with mask or breathing tube

INVENTOR: GOLD, B ; LURIE, K G ; SWEENEY, M

PRIORITY-DATA: 1995US-0403009 (March 10, 1995), 1993US-0149204 (November 9, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9628215 A1</u>	September 19, 1996	E	048	A62B007/00
<u>AU 9649257 A</u>	October 2, 1996		000	
<u>US 5692498 A</u>	December 2, 1997		023	A62B009/02
<u>EP 898485 A1</u>	March 3, 1999	E	000	A62B007/00
<u>CN 1183731 A</u>	June 3, 1998		000	A62B007/00
<u>EP 898485 B1</u>	May 2, 2003	E	000	A62B007/00
<u>DE 69627898 E</u>	June 5, 2003		000	A62B007/00

INT-CL (IPC): A61 M 16/04; A61 M 16/20; A62 B 7/00; A62 B 9/02

ABSTRACTED-PUB-NO: US 5692498A

BASIC-ABSTRACT:

The cardio-pulmonary resuscitation device has an airflow impeding structure in the form of a restrictive orifice or a pressure responsive valve (24) placed within or in series with a mask or breathing tube (36).

The valve is biased to open to permit the inflow of air when the intra-thoracic pressure falls below a threshold level in the range from 0 cm. of mercury to 100 cm. of mercury, and has a further airflow impeding structure by-pass.

ADVANTAGE - Enhances extent and duration of negative intra-thoracic pressure during decompression of the patient's chest to enhance venous blood flow into the heart and lungs from the peripheral venous vasculature when performing cardio-pulmonary resuscitation.

ABSTRACTED-PUB-NO:

WO 9628215A EQUIVALENT-ABSTRACTS:

The cardio-pulmonary resuscitation device has an airflow impeding structure in the form of a restrictive orifice or a pressure responsive valve (24) placed within or in series with a mask or breathing tube (36).

The valve is biased to open to permit the inflow of air when the intra-thoracic pressure falls below a threshold level in the range from 0 cm. of mercury to 100 cm. of mercury, and has a further airflow impeding structure by-pass.

ADVANTAGE - Enhances extent and duration of negative intra-thoracic pressure during decompression of the patient's chest to enhance venous blood flow into the heart and lungs from the peripheral venous vasculature when performing cardio-pulmonary resuscitation.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 7. Document ID: WO 9513108 A1, AU 9510918 A, EP 728028 A1, US 5551420 A, EP 728028 A4, JP 09508811 W, AU 687942 B, EP 728028 B1, DE 69432708 E, ES 2199976 T3

L4: Entry 7 of 9

File: DWPI

May 18, 1995

DERWENT-ACC-NO: 1995-193914

DERWENT-WEEK: 200469

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Method for increasing cardiopulmonary circulation - involves impeding airflow into patient's lungs by placing ventilation tube in patient's airway

INVENTOR: GOLD, B ; LURIE, K G ; SWEENEY, M

PRIORITY-DATA: 1993US-0149204 (November 9, 1993)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>WO 9513108 A1</u>	May 18, 1995		031	A61M015/00
<u>AU 9510918 A</u>	May 29, 1995		000	
<u>EP 728028 A1</u>	August 28, 1996	E	031	A61M015/00
<u>US 5551420 A</u>	September 3, 1996		013	A62B009/02
<u>EP 728028 A4</u>	June 4, 1997		000	
<u>JP 09508811 W</u>	September 9, 1997		031	A61M016/00
<u>AU 687942 B</u>	March 5, 1998		000	
<u>EP 728028 B1</u>	May 21, 2003	E	000	A61M015/00
<u>DE 69432708 E</u>	June 26, 2003		000	A61M015/00
<u>ES 2199976 T3</u>	March 1, 2004		000	A61M015/00

INT-CL (IPC): A61 H 31/00; A61 M 15/00; A61 M 16/00; A62 B 7/00; A62 B 9/02; A62 B 9/06; A62 B 18/02

ABSTRACTED-PUB-NO: US 5551420A

BASIC-ABSTRACT:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.5&ref=4&dbname=PGPB,USPT,USO...> 11/16/04

The method comprises compressing a patient's chest to force blood out of the patient's thorax and then decompressing the patient's chest to induce venous blood to flow into the heart and lungs from the peripheral venous vasculature. It then involves impeding air flow into the patient's lungs to enhance the extent and duration of negative intrathoracic pressure during decompression of the patient's chest.

Venous blood flow into the heart and lungs from the peripheral venous vasculature is enhanced.

USE - For increasing cardiopulmonary circulation when performing cardiopulmonary resuscitation.

ABSTRACTED-PUB-NO:

WO 9513108A EQUIVALENT-ABSTRACTS:

A method for increasing cardiopulmonary circulation induced by chest compression and decompression when performing cardio pulmonary resuscitation, by augmenting at least the negative intrathoracic pressure, said method comprising the steps of:

providing a ventilatory tube having a length which extends at least between a patient's mouth and throat, a source of respiratory gases, and at least one inflow valve;

performing chest compression and chest decompression, wherein during chest decompression, said at least one inflow valve prevents respiratory gases from entering the lungs until a negative intrathoracic pressure level is exceeded at which time said at least one inflow valve opens, said at least one inflow valve assisting in increasing the magnitude and duration of negative intrathoracic pressure during decompression and thereby enhancing the amount of venous blood flow into the heart and lungs; and

periodically, every 2-10 chest compressions, supplying the patient with gas from the respiratory gas source so as to properly ventilate the patient.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	------------

☐ 8. Document ID: DE 4234550 C1, GB 2271551 B, GB 2271551 A, FR 2698213 A1, US 5371942 A

L4: Entry 8 of 9

File: DWPI

Sep 16, 1993

DERWENT-ACC-NO: 1993-289420

DERWENT-WEEK: 199608

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Pre-fabricated cable tree fitting system for automobile - has gripper used to lift cable tree from carrier and insert it in passenger space via front or rear windscreen

INVENTOR: GOLD, B; KAYSER, E

PRIORITY-DATA: 1992DE-4234550 (October 14, 1992)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
DE 4234550 C1	September 16, 1993		009	H02G001/00
GB 2271551 B	January 31, 1996		001	B62D065/00

<u>GB 2271551 A</u>	April 20, 1994	017	B62D065/00
<u>FR 2698213 A1</u>	May 20, 1994	000	H02G003/00
<u>US 5371942 A</u>	December 13, 1994	009	B23P021/00

INT-CL (IPC): B23P 21/00; B25J 15/08; B60R 16/02; B62D 65/00; H01B 7/00; H02G 1/00; H02G 3/00; H05K 13/06

ABSTRACTED-PUB-NO: DE 4234550C
BASIC-ABSTRACT:

The cable tree fitting system uses a gripper (20) independently movable in all 3 coordinate directions via a programme control, to fit the cable tree through the front or rear windscreen opening before lowering it on to the floor of the passenger space.

The cable tree is supported by a carrier (40) for 2 parallel arms (11) and a transverse arm (12) of the cable tree, engaged by a pair of gripper arms (22) fitting beneath the 2 parallel arms (11) to lift the cable tree, upon pivoting the gripper arms.

USE - For automatic fitting of pre-fabricated cable tree in vehicle passenger space in automatic car assembly line.

ABSTRACTED-PUB-NO:

GB 2271551B EQUIVALENT-ABSTRACTS:

A prefabricated cable harness and an arrangement for installing said cable harness in the interior of a still empty vehicle body of a passenger car at the initial stage of its final assembly,

- the cable harness consisting of a plurality of branches, two of which comprise longitudinal branches arranged in such a way that in the installed state they come to rest on the inside of a respective body sill beam and at least one transverse branch arranged in such a way that in the installed state it runs on the inside transversely across the floor of the passenger compartment so that the cable harness has an H-shaped or ladder-shaped structure which extends over the entire inner width of the passenger compartment;

- each branch consisting of a multiplicity of conductors which run in an enclosure which is flexible to a limited degree, is shaped in a defined fashion and matched to the shape of the vehicle body along the laying path;

- the conductors at the junction points of the different branches passing through an adjacent enclosure without interrupting and in different courses;

- cable conductors or flexible bundles with a plurality of conductors which are to be laid individually in each case and are to be connected to electrical loads emerge at least at both ends of the enclosures of the two longitudinal branches; characterized by the following features;

- a program-controllable gripper adapted to be moved independently in all three spatial directions by a gripper guide and adapted to the cable harness is provided, the displacement space of the said gripper extending between a positionally defined location at which the cable harness is prepared and the location at which the vehicle body is prepared and in which gripper two parallel gripper arms project freely from a gripper holder in the longitudinal direction of the vehicle so that the gripper arms can be inserted into the interior of the vehicle through the windscreen opening or rear window opening and can be lowered to the level of the floor of the passenger compartment;

- in addition, having an elevating platform for preparing the cable harness which is held on a cable harness carrier as a transport vessel, in a defined shape, at least

approximate to the later installation position, of the cable harness;

- for receiving the longitudinal branches and the cable termination bundles of the cable harness, which bundles are enclosed or bound provisionally with reversible material and turned back parallel to the longitudinal branches, the cable harness carrier has upwardly open rows of forks and a number of cross-struts corresponding to the number of transverse branches for receiving the transverse branches, the transverse branches having in their enclosure one articulation point on each side of the centre for bending the transverse branches and for pivoting the two longitudinal branches towards the centre in order to rethe width requirement of the cable harness, the cable termination bundles which are folded back in the cable harness carrier lying at least approximately coaxially with respect to the articulation points of the transverse branches;

- a plurality of prongs for engaging under the longitudinal branches and the cable termination bundles being arranged on the two gripper arms, the engagement taking place by pivoting the gripper arms about a longitudinal axis out of their position of rest into their working position and the setting down of the cable harness being achievable by means of a reverse pivoting movement.

US 5371942A

A program-controllable flat gripper can be moved independently in all three spatial directions and is adapted to grip and move the cable harness. A displacement space of the gripper extends between a location at which the cable harness is stored and a location at which the cable harness is inserted into the vehicle body. A holder has two parallel arms projecting freely in a longitudinal direction of the vehicle body so that the holder arms can be inserted into the interior of the vehicle body through one of a windscreen opening and a rear window opening and thereafter can be lowered to a floor level of the passenger compartments.

There is a scissor-type elevating platform upon which the cable harness can be positioned at cable harness storage location. The cable harness carrier has upwardly open rows of forks for receiving the longitudinal branches and the flexible bundles of the cable harness.

USE/ADVANTAGE - With this arrangement, the bulky and heavy cable harness can be installed reliably and rationally in the vehicle body. Possible damage to the vehicle body and to the cable harness by chafing is avoided during installation. For installing a cable harness in a motor vehicle.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWOC	Draws	Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------	-----

☐ 9. Document ID: GB 2032530 A, GB 2032530 B

L4: Entry 9 of 9

File: DWPI

May 8, 1980

DERWENT-ACC-NO: 1980-E2056C

DERWENT-WEEK: 198019

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Rotary positive displacement machine - has externally toothed rotor, internally toothed outer annulus and interposed rotary core with undulating cam traces

INVENTOR: GOLD, B

PRIORITY-DATA: 1979GB-0036394 (October 19, 1979), 1978GB-0041290 (October 20, 1978)

PATENT-FAMILY:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.5&ref=4&dbname=PGPB,USPT,USO...> 11/16/04

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
GB 2032530 A	May 8, 1980		000	
GB 2032530 B	January 6, 1983		000	

INT-CL (IPC): F01C 1/00

ABSTRACTED-PUB-NO: GB 2032530A
BASIC-ABSTRACT:

The rotary motion machine has a co-axial assembly comprising a fixed outer annular member (1), a rotary intermediate annular core and an inner rotor (14). The member and rotor are respectively internally and externally toothed or splined to guide pistons (4, 12) in the axial direction.

The core has undulating cam tracks with which the pistons engage, each by twin rollers (10), and carries gear-like gates (9) which mesh with the member (1) and the rotor. These gates and the pinstons divide an annular chamber (2) into curved triangular sub-chambers.

ABSTRACTED-PUB-NO:

GB 2032530B EQUIVALENT-ABSTRACTS:

The rotary motion machine has a co-axial assembly comprising a fixed outer annular member (1), a rotary intermediate annular core and an inner rotor (14). The member and rotor are respectively internally and externally toothed or splined to guide pistons (4, 12) in the axial direction.

The core has undulating cam tracks with which the pistons engage, each by twin rollers (10), and carries gear-like gates (9) which mesh with the member (1) and the rotor. These gates and the pinstons divide an annular chamber (2) into curved triangular sub-chambers.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
Gold-B.IN.	9

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 4 of 4 returned.

☐ 1. Document ID: US 20040048816 A1

Using default format because multiple data bases are involved.

L7: Entry 1 of 4

File: PGPB

Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040048816
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040048816 A1

TITLE: Restenosis treatment

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Zohlhofer, Dietlind	Munchen		DE	
Bauerle, Patrick	Gauting		DE	
Klein, Christoph	Munchen		DE	
Neumann, Franz-Josef	Munchen		DE	

US-CL-CURRENT: 514/44; 424/145.1, 604/500

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 2. Document ID: US 20040039010 A1

L7: Entry 2 of 4

File: PGPB

Feb 26, 2004

PGPUB-DOCUMENT-NUMBER: 20040039010
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040039010 A1

TITLE: Methods for treatment of acute lymphocytic leukemia

PUBLICATION-DATE: February 26, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Grupp, Stephan A.	Havertown	PA	US	
Brown, Valerie I.	Philadelphia	PA	US	

US-CL-CURRENT: 514/291; 424/145.1

ABSTRACT:

Methods for treating patients having an early B cell derived acute lymphoblastic leukemia with rapamycin or a derivative thereof are provided. Also provided are methods for treating patients having an early B cell derived acute lymphoblastic leukemia with rapamycin or a derivative thereof in combination with an IL-7 inhibitor. Finally methods for preventing GVHD in ALL patients following a bone marrow transplant are disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20020086015 A1

L7: Entry 3 of 4

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086015
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020086015 A1

TITLE: Compositions and methods for promoting nerve regeneration

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gold, Bruce G.	West Linn	OR	US	

US-CL-CURRENT: 424/145.1; 514/2, 514/34

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBPS52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 6641810 B2

L7: Entry 4 of 4

File: USPT

Nov 4, 2003

US-PAT-NO: 6641810
DOCUMENT-IDENTIFIER: US 6641810 B2
**** See image for Certificate of Correction ****

TITLE: Methods of using geldanamycin and FK506 to treat peripheral nerve damage

DATE-ISSUED: November 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBPS52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

34 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L6 AND FKBP12	4

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 51 of 51 returned.

☐ 1. Document ID: US 20040185050 A1

Using default format because multiple data bases are involved.

L13: Entry 1 of 51

File: PGPB

Sep 23, 2004

PGPUB-DOCUMENT-NUMBER: 20040185050

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040185050 A1

TITLE: Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists

PUBLICATION-DATE: September 23, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mota, Maria M.	Lisboa	NY	PT	
Rodriguez, Ana	Great Neck		US	
Giordano, Silvia	Parede		US	
Rodrigues, Margarida Cunha			PT	

US-CL-CURRENT: 424/151.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 2. Document ID: US 20040172127 A1

L13: Entry 2 of 51

File: PGPB

Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040172127

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040172127 A1

TITLE: Modular stent having polymer bridges at modular unit contact sites

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Kantor, John	Santa Rosa	CA	US	

US-CL-CURRENT: 623/1.16; 623/1.46

ABSTRACT:

A radially expandable modular stent for implantation within the body of a patient is

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.14&ref=13&dbname=PGPB,USPT,U...> 11/16/04

disclosed. The modular stent includes a first stent module defining a first passageway, at least a second stent module defining at least a second passageway, and a least one polymer bridge in communication with the first stent module and the second stent module. The polymer bridge couples the first stent module to the second stent module such that the first passageway and the second passageway are in fluid communication.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 3. Document ID: US 20040102393 A1

L13: Entry 3 of 51

File: PGPB

May 27, 2004

PGPUB-DOCUMENT-NUMBER: 20040102393
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040102393 A1

TITLE: Modulation of heat shock protein 90-alpha expression

PUBLICATION-DATE: May 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bennett, C. Frank	Carlsbad	CA	US	
Dean, Nicholas M.	Olivenhain	CA	US	
Dobie, Kenneth W.	Del Mar	CA	US	

US-CL-CURRENT: 514/44; 435/375, 536/23.5

ABSTRACT:

Compounds, compositions and methods are provided for modulating the expression of heat shock protein 90-alpha. The compositions comprise oligonucleotides, targeted to nucleic acid encoding heat shock protein 90-alpha. Methods of using these compounds for modulation of heat shock protein 90-alpha expression and for diagnosis and treatment of disease associated with expression of heat shock protein 90-alpha are provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 4. Document ID: US 20040101532 A1

L13: Entry 4 of 51

File: PGPB

May 27, 2004

PGPUB-DOCUMENT-NUMBER: 20040101532
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040101532 A1

TITLE: Methods and compositions for heat shock protein mediated immunotherapy of melanoma

PUBLICATION-DATE: May 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Houghton, Alan	New York	NY	US	
Livingston, Philip	New York	NY	US	
Al-Awqati, Qais	New York	NY	US	
Mayhew, Mark	New York	NY	US	
Hoe, Mee	Irvington	NY	US	

US-CL-CURRENT: 424/185.1; 514/15

ABSTRACT:

The present invention relates to immunotherapeutic compositions comprising an effective amount of a molecular chaperone such as a heat shock protein, preferably hsp70, non-covalently bound to one or more javelinized melanoma antigens and to methods of using the immunotherapeutic compositions to induce an immune response against melanoma in a subject. The immunotherapeutic composition may contain one or more heat shock proteins, such as one or more of hsp70, hsp90, gp96, BiP, and hsp40, and may contain one or more javelinized melanoma antigens.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Drawings
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 20040082498 A1

L13: Entry 5 of 51

File: PGPB

Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040082498

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040082498 A1

TITLE: Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders

PUBLICATION-DATE: April 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Strehlow, David	Wayland	MA	US	

US-CL-CURRENT: 514/1; 424/130.1

ABSTRACT:

A method for prophylaxis or treatment of a mammal, particularly human, at risk for a fibrogenic disorder is disclosed. The compositions and methods of the invention are directed both to treatments for existing fibrogenic disorders and prevention thereof. Such disorders include, but are not limited to, connective tissue diseases, such as scleroderma (or systemic sclerosis), polymyositis, systemic lupus erythematosus and rheumatoid arthritis, and other fibrotic disorders, including liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis. A therapeutic composition according to the invention includes, as a therapeutic agent, an inhibitor of a collagen promoter in a pharmaceutically acceptable inert carrier vehicle, preferably for local, and particularly topical, application. Exemplary inhibitors include those that interfere with heat shock protein 90 (Hsp 90) chaperone function, e.g., the specific inhibitor geldanamycin or other known Hsp90 inhibitors such as

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 20040077058 A1

L13: Entry 6 of 51

File: PGPB

Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040077058

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040077058 A1

TITLE: Recombinant polynucleotides encoding pro-geldanamycin producing polyketide synthase and accessory proteins, and uses thereof

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hutchinson, Richard C.	San Mateo	CA	US	
Reid, Ralph C.	San Rafael	CA	US	
Hu, Zhihao	Castro Valley	CA	US	
Rascher, Andreas	San Francisco	CA	US	
Schirmer, Andreas	Hayward	CA	US	
McDaniel, Robert	Palo Alto	CA	US	

US-CL-CURRENT: 435/119; 435/252.3, 536/23.2

ABSTRACT:

The invention relates to recombinant polyketide synthase enzymes, polyketide modifying proteins, and other proteins involved in polyketide biosynthesis or function. The invention provides domains of geldanamycin and herbimycin polyketide synthases, polynucleotides that encode such enzymes, and to host cells in which such encoding polynucleotides can be advantageously expressed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 7. Document ID: US 20040071656 A1

L13: Entry 7 of 51

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040071656

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040071656 A1

TITLE: Modulation of heat-shock-protein-based immunotherapies

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Wieland, Felix
Hartl, Franz-Ulrich

Heidelberg
Kottgeisering

DE
DE

US-CL-CURRENT: 424/85.1; 424/185.1, 424/85.2

ABSTRACT:

Methods and compositions are provided for modulating the immune response to an antigen based upon the finding that the cell surface protein CD40 is a mammalian heat shock protein (hsp) receptor. Cell surface CD40 mediates the binding, cell signaling, and uptake of hsp and particularly hsp with antigen bound thereto. Methods are provided for modulating hsp-antigen uptake and an immune response to the antigen by altering CD40 expression, as well as utilizing CD40-binding fragments of mammalian hsp and muteins thereof for targeting antigens to CD40-expressing cells. Screening methods for agonists and antagonists of the CD40-hsp interaction are also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 8. Document ID: US 20040063610 A1

L13: Entry 8 of 51

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063610

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040063610 A1

TITLE: Compositions and methods for promoting nerve regeneration

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gold, Bruce G.	West Linn	OR	US	

US-CL-CURRENT: 514/2; 424/143.1, 514/183, 514/291

ABSTRACT:

FKS06 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor-complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 9. Document ID: US 20040053909 A1

L13: Entry 9 of 51

File: PGPB

Mar 18, 2004

PGPUB-DOCUMENT-NUMBER: 20040053909

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040053909 A1

TITLE: Geldanamycin derivative and method of treating cancer using same

PUBLICATION-DATE: March 18, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Snader, Kenneth M.	Germantown	MD	US	
Vishnuvajjala, B. Rao	Rockville	MD	US	
Hollingshead, Melinda G.	Middletown	MD	US	
Sausville, Edward A.	Silver Spring	MD	US	

US-CL-CURRENT: 514/183; 540/461

ABSTRACT:

A geldanamycin derivative exhibiting significant preliminary in vivo activity, particularly significant oral in vivo activity, and a method of treating or preventing cancer in a host comprising administering a geldanamycin derivative to a host in an amount sufficient to treat or prevent cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 10. Document ID: US 20040018572 A1

L13: Entry 10 of 51

File: PGPB

Jan 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040018572

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040018572 A1

TITLE: Mutant Plk protein and gene encoding the same

PUBLICATION-DATE: January 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Osada, Hiroyuki	Niiza-shi		JP	
Simizu, Siro	Tokorozawa-shi		JP	

US-CL-CURRENT: 435/7.23

ABSTRACT:

A mutant Plk protein having a mutation in C-terminal domain thereof specified by amino acid residues of from 439 to 603 of amino acid sequence of wild-type Plk protein wherein said mutation decreases affinity with Hsp90 protein, and a gene encoding said mutant Plk protein are provided. A method for detecting an abnormal cell which comprises the step of detecting the mutant Plk protein or the gene encoding the protein is also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 11. Document ID: US 20040014026 A1

L13: Entry 11 of 51

File: PGPB

Jan 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040014026
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040014026 A1

TITLE: Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkappaB

PUBLICATION-DATE: January 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ben-Neriah, Yinon	Mevasseret Zion		IL	
Alkalay-Snir, Irit	Jerusalem		IL	
Hatzubai, Ada	Kibutz Tzuba		IL	
Shushan, Etti Ben	Akiva		IL	
Davis, Matti	Modiin		IL	
Yaron, Avraham	Jerusalem		IL	

US-CL-CURRENT: 435/4; 435/23

ABSTRACT:

Compounds that inhibit ubiquitin-mediated proteolysis of phosphorylated I.kappa.B by interfering, directly or indirectly, with the ability of .beta.-TrCP/E3RS to engage in protein-protein association involving hnRNP-U, are useful as drugs for treating conditions associated with NF-.kappa.B activation. Cellular and non-cellular screening methods for identifying such compounds are based on monitoring the association/dissociation of .beta.-TrCP/IE3RS.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 12. Document ID: US 20030216369 A1

L13: Entry 12 of 51

File: PGPB

Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030216369
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030216369 A1

TITLE: Methods for treating cell proliferative disorders and viral infections

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rosen, Neal	Englewood	NJ	US	
Srethapakdi, Mary	Sukumvit		TH	

US-CL-CURRENT: 514/183

ABSTRACT:

The present invention concerns methods for treating cell proliferative diseases, tumors associated with viral infections, and certain viral infections. The disclosed methods use compounds which inhibit heat shock protein 90 proteins. Such methods block Rb negative or deficient cells in the G2/M phase of the cell cycle and rapidly causes their destruction.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 13. Document ID: US 20030211469 A1

L13: Entry 13 of 51

File: PGPB

Nov 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030211469
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030211469 A1

TITLE: Inhibiting hepatitis c virus processing and replication

PUBLICATION-DATE: November 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Waxman, Lloyd	Kintnersville	PA	US	

US-CL-CURRENT: 435/5; 514/183

ABSTRACT: .

The present invention features methods for inhibiting HCV replication and processing by targeting heat shock protein 90 (HSP90). HSP90 is a cellular chaperone protein that was found to be an essential factor in NS2/3 self-cleavage. HSP90 can be targeted using compounds inhibiting the ability of HSP90 to facilitate NS2/3 cleavage.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 14. Document ID: US 20030207856 A1

L13: Entry 14 of 51

File: PGPB

Nov 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030207856
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030207856 A1

TITLE: Medical devices and compositions for delivering anti-proliferatives to anatomical sites at risk for restenosis

PUBLICATION-DATE: November 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Tremble, Patrice	Santa Rosa	CA	US
Hendriks, Marc	Brunssum	CA	NL
Carlyle, Wenda	Silverado		US

US-CL-CURRENT: 514/183; 604/96.01

ABSTRACT:

Methods, compositions and devices for inhibiting restenosis are provided. Specifically, molecular chaperone inhibitor compositions and medical devices useful for the site specific delivery of molecular chaperones are disclosed. In one embodiment the medical device is a vascular stent coated with a molecular chaperone inhibitor selected from the group consisting of geldanamycin, herbimycin, macbecin and derivatives and analogues thereof. In another embodiment an injection catheter for delivery an anti-restenotic effective amount of geldanamycin to the adventitia is provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draws	Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-------	-----

☐ 15. Document ID: US 20030194409 A1

L13: Entry 15 of 51

File: PGPB

Oct 16, 2003

PGPUB-DOCUMENT-NUMBER: 20030194409

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030194409 A1

TITLE: Conjugate heat shock protein-binding peptides

PUBLICATION-DATE: October 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rothman, James E.	New York	NY	US	
Mayhew, Mark	Tarrytown	NY	US	
Hoe, Mee H.	New York	NY	US	
Houghton, Alan	New York	NY	US	
Hartl, Ulrich	Munich	NY	DE	
Ouerfelli, Ouathek	New York	NY	US	
Moroi, Yoichi	New York		US	

US-CL-CURRENT: 424/178.1; 435/7.1, 514/183, 530/391.1

ABSTRACT:

The present invention relates (i) to conjugate peptides engineered to noncovalently bind to heat shock proteins; (ii) to compositions comprising such conjugate peptides, optionally bound to heat shock protein; and (iii) to methods of using such compositions to induce an immune response in a subject in need of such treatment. It is based, at least in part, on the discovery of tethering molecules which may be used to non-covalently link antigenic peptides to heat shock proteins. The present invention also provides for methods of identifying additional tethers which may be comprised, together with antigenic sequences, in conjugate peptides.

☐ 16. Document ID: US 20030166530 A1

L13: Entry 16 of 51

File: PGPB

Sep 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030166530
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030166530 A1

TITLE: Conjugate heat shock protein-binding peptides

PUBLICATION-DATE: September 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rothman, James E.	New York	NY	US	
Mayhew, Mark	Tarrytown	NY	US	
Hoe, Mee H.	New York	NY	US	
Houghton, Alan	New York	NY	US	
Hartl, Ulrich	Munich	NY	DE	
Ouerfelli, Ouathak	New York	NY	US	
Moroi, Yoichi	New York		US	

US-CL-CURRENT: 514/12; 435/5, 435/7.1, 514/34, 514/45, 530/350

ABSTRACT:

The present related (i) to conjugate peptides engineered to noncovalently bind to heat shock proteins; (ii) to compositions comprising such conjugate peptides, optionally bound to heat shock protein; and (iii) to methods of using such compositions to induce an immune response in a subject in need of such treatment. It is based, at least in part, on the discovery of tethering molecules which may be used to non-covalently link antigenic peptides to heat shock proteins. The present invention also provides for methods of identifying additional tethers which may be comprised, together with antigenic sequences, in conjugate peptides.

☐ 17. Document ID: US 20030158105 A1

L13: Entry 17 of 51

File: PGPB

Aug 21, 2003

PGPUB-DOCUMENT-NUMBER: 20030158105
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20030158105 A1

TITLE: Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571

PUBLICATION-DATE: August 21, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Sawyers, Charles L.	Los Angeles	CA	US
Gorre, Mercedes E.	Los Angeles	CA	US
Shah, Neil Pravin	Woodland Hills	CA	US
Nicoll, John	Los Angeles	CA	US

US-CL-CURRENT: 514/12; 435/194, 435/6, 435/7.23

ABSTRACT:

The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw	Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------	-----

☐ 18. Document ID: US 20030148456 A1

L13: Entry 18 of 51

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148456

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030148456 A1

TITLE: Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mizzen, Lee A.	Victoria		CA	
Chu, N. Randall	Victoria		CA	
Wu, Huacheng Bill	Victoria		CA	

US-CL-CURRENT: 435/69.1; 424/204.1, 435/6

ABSTRACT:

The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression vector can be introduced into cells of a subject, or it can be used to transduce cells of the subject ex vivo, resulting in the expression of an HPV protein antigen-stress protein fusion protein that will stimulate the subject's immune response to the HPV protein

antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates and to expression vectors encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 19. Document ID: US 20030134787 A1

L13: Entry 19 of 51

File: PGPB

Jul 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030134787

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030134787 A1

TITLE: Conjugate heat shock protein-binding peptides

PUBLICATION-DATE: July 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Rothman, James E.	New York	NY	US	
Mayhew, Mark	Tarrytown	NY	US	
Hoe, Mee H.	New York	NY	US	
Houghton, Alan	New York	NY	US	
Hartl, Ulrich	Munich	NY	DE	
Ouerfelli, Ouathek	New York	NY	US	
Moroi, Yoichi	New York		US	

US-CL-CURRENT: 514/12; 435/5, 435/7.1

ABSTRACT:

The present invention relates (i) to conjugate peptides engineered to noncovalently bind to heat shock proteins; (ii) to compositions comprising such conjugate peptides, optionally bound to heat shock protein; and (iii) to methods of using such compositions to induce an immune response in a subject in need of such treatment. It is based, at least in part, on the discovery of tethering molecules which may be used to non-covalently link antigenic peptides to heat shock proteins. The present invention also provides for methods of identifying additional tethers which may be comprised, together with antigenic sequences, in conjugate peptides.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 20. Document ID: US 20030114450 A1

L13: Entry 20 of 51

File: PGPB

Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030114450

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030114450 A1

TITLE: Benzoquinone ansamycins

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Santi, Daniel	San Francisco	CA	US	
Myles, David C.	Kensington	CA	US	
Tian, Zong-Qiang	Fremont	CA	US	
Hutchinson, C. Richard	San Mateo	CA	US	
Johnson, Robert	Lafayette	CA	US	
Zhou, Yi-Qing	Lafayette	CA	US	
Feng, Li	Fremont	CA	US	

US-CL-CURRENT: 514/234.5; 514/252.13, 514/320, 514/337, 514/397, 540/456

ABSTRACT:

The invention relates to benzoquinone ansamycin analogs useful for the treatment of cancer and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation. Therapies involving the administration of such benzoquinone ansamycin analogs, optionally in combination with an inhibitor of an HSP90 client protein, are useful to treat cancer and non-cancerous disease conditions.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 21. Document ID: US 20030073218 A1

L13: Entry 21 of 51

File: PGPB

Apr 17, 2003

PGPUB-DOCUMENT-NUMBER: 20030073218
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030073218 A1

TITLE: High affinity inhibitors for target validation and uses thereof

PUBLICATION-DATE: April 17, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shokat, Kevan M.	San Francisco	CA	US	

US-CL-CURRENT: 435/184; 424/94.1

ABSTRACT:

This invention provides general methods for discovering mutant inhibitors for any class of enzymes as well as the specific inhibitors so identified. More specifically, this invention provides general methods for discovering specific inhibitors for multi-substrate enzymes. Examples of such multi-substrate enzymes include, but are

not limited to, kinases and transferases. The mutant inhibitors identified by the methods of this invention can be used to highly selectively disrupt cell functions such as oncogenic transformation. In one particular example, this invention provides a Src protein kinase inhibitor, pharmaceutical compositions thereof and methods of disrupting transformation in a cell that expresses the target v-src comprising contacting the cell with the protein kinase inhibitor.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 22. Document ID: US 20030050469 A1

L13: Entry 22 of 51

File: PGPB

Mar 13, 2003

PGPUB-DOCUMENT-NUMBER: 20030050469

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030050469 A1

TITLE: Induction of a Th1-like response in vitro

PUBLICATION-DATE: March 13, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Siegel, Marvin	Blue Bell	PA	US	
Chu, N. Randall	Victoria		CA	
Mizzen, Lee A.	Victoria		CA	

US-CL-CURRENT: 536/23.72; 424/185.1, 424/192.1, 424/204.1, 424/248.1, 435/320.1, 435/5, 435/7.1, 435/7.21, 435/7.23, 435/7.24, 530/350, 530/403, 536/23.4, 536/23.7

ABSTRACT:

The invention provides compositions and methods for stimulating a Th1-like response in vitro. Compositions include fusion proteins and conjugates that contain at least a portion of a heat shock protein. A Th1-like response can be elicited by contacting in vitro a cell sample containing naive lymphocytes with a fusion protein or conjugate of the invention. The Th1-like response can be detected by measuring IFN-gamma produced by the cell sample.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 23. Document ID: US 20030028927 A1

L13: Entry 23 of 51

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030028927

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030028927 A1

TITLE: Methods and compositions for revealing hidden genetic variation in plants

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lindquist, Susan	Chicago	IL	US	
Queitsch, Christine	North Cambridge	MA	US	
Sangster, Todd A.	Chicago	IL	US	

US-CL-CURRENT: 800/289; 435/6

ABSTRACT:

The present invention regards a method of unmasking or revealing genetic variation in eukaryotic organisms, such as plants, to eukaryotic organisms, particularly plants, produced by the method, and eukaryotic organisms, particularly plants, that exhibit a phenotype (phenotype trait) masked by Hsp90 function (activity). Specifically, the present invention is directed to the detecting genetic variation in a plant by interfering with the Hsp90 buffer system. More specifically, endogenous Hsp90 activity is inhibited by drugs or genetic manipulation that results in the manifestation of pre-existing yet otherwise undetected genetic variations, such as polymorphisms.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMBO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 24. Document ID: US 20030008349 A1

L13: Entry 24 of 51

File: PGPB

Jan 9, 2003

PGPUB-DOCUMENT-NUMBER: 20030008349

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030008349 A1

TITLE: Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress

PUBLICATION-DATE: January 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Voellmy, Richard	Miami	FL	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 536/23.2

ABSTRACT:

The exposure of cells, tissues and organs to "stress," such as elevated temperature, stimulates production of active heat stress transcription factors (HSF), which in turn, induce expression of genes regulated by stress promoters. Normally, the activity of stress promoters declines after cells, tissues and organs are returned to a normal condition. Mutant forms of HSF, however, can constitutively transactivate stress genes, in the absence of stress. By taking advantage of such mutant HSF, molecular circuits can be devised to provide a sustained expression of a gene of interest using a single application of stress. One form of molecular circuit comprises (a) a first nucleic acid molecule that comprises a gene encoding a transcription factor and a promoter activatable by stress and by the transcription factor, wherein the stress-activatable promoter and the transcription factor gene are operably linked, and (b) a second nucleic acid molecule that comprises a gene of interest and a second promoter activatable by the transcription factor, wherein the

second promoter and the gene of interest are operably linked.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 25. Document ID: US 20020146797 A1

L13: Entry 25 of 51

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020146797

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020146797 A1

TITLE: Engineered protein kinases which can utilize modified nucleotide triphosphate substrates

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shokat, Kevan M.	San Francisco	CA	US	

US-CL-CURRENT: 435/194; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The invention relates to methods for designing inhibitors of serine/threonine kinases and tyrosine kinases, particularly MAP kinases, through the use of ATP-binding site mutants of those kinases. The methods of this invention take advantage of the fact that the mutant kinases are capable of binding inhibitory compounds of other kinases with greater affinity than the corresponding wild-type kinase. The invention further relates to the mutant kinases themselves and crystallizable co-complexes of the mutant kinase and the inhibitory compound.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 26. Document ID: US 20020086015 A1

L13: Entry 26 of 51

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086015

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020086015 A1

TITLE: Compositions and methods for promoting nerve regeneration

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gold, Bruce G.	West Linn	OR	US	

US-CL-CURRENT: 424/145.1; 514/2, 514/34

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBPS52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 27. Document ID: US 20020076713 A1

L13: Entry 27 of 51

File: PGPB

Jun 20, 2002

PGPUB-DOCUMENT-NUMBER: 20020076713

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020076713 A1

TITLE: Mutant Plk protein and gene encoding the same

PUBLICATION-DATE: June 20, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Osada, Hiroyuki	Niiza-shi		JP	
Simizu, Siro	Tokorozawa-shi		JP	

US-CL-CURRENT: 435/6; 435/226, 435/7.23, 536/23.2

ABSTRACT:

A mutant Plk protein having a mutation in C-terminal domain thereof specified by amino acid residues of from 439 to 603 of amino acid sequence of wild-type Plk protein wherein said mutation decreases affinity with Hsp90 protein, and a gene encoding said mutant Plk protein are provided. A method for detecting an abnormal cell which comprises the step of detecting the mutant Plk protein or the gene encoding the protein is also provided.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 28. Document ID: US 20020016976 A1

L13: Entry 28 of 51

File: PGPB

Feb 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020016976

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020016976 A1

TITLE: Engineered protein kinases which can utilize modified nucleotide triphosphate substrates

PUBLICATION-DATE: February 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shokat, Kevan M.	San Francisco	CA	US	

US-CL-CURRENT: 800/8; 424/94.5, 435/15, 435/194, 536/23.2

ABSTRACT:

Engineered protein kinases which can utilize modified nucleotide triphosphate substrates that are not as readily utilized by the wild-type forms of those enzymes, and methods of making and using them. Modified nucleotide triphosphate substrates and methods of making and using them. Methods for using such engineered kinases and such modified substrates to identify which protein substrates the kinases act upon, to measure the extent of such action, and to determine if test compounds can modulate such action. Also Engineered forms of multi-substrate enzymes which covalently attach part or all of at least one (donor) substrate to at least one other (recipient) substrate, which engineered forms will accept modified substrates that are not as readily utilized by the wild-type forms of those enzymes. Methods for making and using such engineered enzymes. Modified substrates and methods of making and using them. Methods for using such engineered enzymes and such modified substrates to identify the recipient substrates the enzymes act upon, to measure the extent of such action, and to measure whether test compounds modulate such action.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FORM	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 29. Document ID: US 20020001629 A1

L13: Entry 29 of 51

File: PGPB

Jan 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020001629

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020001629 A1

TITLE: Compositions and methods relating to prevention of chemotherapy-induced alopecia

PUBLICATION-DATE: January 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Voellmy, Richard W.	Miami	FL	US	

US-CL-CURRENT: 424/620; 424/642, 424/650, 514/2, 514/44, 514/690

ABSTRACT:

The present invention relates to a method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal an effective amount of a composition comprising a chemical inducer of the stress protein response sufficiently prior to the administration of a chemotherapeutic drug. It also relates to pharmaceutical compositions for the prevention of chemotherapy-induced alopecia. It further relates to a method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the

animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal an effective heat dose sufficiently prior to the administration of a chemotherapeutic drug.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FWMC	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 30. Document ID: US 6734211 B1

L13: Entry 30 of 51

File: USPT

May 11, 2004

US-PAT-NO: 6734211

DOCUMENT-IDENTIFIER: US 6734211 B1

TITLE: Compositions and methods for promoting nerve regeneration

DATE-ISSUED: May 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 514/513

ABSTRACT:

Neurite outgrowth and nerve regeneration are promoted by disruption of the steroid receptor complex and stimulation of MAP kinase/kinase activity. This disruption can take the form of disruption of the physical assembly or function of the steroid receptor complex, such as the mature complex or a precursor of the mature complex that is required for assembly of the mature complex. Geldanamycin and its analogs, bastadin and members of the bastadin family, and radicicol and its analogs, as well as FKBP-52 antibody, are shown to disrupt the complex and promote nerve growth. Assays for finding neurotrophic compounds, as well as compounds found by these assays, pharmaceutical compositions into which they are incorporated, and methods of treating subjects having neuronal dysfunction caused by injury or disease are disclosed. Any of these compounds can be used in combination with a therapeutically effective amount of heat, such as heat applied locally to an area where nerve growth is desired, or systemically in an organism in which neurite growth is desired. Alternatively, these compounds can be used in association with a template, such as a tubular member that defines an anatomic pathway along which nerve regeneration is desired (particularly around a transected or partially transected nerve).

13 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FWMC	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	-------------

☐ 31. Document ID: US 6670348 B1

L13: Entry 31 of 51

File: USPT

Dec 30, 2003

US-PAT-NO: 6670348

DOCUMENT-IDENTIFIER: US 6670348 B1

TITLE: Methods and compositions for destruction of selected proteins

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rosen; Neal	Englewood	NJ		
Danishefsky; Samuel	Englewood	NY		
Ouerfelli; Ouathek	New York	NY		
Kuduk; Scott D.	Harleysville	PA		
Sepp-Lorenzino; Laura	New Haven	CT		

US-CL-CURRENT: 514/176; 514/182, 514/183, 514/26, 514/27, 514/450, 536/6.4, 540/107, 540/109, 540/112, 540/113, 540/115 , 540/2, 540/461, 549/268, 552/502, 552/625, 552/638

ABSTRACT:

Compounds having an ansamycin anitibiotic, or other moiety which binds to hsp90, coupled to a targeting moiety which binds specifically to a protein, receptor or marker can provide effective targeted delivery of the ansamycin antibiotic leading to the degradation of proteins and death of the targeted cells. These compositions may have different specificity than the ansamycin alone, allowing for a more specific targeting of the therapy, and can be effective in instances where the ansamycin alone has no effect. Thus, these compounds provide an entirely new class of targeted chemotherapy agents with application, depending on the nature of the targeting moiety, to treatment of a variety of different forms of cancer. Such agents can further be used to promote selective degradation of proteins associated with the pathogenesis of others diseases, including antigens associated with autoimmune disorders and pathogenic proteins associated with Alzheimer's disease. Exemplary targeting moieties which may be employed in compounds of the invention include testosterone, estradiol, tamoxifen and wortmannin.

40 Claims, 20 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	RMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 32. Document ID: US 6670187 B2

L13: Entry 32 of 51

File: USPT

Dec 30, 2003

US-PAT-NO: 6670187

DOCUMENT-IDENTIFIER: US 6670187 B2

TITLE: Mutant Plk protein and gene encoding the same

DATE-ISSUED: December 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Osada; Hiroyuki	Niiza			JP
Simizu; Siro	Tokorozawa			JP

US-CL-CURRENT: 435/455; 435/194, 530/350, 536/23.2, 536/23.5

ABSTRACT:

A mutant Plk protein having a mutation in C-terminal domain thereof specified by amino acid residues of from 439 to 603 of amino acid sequence of wild-type Plk protein wherein said mutation decreases affinity with Hsp90 protein, and a gene encoding said mutant Plk protein are provided. A method for detecting an abnormal cell which comprises the step of detecting the mutant Plk protein or the gene encoding the protein is also provided.

7 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 33. Document ID: US 6657055 B2

L13: Entry 33 of 51

File: USPT

Dec 2, 2003

US-PAT-NO: 6657055

DOCUMENT-IDENTIFIER: US 6657055 B2

**** See image for Certificate of Correction ****

TITLE: Induction of a Th1-like response in vitro

DATE-ISSUED: December 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Siegel; Marvin	Blue Bell	PA		
Chu; N. Randall	Victoria			CA
Mizzen; Lee A.	Victoria			CA

US-CL-CURRENT: 536/23.72; 435/69.7

ABSTRACT:

The invention provides compositions and methods for stimulating a Th1-like response in vitro. Compositions include fusion proteins and conjugates that contain at least a portion of a heat shock protein. A Th1-like response can be elicited by contacting in vitro a cell sample containing naive lymphocytes with a fusion protein or conjugate of the invention. The Th1-like response can be detected by measuring IFN-gamma produced by the cell sample.

54 Claims, 37 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 37

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 34. Document ID: US 6653469 B1

US-PAT-NO: 6653469

DOCUMENT-IDENTIFIER: US 6653469 B1

TITLE: Antibiotic purification method

DATE-ISSUED: November 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mangena; Murty	Lexington	KY		

US-CL-CURRENT: 540/468; 585/800

ABSTRACT:

Taught is a process for purifying a benzoquinoid ansamycin antibiotic such as geldanamycin through the use of a fluid comprising supercritical carbon dioxide. In certain embodiments the fluid also includes an aliphatic alcohol such as methanol or ethanol.

23 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	-----	----------

☐ 35. Document ID: US 6641810 B2

L13: Entry 35 of 51

File: USPT

Nov 4, 2003

US-PAT-NO: 6641810

DOCUMENT-IDENTIFIER: US 6641810 B2

**** See image for Certificate of Correction ****

TITLE: Methods of using geldanamycin and FK506 to treat peripheral nerve damage

DATE-ISSUED: November 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 424/145.1; 514/183, 514/330, 514/423, 514/428, 514/465, 514/466

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBPS52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

34 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 36. Document ID: US 6524825 B1

L13: Entry 36 of 51

File: USPT

Feb 25, 2003

US-PAT-NO: 6524825

DOCUMENT-IDENTIFIER: US 6524825 B1

**** See image for Certificate of Correction ****

TITLE: Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins

DATE-ISSUED: February 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mizzen; Lee A.	Victoria			CA
Chu; N. Randall	Victoria			CA
Wu; Huacheng Bill	Victoria			CA

US-CL-CURRENT: 435/69.7; 424/192.1, 424/9.34, 435/39, 435/5, 435/7.1

ABSTRACT:

The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression vector can be introduced into cells of a subject, or it can be used to transduce cells of the subject ex vivo, resulting in the expression of an HPV protein antigen-stress protein fusion protein that will stimulate the subject's immune response to the HPV protein antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates and to expression vectors encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.

100 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 37. Document ID: US 6521417 B1

L13: Entry 37 of 51

File: USPT

Feb 18, 2003

US-PAT-NO: 6521417

DOCUMENT-IDENTIFIER: US 6521417 B1

TITLE: Engineered protein kinases which can utilize modified nucleotide triphosphate substrates

DATE-ISSUED: February 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shokat; Kevan M.	San Francisco	CA		

US-CL-CURRENT: 435/15; 435/194

ABSTRACT:

Engineered protein kinases which can utilize modified nucleotide triphosphate substrates that are not as readily utilized by the wild-type forms of those enzymes, and methods of making and using them are disclosed. Modified nucleotide triphosphate substrates and methods of making and using them are disclosed. Methods are disclosed for using such engineered kinases and such modified substrates to identify which protein substrates the kinases act upon, to measure the extent of such action, and to determine if test compounds can modulate such action. Engineered forms of multi-substrate enzymes which covalently attach part or all of at least one (donor) substrate to at least one other (recipient) substrate, which engineered forms will accept modified substrates that are not as readily utilized by the wild-type forms of those enzymes are disclosed. Methods for making and using such engineered enzymes are disclosed. Modified substrates and methods of making and using them are disclosed. Methods are disclosed for using such engineered enzymes and such modified substrates to identify the recipient substrates the enzymes act upon, to measure the extent of such action, and to measure whether test compounds modulate such action.

8 Claims, 44 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 24

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	------------

☐ 38. Document ID: US 6495347 B1

L13: Entry 38 of 51

File: USPT

Dec 17, 2002

US-PAT-NO: 6495347

DOCUMENT-IDENTIFIER: US 6495347 B1

**** See image for Certificate of Correction ****

TITLE: Induction of a Th1-like response in vitro

DATE-ISSUED: December 17, 2002

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.14&ref=13&dbname=PGPB,USPT,U...> 11/16/04

NAME	CITY	STATE	ZIP CODE	COUNTRY
Siegel; Marvin	Blue Bell	PA		
Chu; N. Randall	Victoria			CA
Mizzen; Lee A.	Victoria			CA

US-CL-CURRENT: 435/69.7; 424/192.1

ABSTRACT:

The invention provides compositions and methods for stimulating a Th1-like response in vitro. Compositions include fusion proteins and conjugates that contain at least a portion of a heat shock protein. A Th1-like response can be elicited by contacting in vitro a cell sample containing naive lymphocytes with a fusion protein or conjugate of the invention. The Th1-like response can be detected by measuring IFN-gamma produced by the cell sample.

64 Claims, 39 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 37

Full	Title	Citation	Front	Review	Classification	Date	Reference	Publication	Patent	Claims	Kind	Draw. Des.

☐ 39. Document ID: US 6390821 B1

L13: Entry 39 of 51

File: USPT

May 21, 2002

US-PAT-NO: 6390821

DOCUMENT-IDENTIFIER: US 6390821 B1

TITLE: Engineered protein kinases which can utilize modified nucleotide triphosphate substrates

DATE-ISSUED: May 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shokat; Kevan M.	San Francisco	CA		

US-CL-CURRENT: 434/194; 536/23.2

ABSTRACT:

Engineered protein kinases which can utilize modified nucleotide triphosphate substrates that are not as readily utilized by the wild-type forms of those enzymes, and methods of making and using them. Modified nucleotide triphosphate substrates and methods of making and using them. Methods for using such engineered kinases and such modified substrates to identify which protein substrates the kinases act upon, to measure the extent of such action, and to determine if test compounds can modulate such action. Also engineered forms of multi-substrate enzymes which covalently attach part or all of at least one (donor) substrate to at least one other (recipient) substrate, which engineered forms will accept modified substrates that are not as readily utilized by the wild-type forms of those enzymes. Methods for making and using such engineered enzymes. Modified substrates and methods of making and using them. Methods for using such engineered enzymes and such modified substrates to identify the recipient substrates the enzymes act upon, to measure the extent of such action, and to measure whether test compounds modulate such action.

6 Claims, 41 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 24

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 40. Document ID: US 6383790 B1

L13: Entry 40 of 51

File: USPT

May 7, 2002

US-PAT-NO: 6383790
DOCUMENT-IDENTIFIER: US 6383790 B1

TITLE: High affinity protein kinase inhibitors

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shokat; Kevan M.	San Francisco	CA		

US-CL-CURRENT: 435/194; 435/184, 514/262.1, 544/262

ABSTRACT:

This invention provides general methods for discovering mutant inhibitors for any class of enzymes as well as the specific inhibitors so identified. More specifically, this invention provides general methods for discovering specific inhibitors for multi-substrate enzymes. Examples of such multi-substrate enzymes include, but are not limited to, kinases and transferases. The mutant inhibitors identified by the methods of this invention can be used to highly selectively disrupt cell functions such as oncogenic transformation. In one particular example, this invention provides a Src protein kinase inhibitor, pharmaceutical compositions thereof and methods of disrupting transformation in a cell that expresses the target v-src comprising contacting the cell with the protein kinase inhibitor.

60 Claims, 65 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 37

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 41. Document ID: US 6342596 B1

L13: Entry 41 of 51

File: USPT

Jan 29, 2002

US-PAT-NO: 6342596
DOCUMENT-IDENTIFIER: US 6342596 B1

TITLE: Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress

DATE-ISSUED: January 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Voellmy; Richard	Miami	FL		

US-CL-CURRENT: 536/24.1; 435/235.1, 435/252.3, 435/320.1, 435/455, 435/456, 435/69.1, 536/23.1

ABSTRACT:

The exposure of cells, tissues and organs to "stress," such as elevated temperature, stimulates production of active heat stress transcription factors (HSF), which in turn, induce expression of genes regulated by stress promoters. Normally, the activity of stress promoters declines after cells, tissues and organs are returned to a normal condition. Mutant forms of HSF, however, can constitutively transactivate stress genes, in the absence of stress. By taking advantage of such mutant HSF, molecular circuits can be devised to provide a sustained expression of a gene of interest using a single application of stress. One form of molecular circuit comprises (a) a first nucleic acid molecule that comprises a gene encoding a transcription factor and a promoter activatable by stress and by the transcription factor, wherein the stress-activatable promoter and the transcription factor gene are operably linked, and (b) a second nucleic acid molecule that comprises a gene of interest and a second promoter activatable by the transcription factor, wherein the second promoter and the gene of interest are operably linked.

36 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Footnote	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	----------	------------

☐ 42. Document ID: US 6210974 B1

L13: Entry 42 of 51

File: USPT

Apr 3, 2001

US-PAT-NO: 6210974

DOCUMENT-IDENTIFIER: US 6210974 B1

**** See image for Certificate of Correction ****

TITLE: Compositions and methods for promoting nerve regeneration

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 436/501; 436/34, 436/63, 436/86, 436/91

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

17 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 43. Document ID: US 6174875 B1

L13: Entry 43 of 51

File: USPT

Jan 16, 2001

US-PAT-NO: 6174875

DOCUMENT-IDENTIFIER: US 6174875 B1

**** See image for Certificate of Correction ****

TITLE: Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke

DATE-ISSUED: January 16, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
DeFranco; Donald B.	Pittsburgh	PA		
Callaway; Clifton W.	Pittsburgh	PA		
Lipinski; Christopher	Pittsburgh	PA		
Xiao; Nianqing	Pittsburgh	PA		

US-CL-CURRENT: 514/183

ABSTRACT:

The present invention provides a method of inhibiting oxidative-stress induced cell death in a cell comprising contacting the cell with a composition comprising a benzoquinoid ansamycin. The present invention further provides a method of reducing neurological injury resulting from cardiac arrest or stroke comprising administering to a patient a composition comprising a benzoquinoid ansamycin.

12 Claims, 6 Drawing figures
Exemplary Claim Number: 1,5
Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 44. Document ID: US 6121269 A

L13: Entry 44 of 51

File: USPT

Sep 19, 2000

US-PAT-NO: 6121269

DOCUMENT-IDENTIFIER: US 6121269 A

TITLE: Reduction of hair growth

DATE-ISSUED: September 19, 2000

INVENTOR-INFORMATION:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.14&ref=13&dbname=PGPB,USPT,U...> 11/16/04

NAME	CITY	STATE	ZIP CODE	COUNTRY
Henry; James P.	Myersville	MD	21773	
Ahluwalia; Gurpreet S.	Gaithersburg	MD	20852	

US-CL-CURRENT: 424/401; 514/295, 514/415, 514/520, 514/535, 514/567, 514/629

ABSTRACT:

Mammalian hair growth is reduced by applying to the skin an inhibitor of protein-tyrosine kinase.

46 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWMC	Draw Des

☐ 45. Document ID: US 6015659 A

L13: Entry 45 of 51

File: USPT

Jan 18, 2000

US-PAT-NO: 6015659

DOCUMENT-IDENTIFIER: US 6015659 A

**** See image for Certificate of Correction ****

TITLE: Inducement of thermotolerance with benzoquinonoid ansamycins

DATE-ISSUED: January 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Welch; William J.	San Francisco	CA		
Hegde; Ramanujan	San Francisco	CA		

US-CL-CURRENT: 435/1.2; 435/1.1, 514/187, 540/461

ABSTRACT:

Thermotolerant phenotypes are developed in cells, tissues, organs and organisms by the administration of benzoquinonoid ansamycins such as herbimycin A and any of various analogs. The general stress tolerance resulting from this inducement offers benefits in a variety of ways, including rendering surgical patients more able to withstand the rigors of surgery, prolonging the shelf life of organs excised from organ donors, and prolonging the viability of tissue-cultured cells and organs.

24 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWMC	Draw Des

☐ 46. Document ID: US 5968921 A

L13: Entry 46 of 51

File: USPT

Oct 19, 1999

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.14&ref=13&dbname=PGPB,USPT,U...> 11/16/04

US-PAT-NO: 5968921

DOCUMENT-IDENTIFIER: US 5968921 A

**** See image for Certificate of Correction ****

TITLE: Compositions and methods for promoting nerve regeneration

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 514/183; 514/330, 514/423, 514/428, 514/465, 514/466, 514/534,
514/547, 514/548, 514/549

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

36 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 47. Document ID: WO 3013430 A2

L13: Entry 47 of 51

File: EPAB

Feb 20, 2003

PUB-NO: WO003013430A2

DOCUMENT-IDENTIFIER: WO 3013430 A2

TITLE: BENZOQUINONE ANSAMYCINS

PUBN-DATE: February 20, 2003

INVENTOR-INFORMATION:

NAME	COUNTRY
SANTI, DANIEL	
MYLES, DAVID C	
TIAN, ZQ	
HUTCHINSON, C RICHARD	
JOHNSON, ROBERT	
ZHOU, YI-QING	
FENG, LI	

INT-CL (IPC): A61 K 0/

EUR-CL (EPC): C07D225/06; C07D491/08

ABSTRACT:

☐ 48. Document ID: US 20030194409 A1

L13: Entry 48 of 51

File: DWPI

Oct 16, 2003

DERWENT-ACC-NO: 2003-899769

DERWENT-WEEK: 200382

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Identification of a peptide binding to a heat shock protein involves contacting a phage display library of several bacteriophages expressing in a surface protein of inserted peptides with a target followed by isolation and identification

INVENTOR: HARTL, U; HOE, M H ; HOUGHTON, A ; MAYHEW, M ; MOROI, Y ; OUEFFELLI, O ; ROTHMAN, J E

PRIORITY-DATA: 2002US-0053498 (January 17, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030194409 A1	October 16, 2003		062	A61K039/395

INT-CL (IPC): A61 K 31/33; A61 K 39/395; C07 K 16/46; G01 N 33/53

ABSTRACTED-PUB-NO: US20030194409A

BASIC-ABSTRACT:

NOVELTY - Identification of a peptide binding to a heat shock protein (hsp) involves contacting a phage display library of several bacteriophage expressing in a surface protein of inserted peptides with a hsp target or hsp target bound to a benzoquinone ansamycin antibiotic in a physiologic binding buffer or binding buffer; isolating the phage; and identifying the inserted peptide expressed in the surface protein of the phage.

DETAILED DESCRIPTION - Identification (M1) a peptide which binds to a heat shock protein involves:

- (1) contacting a phage display library of several bacteriophage expressing in a surface protein of inserted peptides with a hsp target or hsp target bound to a benzoquinone ansamycin antibiotic in a physiologic binding buffer (b1) or binding buffer (b2);
- (2) isolating the phage, binds to the hsp target; and
- (3) identifying the inserted peptide expressed in the surface protein of the phage.

INDEPENDENT CLAIMS are included for following:

- (a) a conjugate peptide (c1) comprising a tether which comprises a peptide identified by (M1) and an antigenic peptide;
- (b) a conjugate peptide (c2) comprising an antigenic peptide and a benzaquinone ansamycin antibiotic;
- (c) induction of an immune response in a subject involving administering (c1) bound to a heat shock protein or (c2); and

(d) induction of immune response in a subject involving administering a composition comprising a conjugate peptide which comprises a portion which may be bound to a heat shock protein under physiologic conditions and a portion which is antigenic (where a heat shock protein is not concurrently administered with the conjugate peptide).

ACTIVITY - Antibacterial; Virucide; Protozoacide; Fungicide; Antiparasite; Hepatotropic; Antiinflammatory; Antimalarial; Cytostatic; Anti-HIV; Immunosuppressive; Antirheumatic; Antiarthritic; Dermatological; Antidiabetic; Antithyroid; Neuroprotective.

MECHANISM OF ACTION - Immune response inducer; Vaccine. An in vivo tumor progression in vivo assay was carried out as follows: C57BL/6 mice, 8 - 10 weeks old, were immunized intradermally with one of the following (eight mice in each group): a) TiterMax (5 micro liter) and OVA peptide (Ser Ile Ile Asn Phe Glu Lys Leu) (5 micro gram); b) hsp70 (15 micro gram) and OVA peptide (5 micro gram); c) TiterMax (5 micro liter) and (OVA-BiP) (Ser Ile Ile Asn Phe Glu Lys Leu Gly Ser Gly His Trp Asp Phe Ala Trp Pro Trp) (12 micro liter); d) hsp70 (15 micro gram) and OVA-BiP (12 micro gram); e) control (four animals only in this group); f) OVA peptide (5 micro gram) or g) OVA-BiP (12 micro gram). The mice then were injected with 4 multiply 10 to the power of 6 EG7 cells. Tumor size was evaluated over time by measuring two diameters, the greatest diameter and the diameter perpendicular to the greatest diameter, and then calculating the average diameter. The results showed that: when the patient was administered with TiterMax adjuvant, OVA-BiP was superior to OVA peptide in reducing tumor diameter and in preventing detectable tumor formation altogether. Further, tumor size in mice immunized with hsp70 and OVA-BiP was less then in mice immunized with hsp70 and OVA-peptide. In mice receiving peptide alone (without TiterMax or hsp70), while no animals were tumor free when OVA-peptide was the sole immunogen. 2/8 Animals immunized with OVA-BiP were tumor-free and the average tumor diameters were smaller. It was therefore appeared that the conjugate peptide associated with hsp70 was more effective than the antigenic peptide alone at preventing or reducing tumor formation in vivo.

USE - For identifying a peptide, which binds to a heat shock protein, which is used in conjugate peptide; for inducing an immune response (claimed); for the treatment of an infectious diseases (e.g. diseases caused by a bacterium, virus, protozoan, mycoplasma, fungus, yeast, parasite or prion such as human papilloma virus, herpes virus such as herpes simplex or herpes zoster; retrovirus such as human immunodeficiency virus 1 or 2, hepatitis virus, an influenza virus, rhinovirus, respiratory syncytial virus, cytomegalovirus, an adenovirus, Mycoplasma pneumoniae, bacterium of the genus Salmonella, Staphylococcus, Streptococcus, Enterococcus, Clostridium, Escherichia, Klebsiella, Vibrio or mycobacterium, or protozoan such as an amoeba, malarial parasite or Trypanosoma cruzi) or malignant disease; for treating or preventing neoplastic disease (e.g. sarcoma, lymphoma, leukemia, melanoma, carcinoma of the breast, carcinoma of the prostate, ovarian carcinoma, carcinoma of the cervix, uterine carcinoma, colon carcinoma, carcinoma of the lung, glioblastoma, and astrocytoma) or immunologic disease or disorder (e.g. AIDS, ARC and impairment of immunity associated with various cancers); for treating autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, diabetes mellitus, thyroiditis, and multiple sclerosis.

ADVANTAGE - The method uses filamentous phage expression library panning, and provides improvements over prior art phage panning protocols; stimulate conditions found in the native cellular location for peptide/heat shock protein binding; uses compounds which facilitate the binding of peptide to heat shock protein, such as ansamycin antibiotics and isolate regions of heat shock protein which are associated with peptide binding and use the isolated regions as the substrate in the phage panning protocol. The conjugate peptide induces the immune response. The identified peptide is used in conjugate peptide to noncovalently link antigen with the heat shock proteins hsp90 or gp96.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

DERWENT-ACC-NO: 2003-829433

DERWENT-WEEK: 200407

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New benzoquinone ansamycin-derived compound, useful for treating cancer, and other diseases or conditions characterized by undesired cellular proliferation or hyperproliferation e.g., psoriasis, stenosis, and restenosis

INVENTOR: FENG, L; HUTCHINSON, C R ; JOHNSON, R ; MYLES, D C ; SANTI, D ; TIAN, Z ; ZHOU, Y

PRIORITY-DATA: 2002US-0212962 (August 5, 2002), 2001US-310079P (August 6, 2001), 2002US-389255P (June 14, 2002), 2002US-393929P (July 3, 2002), 2002US-395275P (July 12, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US 20030114450 A1	June 19, 2003		036	A61K031/5377

INT-CL (IPC): A61 K 31/4178; A61 K 31/443; A61 K 31/454; A61 K 31/496; A61 K 31/5377; C07 D 267/22

ABSTRACTED-PUB-NO: US20030114450A

BASIC-ABSTRACT:

NOVELTY - Benzoquinone ansamycin-derived compounds (I), are new.

DETAILED DESCRIPTION - Benzoquinone ansamycin-derived compounds of formula (I), their salts and prod

rugs, are new.

R1 = MeO, (CH₂)₃N or R⁹-NH;

R⁹ = H, 1-6C alkyl, 1-6C alkenyl, 1-6C alkynyl, 3-6C cycloalkyl, piperidinyl, N-alkylpiperidinyl, hexahydropyranyl, furfuryl, tetrahydrofurfuryl, pyrrolidinyl, N-alkylpyrrolidinyl, piperazinylamino, N-alkylpiperazinyl, morpholinyl, N-alkylaziridinylmethyl, (1-azabicyclo(1.3.0)hex-1-yl)ethyl, 2-(N-methyl-pyrrolidin-2-yl)ethyl, 2-(4-imidazolyl)ethyl, 2-(1-methyl-4-imidazolyl-)ethyl, 2-(1-methyl-5-imidazolyl)ethyl, 2-(4-pyridyl)ethyl, and 3-(4-morpholino)-1-propyl;

R2 = H, halo, OR₁₀, NHR₁₀, SR₁₀, aryl, or heteroaryl;

R₁₀ = 1-6C alkyl, 1-6C alkenyl, 1-6C alkynyl, or 3-6C cycloalkyl;

R3 = H, OH, or OMe;

R4 = H or Me;

R5 = OH or OC(O)-CH₂NH₂;

R6 = H; and

R1+R5 = NH-Z-O; or

R5+R6 = =O or =N-OR₁₁;

Z = a linker comprising 1-6 C atoms and 0-2 N atoms, where O is attached at the position of R5;

R11 = H, 1-6C alkyl, 1-6C alkenyl, 1-6C alkynyl, 3-6C cycloalkyl, aryl, or heteroaryl;

R7 = H;

R8 = H or OH; or

R7+R8 = a bond; and

X = O or a bond;

provided that:

(i) when R3 = H, R4 = Me, R7 = H and R8 = H or R7+R8 = a bond, then either R6 = H and R1+R5 = NH-Z-O, or R1 = (CH2)3N or R9-NH and R9 = piperidinyl, N-alkylpiperidinyl, hexahydropyranyl, furfuryl, tetrahydrofurfuryl, pyrrolidinyl, N-alkylpyrrolidinyl, piperazinylamino, N-alkylpiperazinyl, morpholinyl, N-alkylaziridinylmethyl, (1-azabicyclo(1.3.0)hex-1-yl-)ethyl, 2-(N-methyl-pyrrolidin-2-yl)ethyl, 2-(4-imidazolyl)ethyl, 2-(1-methyl-4-imidazolyl)ethyl, and 3-(4-morpholino)-1-propyl; and

(ii) when R3 = H and R4 = Me, then R7 = H and R8 = OH.

An INDEPENDENT CLAIM is also included for treating a disease or condition characterized by undesired cellular proliferation or hyperproliferation in a subject involving:

(a) administering to the subject a substantially sub-toxic dose of an Hsp90 client protein inhibitor, waiting a period of time sufficient to allow development of a substantially efficacious response, and administering to the subject a synergistic dose of a benzoquinone ansamycin; or

(b) administering to the subject a synergistic dose of a benzoquinone ansamycin, waiting a period of time sufficient to allow development of a substantially efficacious response, and administering to the subject a sub-toxic dose of an Hsp90 client protein inhibitor.

ACTIVITY - Cytostatic; Vasotropic; Nootropic; Neuroprotective; Anticonvulsant; Antipsoriatic; Antiparkinsonian.

SKBr3 and H358 cells lines were obtained from American Type Culture Collection. Cells were maintained in McCoy's 5A medium with 10 % fetal bovine serum. Cells were selected in duplicate in opaque-walled 96-well micro t plates at 4000 cells per well and allowed to attach overnight. Serial dilutions of each drug were added, and the cells were incubated for 72 hours. The IC50 was determined. For the drug combination assay, cells were seeded in duplicate in 96-well plates (4000 cells/well). After an overnight incubation, cells were treated with drug alone or in combination. Based on the IC50 values of each individual drug, combined drug treatment was designed at constant ratios of two drugs, i.e., equivalent to the ratio of their IC50. Three different treatment schedules were used. The first treatment schedule used simultaneous exposure to both 17-AAG and the second cytotoxic agent for 72 hours. In the second schedule, the cells were exposed to 24 hours of 17-allylamino-17-desmethoxygeldanamycin (17-AAG) or 17-(2-(dimethylamino)ethylamino)-17-desmethoxygeldanamycin (17-DMAG). The second cytotoxic agent was then added to the cells and incubated for 48 hours. In the third treatment schedule, cells were exposed to the second cytotoxic agent alone for 24 hours followed by addition of 17-AAG or 17-DMAG for 48 hours. Cell viability was determined by luminescent assay. Combination analysis was performed using CalcuSyn software. The combination index (CI) refers to a measure of the additivity of the effects of two drugs administered in combination. Addition of 17-AAG or 17-DMAG to cell after exposure to Iressa (a protein kinase

inhibitor) synergistically increased the cytotoxicity of Iressa. An additive effect was detected when cells were exposed to 17-AAG or 17-DMAG before Iressa. Exposure of cells to 17-AAG or 17-DMAG and Iressa simultaneously also produced an additive effect. In contrast, addition of 17-AAG or 17-DMAG to cells after exposure to paclitaxel additively increased the cytotoxicity of paclitaxel. A synergistic effect was observed when cells were exposed to paclitaxel first, and were later treated with 17-AAG or 17-DMAG.

MECHANISM OF ACTION - None given.

USE - (I) Is useful for treating a disease or condition characterized by undesired cellular proliferation or hyperproliferation e.g. cancer. (claimed). (I) Is also useful for treating non-cancerous diseases such as stenosis or restenosis, psoriasis, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease etc., and is useful at sub-cytotoxic levels in combination with other agents in order to achieve highly selective activity in the treatment of non-cancerous diseases. The compounds are useful for reducing a cellular levels of Hsp90 client proteins which are then effectively inhibited by the second agent.

ADVANTAGE - Use of the benzoquinone ansamycin allows for use of a lower therapeutic dose of the second agent, thus significantly widening the therapeutic window for treatment. The therapeutic dose of the second agent is lowered by at least 10 %.

DESCRIPTION OF DRAWING(S) - The figure shows the results of treating H358 cells with 17-allylamino-17-desmethoxygeldanamycin and the microtubule stabilizing agent paclitaxel.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 50. Document ID: AU 2002330998 A1, WO 2003013430 A2, EP 1420747 A2

L13: Entry 50 of 51

File: DWPI

Feb 24, 2003

DERWENT-ACC-NO: 2003-440986

DERWENT-WEEK: 200460

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New benzoquinone ansamycin derivatives, useful with other cytostatic drugs in the synergistic treatment of cancer

INVENTOR: FENG, L; HUTCHINSON, C R ; JOHNSON, R ; MYLES, D C ; SANTI, D ; TIAN, Z ; ZHOU, Y

PRIORITY-DATA: 2002US-395275P (July 12, 2002), 2001US-310079P (August 6, 2001), 2002US-389255P (June 14, 2002), 2002US-393929P (July 3, 2002)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2002330998 A1	February 24, 2003		000	A61K000/00
WO 2003013430 A2	February 20, 2003	E	077	A61K000/00
EP 1420747 A2	May 26, 2004	E	000	A61K006/00

INT-CL (IPC): A61 K 0/00; A61 K 6/00

ABSTRACTED-PUB-NO: WO2003013430A

BASIC-ABSTRACT:

NOVELTY - Benzoquinone ansamycin derivatives and their salts and prodrugs are new.

DETAILED DESCRIPTION - Benzoquinone ansamycin derivatives of formula (I) and their salts and prodrugs are new.

R1 = MeO, (CH₂)₃N or R₉NH; or

R₉ = H, optionally substituted 1-6C alkyl, optionally substituted 1-6C alkenyl, optionally substituted 1-6C alkynyl, optionally substituted 3-6C cycloalkyl, piperidinyl, N-alkylpiperidinyl, hexahydropyranyl, furfuryl, tetrahydrofurfuryl, pyrrolidinyl, N-alkylpyrrolidinyl, piperazinylamino, N-alkylpiperazinyl, morpholinyl, N-alkylaziridinylmethyl, (1-azabicyclo(1.3.0)hex-1-yl)-ethyl (sic), 2-(N-methylpyrrolidin-2-yl)-methyl, 2-(4-imidazolyl)-ethyl, 2-(1-methyl-4-imidazolyl)-ethyl, 2-(1-methyl-5-imidazolyl)-ethyl, 2-(4-pyridyl)-ethyl or 3-(4-morpholino)-1-propyl;

Z = linker comprising 1-6 C-atoms and 0-2 N-atoms;

R₂ = H, halo, OR₁₀, NHR₁₀, SR₁₀, aryl or heteroaryl;

R₁₀ = optionally substituted 1-6C alkyl, optionally substituted 1-6C alkenyl, optionally substituted 1-6C alkynyl or optionally substituted 3-6C cycloalkyl;

R₃ = H, OH or OMe;

R₄ = H or CH₃;

R₅ = OH or OCOCH₂NH₂;

R₆ = H; or

R₅+R₆ = =O or =NOR₁₁; or

R₆ = H; and

R₁+R₅ = NH-Z-O;

R₁₁ = H, optionally substituted 1-6C alkyl, optionally substituted 1-6C alkenyl, optionally substituted 1-6C alkynyl, optionally substituted 3-6C cycloalkyl, aryl or heteroaryl;

R₇ = H; and

R₈ = H; or

R₇+R₈ = a bond;

provided that:

(i) when R₃ = H, R₄ = CH₃ and R₇, R₈ = H or bond, then R₆ = H and R₁+R₅ = NH-Z-O, or R₁ = (CH₂)₃N or R₉NH; and

(ii) when R₃ = H and R₄ = CH₃, then R₇ = H and R₈ = OH.

INDEPENDENT CLAIMS are also included for:

(1) a method for treating diseases characterized by undesired cellular proliferation or hyperproliferation comprising administration of (I);

(2) a method for treating diseases characterized by undesired cellular proliferation or hyperproliferation comprising administration of an Hsp90 client protein inhibitor, waiting for an efficacious response and administration of a synergistic dose of a benzoquinone ansamycin derivative;

(3) a method for treating diseases characterized by undesired cellular proliferation

or hyperproliferation comprising administration of a benzoquinone ansamycin derivative, waiting for an efficacious response and administration of a synergistic dose of an Hsp90 client protein inhibitor; and

(4) a method for treating diseases characterized by undesired cellular proliferation or hyperproliferation comprising administration of a combination of the novel composition with a cytotoxic drug (5-fluorouracil, methotrexate, vinblastine, cyclophosphamide, mechlorethamine, chlorambucil, melphalan, ifosfamide, bleomycin, mitomycin or doxorubicin).

ACTIVITY - Cytostatic.

SKBr3 and H358 cells were exposed to Iressa for 24 hours and then 17-allylamino-17-desmethoxy-geldanamycin (Ia) was added for 48 hours. The combined index was reduced to 0.6, indicating synergistic activity. Simultaneous administration of initial administration of (Ia) gave no synergistic effect.

MECHANISM OF ACTION - None given.

USE - (I) Are useful for treating diseases characterized by undesired cellular proliferation or hyperproliferation, especially cancer (claimed).

ADVANTAGE - Administration of the combination of benzoquinone ansamycin derivative and other cytotoxic drug shows synergistic activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Abstract	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	----------	----------	--------	------	------------

☐ 51. Document ID: AU 2003203658 A1, WO 9922761 A1, AU 9911130 A, EP 1027070 A1, JP 2002501722 W, AU 761432 B, US 20030134787 A1, US 20030166530 A1

L13: Entry 51 of 51

File: DWPI

Jun 12, 2003

DERWENT-ACC-NO: 1999-313177

DERWENT-WEEK: 200456

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Identifying peptides which bind heat shock proteins

INVENTOR: HARTI, U; HOE, M H ; HOUGHTON, A N ; MAYHEW, M ; MOROI, Y ; OUEFFELLI, O ; ROTHMAN, J E ; HARTL, U ; HOUGHTON, A

PRIORITY-DATA: 1997US-0961707 (October 31, 1997), 2002US-0052578 (January 17, 2002), 2002US-0053520 (January 17, 2002), 2003AU-0203658 (April 11, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
AU 2003203658 A1	June 12, 2003		000	A61K039/00
WO 9922761 A1	May 14, 1999	E	154	A61K039/00
AU 9911130 A	May 24, 1999		000	
EP 1027070 A1	August 16, 2000	E	000	A61K039/00
JP 2002501722 W	January 22, 2002		263	C12N015/09
AU 761432 B	June 5, 2003		000	A61K039/00
US 20030134787 A1	July 17, 2003		000	A61K038/17
US 20030166530 A1	September 4, 2003		000	C12Q001/70

INT-CL (IPC): A61 K 31/704; A61 K 31/7072; A61 K 31/7076; A61 K 35/00; A61 K 35/02; A61 K 38/17; A61 K 39/00; A61 K 39/385; A61 K 39/39; A61 K 47/42; A61 K 47/48; A61 P

3/10; A61 P 29/00; A61 P 31/04; A61 P 31/10; A61 P 31/16; A61 P 31/18; A61 P 31/22;
A61 P 33/04; A61 P 33/06; A61 P 37/02; C07 K 14/435; C07 K 14/47; C07 K 14/705; C07 K
19/00; C12 N 15/00; C12 N 15/09; C12 N 15/12; C12 Q 1/70; G01 N 33/53

ABSTRACTED-PUB-NO: WO 9922761A
BASIC-ABSTRACT:

NOVELTY - Identifying a peptide (P) binding to a heat shock protein (hsp) by:

(a) contacting a phage (Ph) display library having bacteriophage expressing, in a surface protein (SP), inserted (P's) with a hsp target, and bound to a benzoquinone ansamycin antibiotic (BAA), in a physiologic binding buffer;

(b) isolating a (Ph) binding to the hsp target; and

(c) identifying the inserted (P) expressed in the (Ph) (SP).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a method of inducing an immune response in a subject comprising administering a composition comprising a conjugate (P), where the conjugate (P) comprises:

(i) a portion which may be bound to a hsp under physiologic conditions; and

(ii) a portion which is antigenic, where a hsp is not concurrently administered with the conjugate (P);

(2) a conjugate (P) comprising an antigenic peptide and a BAA.

USE - The peptides which bind to a hsp can be used as tethering peptides for a hsp which may serve as an accessory in a chaperone process and/or may comprise a cytokine. They can also be coupled to antigens to induce an immune response. Such compositions can be used for treating neoplastic disease, e.g. cancers, infectious diseases, e.g. diseases caused by a bacterium, virus, protozoan, mycoplasma, fungus, yeast, parasite or prion, or a disease of the immune system, e.g. acquired immune deficiencies or autoimmune diseases.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
benzoquinone ansamycin	51

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 40 of 40 returned.

☐ 1. Document ID: US 20040198651 A1

Using default format because multiple data bases are involved.

L11: Entry 1 of 40

File: PGPB

Oct 7, 2004

PGPUB-DOCUMENT-NUMBER: 20040198651

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040198651 A1

TITLE: Secreted proteins

PUBLICATION-DATE: October 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Klammer, Aaron A.	Boulder	CO	US	
Hafalia, April JA	Daly City	CA	US	
Duggan, Brendan M	Sunnyvale	CA	US	
Warren, Bridget A	San Marcos	CA	US	
Emerling, Brooke M	Chicago	IL	US	
Tribouley, Catherine M	San Francisco	CA	US	
Arvizu, Chandra S	San Diego	CA	US	
Honchell, Cynthia D	San Carlos	CA	US	
Nguyen, Danniel B	San Jose	CA	US	
Kallick, Deborah A	Galveston	TX	US	
Yue, Henry	Sunnyvale	CA	US	
Au-Young, Janice K	Brisbane	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Li, Joana X.	Millbrae	CA	US	
Thangavelu, Kavitha	Sunnyvale	CA	US	
Gietzen, Kimberly J	San Jose	CA	US	
Ding, Li	Creve Coeur	MO	US	
Baughn, Mariah R	Los Angeles	CA	US	
Yao, Monique G	Mountain View	CA	US	
Chawla, Narinder K	Union City	CA	US	
Mason, Patricia M	Morgan Hill	CA	US	
Lal, Preeti G.	Santa Clara	CA	US	
Graul, Richard C	San Francisco	CA	US	
Reddy, Roopa M	Fremont	CA	US	
Becha, Shanya D	San Francisco	CA	US	
Kareht, Stephanie K	Redwood City	CA	US	
Richardson, Thomas W	Redwood City	CA	US	
Tran, Uyen K	San Jose	CA	US	
Elliott, Vicki S	San Jose	CA	US	

Tang, Y Tom	San Jose	CA	US
Azimzai, Yalda	Oakland	CA	US
Lu, Yan	Mountain View	CA	US
Xu, Yuming	Mountain View	CA	US

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMO	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 2. Document ID: US 20040158039 A1

111: Entry 2 of 40

File: PGPB

Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040158039

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040158039 A1

TITLE: Secreted proteins

PUBLICATION-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yue, Henry	Sunnyvale	CA	US	
Lee, Ernestine A.	Kensington	CA	US	
Becha, Shanya D	San Francisco	CA	US	
Baughn, Mariah R	Los Angeles	CA	US	
Yao, Monique G	Mountain View	CA	US	
Tang, Y Tom	San Jose	CA	US	
Au-Young, Janice K	Brisbane	CA	US	
Lal, Preeti G	Santa Clara	CA	US	
Warren, Bridget A	San Marcos	CA	US	
Duggan, Brendan M	Sunnyvale	CA	US	
Tran, Uyen K	San Jose	CA	US	
Thangavelu, Kavitha	Sunnyvale	CA	US	
Richardson, Thomas W	Redwood City	CA	US	
Bandman, Olga	Mountain View	CA	US	
Jones, Karen A	Bollington	CA	GB	
Yang, Junming	San Jose	IL	US	
Emerling, Brooke M	Chicago	CA	US	
Swarnakar, Anita	San Francisco	CA	US	
Luo, Wen	San Diego	CA	US	
Chawla, Narinder K	Union City	CA	US	
Azimzai, Yalda	Oakland	IL	US	
Khan, Farrah A	Des Plaines	CA	US	
Lu, Dyung Aina M	San Jose	CA	US	
Griffin, Jennifer A	Fremont	CA	US	
Lee, Soo Yeun	Mountain View	CT	US	
Burford, Neil	Durham	CA	US	
Elliott, Vicki S	San Jose	CA	US	
Honchell, Cynthia D	San Francisco	CA	US	

He, Ann	San Jose	CA	US
Mason, Patricia M	Morgan Hill	CA	US
Li, Joana X	Millbrae	CA	US
Hafalia, April JA	Daly City	CA	US
Gururajan, Rajagopal	San Jose		US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	PMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 3. Document ID: US 20040138414 A1

L11: Entry 3 of 40

File: PGPB

Jul 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040138414

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040138414 A1

TITLE: Secreted proteins

PUBLICATION-DATE: July 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yue, Henry	Sunnyvale	CA	US	
Tang, Y Tom	San Jose	CA	US	
Nguyen, Danniel B	San Jose	CA	US	
Yao, Monique G	Carmel	IN	US	
Xu, Yuming	Mountain View	CA	US	
Tribouley, Catherine M	San Francisco	CA	US	
Sanjanwala, Madhusudan M	Los Altos	CA	US	
Chawla, Narinder K	Union City	CA	US	
Baughn, Mariah R	San Leandro	CA	US	
Sapperstein, Stephanie K	Redwood City	CA	US	
Lal, Preeti G	Santa Clara	CA	US	
Thornton, Michael B	Oakland	CA	US	
Gandhi, Ameena R	San Francisco	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Elliott, Vicki S	San Jose	CA	US	
Arvizu, Chandra S	San Jose	CA	US	
Thangavelu, Kavitha	Sunnyvale	CA	US	
Gietzen, Kimberly J	San Jose	CA	US	
Ding, Li	Creve Couer	MO	US	

Au-Young, Janice K	Brisbane	CA	US
Tran, Bao	Santa Clara	CA	US
Policky, Jennifer L	San Jose	CA	US
Lee, Sally	San Jose	CA	US
Lu, Dyung Aina M	San Jose	CA	US
Burford, Neil	Durham	CT	US
Warren, Bridget A	Encinitas	CA	US
Gururajan, Rajagopal	San Jose	CA	US
Duggan, Brendan M	Sunnyvale	CA	US
Honchell, Cynthia D	San Carlos	CA	US
Hafalia, April JA	Daly City	CA	US

US-CL-CURRENT: 530/350

ABSTRACT:

The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20040101930 A1

L11: Entry 4 of 40

File: PGPB

May 27, 2004

PGPUB-DOCUMENT-NUMBER: 20040101930

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040101930 A1

TITLE: Secreted proteins

PUBLICATION-DATE: May 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackson, Jennifer L.	Santa Cruz	CA	US	
Tang, Y. Tom	San Jose	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Elliott, Vicki S	San Jose	CA	US	
Tribouley, Catherine M	San Francisco	CA	US	
Lee, Ernestine A	Castro Valley	CA	US	
Ramkumar, Jayalaxmi	Fremont	CA	US	
Lal, Preeti G	Santa Clara	CA	US	
Xu, Yuming	Mountain View	CA	US	
Warren, Bridget A	Encinitas	CA	US	
Hafalia, April J.A.	Santa Clara	CA	US	
Baughn, Mariah R	San Leandro	CA	US	
Azimzai, Yalda	Oakland	CA	US	

Batra, Sajeev	Oakland	CA	US
Burford, Neil	Durham	CT	US
Yao, Monique G	Carmel	IN	US
Nguyen, Dannel B	San Jose	CA	US
Lu, Dyung Aina M	SanJose	CA	US
Chawla, Narinder K	Union City	CA	US
Gandhi, Ameena R	San Francisco	CA	US
Au-Young, Janice K	Brisbane	CA	US
Arvizu, Chandra S	San Jose	CA	US

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 530/350, 536/23.5

ABSTRACT:

The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FORM	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 20040101882 A1

L11: Entry 5 of 40

File: PGPB

May 27, 2004

PGPUB-DOCUMENT-NUMBER: 20040101882

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040101882 A1

TITLE: Secreted proteins

PUBLICATION-DATE: May 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yue, Henry	Sunnyvale	CA	US	
Yang, Junming	San Jose	CA	US	
Elliott, Vicki S	San Jose	CA	US	
Duggan, Brendan M	Sunnyvale	CA	US	
Honchell, Cynthia D	San Carlos	CA	US	
Lee, Sally	San Carlos	CA	US	
Thangavelu, Kavitha	Sunnyvale	CA	US	
Gietzen, Kimberly J	San Jose	CA	US	
Forsythe, Ian J	Edmonton	CA	CA	
Lu, Dyung Aina M	San Jose	CA	US	
Griffin, Jennifer A	Fremont	CA	US	
Gururajan, Rajagopol	San Jose	CA	US	
Lal, Preeti G	Santa Clara	CA	US	
Baughn, Mariah R	Los Angeles	CA	US	
Xu, Yuming	Mountain View	CA	US	

Tang, Y Tom	San Jose	CA	US
Azimzai, Yalda	Oakland	CA	US
Au-Young, Janice K	Brisbane	TX	US
Kallick, Deborah A	Galveston	CA	US
Chawla, Narinder K	Union City	CA	US
Mason, Patricia M	Morgan Hill	CA	US
Tran, Uyen K	San Jose		US

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 6. Document ID: US 20040087773 A1

L11: Entry 6 of 40

File: PGPB

May 6, 2004

PGPUB-DOCUMENT-NUMBER: 20040087773

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040087773 A1

TITLE: Molecules for disease detection and treatment

PUBLICATION-DATE: May 6, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Lal, Preeti G	Santa Clara	CA	US	
Baughn, Mariah R	Los Angeles	CA	US	
Yao, Monique G	Mountain View	CA	US	
Chawla, Narinder K	Union City	CA	US	
Elliott, Vicki S	San Jose	CA	US	
Xu, Yuming	Mountain View	CA	US	
Honchell, Cynthia D	San Carlos	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Ding, Li	Creve Couer	MO	US	
Gietzen, Kimberly J	San Jose	CA	US	
Ison, Craig H	San Jose	CA	US	
Lu, Dyung Aina M	San Jose	CA	US	
Hafalia, April JA	Daly City	CA	US	
Gandhi, Ameena R	San Francisco	CA	US	
Thangavelu, Kavitha	Sunnyvale	CA	US	
Sanjanwala, Madhusudan M	Los Altos	CA	US	
Tang, Y Tom	San Jose	CA	US	

Ramkumar, Jayalaxmi	Fremont	CA	US
Griffin, Jennifer A	Fremont	CA	US
Swarnakar, Anita	San Francisco	CA	US
Azimzai, Yalda	Oakland	CA	US
Sapperstein, Stephanie K	Redwood City	CA	US
Burford, Neil	Durham	CT	US
Lee, Ernestine A	Castro Valley	CA	US
Lu, Yan	Mountain View	CA	US
Tran, Uyen K	San Jose	CA	US
Marquis, Joseph P	San Jos	CA	US

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.5

ABSTRACT:

The invention provides full-length human molecules for disease detection and treatment (MDDT) and polynucleotides which identify and encode MDDT. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of MDDT.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 7. Document ID: US 20040082508 A1

L11: Entry 7 of 40

File: PGPB

Apr 29, 2004

PGPUB-DOCUMENT-NUMBER: 20040082508

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040082508 A1

TITLE: Secreted proteins

PUBLICATION-DATE: April 29, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yue, Henry	Sunnyvale	CA	US	
Yao, Monique G	Carmel	IN	US	
Gandhi, Ameena R	San Francisco	CA	US	
Baughn, Mariah R	San Leandro	CA	US	
Swarnakar, Anita	San Francisco	CA	US	
Chawla, Narinder K	Union City	CA	US	
Sanjanwala, Madhusudan M	Los Altos	CA	US	
Thornton, Michael B	Oakland	CA	US	
Elliott, Vicki S	San Jose	CA	US	
Lu, Yan	Mountain View	CA	US	
Gietzen, Kimberly J	San Jose	CA	US	
Burford, Neil	Durhama	CT	US	
Ding, Li	Creve Coeur	MO	US	
Hafalia, April JA	Daly City	CA	US	

Tang, Y Tom	San Jose	CA	US
Bandman, Olga	Mountain View	CA	US
Warren, Bridget A	Encinitas	CA	US
Honchell, Cynthia D	San Carlos	CA	US
Lu, Dyung Aina M	San Jose	CA	US
Thangavelu, Kavitha	Sunnyvale	CA	US
Lee, Sally	San Jose	CA	US
Xu, Yuming	Mountain View	CA	US
Yang, Junming	San Jose	CA	US
Lal, Preeti G	Santa Clara	CA	US
Tran, Bao	Santa Clara	CA	US
Ison, Craig H	San Jose	CA	US
Duggan, Brendan M	Sunnyvale	CA	US
Kareht, Stephanie K	Redwood City	CA	US

US-CL-CURRENT: 514/12; 435/320.1, 435/325, 435/6, 435/69.1, 530/350, 536/23.5

ABSTRACT:

The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 8. Document ID: US 20040072160 A1

L11: Entry 8 of 40

File: PGPB

Apr 15, 2004

PGPUB-DOCUMENT-NUMBER: 20040072160

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040072160 A1

TITLE: Molecular toxicology modeling

PUBLICATION-DATE: April 15, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mendrick, Donna	Gaithersburg	MD	US	
Porter, Mark	Gaithersburg	MD	US	
Johnson, Kory	Gaithersburg	MD	US	
Higgs, Brandon	Gaithersburg	MD	US	
Castle, Arthur	Gaithersburg	MD	US	
Elashoff, Michael	Gaithersburg	MD	US	

US-CL-CURRENT: 435/6; 435/91.2, 436/84

ABSTRACT:

The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known renal toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMWD	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 20040063924 A1

L11: Entry 9 of 40

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063924

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040063924 A1

TITLE: Secreted proteins

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tang, Y Tom	San Jose	CA	US	
Yue, Henry	Sunnyvale	CA	US	
Gandhi, Ameena R.	San Francisco	CA	US	
Yao, Monique G.	Mountain View	CA	US	
Warren, Bridget A.	San Marcos	CA	US	
Ding, Li	Creve Coeur	MO	US	
Duggan, Brendan M.	Sunnyvale	CA	US	
Xu, Yuming	Mountain View	CA	US	
Yang, Junming	San Jose	CA	US	
Thangavelu, Kavitha	Sunnyvale	CA	US	
Lal, Preeti G.	Santa Clara	CA	US	
Honchell, Cynthia D.	San Carlos	CA	US	
Chawla, Narinder K.	Union City	CA	US	
Lee, Sally	San Jose	CA	US	
Lee, Ernestine A.	Castro Valley	CA	US	
Richardson, Thomas W.	Redwood City	CA	US	
Baughn, Mariah R.	Los Angeles	CA	US	
Elliott, Vicki S.	San Jose	CA	US	

US-CL-CURRENT: 536/23.5; 435/320.1, 435/325, 435/69.1, 530/350

ABSTRACT:

The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

☐ 10. Document ID: US 20040063610 A1

L11: Entry 10 of 40

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063610
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040063610 A1

TITLE: Compositions and methods for promoting nerve regeneration

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gold, Bruce G.	West Linn	OR	US	

US-CL-CURRENT: 514/2; 424/143.1, 514/183, 514/291

ABSTRACT:

FKS06 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor-complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

☐ 11. Document ID: US 20040048279 A1

L11: Entry 11 of 40

File: PGPB

Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040048279
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040048279 A1

TITLE: Method for detecting methylation states for a toxicological diagnostic

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Olek, Alexander	Berlin		DE	
Piepenbrock, Christian	Berlin		DE	
Berlin, Kurt	Stahnsdorf		DE	

US-CL-CURRENT: 435/6

ABSTRACT:

The present invention concerns a method for toxicological diagnosis. A DNA sample is

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.12&ref=11&dbname=PGPB,USPT,U...> 11/16/04

taken from an organism or a cell culture, which has previously been subjected to a specific substance that is to be investigated for its toxicological effect. The DNA contained in this sample is chemically pretreated and the base sequence of a part of the modified DNA is determined. A methylation state characteristic for the sample or a characteristic methylation pattern is concluded from this. The effect of a substance on the organism or the cell culture is concluded by comparison with data of the methylation states of other samples and/or compared with other substances from a toxicological point of view.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	HTML	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 12. Document ID: US 20040048249 A1

L11: Entry 12 of 40

File: PGPB

Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040048249

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040048249 A1

TITLE: Novel nucleic acids and secreted polypeptides

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tang, Y. Tom	San Jose	CA	US	
Yang, Yonghong	San Jose	CA	US	
Weng, Gezhi	Piedmont	CA	US	
Zhang, Jie	Campbell	CA	US	
Ren, Feiyan	Cupertino	CA	US	
Xue, Aidong	Sunnyvale	CA	US	
Wang, Jian-Rui	Cupertino	CA	US	
Wehrman, Tom	Stanford	CA	US	
Ghosh, Malabika J.	Sunnyvale	CA	US	
Wang, Dunrui	Poway	CA	US	
Zhao, Qing A.	San Jose	CA	US	
Wang, Zhiwei	Sunnyvale	CA	US	

US-CL-CURRENT: 435/6; 435/183, 435/320.1, 435/325, 435/455, 435/69.1, 530/350, 536/23.2

ABSTRACT:

The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	HTML	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 13. Document ID: US 20040044181 A1

L11: Entry 13 of 40

File: PGPB

Mar 4, 2004

PGPUB-DOCUMENT-NUMBER: 20040044181
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040044181 A1

TITLE: Novel nucleic acids and polypeptides

PUBLICATION-DATE: March 4, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Tang, Y. Tom	San Jose	CA	US	
Liu, Chenghua	San Jose	CA	US	
Asundi, Vinod	Foster City	CA	US	
Wehrman, Tom	Stanford	CA	US	
Ren, Feiyan	Cupertino	CA	US	
Zhou, Ping	Cupertino	CA	US	
Zhao, Qing A.	San Jose	CA	US	
Drmanac, Radoje T.	Palo Alto	CA	US	
Zhang, Jie	Campbell	CA	US	
Xue, Aidong	Sunnyvale	CA	US	
Wang, Jian-Rui	Cupertino	CA	US	
Wang, Dunrui	Poway	CA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 14. Document ID: US 20030233670 A1

L11: Entry 14 of 40

File: PGPB

Dec 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030233670
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030233670 A1

TITLE: Gene sequences and uses thereof in plants

PUBLICATION-DATE: December 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Edgerton, Michael D.	St. Louis	MO	US	
Chomet, Paul S.	Mystic	CT	US	
Laccetti, Lucille B.	Groton	CT	US	

US-CL-CURRENT: 800/278; 435/200, 435/320.1, 435/419, 435/6, 435/69.1, 536/23.2

ABSTRACT:

The invention provides polynucleotides and proteins encoded by the polypeptides. The disclosed polynucleotides and polypeptides find use in production of transgenic plants to produce plants having improved properties. The invention further provides methods of producing fertile transgenic plants, preferably maize, with desirable phenotypes and progeny of any generation derived from the fertile transgenic plants.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 15. Document ID: US 20030224386 A1

L11: Entry 15 of 40

File: PGPB

Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224386

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030224386 A1

TITLE: Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Guild, Braydon C.	Concord	MA	US	
Liao, Hua	Newton	MA	US	
Jones, Michael D.	Arlington	MA	US	
Zolg, Johannes W.	Weilheim	MA	DE	
Wu, Jiang	Waltham		US	

US-CL-CURRENT: 435/6

ABSTRACT:

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human Rheumatoid Arthritis (RA). A variety of newly-identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with RA.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 16. Document ID: US 20030176665 A1

L11: Entry 16 of 40

File: PGPB

Sep 18, 2003

PGPUB-DOCUMENT-NUMBER: 20030176665

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030176665 A1

TITLE: Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them

PUBLICATION-DATE: September 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Scholz, Christian	Penzberg		DE	
Andres, Herbert	Penzberg		DE	
Faatz, Elke	Huglfing		DE	
Engel, Alfred	Tutzing		DE	
Sizmann, Dorothea	Penzberg		DE	

US-CL-CURRENT: 530/395; 435/68.1

ABSTRACT:

The present invention relates to the diagnosis of HIV infections. It especially teaches the production of a soluble retroviral surface glycoprotein- (or transmembrane glycoprotein)-chaperone complex and the advantageous use of a chaperone-antigen complex especially in the detection of antibodies to HIV in immunoassays, preferably according to the double antigen bridge concept, or as an immunogen. The invention also discloses soluble complexes comprising a variant of HIV-1 gp41 or a variant of HIV-2 gp36, respectively, and a chaperone selected from the peptidyl-prolyl-isomerase class of chaperones. Variants comprising specific amino-acid substitutions in the N-helical domain of HIV-1 gp41 or of HIV-2 gp36, respectively, are also described.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 17. Document ID: US 20030170268 A1

L11: Entry 17 of 40

File: PGPB

Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030170268

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030170268 A1

TITLE: Human papilloma virus treatment

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Neefe, John R.	Devon	PA	US	
Goldstone, Stephen E.	New York	NY	US	
Winnett, Mark T.	Phoenixville	PA	US	
Siegel, Marvin	Blue Bell	PA	US	
Boux, Leslie J.	Victoria		CA	

US-CL-CURRENT: 424/201.1; 424/204.1, 424/278.1, 536/23.72

ABSTRACT:

Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.12&ref=11&dbname=PGPB,USPT,U...> 11/16/04

thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 18. Document ID: US 20030152921 A1

L11: Entry 18 of 40

File: PGPB

Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030152921
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030152921 A1

TITLE: Full-length human cDNAs encoding potentially secreted proteins

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dumas Milne Edwards, Jean-Baptiste	Paris		FR	
Bougueleret, Lydie	Petit Lancy		CH	
Jobert, Severin	Paris		FR	

US-CL-CURRENT: 435/6; 435/183, 536/23.2

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 19. Document ID: US 20030148456 A1

L11: Entry 19 of 40

File: PGPB

Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030148456
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030148456 A1

TITLE: Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mizzen, Lee A.	Victoria		CA	
Chu, N. Randall	Victoria		CA	
Wu, Huacheng Bill	Victoria		CA	

US-CL-CURRENT: 435/69.1; 424/204.1, 435/6

ABSTRACT:

The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression vector can be introduced into cells of a subject, or it can be used to transduce cells of the subject ex vivo, resulting in the expression of an HPV protein antigen-stress protein fusion protein that will stimulate the subject's immune response to the HPV protein antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates and to expression vectors encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	RMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 20. Document ID: US 20030068787 A1

L11: Entry 20 of 40

File: PGPB

Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030068787

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030068787 A1

TITLE: Antibody specifically binding cyclophilin-type peptidyl-prolyl cis/trans isomerase

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Jackson, Jennifer L.	Fremont	CA	US	
Corley, Neil C.	Castro Valley	CA	US	
Guegler, Karl J.	Menlo Park	CA	US	
Arvizu, Chandra S.	San Jose	CA	US	

US-CL-CURRENT: 435/70.21; 435/183, 530/388.1, 530/413<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.12&ref=11&dbname=PGPB,USPT,U...> 11/16/04

ABSTRACT:

The invention provides a human cyclophilin-type peptidyl-prolyl cis/trans isomerase (CPCI), a cDNA that encodes CPCI and an antibody that specifically binds CPCI. The invention also provides methods to diagnose, to stage, to treat, or to monitor the treatment of disorders associated with expression of CPCI.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 21. Document ID: US 20020155434 A1

L11: Entry 21 of 40

File: PGPB

Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155434

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020155434 A1

TITLE: Hepatitis B virus treatment

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mizzen, Lee A.	Victoria	PA	CA	
Siegel, Marvin	Blue Bell		US	
Liu, Hongwei	Victoria		CA	

US-CL-CURRENT: 435/5; 424/192.1, 424/204.1, 424/225.1, 424/227.1

ABSTRACT:

The invention relates to HBV antigen-containing compositions that are useful in treating or preventing HBV infection. The content of the compositions can vary, as described herein, but the compositions comprise a stress protein, or a portion (e.g., a fragment) or derivative thereof, and an HBV antigen.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 22. Document ID: US 20020147133 A1

L11: Entry 22 of 40

File: PGPB

Oct 10, 2002

PGPUB-DOCUMENT-NUMBER: 20020147133

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020147133 A1

TITLE: Bifunctional molecules and therapies based thereon

PUBLICATION-DATE: October 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

Briesewitz, Roger	Mountain View	CA	US
Crabtree, Gerald R.	Woodside	CA	US
Wandless, Thomas	Menlo Park	CA	US
Ray, Gregory Thomas	Stanford	CA	US
Vogel, Kurt William	Palo Alto	CA	US

US-CL-CURRENT: 514/2

ABSTRACT:

Bifunctional molecules and methods for their use in the production of binary complexes in a host are provided. The bifunctional molecule is a conjugate of a drug moiety and a presenter protein ligand. In the subject methods, an effective amount of the bifunctional molecule is administered to the host. The bifunctional molecule binds to the presenter protein to produce a binary complex that exhibits at least one of improved affinity, specificity or selectivity as compared to the corresponding free drug. The subject methods and compositions find use in a variety of therapeutic applications.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 23. Document ID: US 20020110566 A1

L11: Entry 23 of 40

File: PGPB

Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020110566

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020110566 A1

TITLE: Human papilloma virus treatment

PUBLICATION-DATE: August 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Neefe, John R.	Devon	PA	US	
Goldstone, Stephen E.	New York	NY	US	
Winnett, Mark T.	Phoenixville	PA	US	
Siegel, Marvin	Blue Bell	PA	US	
Boux, Leslie J.	Victoria		CA	

US-CL-CURRENT: 424/204.1

ABSTRACT:

Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.

☐ 24. Document ID: US 20020102604 A1

L11: Entry 24 of 40

File: PGPB

Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020102604
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20020102604 A1

TITLE: Full-length human cDNAs encoding potentially secreted proteins

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Milne Edwards, Jean-Baptiste Dumas	Paris		FR	
Bougueleret, Lydie	Petit Lancy		CH	
Jobert, Severin	Paris		FR	

US-CL-CURRENT: 435/7.1; 530/350, 536/23.1

ABSTRACT:

The invention concerns GENSET polynucleotides and polypeptides. Such GENSET products may be used as reagents in forensic analyses, as chromosome markers, as tissue/cell/organelle-specific markers, in the production of expression vectors. In addition, they may be used in screening and diagnosis assays for abnormal GENSET expression and/or biological activity and for screening compounds that may be used in the treatment of GENSET-related disorders.

☐ 25. Document ID: US 20020086015 A1

L11: Entry 25 of 40

File: PGPB

Jul 4, 2002

PGPUB-DOCUMENT-NUMBER: 20020086015
 PGPUB-FILING-TYPE: new
 DOCUMENT-IDENTIFIER: US 20020086015 A1

TITLE: Compositions and methods for promoting nerve regeneration

PUBLICATION-DATE: July 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gold, Bruce G.	West Linn	OR	US	

US-CL-CURRENT: 424/145.1; 514/2, 514/34

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBPS52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 26. Document ID: US 20020009730 A1

L11: Entry 26 of 40

File: PGPB

Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020009730
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020009730 A1

TITLE: Human stress array

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chenchik, Alex	Palo Alto	CA	US	
Lukashev, Matvey E.	Newton	MA	US	

US-CL-CURRENT: 435/6; 536/24.3

ABSTRACT:

Human stress arrays and methods for their use are provided. The subject arrays include a plurality of polynucleotide spots, each of which is made up of a polynucleotide probe composition of unique polynucleotides corresponding to a human stress gene. The subject arrays find use in hybridization assays, particularly in assays for the identification of differential gene expression of human stress genes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 27. Document ID: US 6818643 B1

L11: Entry 27 of 40

File: USPT

Nov 16, 2004

US-PAT-NO: 6818643
DOCUMENT-IDENTIFIER: US 6818643 B1

TITLE: Neurotrophic bicyclic diamides

DATE-ISSUED: November 16, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dubowchik; Gene Michael	Middlefield	CT		
Provencal; David Paul	Cromwell	CT		

US-CL-CURRENT: 514/249; 514/300, 544/349, 546/121

ABSTRACT:

The present invention relates to the design, synthesis, and the peptidyl-prolyl isomerase (PPIase or rotamase) inhibitory activity of novel bicyclic diamide compounds that are neuroprotective and/or neurotrophic agents (i.e. compounds capable of stimulating growth or proliferation of nervous tissue) and that bind to immunophilins such as FKBP12 and inhibit their rotamase activity. This invention also relates to pharmaceutical compositions comprising these compounds.

7 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	------------

☐ 28. Document ID: US 6797491 B2

L11: Entry 28 of 40

File: USPT

Sep 28, 2004

US-PAT-NO: 6797491

DOCUMENT-IDENTIFIER: US 6797491 B2

TITLE: Human papilloma virus treatment

DATE-ISSUED: September 28, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Neefe; John R.	Devon	PA		
Goldstone; Stephen E.	New York	NY		
Winnett; Mark T.	Phoenixville	PA		
Siegel; Marvin	Blue Bell	PA		
Boux; Leslie J.	Victoria			CA

US-CL-CURRENT: 435/69.1; 424/192.1, 424/204.1, 424/234.1, 536/23.72

ABSTRACT:

Disclosed is a method of treating a wart in a subject by administering to the subject a composition containing (1) a heat shock protein or an immunostimulatory fragment thereof, and (2) a protein of a human papilloma virus or an antigenic fragment thereof. Also disclosed is a method of treating a human papilloma virus infection in a subject infected or suspected of being infected with a human papilloma virus of a first type by administering to the subject a composition containing (1) a heat shock protein or an antigenic fragment thereof, and (2) a protein of a human papilloma virus of a second type or an antigenic fragment thereof, where the first type and second type are different.

35 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference		Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--------	------	------------

☐ 29. Document ID: US 6734211 B1

L11: Entry 29 of 40

File: USPT

May 11, 2004

US-PAT-NO: 6734211

DOCUMENT-IDENTIFIER: US 6734211 B1

TITLE: Compositions and methods for promoting nerve regeneration

DATE-ISSUED: May 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 514/513

ABSTRACT:

Neurite outgrowth and nerve regeneration are promoted by disruption of the steroid receptor complex and stimulation of MAP kinase/kinase activity. This disruption can take the form of disruption of the physical assembly or function of the steroid receptor complex, such as the mature complex or a precursor of the mature complex that is required for assembly of the mature complex. Geldanamycin and its analogs, bastadin and members of the bastadin family, and radicicol and its analogs, as well as FKBP-52 antibody, are shown to disrupt the complex and promote nerve growth. Assays for finding neurotrophic compounds, as well as compounds found by these assays, pharmaceutical compositions into which they are incorporated, and methods of treating subjects having neuronal dysfunction caused by injury or disease are disclosed. Any of these compounds can be used in combination with a therapeutically effective amount of heat, such as heat applied locally to an area where nerve growth is desired, or systemically in an organism in which neurite growth is desired. Alternatively, these compounds can be used in association with a template, such as a tubular member that defines an anatomic pathway along which nerve regeneration is desired (particularly around a transected or partially transected nerve).

13 Claims, 10 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 30. Document ID: US 6641810 B2

L11: Entry 30 of 40

File: USPT

Nov 4, 2003

US-PAT-NO: 6641810

DOCUMENT-IDENTIFIER: US 6641810 B2

**** See image for Certificate of Correction ****

TITLE: Methods of using geldanamycin and FK506 to treat peripheral nerve damage

DATE-ISSUED: November 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 424/145.1; 514/183, 514/330, 514/423, 514/428, 514/465, 514/466

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBPS52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

34 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Index	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-------	----------

☐ 31. Document ID: US 6630472 B1

L11: Entry 31 of 40

File: USPT

Oct 7, 2003

US-PAT-NO: 6630472

DOCUMENT-IDENTIFIER: US 6630472 B1

TITLE: Compounds, pharmaceutical compositions, and methods for stimulating neuronal growth and elongation

DATE-ISSUED: October 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kato; Susumu	Osaka			JP
Kawakami; Hiroshi	Osaka			JP
Tada; Hiroki	Osaka			JP
Linton; Maria Angelica	San Diego	CA		
Kalish; Vincent	Annapolis	MD		
Tatlock; John Howard	Vista	CA		
Villafranca; Jesus Ernesto	San Diego	CA		

US-CL-CURRENT: 514/249; 540/520, 544/343, 544/346, 544/349

ABSTRACT:

Compounds that inhibit the peptidyl-prolyl isomerase (rotamase) enzyme activity of the FK-506 binding protein (FKBP) and compositions comprising these compounds are described. The FKBP-inhibiting compounds have a bicyclic [3.3.1], [4.3.1] or polycyclic azaamide nucleus. Pharmaceutical compositions containing such compounds help stimulate the outgrowth of neurites in nerve cells and augmenting nerve regeneration. Methods of treating nerve cells with such compositions are useful to promote repair of neuronal damage caused by disease and physical trauma.

26 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	AMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 32. Document ID: US 6524825 B1

L11: Entry 32 of 40

File: USPT

Feb 25, 2003

US-PAT-NO: 6524825

DOCUMENT-IDENTIFIER: US 6524825 B1

**** See image for Certificate of Correction ****

TITLE: Immune responses against HPV antigens elicited by compositions comprising an HPV antigen and a stress protein or an expression vector capable of expression of these proteins

DATE-ISSUED: February 25, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mizzen; Lee A.	Victoria			CA
Chu; N. Randall	Victoria			CA
Wu; Huacheng Bill	Victoria			CA

US-CL-CURRENT: 435/69.7; 424/192.1, 424/9.34, 435/39, 435/5, 435/7.1

ABSTRACT:

The present invention relates to compositions for inducing an immune response, preferably a cellular, in particular a cell-mediated, cytolytic immune response, to human papillomavirus (HPV) protein antigens displayed by HPV or exhibited by infected cells including cells from cervical and other tumors. In one embodiment, compositions comprise an HPV protein antigen joined to a stress protein (or heat shock protein (Hsp)). The HPV protein antigen may be joined to the stress protein by chemical conjugation or noncovalently using linking moieties, or the HPV protein antigen and the stress protein may be joined in a fusion protein containing both HPV protein antigen and stress protein sequences. In another embodiment, compositions comprise an expression vector including, in expressible form, sequences encoding the HPV protein antigen and sequences encoding the stress protein. The expression vector can be introduced into cells of a subject, or it can be used to transduce cells of the subject ex vivo, resulting in the expression of an HPV protein antigen-stress protein fusion protein that will stimulate the subject's immune response to the HPV protein antigen. The present invention also relates to compositions comprising a stress protein linked to an HPV antigen and another pharmacologically acceptable component, to stress protein-HPV protein antigen fusions and conjugates and to expression vectors encoding and capable of directing the expression in a subject's cells of a fusion protein comprising a stress protein and an HPV protein antigen sequence. The present invention also relates to uses of these compositions to induce immune responses against HPV and HPV protein antigen-exhibiting cells including HPV-associated tumors.

100 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 13

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	AMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	-----	----------

☐ 33. Document ID: US 6458575 B1

L11: Entry 33 of 40

File: USPT

Oct 1, 2002

US-PAT-NO: 6458575

DOCUMENT-IDENTIFIER: US 6458575 B1

**** See image for Certificate of Correction ****

TITLE: Cyclophilin-type peptidyl-prolyl Cis/trans isomerase

DATE-ISSUED: October 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	Mountain View	CA		
Corley; Neil C.	Mountain View	CA		
Guegler; Karl J.	Menlo Park	CA		
Patterson; Chandra	Mountain View	CA		

US-CL-CURRENT: 435/233; 435/262, 435/4, 530/300, 530/350, 530/412

ABSTRACT:

The invention provides a human cyclophilin-type peptidyl-prolyl cis/trans isomerase (CPCI) and polynucleotides which identify and encode CPCI. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of CPCI.

7 Claims, 5 Drawing figures

Exemplary Claim Number: 2

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 34. Document ID: US 6432692 B1

L11: Entry 34 of 40

File: USPT

Aug 13, 2002

US-PAT-NO: 6432692

DOCUMENT-IDENTIFIER: US 6432692 B1

TITLE: Sensitive bioassay for detecting agonists of the aryl hydrocarbon receptor

DATE-ISSUED: August 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bradfield; Christopher A.	Madison	WI		
Carver; Lucy A.	San Diego	CA		
Dunham; Elizabeth E.	Madison	WI		

US-CL-CURRENT: 435/254.2; 435/254.21, 435/471, 435/6

ABSTRACT:

Improved cellular assay systems for detecting polycyclic aromatic hydrocarbons, dioxins, PCBs, and other substances which are agonists of the aryl hydrocarbon receptor (AHR) are disclosed. The assays utilize one or more additional cellular proteins involved in the AHR signaling pathway, which improve the sensitivity and maximal responsiveness of the assay systems.

9 Claims, 14 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 35. Document ID: US 6372712 B1

L11: Entry 35 of 40

File: USPT

Apr 16, 2002

US-PAT-NO: 6372712

DOCUMENT-IDENTIFIER: US 6372712 B1

TITLE: Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand

DATE-ISSUED: April 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Briesewitz; Roger	Mountain View	CA		
Crabtree; Gerald R.	Woodside	CA		
Wandless; Thomas	Menlo Park	CA		
Ray; Gregory Thomas	Stanford	CA		
Vogel; Kurt William	Palo Alto	CA		

US-CL-CURRENT: 514/2; 424/94.1, 424/94.5, 435/177, 514/9, 530/402, 530/812

ABSTRACT:

Bifunctional molecules and methods for their use in the production of binary complexes in a host are provided. The bifunctional molecule is a conjugate of a drug moiety and a presenter protein ligand. The molecular weight of the bifunctional molecule is preferably less than about 5000 daltons, and the drug moiety may have a molecular weight of from about 50 to 2000 daltons. The drug moiety and presenter protein ligand may be covalently linked directly or through a linking group. The drug moiety binds to a drug target such as a protein and the presenter protein ligand binds to a presenter protein that is not the drug target such as extracellular or intracellular protein. Presenter proteins include peptidyl prolyl isomerase (FKBP), Heat Shock Protein 90 (Hsp90), steroid hormone receptors, cytoskeletal proteins, albumin and vitamin receptors. When the presenter protein is FKBP, ligands include FK506, rapamycin and cyclosporin A which may have an introduced functional group such as hydroxyl, amino, carboxyl, aldehyde, carbonate, carbamate, azide, thiol or ester for attaching the drug moiety. In the methods of use, an effective amount of the bifunctional molecule is administered to the host. The bifunctional molecule binds to the presenter protein to produce a binary complex such that the drug exhibits at least one of improved affinity, specificity or selectivity as compared to the corresponding free drug. The methods and bifunctional molecules find use in a variety of therapeutic applications.

15 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 36. Document ID: US 6210974 B1

L11: Entry 36 of 40

File: USPT

Apr 3, 2001

US-PAT-NO: 6210974

DOCUMENT-IDENTIFIER: US 6210974 B1

**** See image for Certificate of Correction ****

TITLE: Compositions and methods for promoting nerve regeneration

DATE-ISSUED: April 3, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 436/501; 436/34, 436/63, 436/86, 436/91

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

17 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 37. Document ID: US 6030825 A

L11: Entry 37 of 40

File: USPT

Feb 29, 2000

US-PAT-NO: 6030825

DOCUMENT-IDENTIFIER: US 6030825 A

TITLE: Cyclophilin-type peptidyl-prolyl cis/trans isomerase

DATE-ISSUED: February 29, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hillman; Jennifer L.	Mountain View	CA		
Corley; Neil C.	Mountain View	CA		

Guegler; Karl J.
Patterson; Chandra

Menlo Park
Mountain View

CA
CA

US-CL-CURRENT: 435/233; 435/320.1, 435/325, 435/6, 435/69.1, 536/23.1, 536/23.2

ABSTRACT:

The invention provides a human cyclophilin-type peptidyl-prolyl cis/trans isomerase (CPCI) and polynucleotides which identify and encode CPCI. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of CPCI.

10 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 38. Document ID: US 6015709 A

L11: Entry 38 of 40

File: USPT

Jan 18, 2000

US-PAT-NO: 6015709

DOCUMENT-IDENTIFIER: US 6015709 A

TITLE: Transcriptional activators, and compositions and uses related thereto

DATE-ISSUED: January 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Natesan; Sridaran	Chestnut Hill	MA		

US-CL-CURRENT: 435/366; 435/252.3, 435/254.11, 435/325, 536/23.4

ABSTRACT:

The present invention relates to chimeric transcriptional activators.

44 Claims, 20 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 39. Document ID: US 5968921 A

L11: Entry 39 of 40

File: USPT

Oct 19, 1999

US-PAT-NO: 5968921

DOCUMENT-IDENTIFIER: US 5968921 A

**** See image for Certificate of Correction ****

TITLE: Compositions and methods for promoting nerve regeneration

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 514/183; 514/330, 514/423, 514/428, 514/465, 514/466, 514/534,
514/547, 514/548, 514/549

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

36 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	FWMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	------	------------

☐ 40. Document ID: US 5763590 A

L11: Entry 40 of 40

File: USPT

Jun 9, 1998

US-PAT-NO: 5763590

DOCUMENT-IDENTIFIER: US 5763590 A

TITLE: Isolation of an M.sub.r 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA

DATE-ISSUED: June 9, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Peattie; Debra A.	Cambridge	MA		
Harding; Matthew W.	Acton	MA		
Livingston; David J.	Newtonville	MA		

US-CL-CURRENT: 536/23.5; 435/233, 530/350, 536/23.2

ABSTRACT:

An FK506 binding protein of mammalian origin of approximate size (M.sub.r) 52,000, isolated by FK506 affinity chromatography and a corresponding human cDNA of approximate size 2.2 Kb, isolated by screening a human placenta cDNA library with a DNA probe whose sequence predicts a consensus amino acid sequence present in five FKBP12 sequences and in the human FKBP13 sequence.

2 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
L10 AND HSP90	40

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 64 of 64 returned.

☐ 1. Document ID: US 20040106652 A1

Using default format because multiple data bases are involved.

L9: Entry 1 of 64

File: PGPB

Jun 3, 2004

PGPUB-DOCUMENT-NUMBER: 20040106652

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040106652 A1

TITLE: Heterocyclic ketone and thioester compounds and uses

PUBLICATION-DATE: June 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hamilton, Gregory S.	Catonsville	MD	US	
Li, Jia-He	Cockeysville	MD	US	

US-CL-CURRENT: [514/355](#); [514/345](#), [514/423](#), [514/424](#), [546/301](#), [546/315](#), [548/530](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	------------

☐ 2. Document ID: US 20040063610 A1

L9: Entry 2 of 64

File: PGPB

Apr 1, 2004

PGPUB-DOCUMENT-NUMBER: 20040063610

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20040063610 A1

TITLE: Compositions and methods for promoting nerve regeneration

PUBLICATION-DATE: April 1, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Gold, Bruce G.	West Linn	OR	US	

US-CL-CURRENT: [514/2](#); [424/143.1](#), [514/183](#), [514/291](#)

ABSTRACT:

FKS06 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor-complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.10&ref=9&dbname=PGPB,USPT,US...> 11/16/04

receptor complexes or block association of hsp90 with steroid receptor complexes.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 3. Document ID: US 20030203890 A1

L9: Entry 3 of 64

File: PGPB

Oct 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030203890

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030203890 A1

TITLE: Method for treating nerve injury caused as a result of surgery

PUBLICATION-DATE: October 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Steiner, Joseph P.	Mount Airy	MD	US	
Snyder, Solomon	Baltimore	MD	US	
Burnett, Arthur L.	Baltimore	MD	US	

US-CL-CURRENT: 514/211.01; 514/217.11, 514/218, 514/227.5, 514/237.5, 514/255.01,
514/330, 514/365, 514/374, 514/385, 514/423

ABSTRACT:

The present invention relates generally to methods for treating or preventing nerve injury in a warm-blooded animal caused as a consequence of surgery by administering neurotrophic compounds described below. The invention relates more specifically to methods for treating or preventing nerve injury caused as a consequence of prostate surgery as well as erectile dysfunction.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	MMOC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 4. Document ID: US 20030114492 A1

L9: Entry 4 of 64

File: PGPB

Jun 19, 2003

PGPUB-DOCUMENT-NUMBER: 20030114492

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030114492 A1

TITLE: Method of using neurotrophic sulfonamide compounds

PUBLICATION-DATE: June 19, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hamilton, Gregory S.	Catonsville	MD	US	
Li, Jia-He	Cockeysville	MD	US	
Steiner, Joseph P.	Hampstead	MD	US	

US-CL-CURRENT: 514/330; 514/318, 514/326, 514/340, 514/422, 514/423, 514/424

ABSTRACT:

This invention relates to a method of using neurotrophic low molecular weight, small molecule sulfonamide compounds having an affinity for FKBP-type immunophilins, as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 5. Document ID: US 20020111347 A1

L9: Entry 5 of 64

File: PGPB

Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020111347

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020111347 A1

TITLE: Amino-alkyl derivatives

PUBLICATION-DATE: August 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Harbeson, Scott	Cambridge	MA	US	
Mullican, Michael	Needham	MA	US	

US-CL-CURRENT: 514/227.5; 514/231.2, 514/252.12, 514/317, 514/428, 514/649, 514/666

ABSTRACT:

The present invention relates to amino-alkyl derivatives for treating or preventing neuronal damage associated with neurological diseases. The invention also provides compositions comprising the compounds of the present invention and methods of utilizing those compositions for treating or preventing neuronal damage.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	EMMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 6. Document ID: US 20020049199 A1

L9: Entry 6 of 64

File: PGPB

Apr 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020049199

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020049199 A1

TITLE: N-linked carbamates and ureas of heterocyclic thioesters

PUBLICATION-DATE: April 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
------	------	-------	---------	---------

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.10&ref=9&dbname=PGPB,USPT,US...> 11/16/04

Hamilton, Gregory S.	Catonsville	MD	US
Li, Jia-He	Cockeysville	MD	US
Huang, Wei	Chesterfield	MO	US

US-CL-CURRENT: 514/217.11; 514/330, 514/365, 514/375, 514/385, 514/423, 540/607, 546/245, 548/553

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 7. Document ID: US 20020049193 A1

L9: Entry 7 of 64

File: PGPB

Apr 25, 2002

PGPUB-DOCUMENT-NUMBER: 20020049193
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020049193 A1

TITLE: N-linked sulfonamides of heterocyclic thioesters

PUBLICATION-DATE: April 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hamilton, Gregory S.	Catonsville	MD	US	
Li, Jai-He	Cockeysville	MD	US	
Huang, Wei	Wildwood	MO	US	

US-CL-CURRENT: 514/211.01; 514/212.01, 514/219, 514/227.5, 514/237.5, 514/255.01, 514/330, 514/365, 514/374, 514/385, 514/423, 540/488, 540/575, 540/604, 544/158, 544/386, 544/58.4, 546/225, 548/200, 548/236, 548/322.5, 548/530

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule N-linked sulfonamides of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIG	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	----------

☐ 8. Document ID: US 20020016341 A1

L9: Entry 8 of 64

File: PGPB

Feb 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020016341
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020016341 A1

TITLE: Heterocyclic thioester and ketone hair growth compositions and uses

PUBLICATION-DATE: February 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Steiner, Joseph P.	Finksburg	MD	US	
Hamilton, Gregory S.	Catonsville	MD	US	

US-CL-CURRENT: 514/330; 514/423

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using heterocyclic thioesters and ketones.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 9. Document ID: US 20020010205 A1

L9: Entry 9 of 64

File: PGPB

Jan 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020010205
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020010205 A1

TITLE: N-linked sulfone of heterocyclic thioester hair growth compositions and uses

PUBLICATION-DATE: January 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Stainer, Joseph P.	Finksburg	MD	US	
Hamilton, Gregory S.	Catonsville	MD	US	

US-CL-CURRENT: 514/428; 514/227.8, 514/231.5, 514/252.13, 514/256, 514/314, 514/326, 514/422

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using N-linked sulfonamides of heterocyclic thioesters.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 10. Document ID: US 20010049381 A1

L9: Entry 10 of 64

File: PGPB

Dec 6, 2001

PGPUB-DOCUMENT-NUMBER: 20010049381
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010049381 A1

TITLE: Pyrrolidine derivative hair growth compositions and uses

PUBLICATION-DATE: December 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Steiner, Joseph P.	Finksburg	MD	US	
Hamilton, Gregory S.	Catonsville	MD	US	

US-CL-CURRENT: 514/343; 514/414, 514/422, 514/423

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using pyrrolidine derivatives.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 11. Document ID: US 20010041733 A1

L9: Entry 11 of 64

File: PGPB

Nov 15, 2001

PGPUB-DOCUMENT-NUMBER: 20010041733
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20010041733 A1

TITLE: Heterocyclic ester and amide hair growth compositions and uses

PUBLICATION-DATE: November 15, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Steiner, Joseph P.	Finksburg	MD	US	
Hamilton, Gregory S.	Catonsville	MD	US	

US-CL-CURRENT: 514/423; 514/330

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using heterocyclic esters or amides.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	------------

☐ 12. Document ID: US 20010036947 A1

L9: Entry 12 of 64

File: PGPB

Nov 1, 2001

PGPUB-DOCUMENT-NUMBER: 20010036947

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010036947 A1

TITLE: Pipecolic acid derivative hair growth compositions and uses

PUBLICATION-DATE: November 1, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Steiner, Joseph P.	Finksburg	MD	US	
Hamilton, Gregory S.	Catonsville	MD	US	

US-CL-CURRENT: 514/291; 514/330

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using pipecolic acid derivatives.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 13. Document ID: US 20010036942 A1

L9: Entry 13 of 64

File: PGPB

Nov 1, 2001

PGPUB-DOCUMENT-NUMBER: 20010036942

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010036942 A1

TITLE: N-oxides of heterocyclic esters, amides, thioesters, and ketones

PUBLICATION-DATE: November 1, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hamilton, Gregory S.	Catonsville	MD	US	
Steiner, Joseph P.	Hampstead	MD	US	
Burak, Eric S.	Forest Hill	MD	US	

US-CL-CURRENT: 514/217.11; 514/211.01, 514/227.5, 514/237.5, 514/247, 514/255.01, 514/256, 514/350, 514/423, 540/607, 544/175, 544/335, 544/387, 546/226, 548/538

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 14. Document ID: US 20010034362 A1

L9: Entry 14 of 64

File: PGPB

Oct 25, 2001

PGPUB-DOCUMENT-NUMBER: 20010034362

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010034362 A1

TITLE: Pyrrolidine derivatives for vision and memory disorders

PUBLICATION-DATE: October 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ross, Douglas T.	North Wales	PA	US	
Sauer, Hansjorg	Silver Spring	MD	US	
Hamilton, Gregory S.	Catonsville	MD	US	
Steiner, Joseph P.	Finksburg	MD	US	

US-CL-CURRENT: 514/423; 514/340, 514/422

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using pyrrolidine derivatives.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 15. Document ID: US 20010029261 A1

L9: Entry 15 of 64

File: PGPB

Oct 11, 2001

PGPUB-DOCUMENT-NUMBER: 20010029261

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20010029261 A1

TITLE: Small molecule sulfonamide hair growth compositions and uses

PUBLICATION-DATE: October 11, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Steiner, Joseph P.	Finksburg	MD	US	
Hamilton, Gregory S.	Catonsville	MD	US	

US-CL-CURRENT: 514/386; 514/423

ABSTRACT:

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.10&ref=9&dbname=PGPB,USPT,US...> 11/16/04

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using small molecule sulfonamides.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 16. Document ID: US 6641810 B2

L9: Entry 16 of 64

File: USPT

Nov 4, 2003

US-PAT-NO: 6641810

DOCUMENT-IDENTIFIER: US 6641810 B2

**** See image for Certificate of Correction ****

TITLE: Methods of using geldanamycin and FK506 to treat peripheral nerve damage

DATE-ISSUED: November 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 424/145.1; 514/183, 514/330, 514/423, 514/428, 514/465, 514/466

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBPS52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

34 Claims, 15 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 17. Document ID: US 6617333 B2

L9: Entry 17 of 64

File: USPT

Sep 9, 2003

US-PAT-NO: 6617333

DOCUMENT-IDENTIFIER: US 6617333 B2

TITLE: Antineoplastic combinations comprising

DATE-ISSUED: September 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rabindran; Sridhar K.	Chestnut Ridge	NY		
Gibbons, Jr.; James J.	Westwood	NJ		

DOCUMENT-IDENTIFIER: US 6486151 B2

TITLE: N-oxides of heterocyclic esters, amides, thioesters, and ketones

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Hampstead	MD		
Burak; Eric S.	Forest Hill	MD		

US-CL-CURRENT: 514/217.11; 514/311, 514/314, 514/315, 514/316, 514/318, 514/423, 540/529, 546/245, 548/530

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

7 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 20. Document ID: US 6462072 B1

L9: Entry 20 of 64

File: USPT

Oct 8, 2002

US-PAT-NO: 6462072

DOCUMENT-IDENTIFIER: US 6462072 B1

TITLE: Cyclic ester or amide derivatives

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Limburg; David C.	Baltimore	MD		

US-CL-CURRENT: 514/423; 548/533, 548/537

ABSTRACT:

This invention relates to low molecular weight, small molecule cyclic esters and amides having an affinity for FKBP-type immunophilins, pharmaceutical compositions comprising the same, and methods of using the same to effect a neuronal activity.

22 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 21. Document ID: US 6429215 B1

L9: Entry 21 of 64

File: USPT

Aug 6, 2002

US-PAT-NO: 6429215

DOCUMENT-IDENTIFIER: US 6429215 B1

TITLE: N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses

DATE-ISSUED: August 6, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Finksburg	MD		
Hamilton; Gregory S.	Catonsville	MD		

US-CL-CURRENT: 514/314; 514/343, 514/423, 514/880

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using an N-oxide of a heterocyclic ester, amide, thioester, or ketone.

10 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMOC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 22. Document ID: US 6399648 B1

L9: Entry 22 of 64

File: USPT

Jun 4, 2002

US-PAT-NO: 6399648

DOCUMENT-IDENTIFIER: US 6399648 B1

TITLE: N-oxides of heterocyclic ester, amide, thioester, or ketone for vision and memory disorders

DATE-ISSUED: June 4, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ross; Douglas T.	North Wales	PA		
Sauer; Hansjorg	Silver Spring	MD		
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Finksburg	MD		

US-CL-CURRENT: 514/423; 514/330, 514/331, 514/332

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using N-Oxides of heterocyclic esters, amides, thioesters, or ketones

26 Claims, 28 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 23. Document ID: US 6395758 B1

L9: Entry 23 of 64

File: USPT

May 28, 2002

US-PAT-NO: 6395758

DOCUMENT-IDENTIFIER: US 6395758 B1

TITLE: Small molecule carbamates or ureas for vision and memory disorders

DATE-ISSUED: May 28, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ross; Douglas T.	North Wales	PA		
Sauer; Hansjorg	Silver Spring	MD		
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Finksburg	MD		

US-CL-CURRENT: 514/330; 514/423

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using small molecule carbamates and ureas.

27 Claims, 28 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 24. Document ID: US 6384056 B1

L9: Entry 24 of 64

File: USPT

May 7, 2002

US-PAT-NO: 6384056

DOCUMENT-IDENTIFIER: US 6384056 B1

TITLE: Heterocyclic thioesters or ketones for vision and memory disorders

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ross; Douglas T.	North Wales	PA		
Sauer; Hansjorg	Silver Springs	MD		
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Finksburg	MD		

US-CL-CURRENT: 514/330; 514/211.08, 514/222.5, 514/229.5, 514/359, 514/360, 514/365, 514/423

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using heterocyclic thioesters and ketones.

52 Claims, 31 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 25. Document ID: US 6376517 B1

L9: Entry 25 of 64

File: USPT

Apr 23, 2002

US-PAT-NO: 6376517

DOCUMENT-IDENTIFIER: US 6376517 B1

TITLE: Pipecolic acid derivatives for vision and memory disorders

DATE-ISSUED: April 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ross; Douglas T.	North Wales	PA		
Sauer; Hansjorg	Silver Spring	MD		
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Finksburg	MD		

US-CL-CURRENT: 514/330; 514/326

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using pipecolic acid derivatives.

26 Claims, 28 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 26. Document ID: US 6339101 B1

L9: Entry 26 of 64

File: USPT

Jan 15, 2002

US-PAT-NO: 6339101

DOCUMENT-IDENTIFIER: US 6339101 B1

TITLE: N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders

DATE-ISSUED: January 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ross; Douglas T.	North Wales	PA		
Sauer; Hansjorg	Silver Spring	MD		
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Finksburg	MD		

US-CL-CURRENT: 514/424; 514/326, 514/330, 514/345, 514/360, 514/361, 514/423

ABSTRACT:

This invention relates to novel compositions and uses of a N-linked sulfonamide of an N-heterocyclic carboxylic acid or isostere thereof for treating a vision disorder or improving vision or treating memory impairment or enhancing memory performance in an animal.

24 Claims, 12 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	MMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 27. Document ID: US 6337340 B1

L9: Entry 27 of 64

File: USPT

Jan 8, 2002

US-PAT-NO: 6337340

DOCUMENT-IDENTIFIER: US 6337340 B1

TITLE: Carboxylic acids and isosteres of heterocyclic ring compounds having multiple heteroatoms for vision and memory disorders

DATE-ISSUED: January 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
------	------	-------	----------	---------

Ross; Douglas T.	North Wales	PA
Sauer; Hansjorg	Silver Spring	MD
Hamilton; Gregory S.	Catonsville	MD
Steiner; Joseph P.	Finksburg	MD

US-CL-CURRENT: 514/330; 514/222.5, 514/229.2, 514/381, 514/423

ABSTRACT:

This invention relates to novel compositions and uses of carboxylic acid or isostere of a heterocyclic ring compound having two or more heteroatoms within the heterocyclic ring and wherein the heterocyclic ring has at least one substituent attached thereto, the substituent selected from the group consisting of a diketo, a sulfonamide, a urea, a carbamate, and substituted derivatives thereof for treating a vision disorder or improving vision or treating memory impairment or enhancing memory performance in an animal.

24 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

☐ 28. Document ID: US 6335348 B1

L9: Entry 28 of 64

File: USPT

Jan 1, 2002

US-PAT-NO: 6335348

DOCUMENT-IDENTIFIER: US 6335348 B1

TITLE: Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders

DATE-ISSUED: January 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ross; Douglas T.	North Wales	PA		
Sauer; Hansjorg	Silver Spring	MD		
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Finksburg	MD		

US-CL-CURRENT: 514/317; 514/12, 514/318, 514/330, 514/423

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance in an animal, using pipecolic acid derivatives.

19 Claims, 31 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

☐ 29. Document ID: US 6333340 B1

L9: Entry 29 of 64

File: USPT

Dec 25, 2001

US-PAT-NO: 6333340

DOCUMENT-IDENTIFIER: US 6333340 B1

TITLE: Small molecule sulfonamides for vision and memory disorders

DATE-ISSUED: December 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ross; Douglas T.	North Wales	PA		
Sauer; Hansjorg	Silver Spring	MD		
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Finksburg	MD		

US-CL-CURRENT: 514/330; 514/317, 514/318, 514/343, 514/422, 514/423

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance in an animal using small molecule sulfonamides.

26 Claims, 28 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

☐ 30. Document ID: US 6294551 B1

L9: Entry 30 of 64

File: USPT

Sep 25, 2001

US-PAT-NO: 6294551

DOCUMENT-IDENTIFIER: US 6294551 B1

TITLE: N-linked sulfonamides of heterocyclic thioesters

DATE-ISSUED: September 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Li; Jai-He	Cockeysville	MD		
Huang; Wei	Baltimore	MD		

US-CL-CURRENT: 514/307; 514/212.01, 514/217.07, 514/309, 514/311, 514/312, 514/314, 514/315, 514/318, 514/323, 514/408, 514/422, 514/423, 514/424, 514/428, 540/597,

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.10&ref=9&dbname=PGPB,USPT,US...> 11/16/04

540/604, 540/607, 540/609, 540/610, 546/141, 546/146, 546/153, 546/172, 546/174,
546/176, 546/192, 546/200, 546/245, 546/248, 548/518, 548/519, 548/525, 548/530,
548/542, 548/556

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule N-linked sulfonamides of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

34 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 31. Document ID: US 6291510 B1

L9: Entry 31 of 64

File: USPT

Sep 18, 2001

US-PAT-NO: 6291510

DOCUMENT-IDENTIFIER: US 6291510 B1

**** See image for Certificate of Correction ****

TITLE: Small molecule inhibitors of rotamase enzyme activity

DATE-ISSUED: September 18, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Hampstead	MD		

US-CL-CURRENT: 514/423

ABSTRACT:

This invention relates to neurotrophic compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 32. Document ID: US 6274617 B1

L9: Entry 32 of 64

File: USPT

Aug 14, 2001

US-PAT-NO: 6274617

DOCUMENT-IDENTIFIER: US 6274617 B1

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.10&ref=9&dbname=PGPB,USPT,US...> 11/16/04

TITLE: Heterocyclic ester and amide hair growth compositions and uses

DATE-ISSUED: August 14, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Finksburg	MD		
Hamilton; Gregory S.	Catonsville	MD		

US-CL-CURRENT: 514/423; 514/315, 514/330, 514/340, 514/342, 514/880

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using heterocyclic esters or amides.

16 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 33. Document ID: US 6274602 B1

L9: Entry 33 of 64

File: USPT

Aug 14, 2001

US-PAT-NO: 6274602

DOCUMENT-IDENTIFIER: US 6274602 B1

TITLE: Heterocyclic thioester and ketone hair growth compositions and uses

DATE-ISSUED: August 14, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Finksburg	MD		
Hamilton; Gregory S.	Catonsville	MD		

US-CL-CURRENT: 514/330; 514/343, 514/414, 514/423, 514/880

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using heterocyclic thioesters and ketones.

36 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	MMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 34. Document ID: US 6251892 B1

US-PAT-NO: 6251892

DOCUMENT-IDENTIFIER: US 6251892 B1

**** See image for Certificate of Correction ****

TITLE: N-oxides of heterocyclic esters, amides, thioesters, and ketones

DATE-ISSUED: June 26, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Hampstead	MD		
Burak; Eric S.	Forest Hill	MD		

US-CL-CURRENT: 514/211.01; 514/211.08, 514/211.15, 514/217.11, 514/315, 514/423,
540/529, 546/245, 548/530

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters, amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

33 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Abstract	Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	----------	--------	------	----------

☐ 35. Document ID: US 6245783 B1

L9: Entry 35 of 64

File: USPT

Jun 12, 2001

US-PAT-NO: 6245783

DOCUMENT-IDENTIFIER: US 6245783 B1

**** See image for Certificate of Correction ****

TITLE: Method of using neurotrophic sulfonamide compounds

DATE-ISSUED: June 12, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Li; Jia-He	Cockeysville	MD		
Steiner; Joseph P.	Hampstead	MD		

US-CL-CURRENT: 514/330; 514/317, 514/318, 514/343, 514/422, 514/423

ABSTRACT:

This invention relates to a method of using neurotrophic low molecular weight, small molecule sulfonamide compounds having an affinity for FKBP-type immunophilins, as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 36. Document ID: US 6242468 B1

L9: Entry 36 of 64

File: USPT

Jun 5, 2001

US-PAT-NO: 6242468

DOCUMENT-IDENTIFIER: US 6242468 B1

**** See image for Certificate of Correction ****

TITLE: Carbamate and urea compositions and neurotrophic uses

DATE-ISSUED: June 5, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Li; Jia-He	Cockeysville	MD	21030	
Steiner; Joseph P.	Hampstead	MD	21074	
Hamilton; Gregory S.	Catonsville	MD	21228	

US-CL-CURRENT: 514/343; 514/316, 514/317, 514/330, 514/342, 514/423, 514/613

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for effecting a neuronal activity using low molecular weight, small molecule carbamates and ureas having an affinity for FKBP-type immunophilins.

44 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FWMC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	----------

☐ 37. Document ID: US 6239146 B1

L9: Entry 37 of 64

File: USPT

May 29, 2001

US-PAT-NO: 6239146

DOCUMENT-IDENTIFIER: US 6239146 B1

TITLE: Neurotrophic difluoroamide agents

DATE-ISSUED: May 29, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vrudhula; Vivekananda M.	Killingworth	CT		
Dubowchik; Gene M.	Middlefield	CT		
Dasgupta; Bireshwar	Middletown	CT		
Vyas; Dolatrai M.	Madison	CT		

US-CL-CURRENT: 514/318; 514/330, 514/343, 514/423, 546/226, 546/276.4, 546/279.1,
548/532, 548/533

ABSTRACT:

The present invention relates to the design, synthesis, and the peptidyl-prolyl isomerase (PPIase or rotamase) inhibitory activity of novel .alpha.,.alpha.-difluoroacetamido compounds that are neurotrophic agents (i.e. compounds capable of stimulating growth or proliferation of nervous tissue) and that bind to immunophilins such as FKBP12 and inhibit their rotamase activity. This invention also relates to pharmaceutical compositions comprising these compounds.

13 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 38. Document ID: US 6228872 B1

L9: Entry 38 of 64

File: USPT

May 8, 2001

US-PAT-NO: 6228872

DOCUMENT-IDENTIFIER: US 6228872 B1

TITLE: Neurotrophic diamide and carbamate agents

DATE-ISSUED: May 8, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dubowchik; Gene M.	Middlefield	CT		
Ditta; Jonathan L.	Middletown	CT		
Provencal; David P.	Middletown	CT		
Denhart; Derek J.	Wallingford	CT		

US-CL-CURRENT: 514/343; 514/414, 514/423, 546/279.1, 548/467, 548/530

ABSTRACT:

The present invention relates to the design, synthesis, and the peptidyl-prolyl isomerase (PPIase or rotamase) inhibitory activity of novel pyrrolidinemethyl diamide and carbamate compounds that are neurotrophic agents (i.e. compounds capable of stimulating growth or proliferation of nervous tissue) and that bind to immunophilins such as FKBP12 and inhibit their rotamase activity. This invention also relates to pharmaceutical compositions comprising these compounds.

7 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 39. Document ID: US 6218424 B1

L9: Entry 39 of 64

File: USPT

Apr 17, 2001

US-PAT-NO: 6218424

DOCUMENT-IDENTIFIER: US 6218424 B1

**** See image for Certificate of Correction ****

TITLE: Heterocyclic ketone and thioester compounds and uses

DATE-ISSUED: April 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Li; Jia-He	Cockeysville	MD		

US-CL-CURRENT: 514/423; 514/315, 514/330, 514/343, 546/226, 546/279.1, 548/530, 548/539, 548/540

ABSTRACT:

This invention relates to neurotrophic, low molecular weight, small molecule heterocyclic ketone and thioester compounds, compositions containing the same, and the use of such compounds for treating neurological disorders, including physically damaged nerves and neurodegenerative diseases.

75 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 40. Document ID: US 6218423 B1

L9: Entry 40 of 64

File: USPT

Apr 17, 2001

US-PAT-NO: 6218423

DOCUMENT-IDENTIFIER: US 6218423 B1

TITLE: Pyrrolidine derivatives for vision and memory disorders

DATE-ISSUED: April 17, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ross; Douglas T.	North Wales	PA		
Sauer; Hansjorg	Silver Spring	MD		
Hamilton; Gregory S.	Catonsville	MD		

US-CL-CURRENT: 514/423; 514/422, 514/427

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating a vision disorder, improving vision, treating memory impairment, or enhancing memory performance using pyrrolidine derivatives.

37 Claims, 31 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 12

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 41. Document ID: US 6187806 B1

L9: Entry 41 of 64

File: USPT

Feb 13, 2001

US-PAT-NO: 6187806

DOCUMENT-IDENTIFIER: US 6187806 B1

TITLE: N-linked sulfone of heterocyclic thioester hair growth compositions and uses

DATE-ISSUED: February 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Finksburg	MD		
Hamilton; Gregory S.	Catonsville	MD		

US-CL-CURRENT: 514/428; 514/277, 514/336, 514/342, 514/343, 514/880

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using N-linked sulfonamides of heterocyclic thioesters.

15 Claims, 5 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KMMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 42. Document ID: US 6187796 B1

L9: Entry 42 of 64

File: USPT

Feb 13, 2001

US-PAT-NO: 6187796

DOCUMENT-IDENTIFIER: US 6187796 B1

TITLE: Sulfone hair growth compositions and uses

DATE-ISSUED: February 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Finksburg	MD		
Hamilton; Gregory S.	Catonsville	MD		

US-CL-CURRENT: 514/326; 514/330, 514/340, 514/880

ABSTRACT:

This invention relates to pharmaceutical compositions and methods for treating alopecia and promoting hair growth using small molecule sulfonamides.

11 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 43. Document ID: US 6140357 A

L9: Entry 43 of 64

File: USPT

Oct 31, 2000

US-PAT-NO: 6140357

DOCUMENT-IDENTIFIER: US 6140357 A

**** See image for Certificate of Correction ****

TITLE: Small molecule inhibitors of rotamase enzyme activity

DATE-ISSUED: October 31, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Hampstead	MD		

US-CL-CURRENT: 514/423

ABSTRACT:

This invention relates to neurotrophic N-glyoxylprolyl ester compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

11 Claims, 8 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 44. Document ID: US 6054452 A

L9: Entry 44 of 64

File: USPT

Apr 25, 2000

US-PAT-NO: 6054452

DOCUMENT-IDENTIFIER: US 6054452 A

**** See image for Certificate of Correction ****

TITLE: N-oxides of heterocyclic esters, amides, thioesters, and ketones

DATE-ISSUED: April 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Hampstead	MD		
Burak; Eric S.	Forest Hill	MD		

US-CL-CURRENT: 514/217.11; 514/315, 514/423, 540/529, 546/245, 548/530

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters, amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

4 Claims, 1 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	RMIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	------	------------

☐ 45. Document ID: US 6037370 A

L9: Entry 45 of 64

File: USPT

Mar 14, 2000

US-PAT-NO: 6037370

DOCUMENT-IDENTIFIER: US 6037370 A

**** See image for Certificate of Correction ****

TITLE: Methods and compositions for stimulating neurite growth

DATE-ISSUED: March 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armistead; David M.	Maynard	MA		

US-CL-CURRENT: 514/533; 514/330, 514/423, 514/428, 514/438, 514/465, 514/466, 514/534, 514/538, 514/547, 514/549, 514/551

ABSTRACT:

The present invention relates to methods and pharmaceutical compositions for stimulating the growth of neurites in nerve cells. The compositions comprise a neurotrophic amount of a compound which binds to the FK-506 binding protein (FKBP) and a neurotrophic factor, such as nerve growth factor NGF. The methods comprise treating nerve cells with the above-described compositions or compositions comprising the FKBP binding compound without a neurotrophic factor. The methods of this invention can be used to promote repair of neuronal damage caused by disease or physical trauma.

11 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 46. Document ID: US 6022878 A

L9: Entry 46 of 64

File: USPT

Feb 8, 2000

US-PAT-NO: 6022878

DOCUMENT-IDENTIFIER: US 6022878 A

**** See image for Certificate of Correction ****

TITLE: Inhibitors of rotamase enzyme activity

DATE-ISSUED: February 8, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Hampstead	MD		
Snyder; Solomon	Baltimore	MD		
Hamilton; Gregory S.	Catonsville	MD		
Dawson; Ted	Baltimore	MD		

US-CL-CURRENT: 514/317; 514/12, 514/318, 514/330

ABSTRACT:

This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.

42 Claims, 55 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 23

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 47. Document ID: US 5990131 A

L9: Entry 47 of 64

File: USPT

Nov 23, 1999

US-PAT-NO: 5990131

DOCUMENT-IDENTIFIER: US 5990131 A

**** See image for Certificate of Correction ****

TITLE: Heterocyclic thioesters and ketones

DATE-ISSUED: November 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Li; Jia-He	Cockeysville	MD		

US-CL-CURRENT: 514/330; 514/422, 514/423, 546/226, 548/533, 548/540

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule heterocyclic thioesters and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

58 Claims, 13 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	--------------

☐ 48. Document ID: US 5968957 A

L9: Entry 48 of 64

File: USPT

Oct 19, 1999

US-PAT-NO: 5968957

DOCUMENT-IDENTIFIER: US 5968957 A

**** See image for Certificate of Correction ****

TITLE: Method of using neurotrophic sulfonamide compounds

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Li; Jia-He	Cockeysville	MD		
Steiner; Joseph P.	Hampstead	MD		

US-CL-CURRENT: 514/330; 514/317, 514/318, 514/343, 514/422, 514/423

ABSTRACT:

This invention relates to a method of using neurotrophic low molecular weight, small molecule piperidine and pyrrolidine sulfonamide compounds having an affinity for FKBP-type immunophilins, as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 49. Document ID: US 5968921 A

L9: Entry 49 of 64

File: USPT

Oct 19, 1999

US-PAT-NO: 5968921

DOCUMENT-IDENTIFIER: US 5968921 A

**** See image for Certificate of Correction ****

TITLE: Compositions and methods for promoting nerve regeneration

DATE-ISSUED: October 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gold; Bruce G.	West Linn	OR		

US-CL-CURRENT: 514/183; 514/330, 514/423, 514/428, 514/465, 514/466, 514/534,
514/547, 514/548, 514/549

ABSTRACT:

FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid hormone binding portion of the complex (FKBP52 and hsp90, respectively). These and other agents cause hsp90 dissociation from steroid receptor complexes or block association of hsp90 with steroid receptor complexes.

36 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 50. Document ID: US 5935989 A

L9: Entry 50 of 64

File: USPT

Aug 10, 1999

US-PAT-NO: 5935989

DOCUMENT-IDENTIFIER: US 5935989 A

**** See image for Certificate of Correction ****

TITLE: N-linked ureas and carbamates of heterocyclic thioesters

DATE-ISSUED: August 10, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		

Li; Jia-He
Huang; Wei

Cockeysville MD
Baltimore MD

US-CL-CURRENT: 514/423; 548/533

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule N-linked ureas and carbamates of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

21 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 51. Document ID: US 5935954 A

L9: Entry 51 of 64

File: USPT

Aug 10, 1999

US-PAT-NO: 5935954
DOCUMENT-IDENTIFIER: US 5935954 A

TITLE: Compounds with improved multi-drug resistance activity

DATE-ISSUED: August 10, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Armistead; David M.	Maynard	MA		
Saunders; Jeffrey O.	Acton	MA		

US-CL-CURRENT: 514/235.2; 514/235.5, 514/237.2, 514/343, 514/422, 514/423, 544/124, 544/141, 544/143, 544/186, 544/187, 544/193, 544/194, 544/360, 544/372, 544/59, 546/279.1, 548/517, 548/518, 548/531, 548/536

ABSTRACT:

The present invention relates to compounds that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, and for use in multi-drug resistant cancer therapy.

16 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 52. Document ID: US 5874449 A

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.10&ref=9&dbname=PGPB,USPT,US...> 11/16/04

US-PAT-NO: 5874449

DOCUMENT-IDENTIFIER: US 5874449 A

**** See image for Certificate of Correction ****

TITLE: N-linked sulfonamides of heterocyclic thioesters

DATE-ISSUED: February 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Li; Jia-He	Cockeysville	MD		
Huang; Wei	Baltimore	MD		

US-CL-CURRENT: 514/330; 514/423, 514/424, 546/192, 546/245, 548/530, 548/542

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule N-linked sulfonamides of heterocyclic thioesters having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

33 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	------	----------

☐ 53. Document ID: US 5871753 A

L9: Entry 53 of 64

File: USPT

Feb 16, 1999

US-PAT-NO: 5871753

DOCUMENT-IDENTIFIER: US 5871753 A

TITLE: Regulated transcription of targeted genes and other biological events

DATE-ISSUED: February 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Crabtree; Gerald R.	Woodside	CA		
Schreiber; Stuart L.	Boston	MA		
Spencer; David M.	Los Altos	CA		
Wandless; Thomas J.	Cambridge	MA		
Belshaw; Peter	Somerville	MA		
Ho; Steffan	Menlo Park	CA		

US-CL-CURRENT: 424/280.1; 514/183, 514/27, 530/317

ABSTRACT:

Methods and compositions are provided for modified cells, where a chimeric protein consisting of a ligand binding domain fused to an action domain is employed which initiates a signal which activates a biological process: transcription of at least one gene, usually a second construct introduced into the host cells; exocytosis; or an extracellular process. The second construct optimally present provides for a promoter which responds to a transcriptional activation action domain to provide for transcription, when an appropriate ligand binds to the ligand binding domain. Exemplary of the system is the use of an FKBP/CD3.zeta. or transcription factor fusion protein, using dimeric FK506 or FK520 as the ligand and a promoter responsive to NF-AT or other transcription factor requiring two molecules for transcriptional activation.

35 Claims, 22 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 22

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 54. Document ID: US 5859031 A

L9: Entry 54 of 64

File: USPT

Jan 12, 1999

US-PAT-NO: 5859031

DOCUMENT-IDENTIFIER: US 5859031 A

**** See image for Certificate of Correction ****

TITLE: Small molecule inhibitors of rotamase enzyme activity

DATE-ISSUED: January 12, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Hampstead	MD		

US-CL-CURRENT: 514/343; 514/365, 514/422, 514/423, 546/279.1, 548/204, 548/517,
548/526, 548/527, 548/533, 548/538

ABSTRACT:

This invention relates to neurotrophic N-glyoxyl-prolyl ester compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

19 Claims, 26 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 55. Document ID: US 5846981 A

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.10&ref=9&dbname=PGPB,USPT,US...> 11/16/04

US-PAT-NO: 5846981

DOCUMENT-IDENTIFIER: US 5846981 A

**** See image for Certificate of Correction ****

TITLE: Inhibitors of rotamase enzyme activity

DATE-ISSUED: December 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Hampstead	MD		
Snyder; Solomon	Baltimore	MD		
Hamilton; Gregory S.	Catonsville	MD		
Dawson; Ted	Baltimore	MD		

US-CL-CURRENT: 514/317; 514/12, 514/318, 514/330

ABSTRACT:

This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.

10 Claims, 49 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 21

Full	Title	Citation	Front	Review	Classification	Date	Reference				Claims	MMIC	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--	--------	------	----------

☐ 56. Document ID: US 5846979 A

L9: Entry 56 of 64

File: USPT

Dec 8, 1998

US-PAT-NO: 5846979

DOCUMENT-IDENTIFIER: US 5846979 A

**** See image for Certificate of Correction ****

TITLE: N-oxides of heterocyclic esters, amides, thioesters, and ketones

DATE-ISSUED: December 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Hampstead	MD		
Burak; Eric S.	Forest Hill	MD		

US-CL-CURRENT: 514/311; 514/314, 514/316, 514/317, 514/318, 514/320, 514/323,
514/326, 514/332, 514/336, 514/337, 514/339, 514/354, 514/423, 540/597, 540/602,
540/603, 540/607, 540/608, 546/168, 546/186, 546/193, 546/205, 548/517, 548/518,

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule N-oxides of heterocyclic esters, amides, thioesters, and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

20 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 57. Document ID: US 5843960 A

L9: Entry 57 of 64

File: USPT

Dec 1, 1998

US-PAT-NO: 5843960

DOCUMENT-IDENTIFIER: US 5843960 A

**** See image for Certificate of Correction ****

TITLE: Inhibitors of rotamase enzyme activity

DATE-ISSUED: December 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Hampstead	MD		
Snyder; Solomon	Baltimore	MD		
Hamilton; Gregory S.	Catonsville	MD		
Dawson; Ted	Baltimore	MD		

US-CL-CURRENT: 514/317; 514/12, 514/318, 514/330

ABSTRACT:

This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.

6 Claims, 51 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 58. Document ID: US 5801197 A

L9: Entry 58 of 64

File: USPT

Sep 1, 1998

<http://westbrs:9000/bin/gate.exe?f=TOC&state=1clt8p.10&ref=9&dbname=PGPB,USPT,US...> 11/16/04

US-PAT-NO: 5801197
DOCUMENT-IDENTIFIER: US 5801197 A

TITLE: Rotamase enzyme activity inhibitors

DATE-ISSUED: September 1, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Hampstead	MD		
Hamilton; Gregory S.	Catonsville	MD		

US-CL-CURRENT: 514/548; 514/330, 514/423, 514/428, 514/465, 514/466, 514/534,
514/538, 514/547, 514/549, 514/551, 549/441, 560/170, 560/39, 560/43

ABSTRACT:

This invention relates to the method of using specially formulated neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.

4 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full	Title	Creation	Front	Review	Classification	Date	Reference			Claims	FIGS	Drawing Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	-------------

☐ 59. Document ID: US 5798355 A

L9: Entry 59 of 64

File: USPT

Aug 25, 1998

US-PAT-NO: 5798355
DOCUMENT-IDENTIFIER: US 5798355 A
**** See image for Certificate of Correction ****

TITLE: Inhibitors of rotamase enzyme activity

DATE-ISSUED: August 25, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Hampstead	MD		
Snyder; Solomon	Baltimore	MD		
Hamilton; Gregory S.	Catonsville	MD		
Dawson; Ted	Baltimore	MD		

US-CL-CURRENT: 514/248; 514/293, 514/300, 514/302, 514/318, 514/326, 514/330

ABSTRACT:

This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of

peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.

34 Claims, 40 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 60. Document ID: US 5795908 A

L9: Entry 60 of 64

File: USPT

Aug 18, 1998

US-PAT-NO: 5795908

DOCUMENT-IDENTIFIER: US 5795908 A

**** See image for Certificate of Correction ****

TITLE: Small molecule inhibitors of rotamase enzyme activity

DATE-ISSUED: August 18, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Hampstead	MD		

US-CL-CURRENT: 514/423; 548/533

ABSTRACT:

This invention relates to neurotrophic N-glyoxyl-prolyl ester compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

15 Claims, 8 Drawing figures
Exemplary Claim Number: 7
Number of Drawing Sheets: 8

Full	Title	Citation	Front	Review	Classification	Date	Reference	Claims	KWIC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--------	------	------------

☐ 61. Document ID: US 5786378 A

L9: Entry 61 of 64

File: USPT

Jul 28, 1998

US-PAT-NO: 5786378

DOCUMENT-IDENTIFIER: US 5786378 A

**** See image for Certificate of Correction ****

TITLE: Heterocyclic thioesters

DATE-ISSUED: July 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Li; Jia-He	Cockeysville	MD		

US-CL-CURRENT: 514/423; 548/533

ABSTRACT:

This invention relates to neurotrophic low molecular weight, small molecule heterocyclic thioesters and ketones having an affinity for FKBP-type immunophilins, and their use as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

43 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 62. Document ID: US 5721256 A

L9: Entry 62 of 64

File: USPT

Feb 24, 1998

US-PAT-NO: 5721256

DOCUMENT-IDENTIFIER: US 5721256 A

TITLE: Method of using neurotrophic sulfonamide compounds

DATE-ISSUED: February 24, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Li; Jia-He	Cockeysville	MD		
Steiner; Joseph P.	Hampstead	MD		

US-CL-CURRENT: 514/330; 514/317, 514/318, 514/343, 514/422, 514/423

ABSTRACT:

This invention relates to a method of using neurotrophic low molecular weight, small molecule sulfonamide compounds having an affinity for FKBP-type immunophilins, as inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme activity.

16 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	FIGS	Draw Des
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	----------

☐ 63. Document ID: US 5696135 A

US-PAT-NO: 5696135

DOCUMENT-IDENTIFIER: US 5696135 A

**** See image for Certificate of Correction ****

TITLE: Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth

DATE-ISSUED: December 9, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steiner; Joseph P.	Hampstead	MD		
Snyder; Solomon	Baltimore	MD		
Hamilton; Gregory S.	Catonsville	MD		

US-CL-CURRENT: 514/317; 514/12, 514/318, 514/330

ABSTRACT:

This invention relates to the method of using neurotrophic pipecolic acid derivative compounds having an affinity for FKBP-type immunophilins as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity to stimulate or promote neuronal growth or regeneration.

14 Claims, 51 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 21

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	Form	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	------	------------

☐ 64. Document ID: US 5614547 A

L9: Entry 64 of 64

File: USPT

Mar 25, 1997

US-PAT-NO: 5614547

DOCUMENT-IDENTIFIER: US 5614547 A

**** See image for Certificate of Correction ****

TITLE: Small molecule inhibitors of rotamase enzyme

DATE-ISSUED: March 25, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamilton; Gregory S.	Catonsville	MD		
Steiner; Joseph P.	Hampstead	MD		

US-CL-CURRENT: 514/423; 514/365, 514/422, 548/204, 548/517, 548/526, 548/527, 548/533, 548/538

ABSTRACT:

This invention relates to neurotrophic compounds having an affinity for FKBP-type immunophilins, their preparation and use as inhibitors of the enzyme activity associated with immunophilin proteins, and particularly inhibitors of peptidyl-prolyl isomerase or rotamase enzyme activity.

17 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	AMC	Draw. Des.
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	------------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------


Terms	Documents
L8 AND FKBP12	64

Display Format:

[Previous Page](#)

[Next Page](#)

[Go to Doc#](#)



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for FKBP12 AND ansamycin Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Meyer BK, Petrulis JR, Perdew GH.

Related Articles, LI



Aryl hydrocarbon (Ah) receptor levels are selectively modulated by hsp90-associated immunophilin homolog XAP2.

Cell Stress Chaperones. 2000 Jul;5(3):243-54.

PMID: 11005382 [PubMed - indexed for MEDLINE]


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 8 2004 18:23:56



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for FKBP12 AND benzoquinone Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: Meyer BK, Petrulis JR, Perdew GH.

Related Articles, L



Aryl hydrocarbon (Ah) receptor levels are selectively modulated by hsp90-associated immunophilin homolog XAP2.

Cell Stress Chaperones. 2000 Jul;5(3):243-54.

PMID: 11005382 [PubMed - indexed for MEDLINE]


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 8 2004 18:23:56



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search for

Limits Preview/Index History Clipboard Details

Show:

About Entrez

Text Version

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services

Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources

Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 7 of 7

One p

- ☐ 1: [Birge RB, Wadsworth S, Akakura R, Abeysinghe H, Kanojia R, Maclellag M, Desbarats J, Escalante M, Singh K, Sundarababu S, Parris K, Childs G, August A, Siekierka J, Weinstein DE.](#)

Related Articles, Li

☐ A role for schwann cells in the neuroregenerative effects of a non-immunosuppressive fk506 derivative, jnj460.
Neuroscience. 2004;124(2):351-66.
PMID: 14980385 [PubMed - indexed for MEDLINE]

- ☐ 2: [Zhang C, Steiner JP, Hamilton GS, Hicks TP, Poulter MO.](#)

Related Articles, Li

☐ Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats b neuroimmunophilin ligand treatment.
J Neurosci. 2001 Aug 1;21(15):RC156.
PMID: 11459877 [PubMed - indexed for MEDLINE]

- ☐ 3: [Costantini LC, Cole D, Chaturvedi P, Isacson O.](#)

Related Articles, Li

☐ Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease.
Eur J Neurosci. 2001 Mar;13(6):1085-92.
PMID: 11285005 [PubMed - indexed for MEDLINE]

- ☐ 4: [Bocquet A, Lorent G, Fuks B, Grimee R, Talaga P, Daliers J, Klitgaard H.](#)

Related Articles, Li

☐ Failure of GPI compounds to display neurotrophic activity in vitro and in vivo
Eur J Pharmacol. 2001 Mar;164(2-3):173-80.
PMID: 11274996 [PubMed - indexed for MEDLINE]

- ☐ 5: [Gold BG.](#)

Related Articles, Li

☐ Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders.
Expert Opin Investig Drugs. 2000 Oct;9(10):2331-42. Review.
PMID: 11060810 [PubMed - indexed for MEDLINE]

- ☐ 6: [Costantini LC, Isacson O.](#)

Related Articles, Li

☐ Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture.
Exp Neurol. 2000 Jul;164(1):60-70.
PMID: 10877916 [PubMed - indexed for MEDLINE]

- ☐ 7: [Amara JF, Courage NL, Gilman M.](#)

Related Articles, Li


☐ Cell surface tagging and a suicide mechanism in a single chimeric human protein.
Hum Gene Ther. 1999 Nov 1;10(16):2651-5.
PMID: 10566892 [PubMed - indexed for MEDLINE]

Show:

[Write to the Help Desk](#)

NCBI | NLM | NIH

Department of Health & Human Services



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for FKBP12 AND spinal cord Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 4 of 4

One p

Text Version

☐ 1: [Kihira T, Hironishi M, Utunomiya H, Kondo T.](#)

[Related Articles, Li](#)



FKBP12 immunoreactivity in the human spinal cord of motor neuron disease patients.

Neuropathology. 2002 Dec;22(4):269-74.

PMID: 12564766 [PubMed - indexed for MEDLINE]

☐ 2: [Manabe Y, Warita H, Murakami T, Shiote M, Hayashi T, Omori N, Nagano I, Shoji M, Abe K.](#)

[Related Articles, Li](#)



Early decrease of the immunophilin FKBP 52 in the spinal cord of a transgenic model for amyotrophic lateral sclerosis.

Brain Res. 2002 May 10;935(1-2):124-8.

PMID: 12062482 [PubMed - indexed for MEDLINE]

☐ 3: [Kato H, Oikawa T, Otsuka K, Takahashi A, Itoyama Y.](#)

[Related Articles, Li](#)



Postischemic changes in the immunophilin FKBP12 in the rat brain.

Brain Res Mol Brain Res. 2000 Dec 8;84(1-2):58-66.

PMID: 11113532 [PubMed - indexed for MEDLINE]

☐ 4: [Gold BG.](#)

[Related Articles, Li](#)



Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders.

Expert Opin Investig Drugs. 2000 Oct;9(10):2331-42. Review.

PMID: 11060810 [PubMed - indexed for MEDLINE]

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 8 2004 18:23:56



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for benzoquinone ansamycin Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Items 1 - 59 of 59

One p

Text Version

☐ 1: [Smith NF, Hayes A, Nutley BP, Raynaud FI, Workman P.](#)

[Related Articles, LI](#)

Evaluation of the cassette dosing approach for assessing the pharmacokinetics geldanamycin analogues in mice.

Cancer Chemother Pharmacol. 2004 Dec;54(6):475-86. Epub 2004 Jul 29.

PMID: 15526201 [PubMed - in process]

☐ 2: [McLean PJ, Klucken J, Shin Y, Hyman BT.](#)

[Related Articles, LI](#)

Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro.

Biochem Biophys Res Commun. 2004 Aug 27;321(3):665-9.

PMID: 15358157 [PubMed - indexed for MEDLINE]

☐ 3: [Smith NF, Hayes A, Nutley BP, Raynaud FI, Workman P.](#)

[Related Articles, LI](#)

Evaluation of the cassette dosing approach for assessing the pharmacokinetics geldanamycin analogues in mice.

Cancer Chemother Pharmacol. 2004 Jul 29 [Epub ahead of print]

PMID: 15290098 [PubMed - as supplied by publisher]

☐ 4: [Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R.](#)

[Related Articles, LI](#)

Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.

Clin Cancer Res. 2004 Jul 15;10(14):4813-21.

PMID: 15269157 [PubMed - in process]

☐ 5: [Barzilay E, Ben-Califa N, Supino-Rosin L, Kashman Y, Hirschberg K, Elazar Z, Neumann D.](#)

[Related Articles, LI](#)

Geldanamycin-associated inhibition of intracellular trafficking is attributed to co-purified activity.

J Biol Chem. 2004 Feb 20;279(8):6847-52. Epub 2003 Dec 01.

PMID: 14660597 [PubMed - indexed for MEDLINE]

☐ 6: [Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ.](#)

[Related Articles, LI](#)

Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite in tumor bearing mice.

J Pharmacokinet Pharmacodyn. 2003 Jun;30(3):185-219.

PMID: 14571691 [PubMed - indexed for MEDLINE]

☐ 7: [Uehara Y.](#)

[Related Articles, LI](#)

Natural product origins of Hsp90 inhibitors.

Curr Cancer Drug Targets. 2003 Oct;3(5):325-30. Review.

PMID: 14529384 [PubMed - indexed for MEDLINE]

☐ 8: [Kumar R, Musiyenko A, Barik S.](#)

[Related Articles, LI](#)

The heat shock protein 90 of Plasmodium falciparum and antimalarial activity

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts


ClinicalTrials.gov

PubMed Central

its inhibitor, geldanamycin.

Malar J. 2003 Sep 15;2(1):30. Print 2003 Sep 15.

PMID: 14514358 [PubMed - indexed for MEDLINE]


-  **9:** Goetz MP, Toft DO, Ames MM, Erlichman C. Related Articles, Li



The Hsp90 chaperone complex as a novel target for cancer therapy.

Ann Oncol. 2003 Aug;14(8):1169-76. Review.

PMID: 12881371 [PubMed - indexed for MEDLINE]


-  **10:** Zagzag D, Nomura M, Friedlander DR, Blanco CY, Gagner JP, Nomura N, Newcomb EW. Related Articles, Li



Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion.

J Cell Physiol. 2003 Aug;196(2):394-402.

PMID: 12811834 [PubMed - indexed for MEDLINE]

-  **11:** Musser SM, Egorin MJ, Zuhowski EG, Hamburger DR, Parise RA, Covey JM, White KD, Eiseman JL. Related Articles, Li



Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats.

Cancer Chemother Pharmacol. 2003 Aug;52(2):139-46. Epub 2003 May 22.

PMID: 12761648 [PubMed - indexed for MEDLINE]


-  **12:** Neckers L. Related Articles, Li



Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.

Curr Med Chem. 2003 May;10(9):733-9. Review.

PMID: 12678776 [PubMed - indexed for MEDLINE]


-  **13:** Wax S, Piecyk M, Maritim B, Anderson P. Related Articles, Li



Geldanamycin inhibits the production of inflammatory cytokines in activated macrophages by reducing the stability and translation of cytokine transcripts.

Arthritis Rheum. 2003 Feb;48(2):541-50.

PMID: 12571865 [PubMed - indexed for MEDLINE]


-  **14:** Kim S, Kang J, Hu W, Evers BM, Chung DH. Related Articles, Li



Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas.

Int J Cancer. 2003 Jan 20;103(3):352-9.

PMID: 12471618 [PubMed - indexed for MEDLINE]


-  **15:** Lu A, Ran R, Parmentier-Batteur S, Nee A, Sharp FR. Related Articles, Li



Geldanamycin induces heat shock proteins in brain and protects against focal cerebral ischemia.

J Neurochem. 2002 Apr;81(2):355-64.

PMID: 12064483 [PubMed - indexed for MEDLINE]


-  **16:** Mahjesh NJ, Post DE, Willard MT, Kaur B, Van Meir EG, Simons JW, Zhong H. Related Articles, Li



Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteasome pathway in prostate cancer cells.

Cancer Res. 2002 May 1;62(9):2478-82.


PMID: 11980636 [PubMed - indexed for MEDLINE]


-  **17:** Billecke SS, Bender AT, Kanelakis KC, Murphy PJ, Lowe ER, Kamada Y, Pratt WB, Osawa Y. Related Articles, Li




hsp90 is required for heme binding and activation of apo-neuronal nitric-oxide synthase: geldanamycin-mediated oxidant generation is unrelated to any action of hsp90.


J Biol Chem. 2002 Jun 7;277(23):20504-9. Epub 2002 Mar 28.
PMID: 11923316 [PubMed - indexed for MEDLINE]

-  **18:** Xu W, Mimnaugh EG, Kim JS, Trepel JB, Neckers LM. Related Articles, Li


 **Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2.**


Cell Stress Chaperones. 2002 Jan;7(1):91-6.
PMID: 11892991 [PubMed - indexed for MEDLINE]

-  **19:** Bonvini P, Gastaldi T, Falini B, Rosolen A. Related Articles, Li


 **Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosin phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.**


Cancer Res. 2002 Mar 1;62(5):1559-66.
PMID: 11888936 [PubMed - indexed for MEDLINE]

-  **20:** Egorin MJ, Lagattuta TF, Hamburger DR, Covey JM, White KD, Musser SM, Eiseman JL. Related Articles, Li


 **Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.**


Cancer Chemother Pharmacol. 2002 Jan;49(1):7-19.
PMID: 11855755 [PubMed - indexed for MEDLINE]

-  **21:** Soga S, Sharma SV, Shiotsu Y, Shimizu M, Tahara H, Yamaguchi K, Ikuina Y, Murakata C, Tamaoki T, Kurebayashi J, Schulte TW, Neckers LM, Akinaga S. Related Articles, Li


 **Stereospecific antitumor activity of radicicol oxime derivatives.**


Cancer Chemother Pharmacol. 2001 Dec;48(6):435-45.
PMID: 11800023 [PubMed - indexed for MEDLINE]

-  **22:** Kasuya Y, Lu ZR, Kopeckova P, Minko T, Tabibi SE, Kopecek J. Related Articles, Li


 **Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates.**


J Control Release. 2001 Jul 6;74(1-3):203-11.
PMID: 11489496 [PubMed - indexed for MEDLINE]

-  **23:** Malhotra V, Shanley TP, Pittet JF, Welch WJ, Wong HR. Related Articles, Li

 **Geldanamycin inhibits NF-kappaB activation and interleukin-8 gene expression in cultured human respiratory epithelium.**


Am J Respir Cell Mol Biol. 2001 Jul;25(1):92-7.
PMID: 11472980 [PubMed - indexed for MEDLINE]

-  **24:** Sittler A, Lurz R, Lueder G, Priller J, Lehrach H, Hayer-Jarstl MK, Jarstl FU, Wanker EE. Related Articles, Li

 **Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease.**

Hum Mol Genet. 2001 Jun 1;10(12):1307-15. Erratum in: Hum Mol Genet 2001 Aug 1;10(16):1719.
PMID: 11406612 [PubMed - indexed for MEDLINE]

-  **25:** Yang J, Yang JM, Iannone M, Shih WJ, Lin Y, Hait WN. Related Articles, Li

 **Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin.**

Cancer Res. 2001 May 15;61(10):4010-6.
PMID: 11358819 [PubMed - indexed for MEDLINE]

-  **26:** Rosenhagen MC, Young JC, Wozniak GM, Herr AS, Schmidt U, Jarstl Related Articles, Li

[FU, Holsboer F, Rein T.](#)



Synergistic inhibition of the glucocorticoid receptor by radicicol and benzoquinone ansamycins.

Biol Chem. 2001 Mar;382(3):499-504.

PMID: 11347901 [PubMed - indexed for MEDLINE]

☐ **27:** [Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL.](#) [Related Articles, LI](#)



Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.

Cancer Chemother Pharmacol. 2001 Apr;47(4):291-302.

PMID: 11345645 [PubMed - indexed for MEDLINE]

☐ **28:** [Vrana JA, Grant S.](#) [Related Articles, LI](#)



Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade.

Blood. 2001 Apr 1;97(7):2105-14.

PMID: 11264178 [PubMed - indexed for MEDLINE]

☐ **29:** [Xu W, Minnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L.](#) [Related Articles, LI](#)



Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.

J Biol Chem. 2001 Feb 2;276(5):3702-8. Epub 2000 Nov 08.

PMID: 11071886 [PubMed - indexed for MEDLINE]

☐ **30:** [Meyer BK, Petrusis JR, Perdew GH.](#) [Related Articles, LI](#)



Aryl hydrocarbon (Ah) receptor levels are selectively modulated by hsp90-associated immunophilin homolog XAP2.

Cell Stress Chaperones. 2000 Jul;5(3):243-54.

PMID: 11005382 [PubMed - indexed for MEDLINE]

☐ **31:** [Stead P, Latif S, Blackaby AP, Sidebottom PJ, Deakin A, Taylor NL, Life P, Spaul J, Burrell F, Jones R, Lewis J, Davidson I, Mander T.](#) [Related Articles, LI](#)



Discovery of novel ansamycins possessing potent inhibitory activity in a cell based oncostatin M signalling assay.

J Antibiot (Tokyo). 2000 Jul;53(7):657-63.

PMID: 10994806 [PubMed - indexed for MEDLINE]

☐ **32:** [An WG, Schulte TW, Neckers LM.](#) [Related Articles, LI](#)



The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.

Cell Growth Differ. 2000 Jul;11(7):355-60.

PMID: 10939589 [PubMed - indexed for MEDLINE]

☐ **33:** [Stanciu M, Wang Y, Kentor R, Burke N, Watkins S, Kress G, Reynolds L, Klann E, Angiolieri MR, Johnson JW, DeFranco DB.](#) [Related Articles, LI](#)



Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures.

J Biol Chem. 2000 Apr 21;275(16):12200-6.

PMID: 10766856 [PubMed - indexed for MEDLINE]




















☐ **34:** [Neckers L, Schulte TW, Minnaugh E.](#) [Related Articles, LI](#)






















Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity.


Invest New Drugs. 1999;17(4):361-73. Review.

PMID: 10759403 [PubMed - indexed for MEDLINE]

-  **35:** [Kim HR, Kang HS, Kim HD.](#) Related Articles, Li
 Geldanamycin induces heat shock protein expression through activation of HSF1 in K562 erythroleukemic cells.
IUBMB Life. 1999 Oct;48(4):429-33.
PMID: 10632574 [PubMed - indexed for MEDLINE]
-  **36:** [Kim HR, Lee CH, Choi YH, Kang HS, Kim HD.](#) Related Articles, Li
 Geldanamycin induces cell cycle arrest in K562 erythroleukemic cells.
IUBMB Life. 1999 Oct;48(4):425-8.
PMID: 10632573 [PubMed - indexed for MEDLINE]
-  **37:** [Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P.](#) Related Articles, Li
 DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
J Natl Cancer Inst. 1999 Nov 17;91(22):1940-9.
PMID: 10564678 [PubMed - indexed for MEDLINE]
-  **38:** [Davis MA, Carbott DE.](#) Related Articles, Li
 Herbimycin A and geldanamycin inhibit okadaic acid-induced apoptosis and p38 activation in NRK-52E renal epithelial cells.
Toxicol Appl Pharmacol. 1999 Nov 15;161(1):59-74.
PMID: 10558924 [PubMed - indexed for MEDLINE]
-  **39:** [Vasilevskaya IA, O'Dwyer PJ.](#) Related Articles, Li
 Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells.
Cancer Res. 1999 Aug 15;59(16):3935-40.
PMID: 10463587 [PubMed - indexed for MEDLINE]
-  **40:** [Ochel HJ, Schulte TW, Nguyen P, Trepel J, Neckers L.](#) Related Articles, Li
 The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase.
Mol Genet Metab. 1999 Jan;66(1):24-30.
PMID: 9973544 [PubMed - indexed for MEDLINE]
-  **41:** [Galigniana MD, Scruggs JL, Herrington J, Welsh MJ, Carter-Su C, Housley PR, Pratt WB.](#) Related Articles, Li
 Heat shock protein 90-dependent (geldanamycin-inhibited) movement of the glucocorticoid receptor through the cytoplasm to the nucleus requires intact cytoskeleton.
Mol Endocrinol. 1998 Dec;12(12):1903-13.
PMID: 9849964 [PubMed - indexed for MEDLINE]
-  **42:** [Schulte TW, Neckers LM.](#) Related Articles, Li
 The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Cancer Chemother Pharmacol. 1998;42(4):273-9.
PMID: 9744771 [PubMed - indexed for MEDLINE]
-  **43:** [Schulte TW, Akinaga S, Soga S, Sullivan W, Stensgard B, Toft D, Neckers LM.](#) Related Articles, Li
 Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
Cell Stress Chaperones. 1998 Jun;3(2):100-8.
PMID: 9672245 [PubMed - indexed for MEDLINE]
-  **44:** [Lawson B, Brewer JW, Hendershot LM.](#) Related Articles, Li
Geldanamycin, an hsp90/GRP94-binding drug, induces increased transcript

-  of endoplasmic reticulum (ER) chaperones via the ER stress pathway.
J Cell Physiol. 1998 Feb;174(2):170-8.
PMID: 9428803 [PubMed - indexed for MEDLINE]
-  **45:** [Schulte TW, An WG, Neckers LM.](#) [Related Articles, Li](#)
-  Geldanamycin-induced destabilization of Raf-1 involves the proteasome.
Biochem Biophys Res Commun. 1997 Oct 29;239(3):655-9.
PMID: 9367823 [PubMed - indexed for MEDLINE]
-  **46:** [Czar MJ, Galigniana MD, Silverstein AM, Pratt WB.](#) [Related Articles, Li](#)
-  Geldanamycin, a heat shock protein 90-binding benzoquinone ansamycin, inhibits steroid-dependent translocation of the glucocorticoid receptor from the cytoplasm to the nucleus.
Biochemistry. 1997 Jun 24;36(25):7776-85.
PMID: 9201920 [PubMed - indexed for MEDLINE]
-  **47:** [Whitesell L, Sutphin P, An WG, Schulte T, Blagosklonny MV, Neckers L.](#) [Related Articles, Li](#)
-  Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo.
Oncogene. 1997 Jun 12;14(23):2809-16.
PMID: 9190897 [PubMed - indexed for MEDLINE]
-  **48:** [Sullivan W, Stensgard B, Caucutt G, Bartha B, McMahon N, Ahemri ES, Litwack G, Toft D.](#) [Related Articles, Li](#)
-  Nucleotides and two functional states of hsp90.
J Biol Chem. 1997 Mar 21;272(12):8007-12.
PMID: 9065472 [PubMed - indexed for MEDLINE]
-  **49:** [Ibrado AM, Liu L, Bhalla K.](#) [Related Articles, Li](#)
-  Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells.
Cancer Res. 1997 Mar 15;57(6):1109-15.
PMID: 9067280 [PubMed - indexed for MEDLINE]
-  **50:** [Stancato LF, Silverstein AM, Owens-Grillo JK, Chow YH, Jove R, Pratt WB.](#) [Related Articles, Li](#)
-  The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes reducing the specific enzymatic activity of Raf kinase.
J Biol Chem. 1997 Feb 14;272(7):4013-20.
PMID: 9020108 [PubMed - indexed for MEDLINE]
-  **51:** [An WG, Schmitt RC, Neckers L, Blagosklonny MV.](#) [Related Articles, Li](#)
-  Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity.
Cancer Chemother Pharmacol. 1997;40(1):60-4.
PMID: 9137531 [PubMed - indexed for MEDLINE]
-  **52:** [Owens-Grillo JK, Stancato LF, Hoffmann K, Pratt WB, Krishna P.](#) [Related Articles, Li](#)
-  Binding of immunophilins to the 90 kDa heat shock protein (hsp90) via a tetratricopeptide repeat domain is a conserved protein interaction in plants.
Biochemistry. 1996 Dec 3;35(48):15249-55.
PMID: 8952474 [PubMed - indexed for MEDLINE]
-  **53:** [Schulte TW, Blagosklonny MV, Romanova L, Mushinski JF, Monia BP, Johnston JF, Nguyen P, Trepel J, Neckers LM.](#) [Related Articles, Li](#)
-  Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway.

Mol Cell Biol. 1996 Oct;16(10):5839-45.
PMID: 8816498 [PubMed - indexed for MEDLINE]

-  **54:** [Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer J, Neckers L.](#) [Related Articles, Li](#)




p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2.
J Biol Chem. 1996 Mar 1;271(9):4974-7.
PMID: 8617772 [PubMed - indexed for MEDLINE]

-  **55:** [Feuerbach D, Waelchli R, Fehr T, Feyen JH.](#) [Related Articles, Li](#)



Mycotrienins. A new class of potent inhibitors of osteoclastic bone resorption.
J Biol Chem. 1995 Oct 27;270(43):25949-55.
PMID: 7592784 [PubMed - indexed for MEDLINE]

-  **56:** [Schulte TW, Blagosklonny MV, Ingui C, Neckers L.](#) [Related Articles, Li](#)



Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association.
J Biol Chem. 1995 Oct 13;270(41):24585-8.
PMID: 7592678 [PubMed - indexed for MEDLINE]

-  **57:** [Bencheikroun NM, Myers CE, Sinha BK.](#) [Related Articles, Li](#)




Free radical formation by ansamycin benzoquinone in human breast tumor cells: implications for cytotoxicity and resistance.
Free Radic Biol Med. 1994 Sep;17(3):191-200.
PMID: 7982624 [PubMed - indexed for MEDLINE]

-  **58:** [Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM.](#) [Related Articles, Li](#)






Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8324-8.
PMID: 8078881 [PubMed - indexed for MEDLINE]

-  **59:** [Muroi M, Izawa M, Kosai Y, Asai M.](#) [Related Articles, Li](#)



Macbecins I and II, new antitumor antibiotics. II. Isolation and characterization.
J Antibiot (Tokyo). 1980 Feb;33(2):205-12.
PMID: 7380730 [PubMed - indexed for MEDLINE]

Display **Summary**  Show: **500**  **Sort**  **Send to** **Text**


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 8 2004 18:23:56



Entrez PubMed Nucleotides Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for geldanamycin derivative Go Clear

Limits Preview/Index History Clipboard Details

Display Summary Show: 500 Sort Send to Text

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Items 1 - 22 of 22

One p

☐ 1: [Workman P.](#)

[Related Articles](#), [Li](#)

Altered states: selectively drugging the Hsp90 cancer chaperone.
Trends Mol Med. 2004 Feb;10(2):47-51. Review.
PMID: 15106614 [PubMed - indexed for MEDLINE]

☐ 2: [Enmon R.](#), [Yang WH.](#), [Ballangrud AM.](#), [Solit DB.](#), [Heller G.](#), [Rosen N.](#), [Scher HI.](#), [Sgouros G.](#)

[Related Articles](#), [Li](#)

Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
Cancer Res. 2003 Dec 1;63(23):8393-9.
PMID: 14679001 [PubMed - indexed for MEDLINE]

☐ 3: [Nishiyama N.](#), [Nori A.](#), [Malugin A.](#), [Kasuya Y.](#), [Kopeckova P.](#), [Kopecek J.](#)

[Related Articles](#), [Li](#)

Free and N-(2-hydroxypropyl)methacrylamide copolymer-bound geldanamycin derivative induce different stress responses in A2780 human ovarian carcinoma cells.
Cancer Res. 2003 Nov 15;63(22):7876-82.
PMID: 14633716 [PubMed - indexed for MEDLINE]

☐ 4: [Beliakoff J.](#), [Bagatell R.](#), [Paine-Murrieta G.](#), [Taylor CW.](#), [Lykkesfeldt AE.](#), [Whitesell L.](#)

[Related Articles](#), [Li](#)

Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Clin Cancer Res. 2003 Oct 15;9(13):4961-71.
PMID: 14581371 [PubMed - indexed for MEDLINE]

☐ 5: [Chiosis G.](#), [Lucas B.](#), [Huezio H.](#), [Solit D.](#), [Basso A.](#), [Rosen N.](#)

[Related Articles](#), [Li](#)

Development of purine-scaffold small molecule inhibitors of Hsp90.
Curr Cancer Drug Targets. 2003 Oct;3(5):371-6. Review.
PMID: 14529388 [PubMed - indexed for MEDLINE]

☐ 6: [Watanabe K.](#), [Rude MA.](#), [Walsh CT.](#), [Khosla C.](#)

[Related Articles](#), [Li](#)

Engineered biosynthesis of an ansamycin polyketide precursor in Escherichia coli.
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9774-8. Epub 2003 Jul 29.
PMID: 12888623 [PubMed - indexed for MEDLINE]

☐ 7: [Chiosis G.](#), [Huezio H.](#), [Rosen N.](#), [Mimnaugh E.](#), [Whitesell L.](#), [Neckers L.](#)

[Related Articles](#), [Li](#)


17AAG: low target binding affinity and potent cell activity--finding an explanation.
Mol Cancer Ther. 2003 Feb;2(2):123-9.
PMID: 12589029 [PubMed - indexed for MEDLINE]


☐ 8: [Mandler R.](#), [Kobayashi H.](#), [Davis MY.](#), [Waldmann TA.](#), [Brechtel MW.](#)

[Related Articles](#), [Li](#)


Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates.


Bioconjug Chem. 2002 Jul-Aug;13(4):786-91.
PMID: 12121134 [PubMed - indexed for MEDLINE]

-  **9:** [Xu W, Mimnaugh EG, Kim JS, Trepel JB, Neckers LM.](#) Related Articles, Li


 **Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2.**


Cell Stress Chaperones. 2002 Jan;7(1):91-6.
PMID: 11892991 [PubMed - indexed for MEDLINE]

-  **10:** [Kasuya Y, Lu ZR, Kopeckova P, Tabibi SE, Kopecek J.](#) Related Articles, Li

 **Influence of the structure of drug moieties on the in vitro efficacy of HPMA copolymer-geldanamycin derivative conjugates.**

Pharm Res. 2002 Feb;19(2):115-23.
PMID: 11883637 [PubMed - indexed for MEDLINE]

-  **11:** [Soga S, Sharma SV, Shiotsu Y, Shimizu M, Tahara H, Yamaguchi K, Ikuina Y, Murakata C, Tamaoki T, Kurebayashi J, Schulte TW, Neckers LM, Akinaga S.](#) Related Articles, Li

 **Stereospecific antitumor activity of radicicol oxime derivatives.**


Cancer Chemother Pharmacol. 2001 Dec;48(6):435-45.
PMID: 11800023 [PubMed - indexed for MEDLINE]

-  **12:** [Maloney A, Workman P.](#) Related Articles, Li

 **HSP90 as a new therapeutic target for cancer therapy: the story unfolds.**


Expert Opin Biol Ther. 2002 Jan;2(1):3-24. Review.
PMID: 11772336 [PubMed - indexed for MEDLINE]

-  **13:** [Piper PW.](#) Related Articles, Li


 **The Hsp90 chaperone as a promising drug target.**


Curr Opin Investig Drugs. 2001 Nov;2(11):1606-10. Review.
PMID: 11763165 [PubMed - indexed for MEDLINE]

-  **14:** [Kasuya Y, Lu ZR, Kopeckova P, Minko T, Tabibi SE, Kopecek J.](#) Related Articles, Li

 **Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates.**


J Control Release. 2001 Jul 6;74(1-3):203-11.
PMID: 11489496 [PubMed - indexed for MEDLINE]

-  **15:** [Bagatell R, Khan O, Paine-Murrieta G, Taylor CW, Akinaga S, Whitesell L.](#) Related Articles, Li


 **Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.**


Clin Cancer Res. 2001 Jul;7(7):2076-84.
PMID: 11448926 [PubMed - indexed for MEDLINE]

-  **16:** [Yang J, Yang JM, Iannone M, Shih WJ, Lin Y, Hait WN.](#) Related Articles, Li


 **Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin.**






Cancer Res. 2001 May 15;61(10):4010-6.
PMID: 11358819 [PubMed - indexed for MEDLINE]



-  **17:** [Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L.](#) Related Articles, Li

 **Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90.**

J Biol Chem. 2001 Feb 2;276(5):3702-8. Epub 2000 Nov 08.
PMID: 11071886 [PubMed - indexed for MEDLINE]


-  **18:** [Mandler R, Dadachova E, Brechbiel JK, Waldmann TA, Brechbiel MW.](#) Related Articles, Li

-  **Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate.**
Bioorg Med Chem Lett. 2000 May 15;10(10):1025-8.
PMID: 10843208 [PubMed - indexed for MEDLINE]
-  **19:** [Soga S, Neckers LM, Schulte TW, Shiotsu Y, Akasaka K, Narumi H, Agatsuma T, Ikuina Y, Murakata C, Tamaoki T, Akinaga S.](#) [Related Articles, Li](#)
KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules.
Cancer Res. 1999 Jun 15;59(12):2931-8.
PMID: 10383157 [PubMed - indexed for MEDLINE]
-  **20:** [Schulte TW, Neckers LM.](#) [Related Articles, Li](#)
The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Cancer Chemother Pharmacol. 1998;42(4):273-9.
PMID: 9744771 [PubMed - indexed for MEDLINE]
-  **21:** [Sharma SV, Agatsuma T, Nakano H.](#) [Related Articles, Li](#)
Targeting of the protein chaperone, HSP90, by the transformation suppressin agent, radicicol.
Oncogene. 1998 May;16(20):2639-45.
PMID: 9632140 [PubMed - indexed for MEDLINE]
-  **22:** [Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM.](#) [Related Articles, Li](#)
Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8324-8.
PMID: 8078881 [PubMed - indexed for MEDLINE]

Display **Summary**  Show: **500**  **Sort**  **Send to** **Text**

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 8 2004 18:23:56



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search **PubMed** for **FKBP12 AND steroid** **Go** **Clear**

Limits Preview/Index History Clipboard Details

Display **Summary** Show: **500** Sort **Send to** **Text**

About Entrez

Items 1 - 30 of 30

One p:

Text Version

☐ 1: [Davies TH, Sanchez ER.](#)

[Related Articles, Li](#)

Fkbp52.
Int J Biochem Cell Biol. 2005 Jan;37(1):42-7.
PMID: 15381148 [PubMed - in process]

☐ 2: [Hoetzenecker W, Meingassner JG, Ecker R, Stingl G, Stuetz A, Elbe-Burger A.](#)

[Related Articles, Li](#)

Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells.
J Invest Dermatol. 2004 Mar;122(3):673-84.
PMID: 15086553 [PubMed - indexed for MEDLINE]

☐ 3: [Schneekloth JS Jr, Fonseca FN, Koldobskiy M, Mandal A, Deshaies R, Sakamoto K, Crews CM.](#)

[Related Articles, Li](#)

Chemical genetic control of protein levels: selective in vivo targeted degradation.
J Am Chem Soc. 2004 Mar 31;126(12):3748-54.
PMID: 15038727 [PubMed - indexed for MEDLINE]

☐ 4: [Murayama T, Ogawa Y.](#)

[Related Articles, Li](#)

RyR1 exhibits lower gain of CICR activity than RyR3 in the SR: evidence for selective stabilization of RyR1 channel.
Am J Physiol Cell Physiol. 2004 Jul;287(1):C36-45. Epub 2004 Feb 25.
PMID: 14985235 [PubMed - indexed for MEDLINE]

☐ 5: [Onyewu C, Blankenship JR, Del Poeta M, Heitman J.](#)

[Related Articles, Li](#)

Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei.
Antimicrob Agents Chemother. 2003 Mar;47(3):956-64.
PMID: 12604527 [PubMed - indexed for MEDLINE]

☐ 6: [Sinars CR, Cheung-Flynn J, Rimerman RA, Scammell JG, Smith DF, Clardy J.](#)

[Related Articles, Li](#)

Structure of the large FK506-binding protein FKBP51, an Hsp90-binding protein and a component of steroid receptor complexes.
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):868-73. Epub 2003 Jan 21.
PMID: 12538866 [PubMed - indexed for MEDLINE]

☐ 7: [Henthorn DC, Jaxa-Chamiec AA, Meldrum E.](#)

[Related Articles, Li](#)

A GAL4-based yeast three-hybrid system for the identification of small molecule-target protein interactions.
Biochem Pharmacol. 2002 May 1;63(9):1619-28.
PMID: 12007565 [PubMed - indexed for MEDLINE]

☐ 8: [Gingras AC, Raught B, Sonenberg N.](#)

[Related Articles, Li](#)

Regulation of translation initiation by FRAP/mTOR.
Genes Dev. 2001 Apr 1;15(7):807-26. Review. No abstract available.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Catalog

NLM Gateway

TOXNET


Consumer Health


Clinical Alerts


ClinicalTrials.gov


PubMed Central

PMID: 11297505 [PubMed - indexed for MEDLINE]


-  **9:** [Galigniana MD, Radanyi C, Renoir JM, Housley PR, Pratt WB.](#) [Related Articles](#), [Li](#)

 **Evidence that the peptidylprolyl isomerase domain of the hsp90-binding immunophilin FKBP52 is involved in both dynein interaction and glucocorticoid receptor movement to the nucleus.**
J Biol Chem. 2001 May 4;276(18):14884-9. Epub 2001 Feb 13.
PMID: 11278753 [PubMed - indexed for MEDLINE]


-  **10:** [Panhans-Gross A, Novak N, Kraft S, Bieber T.](#) [Related Articles](#), [Li](#)


 **Human epidermal Langerhans' cells are targets for the immunosuppressive macrolide tacrolimus (FK506).**
J Allergy Clin Immunol. 2001 Feb;107(2):345-52.
PMID: 11174203 [PubMed - indexed for MEDLINE]


-  **11:** [Neve H.](#) [Related Articles](#), [Li](#)

 **Mutation of FKBP associated protein 48 (FAP48) at proline 219 disrupts the interaction with FKBP12 and FKBP52.**
Regul Pept. 2001 Mar 2;97(2-3):147-52.
PMID: 11164950 [PubMed - indexed for MEDLINE]


-  **12:** [Griffith EC, Licitra EJ, Liu JO.](#) [Related Articles](#), [Li](#)


 **Yeast three-hybrid system for detecting ligand-receptor interactions.**
Methods Enzymol. 2000;328:89-103. No abstract available.
PMID: 11075340 [PubMed - indexed for MEDLINE]


-  **13:** [Bandyopadhyay A, Shin DW, Ahn JO, Kim DH.](#) [Related Articles](#), [Li](#)

 **Calcineurin regulates ryanodine receptor/Ca(2+)-release channels in rat heart.**
Biochem J. 2000 Nov 15;352 Pt 1:61-70.
PMID: 11062058 [PubMed - indexed for MEDLINE]


-  **14:** [Gold BG.](#) [Related Articles](#), [Li](#)


 **Neuroimmunophilin ligands: evaluation of their therapeutic potential for the treatment of neurological disorders.**
Expert Opin Investig Drugs. 2000 Oct;9(10):2331-42. Review.
PMID: 11060810 [PubMed - indexed for MEDLINE]


-  **15:** [Peterson RT, Beal PA, Comb MJ, Schreiber SL.](#) [Related Articles](#), [Li](#)


 **FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions.**
J Biol Chem. 2000 Mar 10;275(10):7416-23.
PMID: 10702316 [PubMed - indexed for MEDLINE]











-  **16:** [Alarcon CM, Heitman J, Cardenas ME.](#) [Related Articles](#), [Li](#)

 **Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast.**
Mol Biol Cell. 1999 Aug;10(8):2531-46.
PMID: 10436010 [PubMed - indexed for MEDLINE]

-  **17:** [Salh B, Wagey R, Marotta A, Tao JS, Pelech S.](#) [Related Articles](#), [Li](#)

 **Activation of phosphatidylinositol 3-kinase, protein kinase B, and p70 S6 kinases in lipopolysaccharide-stimulated Raw 264.7 cells: differential effects of rapamycin, Ly294002, and wortmannin on nitric oxide production.**
J Immunol. 1998 Dec 15;161(12):6947-54.
PMID: 9862729 [PubMed - indexed for MEDLINE]


-  **18:** [Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC Jr.](#) [Related Articles](#), [Li](#)

-  Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway.
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7772-7.
PMID: 9636226 [PubMed - indexed for MEDLINE]
-  **19:** [Licitra EJ, Liu JO.](#) Related Articles, Li
A three-hybrid system for detecting small ligand-protein receptor interaction
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12817-21.
PMID: 8917502 [PubMed - indexed for MEDLINE]
-  **20:** [Vucich VA, Gasser CS.](#) Related Articles, Li
Novel structure of a high molecular weight FK506 binding protein from *Arabidopsis thaliana*.
Mol Gen Genet. 1996 Oct 16;252(5):510-7.
PMID: 8914512 [PubMed - indexed for MEDLINE]
-  **21:** [Beamish H, Williams R, Chen P, Khanna KK, Hobson K, Watters D, Shiloh Y, Lavin M.](#) Related Articles, Li
Rapamycin resistance in ataxia-telangiectasia.
Oncogene. 1996 Sep 5;13(5):963-70.
PMID: 8806686 [PubMed - indexed for MEDLINE]
-  **22:** [Craescu CT, Rouviere N, Popescu A, Cerpolini E, Lebeau MC, Baulieu EE, Mispelter J.](#) Related Articles, Li
Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution.
Biochemistry. 1996 Aug 27;35(34):11045-52.
PMID: 8780506 [PubMed - indexed for MEDLINE]
-  **23:** [Hollis CM, Hutchinson R.](#) Related Articles, Li
Lack of inhibition of phosphoinositide 3-kinase enzyme activity by FKBP12/rapamycin.
Biochem Soc Trans. 1996 Feb;24(1):66S. No abstract available.
PMID: 8674742 [PubMed - indexed for MEDLINE]
-  **24:** [Sabatini DM, Pierchala BA, Barrow RK, Schell MJ, Snyder SH.](#) Related Articles, Li
The rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity.
J Biol Chem. 1995 Sep 8;270(36):20875-8.
PMID: 7673106 [PubMed - indexed for MEDLINE]
-  **25:** [Han JW, Pearson RB, Dennis PB, Thomas G.](#) Related Articles, Li
Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6l by inducing dephosphorylation of the same subset of sites.
J Biol Chem. 1995 Sep 8;270(36):21396-403.
PMID: 7545671 [PubMed - indexed for MEDLINE]
-  **26:** [Rouviere-Fourmy N, Craescu CT, Mispelter J, Lebeau MC, Baulieu EE.](#) Related Articles, Li
1H and 15N assignment of NMR spectrum, secondary structure and global folding of the immunophilin-like domain of the 59-kDa FK506-binding protein.
Eur J Biochem. 1995 Aug 1;231(3):761-72.
PMID: 7544285 [PubMed - indexed for MEDLINE]
-  **27:** [Tai PK, Albers MW, McDonnell DP, Chang H, Schreiber SL, Faber LE.](#) Related Articles, Li
Potentiation of progesterone receptor-mediated transcription by the

immunosuppressant FK506.

Biochemistry. 1994 Sep 6;33(35):10666-71.

PMID: 7521210 [PubMed - indexed for MEDLINE]

 **28:** [Renoir JM, Pahl A, Keller U, Baulieu EE.](#)


[Related Articles, Li](#)



Immunological identification of a 50 kDa Mr FK506-binding immunophilin a component of the non-DNA binding, hsp90 and hsp70 containing, heterooligomeric form of the chick oviduct progesterone receptor.

C R Acad Sci III. 1993 Dec;316(12):1410-6.

PMID: 7522118 [PubMed - indexed for MEDLINE]

 **29:** [Peattie DA, Harding MW, Fleming MA, DeCenzo MT, Lippke JA, Livingston DJ, Benasutti M.](#)


[Related Articles, Li](#)



Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes.

Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10974-8.

PMID: 1279700 [PubMed - indexed for MEDLINE]

 **30:** [Wiederrecht G, Hung S, Chan HK, Marcy A, Martin M, Calaycay J, Boulton D, Sigal N, Kincaid RL, Siekierka JJ.](#)





[Related Articles, Li](#)



Characterization of high molecular weight FK-506 binding activities reveals novel FK-506-binding protein as well as a protein complex.

J Biol Chem. 1992 Oct 25;267(30):21753-60.

PMID: 1383226 [PubMed - indexed for MEDLINE]

Display **Summary**  Show: **500**  **Sort**  **Send to** **Text** 

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Nov 8 2004 18:23:56

Welcome to STN International! Enter x:x
* * * * * Welcome to STN International * * * * *
* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:04:49 ON 16 NOV 2004

=> file BIOSCIENCE

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

FILE 'ADISCTI' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 13:04:56 ON 16 NOV 2004

FILE 'ANABSTR' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 13:04:56 ON 16 NOV 2004

Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 13:04:56 ON 16 NOV 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 13:04:56 ON 16 NOV 2004

FILE 'CAPLUS' ENTERED AT 13:04:56 ON 16 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 13:04:56 ON 16 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 13:04:56 ON 16 NOV 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved

FILE 'DRUGB' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 13:04:56 ON 16 NOV 2004

FILE 'FOMAD' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 13:04:56 ON 16 NOV 2004

FILE 'HEALSAFE' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 13:04:56 ON 16 NOV 2004

FILE 'MEDLINE' ENTERED AT 13:04:56 ON 16 NOV 2004

FILE 'NIOSHTIC' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 13:04:56 ON 16 NOV 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 13:04:56 ON 16 NOV 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 13:04:56 ON 16 NOV 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 13:04:56 ON 16 NOV 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Prouss Science

FILE 'PS' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 13:04:56 ON 16 NOV 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Prouss Science

FILE 'TOXCENTER' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 13:04:56 ON 16 NOV 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:04:56 ON 16 NOV 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 13:04:56 ON 16 NOV 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 13:04:56 ON 16 NOV 2004

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S FKBP12
53 FILES SEARCHED...
L1 6097 FKBP12

=> S L1 AND spinal cord
33 FILES SEARCHED...
70 FILES SEARCHED...
L2 259 L1 AND SPINAL CORD

=> DUP REM L2
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L2
L3 215 DUP REM L2 (44 DUPLICATES REMOVED)

=> D L3 1-215

L3 ANSWER 1 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 1
AN 10556392 IFIPAT;IFIUDB;IFICDB
TI COMPOSITIONS AND METHODS FOR PROMOTING NERVE REGENERATION
IN Gold Bruce G
PA Oregon Health Sciences University (25323)
PI US 2004063610 A1 20040401
AI US 2003-656701 20030904
RLI US 1997-956691 19971024 CONTINUATION 5968921
US 1999-326728 19990607 CONTINUATION
US 2001-825243 20010402 CONTINUATION 6641810
FI US 2004063610 20040401
US 5968921
US 6641810
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 22
GI 3 Figure(s).

FIG. 1 shows structures of FK506 (left) and a representative FK506 analog, V-10, 367 (right). The bracketed portion of FK506 represents the calcineurin-binding domain, which is absent in V10, 367.
FIGS. 2-8 are histograms showing the stimulation of growth of SHSY5Y cells by geldanamycin and FK506 in the presence of NGF (10 ng/mL) 168 hours after treatment. FIG. 2: control cells (untreated). FIG. 3: NGF only (10 ng/mL). FIG. 4: geldanamycin (1 nM)+NGF (10 ng/mL). FIG. 5: geldanamycin (10 nM)+NGF (10 ng/mL). FIG. 6: FK506 (10 nM)+NGF (10 ng/mL). FIG. 7: geldanamycin (1 nM)+FK506 (10 nM)+NGF (10 ng/mL). FIG. 8: geldanamycin (10 nM)+FK506 (10 nM)+NGF (10 ng/mL).
FIGS. 9-15 are histograms showing the stimulation of growth of SH-SY5Y cells by geldanamycin and FK506 in the presence of NGF (10 ng/mL) 168 hours after treatment. FIG. 9: control cells (untreated). FIG. 10: NGF only (10 ng/mL). FIG. 11: FK506 (1 nM) +NGF (10 ng/mL). FIG. 12: FK506 (10 nM)+NGF (10 ng/mL) FIG. 13: geldanamycin (0.1 nM)+NGF (10 ng/mL). FIG. 14: geldanamycin (0.1 nM)+FK506 (1 nM)+NGF (10 ng/mL). FIG. 15: geldanamycin (0.1 nM)+FK506 (10 nM)+NGF (10 ng/mL).

L3 ANSWER 2 OF 215 USPATFULL on STN
AN 2004:287884 USPATFULL
TI Compositions and methods for treating neurological disorders and diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul, Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Incorporated, Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 2004226056 A1 20041111
AI US 2004-776013 A1 20040209 (10)
RLI Continuation-in-part of Ser. No. US 2001-948904, filed on 10 Sep 2001, ABANDONED Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 2001-975072, filed on 12

filed on 15 Jul 2002, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 12774
INCL INCLM: 800/012.000
NCL NCLM: 800/012.000
IC [7]
ICM: A01K067-00

L3 ANSWER 3 OF 215 USPATFULL on STN
AN 2004:280221 USPATFULL
TI Novel nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Wang, Zhiwei, Sunnyvale, CA, UNITED STATES
Weng, Gezhi, Piedmont, CA, UNITED STATES
Boyle, Bryan J., San Francisco, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
PI US 2004219521 A1 20041104
AI US 2002-128558 A1 20020422 (10)
RLI Continuation-in-part of Ser. No. WO 2000-US35017, filed on 22 Dec 2000,
PENDING Continuation-in-part of Ser. No. US 2000-552317, filed on 25 Apr
2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed
on 21 Jan 2000, PENDING Continuation-in-part of Ser. No. WO 2001-US2623,
filed on 25 Jan 2001, PENDING Continuation-in-part of Ser. No. US
2000-491404, filed on 25 Jan 2000, ABANDONED
PRAI WO 2000-US35017 20001222
WO 2001-US2623 20010125
WO 2001-US3800 20010205
WO 2001-US4927 20010226
WO 2001-US4941 20010305
WO 2001-US8631 20010330
WO 2001-US8656 20010418
US 2001-339453P 20011211 (60)
DT Utility
FS APPLICATION
LN.CNT 13159
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 215 USPATFULL on STN
AN 2004:262074 USPATFULL
TI Polynucleotides encoding a novel human phosphatase, BMY_HPP13
IN Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Schieven, Gary L., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
PI US 2004204576 A1 20041014
AI US 2003-612742 A1 20030702 (10)
PRAI US 2002-393253P 20020702 (60)
DT Utility
FS APPLICATION
LN.CNT 15403
INCL INCLM: 536/023.200
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/196.000; 530/388.260
NCL NCLM: 536/023.200
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/196.000; 530/388.260
IC [7]
ICM: C07H021-04
ICS: C12N009-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 215 USPATFULL on STN

TI Polypropyl inhibitors of cyclophilin
IN Hamilton, Gregory S., Catonsville, MD, UNITED STATES
Wei, Ling, Lutherville, MD, UNITED STATES
Steiner, Joseph P., Mt. Airy, MD, UNITED STATES
PA Guilford Pharmaceuticals, Inc. (U.S. corporation)
PI US 2004204340 A1 20041014
AI US 2003-411333 A1 20030411 (10)
DT Utility
FS APPLICATION
LN.CNT 1070
INCL INCLM: 514/002.000
NCL NCLM: 514/002.000
IC [7]
ICM: A61K038-17

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 215 USPATFULL on STN
AN 2004:255121 USPATFULL
TI Secreted proteins
IN Klammer, Aaron A., Boulder, CO, UNITED STATES
Hafalia, April JA, Daly City, CA, UNITED STATES
Duggan, Brendan M, Sunnyvale, CA, UNITED STATES
Warren, Bridget A, San Marcos, CA, UNITED STATES
Emerling, Brooke M, Chicago, IL, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Arvizu, Chandra S, San Diego, CA, UNITED STATES
Honchell, Cynthia D, San Carlos, CA, UNITED STATES
Nguyen, Danniell B, San Jose, CA, UNITED STATES
Kallick, Deborah A, Galveston, TX, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Au-Young, Janice K, Brisbane, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Li, Joana X., Millbrae, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Gietzen, Kimberly J, San Jose, CA, UNITED STATES
Ding, Li, Creve Coeur, MO, UNITED STATES
Baughn, Mariah R, Los Angeles, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Mason, Patricia M, Morgan Hill, CA, UNITED STATES
Lal, Preeti G., Santa Clara, CA, UNITED STATES
Graul, Richard C, San Francisco, CA, UNITED STATES
Reddy, Roopa M, Fremont, CA, UNITED STATES
Becha, Shanya D, San Francisco, CA, UNITED STATES
Kareht, Stephanie K, Redwood City, CA, UNITED STATES
Richardson, Thomas W, Redwood City, CA, UNITED STATES
Tran, Uyen K, San Jose, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Azimzai, Yalda, Oakland, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES

PI US 2004198651 A1 20041007
AI US 2004-475446 A1 20040329 (10)
WO 2002-US12464 20020419

PRAI US 2001-285207P 20010420 (60)
US 2001-287114P 20010427 (60)
US 2001-288640P 20010503 (60)
US 2001-290516P 20010511 (60)
US 2001-292184P 20010518 (60)
US 2001-343553P 20011221 (60)
US 2002-357002P 20020213 (60)
US 2002-358279P 20020220 (60)
US 2002-366041P 20020319 (60)

DT Utility
FS APPLICATION

LN.CNT 9117
INCL INCLM: 514/012.000
INCLS: 530/350.000; 435/069.100; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 514/012.000
NCLS: 530/350.000; 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: G01N033-574
ICS: A61K038-17; C07K014-47; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 215 USPATFULL on STN
AN 2004:248574 USPATFULL
TI Modified delivery device for coated medical devices
IN Houghton, Michael J., Newark, DE, UNITED STATES
Majercak, David C., Stewartsville, NJ, UNITED STATES
PI US 2004193177 A1 20040930
AI US 2003-403195 A1 20030331 (10)
DT Utility
FS APPLICATION
LN.CNT 3705
INCL INCLM: 606/108.000
NCL NCLM: 606/108.000
IC [7]
ICM: A61F011-00

L3 ANSWER 8 OF 215 USPATFULL on STN
AN 2004:233806 USPATFULL
TI Piperazine and piperidine derivatives
IN Lauffer, David J., Stow, MA, UNITED STATES
Botfield, Martyn C., Boston, MA, UNITED STATES
Ottow, Eckard, Moltkestrasse, GERMANY, FEDERAL REPUBLIC OF
PI US 2004180880 A1 20040916
AI US 2003-677631 A1 20031002 (10)
PRAI US 2002-416134P 20021003 (60)
DT Utility
FS APPLICATION
LN.CNT 1209
INCL INCLM: 514/227.200
INCLS: 514/252.200; 514/253.110; 514/318.000; 544/060.000; 544/124.000;
544/360.000; 546/207.000
NCL NCLM: 514/227.200
NCLS: 514/252.200; 514/253.110; 514/318.000; 544/060.000; 544/124.000;
544/360.000; 546/207.000
IC [7]
ICM: C07D417-02
ICS: C07D413-02; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 215 USPATFULL on STN
AN 2004:221362 USPATFULL
TI Polynucleotides encoding a novel testis-specific tubulin
tyrosine-ligase-like protein, BGS42
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Wu, Shujian, Langhorne, PA, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
PI US 2004171131 A1 20040902
AI US 2003-635977 A1 20030807 (10)
RLI Continuation-in-part of Ser. No. US 2003-615659, filed on 9 Jul 2003,
PENDING
PRAI US 2002-394725P 20020709 (60)
DT Utility
FS APPLICATION
LN.CNT 17362
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12N009-64
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 215 USPATFULL on STN
AN 2004:216463 USPATFULL
TI Coated medical devices
IN Roth, Noah M., Highland Park, NJ, UNITED STATES
Rush, Scott Lyle, Coral Springs, FL, UNITED STATES
Scheuble, Theresa, Rockaway, NJ, UNITED STATES
PI US 2004167572 A1 20040826
AI US 2003-371925 A1 20030220 (10)
DT Utility
FS APPLICATION
LN.CNT 2938
INCL INCLM: 606/219.000

NCL NCLM: 606/219.000
NCLS: 604/265.000; 427/002.100
IC [7]
ICM: A61B017-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 215 USPATFULL on STN
AN 2004:204147 USPATFULL
TI Secreted proteins
IN Yue, Henry, Sunnyvale, CA, UNITED STATES
Lee, Ernestine A., Kensington, CA, UNITED STATES
Becha, Shanya D, San Francisco, CA, UNITED STATES
Baughn, Mariah R, Los Angeles, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Au-Young, Janice K, Brisbane, CA, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Warren, Bridget A, San Marcos, CA, UNITED STATES
Duggan, Brendan M, Sunnyvale, CA, UNITED STATES
Tran, Uyen K, San Jose, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Richardson, Thomas W, Redwood City, CA, UNITED STATES
Bandman, Olga, Mountain View, CA, UNITED STATES
Jones, Karen A, Bollington, UNITED KINGDOM
Yang, Junming, San Jose, CA, UNITED STATES
Emerling, Brooke M, Chicago, IL, UNITED STATES
Swarnakar, Anita, San Francisco, CA, UNITED STATES
Luo, Wen, San Diego, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Azimzai, Yalda, Oakland, CA, UNITED STATES
Khan, Farrah A, Des Plaines, IL, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Griffin, Jennifer A, Fremont, CA, UNITED STATES
Lee, Soo Yeun, Mountain View, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Honchell, Cynthia D, San Francisco, CA, UNITED STATES
He, Ann, San Jose, CA, UNITED STATES
Mason, Patricia M, Morgan Hill, CA, UNITED STATES
Li, Joana X, Millbrae, CA, UNITED STATES
Hafalia, April JA, Daly City, CA, UNITED STATES
Gururajan, Rajagopal, San Jose, CA, UNITED STATES

PI US 2004158039 A1 20040812
AI US 2003-479284 A1 20031124 (10)
WO 2002-US16234 20020521

DT Utility
FS APPLICATION

LN.CNT 9774

INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500

NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500

IC [7]
ICM: C07K014-705
ICS: C12N005-06; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 12 OF 215 USPATFULL on STN
AN 2004:204027 USPATFULL
TI Trisubstituted carbocyclic cyclophilin binding compounds and their use
IN Wu, Yong-Qian, Columbia, MD, UNITED STATES
Belyakov, Sergei, Baltimore, MD, UNITED STATES
Hamilton, Gregory S., Cantonsville, MD, UNITED STATES
Limburg, David, Baltimore, MD, UNITED STATES
Steiner, Joseph P., Mt. Airy, MD, UNITED STATES
Vaal, Mark, Baltimore, MD, UNITED STATES
Wei, Ling, Lutherville, MD, UNITED STATES
Wilkinson, Douglas, Baltimore, MD, UNITED STATES
PI US 2004157919 A1 20040812
AI US 2003-713566 A1 20031114 (10)
RLI Division of Ser. No. US 2002-57203, filed on 25 Jan 2002, GRANTED, Pat.
No. US 6656971
DT Utility
FS APPLICATION
LN.CNT 3143

INCLS: 514/563.000; 514/597.000; 514/602.000; 514/518.000; 558/048.000;
558/231.000; 562/439.000
NCL NCLM: 514/485.000
NCLS: 514/563.000; 514/597.000; 514/602.000; 514/518.000; 558/048.000;
558/231.000; 562/439.000

IC [7]
ICM: A61K031-325
ICS: A61K031-198

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 215 USPATFULL on STN
AN 2004:203344 USPATFULL
TI Polynucleotides encoding a novel testis-specific tubulin
tyrosine-ligase-like protein, BGS42
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Wu, Shujian, Langhorne, PA, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
PI US 2004157234 A1 20040812
AI US 2003-615659 A1 20030709 (10)
PRAI US 2002-394725P 20020709 (60)

DT Utility
FS APPLICATION

LN.CNT 13812

INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/226.000; 435/325.000; 536/023.200

NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/226.000; 435/325.000; 536/023.200

IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 215 USPATFULL on STN
AN 2004:196424 USPATFULL
TI Lectin compositions and methods for modulating an immune response to an
antigen
IN Segal, Andrew H., Boston, MA, UNITED STATES
Young, Elihu, Sharon, MA, UNITED STATES
PA Genitrix, LLC (U.S. corporation)
PI US 2004151728 A1 20040805
AI US 2003-666834 A1 20030919 (10)
RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
PRAI US 2002-404823P 20020820 (60)
US 2003-487407P 20030715 (60)

DT Utility
FS APPLICATION

LN.CNT 39129

INCL INCLM: 424/184.100
INCLS: 424/199.100; 424/200.100; 530/395.000

NCL NCLM: 424/184.100
NCLS: 424/199.100; 424/200.100; 530/395.000

IC [7]
ICM: A61K039-00
ICS: A61K039-12; A61K039-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 215 USPATFULL on STN
AN 2004:191235 USPATFULL
TI Coated endovascular AAA device
IN Rush, Scott Lyle, Coral Springs, FL, UNITED STATES
PI US 2004148010 A1 20040729
AI US 2003-349776 A1 20030123 (10)

DT Utility
FS APPLICATION

LN.CNT 2899

INCL INCLM: 623/001.130
INCLS: 623/001.420; 606/154.000

NCL NCLM: 623/001.130
NCLS: 623/001.420; 606/154.000

IC [7]
ICM: A61F002-06

L3 ANSWER 16 OF 215 USPATFULL on STN
AN 2004:190660 USPATFULL
TI Neuroimmunophilins for selective neuronal radioprotection

Elm̄er, Eskil, Lund, SWEDEN
PI US 2004147433 A1 20040729
AI US 2004-757533 A1 20040115 (10)
RLI Continuation of Ser. No. US 2001-787861, filed on 14 Jun 2001, PENDING A
371 of International Ser. No. WO 1998-US20040, filed on 23 Sep 1998,
PENDING
DT Utility
FS APPLICATION
LN.CNT 838
INCL INCLM: 514/011.000
NCL NCLM: 514/011.000
IC [7]
ICM: A61K038-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 215 USPATFULL on STN
AN 2004:190200 USPATFULL
TI Proteins associated with cell growth, differentiation, and death
IN Yue, Henry, Sunnyvale, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Ison, Craig H, San Jose, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Warren, Bridget A, San Marcos, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Baughn, Mariah R, Los Angeles, CA, UNITED STATES
Ding, Li, Creve Court, MI, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Gietzen, Kimberly J, San Jose, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Duggan, Brendan M, Sunnyvale, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Richardson, Thomas W, Redwood City, CA, UNITED STATES
Tran, Uyen K, San Jose, CA, UNITED STATES
Khare, Reena, Saratoga, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES

PI US 2004146970 A1 20040729
AI US 2003-467535 A1 20030808 (10)
WO 2002-US3715 20020208
DT Utility
FS APPLICATION
LN.CNT 8733
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 514/012.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 514/012.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-47
ICS: A61K038-17; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 215 USPATFULL on STN
AN 2004:179244 USPATFULL
TI Secreted proteins
IN Yue, Henry, Sunnyvale, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Nguyen, Danniel B, San Jose, CA, UNITED STATES
Yao, Monique G, Carmel, IN, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Sanjanwala, Madhusudan M, Los Altos, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Baughn, Mariah R, San Leandro, CA, UNITED STATES
Sapperstein, Stephanie K, Redwood City, CA, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Thornton, Michael B, Oakland, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Gietzen, Kimberly J, San Jose, CA, UNITED STATES
Ding, Li, Creve Couer, MO, UNITED STATES
Au-Young, Janice K, Brisbane, CA, UNITED STATES

Policky, Jennifer L, San Jose, CA, UNITED STATES
 Lee, Sally, San Jose, CA, UNITED STATES
 Lu, Dyung Aina M, San Jose, CA, UNITED STATES
 Burford, Neil, Durham, CT, UNITED STATES
 Warren, Bridget A, Encinitas, CA, UNITED STATES
 Gururajan, Rajagopal, San Jose, CA, UNITED STATES
 Duggan, Brendan M, Sunnyvale, CA, UNITED STATES
 Honchell, Cynthia D, San Carlos, CA, UNITED STATES
 Hafalia, April JA, Daly City, CA, UNITED STATES
 PI US 2004138414 A1 20040715
 AI US 2003-398037 A1 20030328 (10)
 WO 2001-US30042 20010925
 PRAI US 2000-60236869 20000929
 US 2000-60239812 20001011
 US 2000-60240108 20001012
 US 2000-60241282 20001017
 US 2000-60242218 20001020
 DT Utility
 FS APPLICATION
 LN.CNT 11652
 INCL INCLM: 530/350.000
 NCL NCLM: 530/350.000
 IC [7]
 ICM: C07K002-00
 ICS: C07K004-00; C07K005-00; C07K007-00; C07K014-00; C07K016-00;
 C07K017-00; A61K038-00; C07K001-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 215 USPATFULL on STN
 AN 2004:171882 USPATFULL
 TI Proteins Associated with cell growth, differentiation, and death
 IN Azimzai, Yalda, Oakland, CA, UNITED STATES
 Au-Young, Janice K, Brisbane, CA, UNITED STATES
 Batra, Sajeev, Oakland, CA, UNITED STATES
 Baughn, Mariah R, Los Angeles, CA, UNITED STATES
 Becha, Shanya D, San Francisco, CA, UNITED STATES
 Borowsky, Mark L, Northampton, MA, UNITED STATES
 Burford, Neil, Durham, CT, UNITED STATES
 Ding, Li, Creve Couer, MO, UNITED STATES
 Elliott, Vicki S, San Jose, CA, UNITED STATES
 Emerling, Brooke M, Chicago, IL, UNITED STATES
 Gandhi, Ameena R, San Francisco, CA, UNITED STATES
 Gietzen, Kimberly J, San Jose, CA, UNITED STATES
 Griffin, Jennifer A, Fremont, CA, UNITED STATES
 Hafalia, April J A, Daly City, CA, UNITED STATES
 Honchell, Cynthia D, San Carlos, CA, UNITED STATES
 Lal, Preeti G, Santa Clara, CA, UNITED STATES
 Lee, Soo Yeun, Mountain View, CA, UNITED STATES
 Lu, Dyung Aina M, San Jose, CA, UNITED STATES
 Arvizu, Chandra S, San Diego, CA, UNITED STATES
 Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
 Reddy, Roopa M, Fremont, CA, UNITED STATES
 Sanjanwala, Madhusudan M, Los Altos, CA, UNITED STATES
 Tang, Y Tom, San Jose, CA, UNITED STATES
 Chawla, Narinder K, Union City, CA, UNITED STATES
 Wang, Yu-Mei E, Mountain View, CA, UNITED STATES
 Warren, Bridget A, San Marcos, CA, UNITED STATES
 Xu, Yuming, Mountain View, CA, UNITED STATES
 Yang, Junming, Sa Jose, CA, UNITED STATES
 Yao, Monique G, Mountain View, CA, UNITED STATES
 Yue, Henry, Sunnyvale, CA, UNITED STATES
 Zebarradian, Yeganeh, San Francisco, CA, UNITED STATES

PI US 2004132043 A1 20040708
 AI US 2003-474291 A1 20031006 (10)
 WO 2002-US11152 20020405
 DT Utility
 FS APPLICATION
 LN.CNT 10741
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 NCL NCLM: 435/006.000
 NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C07K014-47; C12N015-00

L3 ANSWER 20 OF 215 USPATFULL on STN
 AN 2004:165307 USPATFULL
 TI Lectin compositions and methods for modulating an immune response to an antigen
 IN Segal, Andrew H., Boston, MA, UNITED STATES
 Young, Elihu, Sharon, MA, UNITED STATES
 PA Genitrix, LLC (U.S. corporation)
 PI US 2004126793 A1 20040701
 AI US 2003-666885 A1 20030919 (10)
 RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
 PRAI US 2002-404823P 20020820 (60)
 US 2003-487407P 20030715 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 28979
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000;
 530/395.000; 536/023.500
 NCL NCLM: 435/006.000
 NCLS: 435/069.100; 435/320.100; 435/325.000; 435/419.000; 530/370.000;
 530/395.000; 536/023.500
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C07K014-47; C07K014-415; C12N005-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 21 OF 215 USPATFULL on STN
 AN 2004:164872 USPATFULL
 TI Lectin compositions and methods for modulating an immune response to an antigen
 IN Segal, Andrew H., Boston, MA, UNITED STATES
 Young, Elihu, Sharon, MA, UNITED STATES
 PA Genitrix, LLC (U.S. corporation)
 PI US 2004126357 A1 20040701
 AI US 2003-666886 A1 20030919 (10)
 RLI Division of Ser. No. US 2003-645000, filed on 20 Aug 2003, PENDING
 PRAI US 2002-404823P 20020820 (60)
 US 2003-487407P 20030715 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 39007
 INCL INCLM: 424/085.100
 INCLS: 424/093.200; 424/185.100
 NCL NCLM: 424/085.100
 NCLS: 424/093.200; 424/185.100
 IC [7]
 ICM: A61K048-00
 ICS: A61K039-00; A61K038-19
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 22 OF 215 USPATFULL on STN
 AN 2004:139476 USPATFULL
 TI Heterocyclic ketone and thioester compounds and uses
 IN Hamilton, Gregory S., Catonsville, MD, UNITED STATES
 Li, Jia-He, Cockeysville, MD, UNITED STATES
 PA GPI NIL Holdings, Inc. (U.S. corporation)
 PI US 2004106652 A1 20040603
 AI US 2003-615803 A1 20030710 (10)
 RLI Continuation of Ser. No. US 2002-104242, filed on 25 Mar 2002, ABANDONED
 Continuation of Ser. No. US 2000-733037, filed on 11 Dec 2000, GRANTED,
 Pat. No. US 6417209 Division of Ser. No. US 1999-444200, filed on 22 Nov
 1999, GRANTED, Pat. No. US 6218424 Continuation-in-part of Ser. No. US
 1997-904461, filed on 1 Aug 1997, GRANTED, Pat. No. US 5990131
 Continuation-in-part of Ser. No. US 1996-721765, filed on 25 Sep 1996,
 GRANTED, Pat. No. US 5786378
 DT Utility
 FS APPLICATION
 LN.CNT 1747
 INCL INCLM: 514/355.000
 INCLS: 514/345.000; 514/423.000; 514/424.000; 548/530.000; 546/315.000;
 546/301.000
 NCL NCLM: 514/355.000
 NCLS: 514/345.000; 514/423.000; 514/424.000; 548/530.000; 546/315.000;
 546/301.000

ICM: A61K031-455
ICS: C07D213-46; A61K031-401; A61K031-4015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 23 OF 215 USPATFULL on STN
AN 2004:133393 USPATFULL
TI Secreted proteins
IN Jackson, Jennifer L., Santa Cruz, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Tribouley, Catherine M, San Francisco, CA, UNITED STATES
Lee, Ernestine A, Castro Valley, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Warren, Bridget A, Encinitas, CA, UNITED STATES
Hafalia, April J.A., Santa Clara, CA, UNITED STATES
Baughn, Mariah R, San Leandro, CA, UNITED STATES
Azimzai, Yalda, Oakland, CA, UNITED STATES
Batra, Sajeev, Oakland, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Yao, Monique G, Carmel, IN, UNITED STATES
Nguyen, Danniell B, San Jose, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Au-Young, Janice K, Brisbane, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
PI US 2004101930 A1 20040527
AI US 2002-312354 A1 20021218 (10)
WO 2001-US19862 20010620
DT Utility
FS APPLICATION
LN.CNT 9968
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-705
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 24 OF 215 USPATFULL on STN
AN 2004:133346 USPATFULL
TI Secreted proteins
IN Yue, Henry, Sunnyvale, CA, UNITED STATES
Yang, Junming, San Jose, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Duggan, Brendan M, Sunnyvale, CA, UNITED STATES
Honchell, Cynthia D, San Carlos, CA, UNITED STATES
Lee, Sally, San Carlos, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Gietzen, Kimberly J, San Jose, CA, UNITED STATES
Forsythe, Ian J, Edmonton, CANADA
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Griffin, Jennifer A, Fremont, CA, UNITED STATES
Gururajan, Rajagopol, San Jose, CA, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Baughn, Mariah R, Los Angeles, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Azimzai, Yalda, Oakland, CA, UNITED STATES
Au-Young, Janice K, Brisbane, CA, UNITED STATES
Kallick, Deborah A, Galveston, TX, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Mason, Patricia M, Morgan Hill, CA, UNITED STATES
Tran, Uyen K, San Jose, CA, UNITED STATES
PI US 2004101882 A1 20040527
AI US 2003-471115 A1 20030905 (10)
WO 2002-US7719 20020305
DT Utility
FS APPLICATION
LN.CNT 7734

NCL INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCLM: 435/006.000
IC NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
[7]
ICM: C12Q001-68
ICS: C07H021-04; C12N015-00; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 25 OF 215 USPATFULL on STN
AN 2004:114927 USPATFULL
TI Molecules for disease detection and treatment
IN Lal, Preeti G, Santa Clara, CA, UNITED STATES
Baughn, Mariah R, Los Angeles, CA, UNITED STATES
Yao, Monique G, Mountain View, CA, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Elliott, Vicki S, San Jose, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Honchell, Cynthia D, San Carlos, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Ding, Li, Creve Couer, MO, UNITED STATES
Gietzen, Kimberly J, San Jose, CA, UNITED STATES
Ison, Craig H, San Jose, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
Hafalia, April JA, Daly City, CA, UNITED STATES
Gandhi, Ameena R, San Francisco, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Sanjanwala, Madhusudan M, Los Altos, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Griffin, Jennifer A, Fremont, CA, UNITED STATES
Swarnakar, Anita, San Francisco, CA, UNITED STATES
Azimzai, Yalda, Oakland, CA, UNITED STATES
Sapperstein, Stephanie K, Redwood City, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
Lee, Ernestine A, Castro Valley, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Tran, Uyen K, San Jose, CA, UNITED STATES
Marquis, Joseph P, San Jos, CA, UNITED STATES
PI US 2004087773 A1 20040506
AI US 2003-467433 A1 20030806 (10)
WO 2002-US3709 20020208

DT Utility
FS APPLICATION
LN.CNT 8295
INCL INCLM: 530/350.000
INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 530/350.000
NCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C07K014-47
ICS: C12Q001-68; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 26 OF 215 USPATFULL on STN
AN 2004:114057 USPATFULL
TI Polynucleotides and polypeptides associated with the NF-kB pathway
IN Carman, Julie, Lawrenceville, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nadler, Steven G., Princeton, NJ, UNITED STATES
PI US 2004086896 A1 20040506
AI US 2003-431096 A1 20030507 (10)
RLI Continuation-in-part of Ser. No. US 2002-126103, filed on 19 Apr 2002,
PENDING
PRAI US 2001-284962P 20010419 (60)
US 2001-286645P 20010426 (60)
US 2002-346986P 20020109 (60)
DT Utility
FS APPLICATION
LN.CNT 27042
INCL INCLM: 435/006.000
INCLS: 435/069.500; 435/320.100; 435/325.000; 530/351.000; 530/388.230;
536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.500; 435/320.100; 435/325.000; 530/351.000; 530/388.230;
536/023.500

ICM: C12Q001-68

ICS: C07H021-04; C12P021-02; C07K014-52; C07K016-24

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 27 OF 215 USPATFULL on STN

AN 2004:108106 USPATFULL

TI Secreted proteins

IN Yue, Henry, Sunnyvale, CA, UNITED STATES

Yao, Monique G, Carmel, IN, UNITED STATES

Gandhi, Ameena R, San Francisco, CA, UNITED STATES

Baughn, Mariah R, San Leandro, CA, UNITED STATES

Swarnakar, Anita, San Francisco, CA, UNITED STATES

Chawla, Narinder K, Union City, CA, UNITED STATES

Sanjanwala, Madhusudan M, Los Altos, CA, UNITED STATES

Thornton, Michael B, Oakland, CA, UNITED STATES

Elliott, Vicki S, San Jose, CA, UNITED STATES

Lu, Yan, Mountain View, CA, UNITED STATES

Gietzen, Kimberly J, San Jose, CA, UNITED STATES

Burford, Neil, Durham, CT, UNITED STATES

Ding, Li, Creve Coeur, MO, UNITED STATES

Hafalia, April JA, Daly City, CA, UNITED STATES

Tang, Y Tom, San Jose, CA, UNITED STATES

Bandman, Olga, Mountain View, CA, UNITED STATES

Warren, Bridget A, Encinitas, CA, UNITED STATES

Honchell, Cynthia D, San Carlos, CA, UNITED STATES

Lu, Dyung Aina M, San Jose, CA, UNITED STATES

Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES

Lee, Sally, San Jose, CA, UNITED STATES

Xu, Yuming, Mountain View, CA, UNITED STATES

Yang, Junming, San Jose, CA, UNITED STATES

Lal, Preeti G, Santa Clara, CA, UNITED STATES

Tran, Bao, Santa Clara, CA, UNITED STATES

Ison, Craig H, San Jose, CA, UNITED STATES

Duggan, Brendan M, Sunnyvale, CA, UNITED STATES

Kareht, Stephanie K, Redwood City, CA, UNITED STATES

PI US 2004082508 A1 20040429

AI US 2003-416314 A1 20030508 (10)

WO 2001-US47420 20011108

PRAI US 2000-60247505 20001108

US 2000-60249642 20001109

US 2000-60249824 20001116

US 2000-60252824 20001121

US 2000-60254305 20001208

US 2000-60256448 20001218

DT Utility

FS APPLICATION

LN.CNT 11180

INCL INCLM: 514/012.000

INCLS: 530/350.000; 435/006.000; 435/320.100; 435/325.000; 435/069.100;

536/023.500

NCL NCLM: 514/012.000

NCLS: 530/350.000; 435/006.000; 435/320.100; 435/325.000; 435/069.100;

536/023.500

IC [7]

ICM: C07K014-435

ICS: C12Q001-68; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 28 OF 215 USPATFULL on STN

AN 2004:101806 USPATFULL

TI Neurotrophic tacrolimus analogs

IN Matsuoka, Nobuya, Osaka-shi, JAPAN

Yamaji, Takayuki, Osaka-shi, JAPAN

Gold, Bruce, West Linn, OR, UNITED STATES

PI US 2004077676 A1 20040422

AI US 2003-451361 A1 20031114 (10)

WO 2001-US50419 20011231

DT Utility

FS APPLICATION

LN.CNT 669

INCL INCLM: 514/291.000

NCL NCLM: 514/291.000

IC [7]

ICM: A61K031-4745

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 29 OF 215 USPATFULL on STN
 AN 2004:95568 USPATFULL
 TI Phosphorus-containing compounds and uses thereof
 IN Metcalf, Chester A., III, Needham, MA, UNITED STATES
 Rozamus, Leonard W., Bedford, MA, UNITED STATES
 Wang, Yihan, Newton, MA, UNITED STATES
 Berstein, David L., Waban, MA, UNITED STATES
 PI US 2004073024 A1 20040415
 AI US 2003-635054 A1 20030806 (10)
 RLI Continuation-in-part of Ser. No. US 2003-357152, filed on 3 Feb 2003,
 PENDING
 PRAI US 2002-353252P 20020201 (60)
 US 2002-426928P 20021115 (60)
 US 2002-428383P 20021122 (60)
 US 2002-433930P 20021217 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3658
 INCL INCLM: 540/456.000
 NCL NCLM: 540/456.000
 IC [7]
 ICM: C07D498-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 30 OF 215 USPATFULL on STN
 AN 2004:95366 USPATFULL
 TI N-substituted glycine derivatives
 IN Lauffer, David, Stow, MA, UNITED STATES
 Ledford, Brian, Hopkinton, MA, UNITED STATES
 Mullican, Michael, Needham, MA, UNITED STATES
 PI US 2004072821 A1 20040415
 AI US 2003-677501 A1 20031002 (10)
 RLI Division of Ser. No. US 2002-39896, filed on 3 Jan 2002, GRANTED, Pat.
 No. US 6677359
 DT Utility
 FS APPLICATION
 LN.CNT 847
 INCL INCLM: 514/217.120
 INCLS: 514/317.000; 514/408.000; 540/609.000; 546/229.000; 546/237.000;
 548/571.000
 NCL NCLM: 514/217.120
 NCLS: 514/317.000; 514/408.000; 540/609.000; 546/229.000; 546/237.000;
 548/571.000
 IC [7]
 ICM: A61K031-55
 ICS: A61K031-445; A61K031-40
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 31 OF 215 USPATFULL on STN
 AN 2004:83468 USPATFULL
 TI Secreted proteins
 IN Tang, Y Tom, San Jose, CA, UNITED STATES
 Yue, Henry, Sunnyvale, CA, UNITED STATES
 Gandhi, Ameena R., San Francisco, CA, UNITED STATES
 Yao, Monique G., Mountain View, CA, UNITED STATES
 Warren, Bridget A., San Marcos, CA, UNITED STATES
 Ding, Li, Creve Coeur, MO, UNITED STATES
 Duggan, Brendan M., Sunnyvale, CA, UNITED STATES
 Xu, Yuming, Mountain View, CA, UNITED STATES
 Yang, Junming, San Jose, CA, UNITED STATES
 Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
 Lal, Preeti G., Santa Clara, CA, UNITED STATES
 Honchell, Cynthia D., San Carlos, CA, UNITED STATES
 Chawla, Narinder K., Union City, CA, UNITED STATES
 Lee, Sally, San Jose, CA, UNITED STATES
 Lee, Ernestine A., Castro Valley, CA, UNITED STATES
 Richardson, Thomas W., Redwood City, CA, UNITED STATES
 Baughn, Mariah R., Los Angeles, CA, UNITED STATES
 Elliott, Vicki S., San Jose, CA, UNITED STATES
 PI US 2004063924 A1 20040401
 AI US 2003-470360 A1 20030725 (10)
 WO 2002-US2616 20020128
 DT Utility
 FS APPLICATION
 LN.CNT 7595

NCL INCLS: 530/350.000; 435/069.100; 435/320.100; 435/325.000
NCLM: 536/023.500
NCLS: 530/350.000; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: C07K014-47
ICS: C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 32 OF 215 USPATFULL on STN
AN 2004:77359 USPATFULL
TI Dihydropyrancarboxamides and uses thereof
IN Schreiber, Stuart L., Boston, MA, UNITED STATES
Stavenger, Robert A., Blue Bell, PA, UNITED STATES
Mitchison, Timothy J., Brookline, MA, UNITED STATES
Maliga, Zoltan, East Brunswick, NJ, UNITED STATES
PI US 2004059138 A1 20040325
AI US 2003-649532 A1 20030827 (10)
PRAI US 2002-406140P 20020827 (60)
DT Utility
FS APPLICATION
LN.CNT 4504
INCL INCLM: 549/414.000
INCLS: 549/419.000
NCL NCLM: 549/414.000
NCLS: 549/419.000
IC [7]
ICM: C07D047-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 33 OF 215 USPATFULL on STN
AN 2004:64527 USPATFULL
TI Small molecule inhibitors of rotamase enzyme activity
IN Hamilton, Gregory S., Catonsville, MD, UNITED STATES
Steiner, Joseph P., Hampstead, MD, UNITED STATES
PA GPI NIL Holdings, Inc., Wilmington, DE, UNITED STATES, 19899 (U.S. corporation)
PI US 2004049046 A1 20040311
AI US 2002-219887 A1 20020816 (10)
RLI Continuation of Ser. No. US 2000-605475, filed on 28 Jun 2000, GRANTED, Pat. No. US 6500959 Continuation of Ser. No. US 1997-833629, filed on 8 Apr 1997, GRANTED, Pat. No. US 6140357 Continuation of Ser. No. US 1996-650461, filed on 21 May 1996, GRANTED, Pat. No. US 5859031 Continuation-in-part of Ser. No. US 1995-479436, filed on 7 Jun 1995, GRANTED, Pat. No. US 5614547
DT Utility
FS APPLICATION
LN.CNT 1439
INCL INCLM: 546/279.100
INCLS: 548/465.000; 548/517.000; 548/527.000; 548/536.000
NCL NCLM: 546/279.100
NCLS: 548/465.000; 548/517.000; 548/527.000; 548/536.000
IC [7]
ICM: C07D049-02
ICS: C07D043-02; C07D045-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 34 OF 215 USPATFULL on STN
AN 2004:63784 USPATFULL
TI Novel metalloprotease polypeptide, MP-1
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2004048302 A1 20040311
AI US 2003-651722 A1 20030829 (10)
RLI Division of Ser. No. US 2002-67443, filed on 5 Feb 2002, GRANTED, Pat. No. US 6642041
PRAI US 2001-266518P 20010205 (60)
US 2001-282814P 20010410 (60)
DT Utility
FS APPLICATION
LN.CNT 15444
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200

IC NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
[7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 35 OF 215 USPATFULL on STN
AN 2004:63731 USPATFULL
TI Novel nucleic acids and secreted polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Yang, Yonghong, San Jose, CA, UNITED STATES
Weng, Gezhi, Piedmont, CA, UNITED STATES
Zhang, Jie, Campbell, CA, UNITED STATES
Ren, Feiyan, Cupertino, CA, UNITED STATES
Xue, Aidong, Sunnyvale, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES
Wehrman, Tom, Stanford, CA, UNITED STATES
Ghosh, Malabika J., Sunnyvale, CA, UNITED STATES
Wang, Dunrui, Poway, CA, UNITED STATES
Zhao, Qing A., San Jose, CA, UNITED STATES
Wang, Zhiwei, Sunnyvale, CA, UNITED STATES
PI US 2004048249 A1 20040311
AI US 2002-112944 A1 20020328 (10)
RLI Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000,
PENDING Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan
2000, ABANDONED Continuation-in-part of Ser. No. US 2000-496914, filed
on 3 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US
2000-515126, filed on 28 Feb 2000, ABANDONED Continuation-in-part of
Ser. No. US 2000-519705, filed on 7 Mar 2000, ABANDONED
Continuation-in-part of Ser. No. US 2000-540217, filed on 31 Mar 2000,
ABANDONED Continuation-in-part of Ser. No. US 2000-552929, filed on 18
Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-577408,
filed on 18 May 2000, ABANDONED
PRAI US 2001-306971P 20010721 (60)
DT Utility
FS APPLICATION
LN.CNT 23809
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 435/455.000;
530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 435/455.000;
530/350.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47;
C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 36 OF 215 USPATFULL on STN
AN 2004:58174 USPATFULL
TI Novel nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Asundi, Vinod, Foster City, CA, UNITED STATES
Wehrman, Tom, Stanford, CA, UNITED STATES
Ren, Feiyan, Cupertino, CA, UNITED STATES
Zhou, Ping, Cupertino, CA, UNITED STATES
Zhao, Qing A., San Jose, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
Zhang, Jie, Campbell, CA, UNITED STATES
Xue, Aidong, Sunnyvale, CA, UNITED STATES
Wang, Jian-Rui, Cupertino, CA, UNITED STATES
Wang, Dunrui, Poway, CA, UNITED STATES
PI US 2004044181 A1 20040304
AI US 2003-363616 A1 20030715 (10)
WO 2001-US27093 20010831
DT Utility
FS APPLICATION
LN.CNT 17667
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.500
IC [7]

ICS: C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 37 OF 215 USPATFULL on STN
AN 2004:57405 USPATFULL
TI Polynucleotides encoding a novel metalloprotease, MP-1
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2004043407 A1 20040304
AI US 2003-649273 A1 20030827 (10)
RLI Continuation of Ser. No. US 2002-67443, filed on 5 Feb 2002, GRANTED,
Pat. No. US 6642041
PRAI US 2001-266518P 20010205 (60)
US 2001-282814P 20010410 (60)
DT Utility
FS APPLICATION
LN.CNT 15462
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 38 OF 215 USPATFULL on STN
AN 2004:51579 USPATFULL
TI Methods for treatment of acute lymphocytic leukemia
IN Grupp, Stephan A., Havertown, PA, UNITED STATES
Brown, Valerie I., Philadelphia, PA, UNITED STATES
PI US 2004039010 A1 20040226
AI US 2003-453056 A1 20030530 (10)
PRAI US 2002-384245P 20020530 (60)
DT Utility
FS APPLICATION
LN.CNT 1879
INCL INCLM: 514/291.000
INCLS: 424/145.100
NCL NCLM: 514/291.000
NCLS: 424/145.100
IC [7]
ICM: A61K031-4745
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 39 OF 215 USPATFULL on STN
AN 2004:45026 USPATFULL
TI Piperazine and piperidine derivatives
IN Tomlinson, Ronald, Marlborough, MA, UNITED STATES
Lauffer, David, Stow, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
PI US 2004034019 A1 20040219
AI US 2002-214906 A1 20020808 (10)
DT Utility
FS APPLICATION
LN.CNT 2413
INCL INCLM: 514/227.800
INCLS: 514/231.500; 514/252.130; 544/060.000; 544/359.000; 544/111.000
NCL NCLM: 514/227.800
NCLS: 514/231.500; 514/252.130; 544/060.000; 544/359.000; 544/111.000
IC [7]
ICM: C07D417-02
ICS: C07D413-02; C07D043-02; A61K031-541; A61K031-5377; A61K031-496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 40 OF 215 USPATFULL on STN
AN 2004:44514 USPATFULL
TI Polynucleotides encoding novel human mitochondrial and microsomal
glycerol-3-phosphate acyl-transferases and variants thereof
IN Farrelly, Dennis, Monmouth Junction, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES

Feder, John N., Belle Mead, NJ, UNITED STATES
Wu, Shujian, Langhorne, PA, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
PI US 2004033506 A1 20040219
AI US 2002-308128 A1 20021202 (10)
PRAI US 2001-334904P 20011130 (60)
DT Utility
FS APPLICATION
LN.CNT 28557
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/193.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/193.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-10; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 41 OF 215 USPATFULL on STN
AN 2004:39556 USPATFULL
TI Polynucleotides encoding novel two splice variants of a human cell
surface protein with immunoglobulin folds, BGS5G and BGS5I
IN Lee, Liana M., Somerset, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Wu, Shujian, Langhorne, PA, UNITED STATES
PI US 2004030098 A1 20040212
AI US 2003-403847 A1 20030328 (10)
PRAI US 2002-368671P 20020329 (60)
US 2002-371420P 20020410 (60)
DT Utility
FS APPLICATION
LN.CNT 14213
INCL INCLM: 530/350.000
INCLS: 530/388.220; 536/023.200; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 530/388.220; 536/023.200; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: C07H021-04
ICS: C07K014-705; C07K016-30; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 42 OF 215 USPATFULL on STN
AN 2004:39370 USPATFULL
TI Bicyclic derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
PI US 2004029912 A1 20040212
AI US 2003-632618 A1 20030801 (10)
RLI Division of Ser. No. US 2002-39886, filed on 3 Jan 2002, GRANTED, Pat.
No. US 6660748 Continuation of Ser. No. WO 2000-US18355, filed on 5 Jul
2000, PENDING
PRAI US 1999-142509P 19990706 (60)
DT Utility
FS APPLICATION
LN.CNT 734
INCL INCLM: 514/305.000
INCLS: 514/412.000; 546/134.000; 548/453.000
NCL NCLM: 514/305.000
NCLS: 514/412.000; 546/134.000; 548/453.000
IC [7]
ICM: C07D453-04
ICS: A61K031-46; A61K031-403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 43 OF 215 USPATFULL on STN
AN 2004:25134 USPATFULL
TI Polynucleotide encoding novel human G-protein coupled receptors, and
splice variants thereof
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Mintier, Gabriel, Hightstown, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
PI US 2004018976 A1 20040129
AI US 2003-436715 A1 20030513 (10)

DT Utility
FS APPLICATION
LN.CNT 21273
INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.200; 530/388.220; 435/069.100; 435/320.100;
435/325.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.200; 530/388.220; 435/069.100; 435/320.100;
435/325.000
IC [7]
ICM: A61K038-17
ICS: C07K014-705; C12P021-02; C12N005-06; C07K016-28; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 44 OF 215 USPATFULL on STN
AN 2004:18793 USPATFULL
TI Targets, methods, and reagents for diagnosis and treatment of
schizophrenia
IN Gerber, David J., Somerville, MA, UNITED STATES
Karayiorgou, Maria, New York, NY, UNITED STATES
Miyakawa, Tsuyoshi, Kamigyo-Ku Kyoto, JAPAN
Tonegawa, Susumu, Chestnut Hill, MA, UNITED STATES
PI US 2004014095 A1 20040122
AI US 2003-400348 A1 20030326 (10)
PRAI US 2002-367944P 20020326 (60)
US 2003-452813P 20030307 (60)
DT Utility
FS APPLICATION
LN.CNT 5713
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 45 OF 215 USPATFULL on STN
AN 2004:18781 USPATFULL
TI Detection of heteroduplex polynucleotides using mutant nucleic acid
repair enzymes with attenuated catalytic activity
IN Yuan, Chong-Sheng, San Diego, CA, UNITED STATES
Datta, Abhijit, Carlsbad, CA, UNITED STATES
PI US 2004014083 A1 20040122
AI US 2003-373238 A1 20030224 (10)
RLI Continuation-in-part of Ser. No. US 2000-514016, filed on 25 Feb 2000,
PENDING
DT Utility
FS APPLICATION
LN.CNT 10442
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 46 OF 215 USPATFULL on STN
AN 2004:270056 USPATFULL
TI Neurotrophic pyrrolidines and piperidines, and related compositions and
methods
IN Kanojia, Ramesh M., Bridgewater, NJ, United States
Jordan, Alfonso D., North Wales, PA, United States
Reitz, Allen B., Lansdale, PA, United States
Macielag, Mark J., Branchburg, NJ, United States
Zhao, Boyu, Lansdale, PA, United States
PA Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S.
corporation)
PI US 6809107 B1 20041026
AI US 2000-593852 20000614 (9)
PRAI US 1999-143006P 19990709 (60)
DT Utility
FS GRANTED
LN.CNT 2447
INCL INCLM: 514/312.000
INCLS: 514/314.000; 548/188.000; 548/213.000; 548/238.000; 548/240.000;
548/243.000; 546/153.000; 546/165.000
NCL NCLM: 514/312.000

IC [7]
ICM: A61K031-47
ICS: C07D277-04; C07D275-02; C07D261-02; C07D261-10
EXF 546/271H; 546/94; 546/153; 546/165; 514/340; 514/312; 514/314; 548/188;
548/213; 548/238; 548/240; 548/243
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 47 OF 215 USPATFULL on STN
AN 2004:116775 USPATFULL
TI Compositions and methods for promoting nerve regeneration
IN Gold, Bruce G., West Linn, OR, United States
PA Oregon Health & Sciences University, Portland, OR, United States (U.S. corporation)
PI US 6734211 B1 20040511
WO 2001003692 20010118
AI US 2002-30904 20020429 (10)
WO 2000-US18539 20000707
PRAI US 1999-143180P 19990709 (60)
DT Utility
FS GRANTED
LN.CNT 2153
INCL INCLM: 514/513.000
NCL NCLM: 514/513.000
IC [7]
ICM: A61K031-21
EXF 514/513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 48 OF 215 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN
AN 2004:265623 SCISEARCH
GA The Genuine Article (R) Number: 801EN
TI A role for Schwann cells in the neuroregenerative effects of a
non-immunosuppressive FK506 derivative, JNJ460
AU Birge R B (Reprint); Wadsworth S; Akakura R; Abeysinghe H; Kanojia R;
MacIelag M; Desbarats J; Escalante M; Singh K; Sundarababu S; Parris K;
Childs G; August A; Siekierka J; Weinstein D E
CS Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol,
185 S Orange Ave, Newark, NJ 07214 USA (Reprint); Univ Med & Dent New
Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07214 USA;
GliMed Inc, New York, NY 10032 USA; Albert Einstein Coll Med, Dept Mol
Genet, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Neurosci &
Pathol, Bronx, NY 10461 USA; Johnson & Johnson Pharmaceut Res & Dev,
Raritan, NJ 08869 USA; Rockefeller Univ, Oncol Mol Lab, New York, NY 10021
USA
CYA USA
SO NEUROSCIENCE, (9 MAR 2004) Vol. 124, No. 2, pp. 351-366.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE,
KIDLINGTON, OXFORD OX5 1GB, ENGLAND.
ISSN: 0306-4522.
DT Article; Journal
LA English
REC Reference Count: 78
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 49 OF 215 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN
AN 2004:90494 SCISEARCH
GA The Genuine Article (R) Number: 765UH
TI Immunohistochemical analysis of protein expression after middle cerebral
artery occlusion in mice
AU Erdo F; Trapp T; Mies G; Hossmann K A (Reprint)
CS Max Planck Inst Neurol Res, Dept Expt Neurol, Gleueler Str 50, D-50931
Cologne, Germany (Reprint); Max Planck Inst Neurol Res, Dept Expt Neurol,
D-50931 Cologne, Germany
CYA Germany
SO ACTA NEUROPATHOLOGICA, (FEB 2004) Vol. 107, No. 2, pp. 127-136.
Publisher: SPRINGER-VERLAG, 175 FIFTH AVE, NEW YORK, NY 10010 USA.
ISSN: 0001-6322.
DT Article; Journal
LA English
REC Reference Count: 49
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AN 10369947 IFIPAT;IFIUDB;IFICDB
 TI INHIBITORS OF ROTAMASE ENZYME ACTIVITY; NEUROTROPHIC PIPECOLIC ACID
 DERIVATIVE COMPOUNDS HAVING AN AFFINITY FOR FKBP-TYPE IMMUNOPHILINS;
 TREATING NEURODEGENERATIVE DISORDERS
 IN Dawson Ted; Hamilton Gregory S; Snyder Solomon; Steiner Joseph P
 PA GPI NIL Holding Inc
 PI US 2003114365 A1 20030619
 AI US 2002-228312 20020827
 RLI US 1996-653905 19960528 CONTINUATION 5696135
 US 1997-787162 19970123 CONTINUATION 5843960
 US 1998-113330 19980710 CONTINUATION 6022878
 US 1995-474072 19950607 CONTINUATION-IN-PART 5798355
 US 1999-435323 19991105 DIVISION
 FI US 2003114365 20030619
 US 5696135
 US 5843960
 US 6022878
 US 5798355
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION

CLMN 56

GI 21 Figure(s).
 FIG. 1 FKBP-12 and GAP-43 expression in the facial nucleus after nerve crush. In situ hybridization comparing the time course of expression of mRNA in the facial nucleus for ***FKBP12*** (left) and GAP-43 (right). The right facial nucleus is ipsilateral to the crush, and the left side is an unoperated control (FIG. 1B). In situ hybridization for FKBP-12 on an untreated control (left) and for calcineurin A alpha, beta 7 days following facial nerve crush (right).
 FIG. 2 Localization of FKBP-12 to facial motor neurons following nerve crush. Bright-field photomicrographs of in situ hybridization for FKBP-12 in motor neurons of the facial nucleus 7 days after crush (FIG. 2A), and in motor neurons of control facial nucleus (FIG. 2B).
 FIG. 3 Upregulation of FKBP-12 mRNA in lumbar ***spinal***
 cord motor neurons after sciatic nerve crush. In situ hybridization for FKBP-12 7 days after crush of the right sciatic nerve. Top panel (FIG. 3A) shows the response of motor neurons in the ventral horn of lower lumbar ***spinal*** ***cord*** (indicated by the arrow). Bright field photomicrographs of corresponding motor neuron pools are shown in the bottom panels: (FIG. 3B) left side contralateral to nerve crush, (FIG. 3C) right side ipsilateral to the nerve crush. This experiment was repeated 3 times with similar results.
 FIG. 4 Induction of FKBP and FKBP-12 mRNA in the dorsal root ganglion 1 and 6 weeks after sciatic nerve crush. Dark-field photomicrographs of sections through the L4 dorsal root ganglion ipsilateral to sciatic nerve crush processed for FKBP in situ hybridization are shown in the left panels and for (3H) FK506 autoradiography in the right panels. These results were replicated 3 times for each time point.
 FIG. 5 Ricin lesion of the right facial nerve. Nissl stain (bottom panel, FIG. 5A) reveals extensive degeneration of motor neurons in the right facial nucleus with an accompanying glial proliferation 7 days following injection of ricin into the facial nerve. In situ hybridization for FKBP mRNA 7 days after ricin lesion of the facial nerve/nucleus is shown in the top panel (FIG. 5B). This experiment was replicated 3 times with similar results.
 FIG. 6 (3H)FK506 binding in segments of sciatic nerve 7 days following crush. The diagram illustrates the 3 mm segments of nerve taken: constrictions indicate positions of ligatures applied at day 7 for the 6 hr collection time as described in the methods. The distal ligature site is 10 mm proximal to the original crush site. Anterograde transport of FKBP is 124 mm/ day. Data are the means+-S.E.M. (n=3).
 FIG. 7 Transport of FKBP in the sciatic nerve. Dark-field photomicrographs of sections through a control (untreated) sciatic nerve and a 7 day sciatic nerve crush site processed for FKBP-12 in situ hybridization (FIG. 7A, FIG. 7B) and for (3H)FK-506 autoradiography (FIG. 7C, FIG. 7D). Arrows indicate the site of the nerve crush. This experiment was repeated 3 times with similar results.
 FIG. 8 Levels of (3H)FK506 binding in PC-12 cells maintained in the presence or absence of NGF (50 ng/ml).n=3 for each time point. Bars represent S.E.M.
 FIG. 9 Immunosuppressant mediated enhancement of neurite outgrowth in PC-12 cells. Hoffman contrast photomicrographs (64) of cultures grown for 48 hr in the presence of NGF with or without added FK506 or rapamycin. FIG. 9A: PC-12 cells grown in 1.0 ng/ml NGF. FIG. 9B: 50 ng/ml

100 nM rapamycin. Magnification 200 x .

FIG. 10 Effects of FK506 on neurite outgrowth in PC-12 cells. Cultures were treated with varying concentrations of NGF in the presence or absence of 100 nM FK506, and neurite sprouting was measured at 48 hr. Outgrowth was quantitated as described in Methods by counting cells with neuritic processes greater than 5 μ m. n=4 separate experiments for each point and error bars represent SEM.

FIG. 11 Concentration-response relationship for FK506 potentiation of neurite outgrowth in PC-12 cells. Cells were treated for 48 hr with 1 ng/ml NGF and varying concentrations of FK506. Neurite outgrowth response was measured as described in FIG. 10 and Methods. n=4 separate experiments for each data point *p less-than .001 Students t test.

FIG. 12 (3H)FK-506 autoradiography on dorsal root ganglion explant cultures. After 26 days of cultures with 100 ng/ml NGF the extensive processes display abundant FKBP associated silver grains. Autoradiographic grains are abolished with 1 μ M unlabeled FK506.

FIG. 13 Phase-contrast micrographs of dorsal root ganglia grown with different substances. FIG. 13A: NGF 100 ng/ml, FIG. 13B: FK506 1 μ M, FIG. 13C: FK506 1 μ M and anti-NGF antibody, FIG. 13D: No added growth factor, FIG. 13E: FK506 1 pM, FIG. 13F: FK506 1 μ M. and rapamycin 1 μ M. Scale bar is 205 μ m. NGF produces abundant axon outgrowth (FIG. 13A), as does 1 μ M FK506 (FIG. 13B). The effects of FK506 are substantially decreased by reducing the concentration to 1 pM (FIG. 13E). However, neurite outgrowth with 1 pM FK506 is greater than in its absence (FIG. 13D). FK506 effects are also diminished by adding anti-NGF antibody to eliminate the effects of NGF produced by non-neuronal cells in the cultures. The abundant neurites that occur in large fascicles in response to NGF (100 ng/ml) (FIG. 13A) or 1 μ M FK506 (FIG. 13B) appear white, while small fascicles or individual neurites appear black. Nonneuronal cells, Schwann cells and some fibroblasts, are more evident with 1 pM FK506 (FIG. 13E) or anti-NGF antibody (FIG. 13C) than with 1 μ M FK506 (FIG. 13B). NGF produced by nonneuronal cells in the cultures results in the limited axon outgrowth seen in cultures with no added growth factors (FIG. 13D). The large number of refractile non-neuronal cells, appearing white, tend to overshadow the few neurites (FIG. 13D). Rapamycin completely inhibits axon outgrowth in the presence of FK506 (FIG. 13F). Micrographs are representative of 12-30 ganglia from each experimental condition. Differences between all experimental groups were highly reproducible.

FIG. 14 Effects of FK506 and rapamycin on NGF-mediated neurite extension in PC12 cells. PC12 cells (passage 60) were treated with various concentrations of NGF alone or in the presence of 100 nM FK506, 100 nM rapamycin or 100 nM WAY-124,466. Neurite outgrowth was measured after 96 hours with cells bearing processes longer than the diameter of the cells scoring positive. n=3 separate experiments for each point and error bars represent S.E.M.

FIG. 15 Picomolar concentrations of (A) FK506 and (B) rapamycin and WAY-124,466 potentiate neurite extension elicited by NGF (0.5 ng/ml) in PC12 cells. Low passage PC12 cells were treated for 4 days with 0.5 ng/ml NGF in the presence of various concentrations of FK506 (*), rapamycin () or WAY-124,466 (). Neurite expression was quantitated as described above in FIG. 14. The levels of neurite production in the presence of 0.5 ng/ml NGF (designated L) and 50 ng/ml NGF (designated H) are indicated for comparative purposes.

FIG. 16 Photomicrographs of PC12 cells treated with immunophilin ligands +0.5 ng/ml NGF itself or 50 ng/ml NGF.

FIG. 17 Immunophilin ligands reduce the amount of NGF required to produce maximal neurite extension in chick sensory ganglia. Whole dorsal root ganglion explants were isolated from day 9-10 chick embryos and cultured in Matrigel-coated 12-well dishes containing L15 medium plus high glucose, with 10% fetal calf serum supplemented with 10 μ M Ara C penicillin and streptomycin) at 37 degrees C. in a 5% CO2 environment. Sensory ganglia were treated with 1 ng/ml NGF, 1 ng/ml NGF plus 100 nM FK506 or 100 ng/ml NGF for 48 hr, and neuronal processes were counted and photographed.

FIG. 18 FK506, rapamycin, and WAY-124,466 potentiate NGFdependent neurite production in sensory ganglia. Explants of chick DRG were cultured as described in FIG. 17 above. FK506, rapamycin and WAY-124,466 (100nM each plus or minus 0.1 ng/ml NGF were added to the DRG explant cultures. At 48 hrs., neurite outgrowth was quantitated and the cultures were photographed.

FIG. 19 Photomicrograph of Example 111 promoting neurite outgrowth in Chick dorsal root ganglion cultures. The three panels show neurite outgrowth at 1 pM concentration (left panel), 100 pM concentration (center panel), and 100 nM concentration (right panel) of Example 111.

dorsal root ganglion cultures. The three panels show neurite outgrowth at 1 pM concentration (left panel), 100 pM concentration (center panel), and 100 nM concentration (right panel) of Example 17.
FIG. 21 Photomicrograph of Example 102 promoting neurite outgrowth in dorsal root ganglion cultures. The three panels show neurite outgrowth at 1 pM concentration (left panel), 100 pM concentration (center panel), and 100 nM concentration (right panel) of Example 102.

L3 ANSWER 51 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 3
AN 10288227 IFIPAT;IFIUDB;IFICDB
TI HETEROCYCLIC ESTERS AND AMIDES; USE AS INHIBITORS OF THE ENZYME ACTIVITY ASSOCIATED WITH IMMUNOPHILIN PROTEINS, E.G., PEPTIDYL-PROLYL ISOMERASE, OR ROTAMASE, ENZYME ACTIVITY; TREATING ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AND AMYOTROPHIC LATERAL SCLEROSIS.
IN Hamilton Gregory S; Li Jia-He
PA Unassigned Or Assigned To Individual (68000)
PI US 2003032635 A1 20030213
AI US 2002-177666 20020624
RLI US 1996-719947 19960925 CONTINUATION 5801187
US 2000-733043 20001211 CONTINUATION PENDING
US 1998-27622 19980223 DIVISION 6200972
FI US 2003032635 20030213
US 5801187
US 6200972
DT Utility; Patent Application - First Publication
FS CHEMICAL APPLICATION

CLMN 35
GI 6 Figure(s).
FIG. 1(A) is a representative photomicrograph of compound 1 (1 pM) promoting neurite outgrowth in sensory neurons.
FIG. 1(B) is a representative photomicrograph of compound 1 (10 pM) promoting neurite outgrowth in sensory neurons.
FIG. 1(C) is a representative photomicrograph of compound 1 (100 pM) promoting neurite outgrowth in sensory neurons.
FIG. 2(A) is a representative photomicrograph of compound 2 (10 pM) promoting neurite outgrowth in sensory neurons.
FIG. 2(B) is a representative photomicrograph of compound 2 (100 pM) promoting neurite outgrowth in sensory neurons.
FIG. 2(C) is representative photomicrograph of compound 2 (10 nM) promoting neurite outgrowth in sensory neurons.

L3 ANSWER 52 OF 215 USPATFULL on STN DUPLICATE 4
AN 2003:159911 USPATFULL
TI Azo amino acids derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
PI US 2003109526 A1 20030612
US 6716860 B2 20040406
AI US 2002-307636 A1 20021202 (10)
RLI Division of Ser. No. US 2002-39900, filed on 3 Jan 2002, GRANTED, Pat. No. US 6528533 Continuation of Ser. No. WO 2000-US18416, filed on 5 Jul 2000, PENDING
PRAI US 1999-142569P 19990706 (60)
DT Utility
FS APPLICATION
LN.CNT 1050
INCL INCLM: 514/227.800
INCLS: 514/235.500; 514/253.010; 514/353.000; 514/482.000; 544/060.000; 544/360.000; 544/131.000; 546/306.000; 560/024.000
NCL NCLM: 514/353.000
NCLS: 546/255.000; 546/265.000; 546/322.000; 546/332.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-496; A61K031-44; A61K031-325; C07D417-02; C07D413-02; C07D043-02; C07C281-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 53 OF 215 USPATFULL on STN DUPLICATE 5
AN 2003:120301 USPATFULL
TI Polynucleotides encoding a novel metalloprotease, MP-1
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES

PI US 2003082782 A1 20030501
US 6642041 B2 20031104
AI US 2002-67443 A1 20020205 (10)
PRAI US 2001-266518P 20010205 (60)
US 2001-282814P 20010410 (60)
DT Utility
FS APPLICATION
LN.CNT 17186
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/226.000
NCLS: 435/219.000; 435/252.300; 435/320.100; 536/023.200
IC [7]
ICM: C12N009-64
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 54 OF 215 USPATFULL on STN
AN 2003:335013 USPATFULL
TI Materials and methods involving conditional retention domains
IN Rivera, Victor, Arlington, MA, UNITED STATES
Clackson, Timothy P., Arlington, MA, UNITED STATES
Rothman, James E., New York, NY, UNITED STATES
PA ARIAD Gene Therapeutics, Inc. (U.S. corporation)
PI US 2003235889 A1 20031225
AI US 2003-440799 A1 20030519 (10)
RLI Continuation of Ser. No. US 1999-420819, filed on 19 Oct 1999, GRANTED,
Pat. No. US 6566073 Continuation of Ser. No. US 1998-174799, filed on 19
Oct 1998, ABANDONED
PRAI US 1998-104743P 19981019 (60)
US 1999-137787P 19990602 (60)
DT Utility
FS APPLICATION
LN.CNT 3859
INCL INCLM: 435/069.700
INCLS: 435/320.100; 435/325.000; 530/303.000; 530/387.100; 530/399.000;
435/326.000
NCL NCLM: 435/069.700
NCLS: 435/320.100; 435/325.000; 530/303.000; 530/387.100; 530/399.000;
435/326.000
IC [7]
ICM: C12P021-04
ICS: C12N005-06; C07K014-675; C07K014-62; C07K014-635; C07K016-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 55 OF 215 USPATFULL on STN
AN 2003:330148 USPATFULL
TI Polynucleotide encoding a novel human G-protein coupled receptor,
HGPRBMY40 2
IN Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel, Hightstown, NJ, UNITED STATES
Gopal, Shuba, New York, NY, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
PI US 2003232359 A1 20031218
AI US 2003-391634 A1 20030318 (10)
PRAI US 2002-365350P 20020318 (60)
DT Utility
FS APPLICATION
LN.CNT 13383
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 56 OF 215 USPATFULL on STN
AN 2003:318742 USPATFULL
TI Polynucleotides and polypeptides associated with the NF-kB pathway
IN Carman, Julie, Lawrenceville, NJ, UNITED STATES
Nadler, Steven, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
PI US 2003224486 A1 20031204

PRAI US 2001-284962P 20010419 (60)
 US 2001-286645P 20010426 (60)
 US 2002-346986P 20020109 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 28546
 INCL INCLM: 435/069.500
 INCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500
 NCL NCLM: 435/069.500
 NCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500
 IC [7]
 ICM: C12P021-02
 ICS: C07H021-04; C07K014-52; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 57 OF 215 USPATFULL on STN
 AN 2003:318714 USPATFULL
 TI Novel human G-protein coupled receptor, HGPRBMY23, expressed highly in kidney
 IN Barber, Lauren E., Higganum, CT, UNITED STATES
 Cacace, Angela, Clinton, CT, UNITED STATES
 Feder, John N., Belle Mead, NJ, UNITED STATES
 Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
 Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
 Ryseck, Rolf-Peter, Ewing, NJ, UNITED STATES
 Neubauer, Michael G., Skillman, NJ, UNITED STATES
 Kornacker, Michael G., Princeton, NJ, UNITED STATES
 PI US 2003224458 A1 20031204
 AI US 2003-375157 A1 20030226 (10)
 RLI Continuation-in-part of Ser. No. US 2001-10568, filed on 7 Dec 2001, PENDING
 PRAI US 2000-251926P 20001207 (60)
 US 2001-269795P 20010214 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 14624
 INCL INCLM: 435/007.200
 INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 NCL NCLM: 435/007.200
 NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 IC [7]
 ICM: G01N033-53
 ICS: G01N033-567; C07H021-04; C12P021-02; C12N005-06; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 58 OF 215 USPATFULL on STN
 AN 2003:318706 USPATFULL
 TI Polynucleotide encoding a novel TRP channel family member, LTRPC3, and splice variants thereof
 IN Lee, Ning, Belle Mead, NJ, UNITED STATES
 Chen, Jian, Princeton, NJ, UNITED STATES
 Feder, John N., Belle Mead, NJ, UNITED STATES
 Wu, Shujian, Langhorne, PA, UNITED STATES
 Lee, Liana M., Somerset, NJ, UNITED STATES
 Blonar, Michael A., Malvern, PA, UNITED STATES
 Bol, David, Gaithersburg, MD, UNITED STATES
 Levesque, Paul C., Yardley, PA, UNITED STATES
 Sun, Lucy, Newtown, PA, UNITED STATES
 PI US 2003224450 A1 20031204
 AI US 2003-405793 A1 20030328 (10)
 RLI Continuation-in-part of Ser. No. US 2002-210152, filed on 1 Aug 2002, PENDING
 PRAI US 2001-309544P 20010802 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 23133
 INCL INCLM: 435/007.100
 INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 NCL NCLM: 435/007.100
 NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 IC [7]
 ICM: G01N033-53
 ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2003:318656 USPATFULL
 TI Novel human G-protein coupled receptor, HGPRBMY11, and variants thereof
 IN Barber, Lauren E., Higganum, CT, UNITED STATES
 Cacace, Angela, Clinton, CT, UNITED STATES
 Feder, John N., Belle Mead, NJ, UNITED STATES
 Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
 Bol, David K., Gaithersburg, MD, UNITED STATES
 Ramanathan, Chandra, Wallingford, CT, UNITED STATES
 PI US 2003224400 A1 20031204
 AI US 2003-369405 A1 20030214 (10)
 RLI Continuation-in-part of Ser. No. US 2001-991225, filed on 16 Nov 2001,
 PENDING
 PRAI US 2000-249613P 20001117 (60)
 US 2000-257611P 20001221 (60)
 US 2001-305818P 20010716 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 15695
 INCL INCLM: 435/006.000
 INCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
 536/023.500
 NCL NCLM: 435/006.000
 NCLS: 435/007.100; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
 536/023.500
 IC [7]
 ICM: C12Q001-68
 ICS: G01N033-53; C07H021-04; C07K014-47; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 60 OF 215 USPATFULL on STN
 AN 2003:312692 USPATFULL
 TI Phosphorus-containing compounds and uses thereof
 IN Bernstein, David L., Waban, MA, UNITED STATES
 Metcalf, Chester A., III, Needham, MA, UNITED STATES
 Rozamus, Leonard W., Bedford, MA, UNITED STATES
 Wang, Yihan, Newton, MA, UNITED STATES
 PI US 2003220297 A1 20031127
 AI US 2003-357152 A1 20030203 (10)
 PRAI US 2002-353252P 20020201 (60)
 US 2002-426928P 20021115 (60)
 US 2002-428383P 20021122 (60)
 US 2002-433930P 20021217 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 3696
 INCL INCLM: 514/080.000
 INCLS: 540/456.000
 NCL NCLM: 514/080.000
 NCLS: 540/456.000
 IC [7]
 ICM: A61K031-675
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 61 OF 215 USPATFULL on STN
 AN 2003:312177 USPATFULL
 TI Novel human neurotransmitter transporter
 IN Sharma, Rahul, Gurnee, IL, UNITED STATES
 Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
 Westphal, Ryan, Cheshire, CT, UNITED STATES
 Feder, John N., Belle Mead, NJ, UNITED STATES
 Lee, Liana M., North Brunswick, NJ, UNITED STATES
 PI US 2003219774 A1 20031127
 AI US 2002-319315 A1 20021213 (10)
 PRAI US 2001-340436P 20011214 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 8684
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 NCL NCLM: 435/006.000
 NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C07K014-705; C12P021-02; C12N005-06
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 62 OF 215 USPATFULL on STN
AN 2003:289405 USPATFULL
TI Coated vascular devices
IN Bosma, Gjalt, Opeinde, NETHERLANDS
van der Meulen, De heer Joost, Bergum, NETHERLANDS
PI US 2003204168 A1 20031030
AI US 2002-208581 A1 20020730 (10)
RLI Continuation-in-part of Ser. No. US 2002-136569, filed on 30 Apr 2002,
PENDING
DT Utility
FS APPLICATION
LN.CNT 3252
INCL INCLM: 604/103.020
INCLS: 604/096.010; 604/104.000; 606/194.000; 606/200.000
NCL NCLM: 604/103.020
NCLS: 604/096.010; 604/104.000; 606/194.000; 606/200.000
IC [7]
ICM: A61M031-00
ICS: A61M029-00; A61M037-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 63 OF 215 USPATFULL on STN
AN 2003:289309 USPATFULL
TI Polynucleotide encoding a novel methionine aminopeptidase, protease-39
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Naglich, Joseph, Yardley, PA, UNITED STATES
PI US 2003204070 A1 20031030
AI US 2003-350516 A1 20030123 (10)
PRAI US 2002-351251P 20020123 (60)
US 2002-362872P 20020308 (60)
DT Utility
FS APPLICATION
LN.CNT 17388
INCL INCLM: 536/023.200
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000
NCL NCLM: 536/023.200
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000
IC [7]
ICM: C12N009-64
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 64 OF 215 USPATFULL on STN
AN 2003:289131 USPATFULL
TI Method for treating nerve injury caused as a result of surgery
IN Steiner, Joseph P., Mount Airy, MD, UNITED STATES
Snyder, Solomon, Baltimore, MD, UNITED STATES
Burnett, Arthur L., Baltimore, MD, UNITED STATES
PI US 2003203890 A1 20031030
AI US 2002-156735 A1 20020529 (10)
PRAI US 2001-293544P 20010529 (60)
DT Utility
FS APPLICATION
LN.CNT 7903
INCL INCLM: 514/211.010
INCLS: 514/217.110; 514/218.000; 514/227.500; 514/237.500; 514/255.010;
514/330.000; 514/365.000; 514/374.000; 514/385.000; 514/423.000
NCL NCLM: 514/211.010
NCLS: 514/217.110; 514/218.000; 514/227.500; 514/237.500; 514/255.010;
514/330.000; 514/365.000; 514/374.000; 514/385.000; 514/423.000
IC [7]
ICM: A61K031-554
ICS: A61K031-553; A61K031-55; A61K031-551; A61K031-54; A61K031-537;
A61K031-4172; A61K031-445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 65 OF 215 USPATFULL on STN
AN 2003:282633 USPATFULL
TI Novel human G-protein coupled receptor, HGPRBMY14, related to the orphan
GPCR, GPR73
IN Feder, John N., Belle Mead, NJ, UNITED STATES

Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
 Kornacker, Michael G., Princeton, NJ, UNITED STATES
 Ryseck, Rolf-Peter, Ewing, CT, UNITED STATES
 Cacace, Angela, Clinton, CT, UNITED STATES
 Barber, Lauren E., Higganum, CT, UNITED STATES
 Bol, David K., Gaithersburg, MD, UNITED STATES
 PI US 2003198976 A1 20031023
 AI US 2002-295693 A1 20021114 (10)
 RLI Continuation-in-part of Ser. No. US 2002-67649, filed on 5 Feb 2002,
 PENDING
 PRAI US 2001-266525P 20010205 (60)
 US 2001-329897P 20011016 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 15175
 INCL INCLM: 435/006.000
 INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;
 514/044.000
 NCL NCLM: 435/006.000
 NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;
 514/044.000
 IC [7]
 ICM: C12Q001-68
 ICS: C07H021-04; C12P021-02; C12N005-06; A61K048-00; C07K014-705
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L3 ANSWER 66 OF 215 USPATFULL on STN
 AN 2003:282632 USPATFULL
 TI Proteins associated with cell growth, differentiation, and death
 IN Azimzai, Yalda, Oakland, CA, UNITED STATES
 Au-Young, Janice, Brisbane, CA, UNITED STATES
 Batra, Sajeev, Oakland, CA, UNITED STATES
 Baughn, Mariah R., San Leandro, CA, UNITED STATES
 Becha, Shanya D., Castro Valley, CA, UNITED STATES
 Borowsky, Mark L., Redwood City, CA, UNITED STATES
 Burford, Neil, Durham, CT, UNITED STATES
 Ding, Li, Creve Coeur, MO, UNITED STATES
 Elliott, Vicki S., San Jose, CA, UNITED STATES
 Emerling, Brooke M., Chicago, IL, UNITED STATES
 Gandhi, Ameena R., San Francisco, CA, UNITED STATES
 Gietzen, Kimberly J., San Jose, CA, UNITED STATES
 Griffin, Jennifer A., San Jose, CA, UNITED STATES
 Hafalia, April J. A., Santa Clara, CA, UNITED STATES
 Honchell, Cynthia D., San Carlos, CA, UNITED STATES
 Lal, Preeti G., Santa Clara, CA, UNITED STATES
 Lee, Soo Yeun, Daly City, CA, UNITED STATES
 Lu, Dyung Aina M., San Jose, CA, UNITED STATES
 Arvizu, Chandra S., San Jose, CA, UNITED STATES
 Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
 Reddy, Roopa M., Sunnyvale, CA, UNITED STATES
 Sanjanwala, Madhusudan S., Los Altos, CA, UNITED STATES
 Tang, Y. Tom, San Jose, CA, UNITED STATES
 Chawla, Narinder K., Union City, CA, UNITED STATES
 Wang, Yu-Mei E., Mountain View, CA, UNITED STATES
 Warren, Bridget A., Encinitas, CA, UNITED STATES
 Xu, Yuming, Mountain View, CA, UNITED STATES
 Yang, Junming, San Jose, CA, UNITED STATES
 Yao, Monique G., Carmel, IN, UNITED STATES
 Yue, Henry, Sunnyvale, CA, UNITED STATES
 Zebbarjadian, Yeganeh, San Francisco, CA, UNITED STATES
 PA Incyte Genomics, Inc., Palo Alto, CA (U.S. corporation)
 PI US 2003198975 A1 20031023
 AI US 2002-287218 A1 20021031 (10)
 RLI Continuation of Ser. No. WO 2002-US11152, filed on 5 Apr 2002, PENDING
 PRAI WO 2002-US11152 20020405
 US 2002-349705P 20020115 (60)
 US 2001-295263P 20010601 (60)
 US 2001-295340P 20010601 (60)
 US 2001-293727P 20010525 (60)
 US 2001-291846P 20010518 (60)
 US 2001-291662P 20010516 (60)
 US 2001-287228P 20010427 (60)
 US 2001-286820P 20010426 (60)
 US 2001-283294P 20010411 (60)
 US 2001-282110P 20010406 (60)

FS APPLICATION
LN.CNT 10940
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 530/388.260; 514/044.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
536/023.200; 530/388.260; 514/044.000
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47;
A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 67 OF 215 USPATFULL on STN
AN 2003:277136 USPATFULL
TI Polynucleotides encoding three novel human cell surface proteins with
leucine rich repeats and immunoglobulin folds, BGS2, 3, and 4 and
variants thereof
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Cheng, Janet D., Lawrenceville, NJ, UNITED STATES
PI US 2003195163 A1 20031016
AI US 2002-193477 A1 20020711 (10)
PRAI US 2001-304888P 20010711 (60)
US 2002-372147P 20020412 (60)
DT Utility
FS APPLICATION
LN.CNT 19137
INCL INCLM: 514/044.000
INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/366.000
NCL NCLM: 514/044.000
NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/366.000
IC [7]
ICM: A61K048-00
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-435; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 68 OF 215 USPATFULL on STN
AN 2003:271509 USPATFULL
TI Acyclic piperazine and piperidine derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Tomlinson, Ronald, Marlborough, MA, UNITED STATES
Ottow, Eckhard, Berlin, GERMANY, FEDERAL REPUBLIC OF
Botfield, Martyn, Boston, MA, UNITED STATES
PI US 2003191117 A1 20031009
AI US 2002-170965 A1 20020613 (10)
PRAI US 2001-298328P 20010614 (60)
DT Utility
FS APPLICATION
LN.CNT 1193
INCL INCLM: 514/227.800
INCLS: 514/231.800; 514/235.500; 514/235.800; 514/252.110; 514/253.010;
514/326.000; 514/316.000; 544/060.000; 544/078.000; 544/120.000;
544/129.000; 544/360.000; 544/357.000; 546/186.000
NCL NCLM: 514/227.800
NCLS: 514/231.800; 514/235.500; 514/235.800; 514/252.110; 514/253.010;
514/326.000; 514/316.000; 544/060.000; 544/078.000; 544/120.000;
544/129.000; 544/360.000; 544/357.000; 546/186.000
IC [7]
ICM: A61K031-541
ICS: A61K031-5377; A61K031-496; A61K031-4545; A61K031-454; C07D417-02;
C07D413-02; C07D043-02; C07D041-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 69 OF 215 USPATFULL on STN
AN 2003:265943 USPATFULL
TI Cyclized amino acid derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Ledford, Brian, Hopkinton, MA, UNITED STATES
PI US 2003186960 A1 20031002
AI US 2002-39898 A1 20020103 (10)
DT Utility

LN.CNT 846
INCL INCLM: 514/211.150
INCLS: 514/217.040; 514/218.000; 514/227.800; 514/235.500; 514/253.010;
514/318.000; 514/340.000; 514/341.000; 514/342.000; 540/544.000;
540/575.000; 540/596.000; 544/060.000; 544/360.000; 544/127.000;
546/193.000; 546/269.700; 546/271.400; 546/273.100
NCL NCLM: 514/211.150
NCLS: 514/217.040; 514/218.000; 514/227.800; 514/235.500; 514/253.010;
514/318.000; 514/340.000; 514/341.000; 514/342.000; 540/544.000;
540/575.000; 540/596.000; 544/060.000; 544/360.000; 544/127.000;
546/193.000; 546/269.700; 546/271.400; 546/273.100
IC [7]
ICM: A61K031-551
ICS: A61K031-553; A61K031-554; A61K031-55; A61K031-5377; A61K031-541;
A61K031-496; A61K031-4545; A61K031-4439; C07D417-02; C07D413-02;
C07D043-02

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 70 OF 215 USPATFULL on STN
AN 2003:265252 USPATFULL
TI Novel human leucine-rich repeat domain containing protein, HLLRCR-1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel, Hightstown, NJ, UNITED STATES
PI US 2003186267 A1 20031002
AI US 2002-271078 A1 20021011 (10)
PRAI US 2001-328478P 20011011 (60)
DT Utility
FS APPLICATION
LN.CNT 14036
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 514/012.000; 530/350.000;
536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 514/012.000; 530/350.000;
536/023.500
IC [7]
ICM: C12Q001-68
ICS: A61K038-17; C07H021-04; C12P021-02; C12N005-06; C07K014-715

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 71 OF 215 USPATFULL on STN
AN 2003:258658 USPATFULL
TI Polynucleotide encoding a novel human potassium channel beta-subunit,
K+Mbetal
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana M., Somerset, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
PI US 2003181711 A1 20030925
AI US 2002-264171 A1 20021003 (10)
RLI Continuation-in-part of Ser. No. US 2001-40805, filed on 1 Nov 2001,
PENDING
PRAI US 2000-245366P 20001102 (60)
US 2000-257851P 20001221 (60)
DT Utility
FS APPLICATION
LN.CNT 11490
INCL INCLM: 536/023.500
INCLS: 514/012.000; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
514/044.000
NCL NCLM: 536/023.500
NCLS: 514/012.000; 435/069.100; 435/320.100; 435/325.000; 530/350.000;
514/044.000
IC [7]
ICM: A61K048-00
ICS: A61K038-17; C12P021-02; C12N005-06; C07K014-47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 72 OF 215 USPATFULL on STN
AN 2003:257761 USPATFULL
TI Novel human leucine-rich repeat containing protein expressed

IN Feder, John N., Belle Mead, NJ, UNITED STATES
 Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
 Mintier, Gabe, Hightstown, NJ, UNITED STATES
 PI US 2003180812 A1 20030925
 AI US 2002-183770 A1 20020627 (10)
 RLI Continuation-in-part of Ser. No. US 2001-28374, filed on 20 Dec 2001,
 PENDING
 PRAI US 2000-257773P 20001222 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 12615
 INCL INCLM: 435/007.200
 INCLS: 435/007.230; 514/001.000
 NCL NCLM: 435/007.200
 NCLS: 435/007.230; 514/001.000
 IC [7]
 ICM: G01N033-53
 ICS: C12Q001-68; G01N033-567; G01N033-574; A61K031-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 73 OF 215 USPATFULL on STN
 AN 2003:251172 USPATFULL
 TI Methods for using bag expression as a cell differentiation agent and
 marker
 IN Reed, John C., Rancho Santa Fe, CA, UNITED STATES
 Kermer, Pawel, San Diego, CA, UNITED STATES
 Krajewski, Stanislaw, San Diego, CA, UNITED STATES
 PI US 2003175958 A1 20030918
 AI US 2002-99553 A1 20020315 (10)
 DT Utility
 FS APPLICATION
 LN.CNT 1817
 INCL INCLM: 435/368.000
 INCLS: 435/325.000; 435/455.000
 NCL NCLM: 435/368.000
 NCLS: 435/325.000; 435/455.000
 IC [7]
 ICM: C12N005-08
 ICS: C12N005-06; C12N015-85
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 74 OF 215 USPATFULL on STN
 AN 2003:238382 USPATFULL
 TI Polynucleotide encoding a novel human G-protein coupled receptor,
 HGPRBMY30
 IN Feder, John N., Belle Mead, NJ, UNITED STATES
 Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
 Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
 PI US 2003166540 A1 20030904
 AI US 2002-159339 A1 20020530 (10)
 PRAI US 2001-294411P 20010530 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 14458
 INCL INCLM: 514/012.000
 INCLS: 530/350.000; 536/023.200; 435/069.100; 435/325.000; 435/320.100
 NCL NCLM: 514/012.000
 NCLS: 530/350.000; 536/023.200; 435/069.100; 435/325.000; 435/320.100
 IC [7]
 ICM: A61K038-17
 ICS: C07K014-705; C12P021-02; C12N005-06; C07H021-04
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 75 OF 215 USPATFULL on STN
 AN 2003:232051 USPATFULL
 TI Polynucleotide encoding a novel human potassium channel beta-subunit,
 K+betaM8
 IN Feder, John N., Belle Mead, NJ, UNITED STATES
 Lee, Liana M., North Brunswick, NJ, UNITED STATES
 Chang, Han, Princeton Junction, NJ, UNITED STATES
 PI US 2003162251 A1 20030828
 AI US 2002-234951 A1 20020904 (10)
 PRAI US 2001-317087P 20010904 (60)
 US 2001-329666P 20011016 (60)
 DT Utility

LN.CNT 16624
INCL INCLM: 435/069.100
INCLS: 435/006.000; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/006.000; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 76 OF 215 USPATFULL on STN
AN 2003:231989 USPATFULL
TI Polynucleotide encoding a novel TRP channel family member, LTRPC3, and splice variants thereof
IN Lee, Ning, Belle Mead, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John, Belle Mead, NJ, UNITED STATES
Wu, Shujian, Langhorne, PA, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Blonar, Michael A., Malvern, PA, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
Levesque, Paul C., Yardley, PA, UNITED STATES
Sun, Lucy, Newtown, PA, UNITED STATES
PI US 2003162189 A1 20030828
AI US 2002-210152 A1 20020801 (10)
PRAI US 2001-309544P 20010802 (60)
DT Utility
FS APPLICATION
LN.CNT 22664
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 77 OF 215 USPATFULL on STN
AN 2003:225786 USPATFULL
TI Novel human G-protein coupled receptor, HGPRBMY23, expressed highly in kidney
IN Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Cacace, Angela, Clinton, CT, UNITED STATES
Barber, Lauren, Griswold, CT, UNITED STATES
Ryseck, Rolf P., Ewing, NJ, UNITED STATES
PI US 2003157598 A1 20030821
AI US 2001-10568 A1 20011207 (10)
PRAI US 2000-251926P 20001207 (60)
US 2001-269795P 20010214 (60)
DT Utility
FS APPLICATION
LN.CNT 15361
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.200; 435/006.000
NCL NCLM: 435/069.100
NCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.200; 435/006.000
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 78 OF 215 USPATFULL on STN
AN 2003:225702 USPATFULL
TI Polynucleotide encoding a novel pleckstrin homology domain and proline rich domain containing adapter protein, PMN29
IN Finger, Joshua N., San Marcos, CA, UNITED STATES
Perez-Villar, Juan J., Mercerville, NJ, UNITED STATES
Rajashekar, Reddy, Langhorne, PA, UNITED STATES
Yang, Guchen, Morrisville, PA, UNITED STATES
Kiener, Peter A., Doylestown, PA, UNITED STATES
PI US 2003157514 A1 20030821
AI US 2002-234816 A1 20020904 (10)

DT Utility
FS APPLICATION
LN.CNT 13865
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;
435/007.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500;
435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C07H021-04; C12P021-02; C12N005-06;
C07K014-47

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 79 OF 215 USPATFULL on STN
AN 2003:219773 USPATFULL
TI Novel human G-protein coupled receptor, HGPRBMY11, expressed highly in
heart and variants thereof
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Cacace, Angela M., Clinton, CT, UNITED STATES
Barber, Lauren E., Griswood, CT, UNITED STATES
PI US 2003153063 A1 20030814
AI US 2001-991225 A1 20011116 (9)
PRAI US 2000-249613P 20001117 (60)
US 2000-257611P 20001221 (60)
US 2001-305818P 20010716 (60)

DT Utility
FS APPLICATION
LN.CNT 16070
INCL INCLM: 435/226.000
INCLS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 435/226.000
NCLS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C12N009-64
ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 80 OF 215 USPATFULL on STN
AN 2003:219663 USPATFULL
TI Polynucleotide encoding a novel human potassium channel alpha-subunit,
K α 2
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
PI US 2003152953 A1 20030814
AI US 2002-199869 A1 20020719 (10)
PRAI US 2001-306577P 20010719 (60)

DT Utility
FS APPLICATION
LN.CNT 12606
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-435

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 81 OF 215 USPATFULL on STN
AN 2003:219631 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2003152921 A1 20030814
AI US 2001-876997 A1 20010608 (9)
RLI Continuation-in-part of Ser. No. US 2000-731872, filed on 7 Dec 2000,
PENDING
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)

FS APPLICATION
LN.CNT 27600
INCL INCLM: 435/006.000
INCLS: 435/183.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/183.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C12N009-00; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 82 OF 215 USPATFULL on STN
AN 2003:207892 USPATFULL
TI Acyclic and cyclic amine derivatives
IN Mullican, Michael, Needham, MA, UNITED STATES
Lauffer, David, Stow, MA, UNITED STATES
Tung, Roger, Beverly, MA, UNITED STATES
PI US 2003144253 A1 20030731
AI US 2002-60662 A1 20020130 (10)
PRAI WO 2000-US20491 20000727
US 1999-146582P 19990730 (60)
DT Utility
FS APPLICATION
LN.CNT 2027
INCL INCLM: 514/114.000
INCLS: 514/381.000; 514/475.000; 514/626.000; 514/649.000; 548/254.000;
549/551.000; 564/193.000; 564/336.000; 562/011.000
NCL NCLM: 514/114.000
NCLS: 514/381.000; 514/475.000; 514/626.000; 514/649.000; 548/254.000;
549/551.000; 564/193.000; 564/336.000; 562/011.000
IC [7]
ICM: A61K031-66
ICS: A61K031-336; A61K031-16; A61K031-137; C07F009-28; C07D033-46;
C07D257-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 83 OF 215 USPATFULL on STN
AN 2003:207830 USPATFULL
TI Polynucleotide encoding a novel TRP channel family member, TRP-PLIK2,
and splice variants thereof
IN Lee, Ning, Bellemead, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Wu, Shujian, Langhorne, PA, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Blonar, Michael A., Malvern, PA, UNITED STATES
Bol, David, Langhorne, PA, UNITED STATES
PI US 2003144191 A1 20030731
AI US 2002-153244 A1 20020522 (10)
PRAI US 2001-292599P 20010522 (60)
US 2002-362944P 20020308 (60)
DT Utility
FS APPLICATION
LN.CNT 20954
INCL INCLM: 514/012.000
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 514/012.000
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: A61K031-17
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 84 OF 215 USPATFULL on STN
AN 2003:207348 USPATFULL
TI Novel human leucine-rich repeat containing protein expressed
predominately in bone marrow, HLRRBM1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
PI US 2003143706 A1 20030731
AI US 2001-28374 A1 20011220 (10)
PRAI US 2000-257773P 20001222 (60)
DT Utility

LN.CNT 13850
INCL INCLM: 435/183.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200; 435/006.000
NCL NCLM: 435/183.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200; 435/006.000
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 85 OF 215 USPATFULL on STN
AN 2003:200810 USPATFULL
TI Polynucleotide encoding a novel human growth factor with homology to
epidermal growth factor, BGS-8, expressed highly in immune tissue
IN Wu, Shujian, Langhorne, PA, UNITED STATES
Lee, Liana M., North Brunswick, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
PI US 2003138795 A1 20030724
AI US 2002-173461 A1 20020614 (10)
PRAI US 2001-298340P 20010614 (60)
DT Utility
FS APPLICATION
LN.CNT 13042
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 86 OF 215 USPATFULL on STN
AN 2003:188463 USPATFULL
TI Cyclized amide derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
Ledford, Brian, Attleboro, MA, UNITED STATES
PI US 2003130256 A1 20030710
AI US 2003-358707 A1 20030205 (10)
RLI Division of Ser. No. US 2002-39897, filed on 3 Jan 2002, GRANTED, Pat.
No. US 6552041 Continuation of Ser. No. WO 2000-US18418, filed on 5 Jul
2000, PENDING
PRAI US 1999-142515P 19990706 (60)
DT Utility
FS APPLICATION
LN.CNT 843
INCL INCLM: 514/211.010
INCLS: 514/217.120; 514/218.000; 514/227.500; 514/237.800; 514/252.120;
514/317.000; 514/365.000; 514/374.000; 514/385.000; 514/408.000;
540/544.000; 540/575.000; 544/059.000; 540/609.000; 544/162.000;
546/229.000; 548/146.000; 548/215.000; 548/335.500
NCL NCLM: 514/211.010
NCLS: 514/217.120; 514/218.000; 514/227.500; 514/237.800; 514/252.120;
514/317.000; 514/365.000; 514/374.000; 514/385.000; 514/408.000;
540/544.000; 540/575.000; 544/059.000; 540/609.000; 544/162.000;
546/229.000; 548/146.000; 548/215.000; 548/335.500
IC [7]
ICM: C07D279-12
ICS: C07D277-04; A61K031-55; A61K031-553; A61K031-554; C07D263-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 87 OF 215 USPATFULL on STN
AN 2003:166634 USPATFULL
TI Method of using neurotrophic sulfonamide compounds
IN Hamilton, Gregory S., Catonsville, MD, UNITED STATES
Li, Jia-He, Cockeysville, MD, UNITED STATES
Steiner, Joseph P., Hampstead, MD, UNITED STATES
PI US 2003114492 A1 20030619
AI US 2001-814954 A1 20010323 (9)
RLI Continuation of Ser. No. US 1999-419801, filed on 18 Oct 1999, GRANTED,
Pat. No. US 6245783 Division of Ser. No. US 1998-28517, filed on 23 Feb
1998, GRANTED, Pat. No. US 5968957 Division of Ser. No. US 1997-799407,
filed on 12 Feb 1997, GRANTED, Pat. No. US 5721256
DT Utility

LN.CNT 1009
INCL INCLM: 514/330.000
INCLS: 514/318.000; 514/326.000; 514/340.000; 514/423.000; 514/424.000;
514/422.000
NCL NCLM: 514/330.000
NCLS: 514/318.000; 514/326.000; 514/340.000; 514/423.000; 514/424.000;
514/422.000
IC [7]
ICM: A61K031-4545
ICS: A61K031-445; A61K031-4439; A61K031-401; A61K031-4025
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 88 OF 215 USPATFULL on STN
AN 2003:166515 USPATFULL
TI Polynucleotide encoding a novel cysteine protease of the calpain
superfamily, CAN-12, and variants thereof
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Vaz, Roy J., North Branch, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
PI US 2003114373 A1 20030619
AI US 2002-116519 A1 20020403 (10)
PRAI US 2001-281253P 20010403 (60)
US 2001-288768P 20010504 (60)
US 2001-296180P 20010606 (60)
US 2001-300620P 20010625 (60)
DT Utility
FS APPLICATION
LN.CNT 30149
INCL INCLM: 514/012.000
INCLS: 536/023.200; 530/350.000; 435/069.100; 435/325.000; 435/320.100
NCL NCLM: 514/012.000
NCLS: 536/023.200; 530/350.000; 435/069.100; 435/325.000; 435/320.100
IC [7]
ICM: A61K038-17
ICS: C12P021-02; C12N005-06; C07H021-04; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 89 OF 215 USPATFULL on STN
AN 2003:166513 USPATFULL
TI Polynucleotide encoding a novel human potassium channel beta-subunit,
K+betaM3
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
Ryseck, Rolf-Peter, Ewing, NJ, UNITED STATES
Watson, Andrew J., West Windsor, NJ, UNITED STATES
Carroll, Pamela, Princeton, NJ, UNITED STATES
PI US 2003114371 A1 20030619
AI US 2002-71458 A1 20020207 (10)
PRAI US 2001-267039P 20010207 (60)
US 2001-281224P 20010403 (60)
DT Utility
FS APPLICATION
LN.CNT 13661
INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: A61K038-17
ICS: C07K014-435; C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 90 OF 215 USPATFULL on STN
AN 2003:166496 USPATFULL
TI Polynucleotide encoding a novel potassium channel with homology to the
ether-a-go-go family, HEAG2
IN Feder, John N., Belle Mead, NJ, UNITED STATES

Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
Duclos, Franck, Washington Crossing, PA, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES

PI US 2003114354 A1 20030619
AI US 2002-174613 A1 20020619 (10)
PRAI US 2001-299378P 20010619 (60)
US 2001-300614P 20010625 (60)

DT Utility
FS APPLICATION

LN.CNT 14684

INCL INCLM: 514/001.000
INCLS: 702/019.000; 703/011.000

NCL NCLM: 514/001.000
NCLS: 702/019.000; 703/011.000

IC [7]

ICM: A61K031-00

ICS: G06G007-48; G06G007-58; G06F019-00; G01N033-48; G01N033-50

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 91 OF 215 USPATFULL on STN

AN 2003:159408 USPATFULL

TI Polynucleotide encoding a novel metalloprotease highly expressed in the
testis, MMP-29

IN Wu, Shujian, Langhorne, PA, UNITED STATES

Chen, Jian, Princeton, NJ, UNITED STATES

Feder, John N., Belle Mead, NJ, UNITED STATES

Lee, Liana, North Brunswick, NJ, UNITED STATES

Krystek, Stanley R., Ringoes, NJ, UNITED STATES

PI US 2003109021 A1 20030612

AI US 2002-133797 A1 20020426 (10)

PRAI US 2001-286764P 20010426 (60)

DT Utility
FS APPLICATION

LN.CNT 19916

INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200

NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200

IC [7]

ICM: C12N009-64

ICS: C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 92 OF 215 USPATFULL on STN

AN 2003:146311 USPATFULL

TI Novel human G-protein coupled receptor, HGPRBMY14, related to the orphan
GPCR, GPR73

IN Feder, John N., Belle Mead, NJ, UNITED STATES

Ramanathan, Chandra S., Wallingford, CT, UNITED STATES

Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

Kornacker, Michael, Princeton, NJ, UNITED STATES

Ryseck, Rolf-Peter, Ewing, NJ, UNITED STATES

Cacace, Angela, Clinton, CT, UNITED STATES

Barber, Lauren E., Jewett City, CT, UNITED STATES

PI US 2003100057 A1 20030529

AI US 2002-67649 A1 20020205 (10)

PRAI US 2001-266525P 20010205 (60)

US 2001-329897P 20011016 (60)

DT Utility
FS APPLICATION

LN.CNT 14451

INCL INCLM: 435/069.100
INCLS: 435/183.000; 435/320.100; 435/325.000; 536/023.200; 530/350.000

NCL NCLM: 435/069.100
NCLS: 435/183.000; 435/320.100; 435/325.000; 536/023.200; 530/350.000

IC [7]

ICM: C12P021-02

ICS: C12N005-06; C07K014-435; C07H021-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 93 OF 215 USPATFULL on STN

TI Polynucleotide encoding a novel immunoglobulin superfamily member,
APEX4, and variants and splice variants thereof
IN Finger, Joshua N., San Marcos, CA, UNITED STATES
PI US 2003092017 A1 20030515
AI US 2002-104943 A1 20020322 (10)
PRAI US 2001-278037P 20010322 (60)
US 2001-281223P 20010403 (60)
DT Utility
FS APPLICATION
LN.CNT 13219
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 94 OF 215 USPATFULL on STN
AN 2003:127127 USPATFULL
TI Novel human leucine-rich repeat containing protein expressed
predominately in nervous system tissues, HLRNS1
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabe, Hightstown, NJ, UNITED STATES
PI US 2003087340 A1 20030508
AI US 2001-28392 A1 20011220 (10)
PRAI US 2001-259479P 20010103 (60)
US 2001-260616P 20010109 (60)
DT Utility
FS APPLICATION
LN.CNT 15374
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.500
IC [7]
ICM: C07K014-435
ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 95 OF 215 USPATFULL on STN
AN 2003:99217 USPATFULL
TI Methods of effecting neuronal activity
IN Hamilton, Gregory S., Catonsville, MD, UNITED STATES
Wei, Ling, Lutherville, MD, UNITED STATES
Steiner, Joseph P., Mt. Airy, MD, UNITED STATES
PA Guilford Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003068321 A1 20030410
AI US 2001-947700 A1 20010907 (9)
DT Utility
FS APPLICATION
LN.CNT 448
INCL INCLM: 424/146.100
INCLS: 424/094.630
NCL NCLM: 424/146.100
NCLS: 424/094.630
IC [7]
ICM: A61K038-48
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 96 OF 215 USPATFULL on STN
AN 2003:94014 USPATFULL
TI Coated medical devices
IN Davila, Luis A., Pleasanton, CA, UNITED STATES
Wilson, David J., Branchburg, NJ, UNITED STATES
PI US 2003065377 A1 20030403
AI US 2002-136569 A1 20020430 (10)
RLI Continuation-in-part of Ser. No. US 2001-966447, filed on 28 Sep 2001,
PENDING
DT Utility
FS APPLICATION
LN.CNT 2955

NCL INCLS: 623/001.420; 604/500.000
NCLM: 623/001.130
NCLS: 623/001.420; 604/500.000
IC [7]
ICM: A61F002-06
ICS: A61M031-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 97 OF 215 USPATFULL on STN
AN 2003:93983 USPATFULL
TI Drug releasing anastomosis devices and methods for treating anastomotic sites
IN Evens, Carl J., Branchburg, NJ, UNITED STATES
Weedock, Kevin, Princeton, NJ, UNITED STATES
PI US 2003065346 A1 20030403
AI US 2002-274782 A1 20021021 (10)
RLI Continuation-in-part of Ser. No. US 2001-966447, filed on 28 Sep 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 3454
INCL INCLM: 606/153.000
NCL NCLM: 606/153.000
IC [7]
ICM: A61B017-08

L3 ANSWER 98 OF 215 USPATFULL on STN
AN 2003:93982 USPATFULL
TI Anastomosis devices and methods for treating anastomotic sites
IN Weadock, Kevin, Princeton, NJ, UNITED STATES
PI US 2003065345 A1 20030403
AI US 2002-274770 A1 20021021 (10)
RLI Continuation-in-part of Ser. No. US 2001-966447, filed on 28 Sep 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 3485
INCL INCLM: 606/153.000
NCL NCLM: 606/153.000
IC [7]
ICM: A61B017-08

L3 ANSWER 99 OF 215 USPATFULL on STN
AN 2003:86801 USPATFULL
TI Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY25, expressed highly in immune-related tissues
IN Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES
PI US 2003060409 A1 20030327
AI US 2002-81775 A1 20020221 (10)
PRAI US 2001-270134P 20010221 (60)
US 2001-278952P 20010327 (60)
DT Utility
FS APPLICATION
LN.CNT 13055
INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: A61K038-17
ICS: C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 100 OF 215 USPATFULL on STN
AN 2003:78525 USPATFULL
TI Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
IN Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nelson, Thomas, Lawrenceville, NJ, UNITED STATES
Seiler, Steven, Pennington, NJ, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Cheney, Daniel L., Flemington, NJ, UNITED STATES

PI US 2003054445 A1 20030320 -
AI US 2001-993180 A1 20011114 (9)
PRAI US 2000-248434P 20001114 (60)
US 2000-257610P 20001221 (60)
US 2001-282745P 20010410 (60)
DT Utility
FS APPLICATION
LN.CNT 14427
INCL INCLM: 435/069.100
INCLS: 514/012.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/069.100
NCLS: 514/012.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: A61K038-17
ICS: C07K014-435; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 101 OF 215 USPATFULL on STN
AN 2003:51158 USPATFULL
TI Polynucleotide encoding a novel human potassium channel beta-subunit,
K+betaM6, expressed highly in the small intestine
IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
PI US 2003036115 A1 20030220
AI US 2002-80980 A1 20020221 (10)
PRAI US 2001-270132P 20010221 (60)
US 2001-278953P 20010327 (60)
DT Utility
FS APPLICATION
LN.CNT 12296
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.200
NCL NCLM: 435/069.100
NCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.200
IC [7]
ICM: C07K014-435
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 102 OF 215 USPATFULL on STN
AN 2003:45474 USPATFULL
TI Polynucleotide encoding a novel human potassium channel beta-subunit,
K+betaM2
IN Chang, Han, Princeton Junction, NY, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John, Belle Mead, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Carroll, Pamela, Princeton, NJ, UNITED STATES
PI US 2003032786 A1 20030213
AI US 2002-56884 A1 20020124 (10)
PRAI US 2001-263872P 20010124 (60)
US 2001-269794P 20010214 (60)
DT Utility
FS APPLICATION
LN.CNT 13633
INCL INCLM: 536/023.100
NCL NCLM: 536/023.100
IC [7]
ICM: C07H021-02
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 103 OF 215 USPATFULL on STN
AN 2003:45464 USPATFULL
TI Polynucleotide encoding a novel human potassium channel beta-subunit,
K+Mbeta1
IN Feder, John N., Belle Mead, NJ, UNITED STATES

Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra, Wallingford, CT, UNITED STATES
Siemers, Nathan, Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES

PI US 2003032776 A1 20030213
AI US 2001-40805 A1 20011101 (10)
PRAI US 2000-245366P 20001102 (60)
US 2000-257851P 20001221 (60)
DT Utility
FS APPLICATION
LN.CNT 12037
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/069.100; 435/325.000; 435/320.100
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/069.100; 435/325.000; 435/320.100
IC [7]
ICM: C07K014-435
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 104 OF 215 USPATFULL on STN
AN 2003:45296 USPATFULL
TI Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, HGRA4, and splice variant thereof

IN Feder, John N., Belle Mead, NJ, UNITED STATES
Lee, Liana, North Brunswick, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Jackson, Donald, Lawrenceville, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Siemers, Nathan O., Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES

PI US 2003032608 A1 20030213
AI US 2002-75846 A1 20020213 (10)
PRAI US 2001-269535P 20010216 (60)
DT Utility
FS APPLICATION
LN.CNT 12638
INCL INCLM: 514/044.000
INCLS: 536/023.200; 530/350.000; 435/325.000; 435/320.100; 435/069.100
NCL NCLM: 514/044.000
NCLS: 536/023.200; 530/350.000; 435/325.000; 435/320.100; 435/069.100
IC [7]
ICM: A61K048-00
ICS: C07K014-705; C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 105 OF 215 USPATFULL on STN
AN 2003:23722 USPATFULL
TI Novel human leucine-rich repeat containing protein expressed predominately in small intestine, HLRRS11

IN Feder, John N., Belle Mead, NJ, UNITED STATES
Ramanathan, Chandra S., Wallingford, CT, UNITED STATES
Mintier, Gabriel A., Hightstown, NJ, UNITED STATES

PI US 2003017562 A1 20030123
AI US 2001-29347 A1 20011220 (10)
PRAI US 2000-257774P 20001222 (60)
DT Utility
FS APPLICATION
LN.CNT 14217
INCL INCLM: 435/183.000
INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCL NCLM: 435/183.000
NCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
IC [7]
ICM: C12N009-00
ICS: C12N009-16; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 106 OF 215 USPATFULL on STN
AN 2003:268211 USPATFULL
TI Compounds, pharmaceutical compositions, and methods for stimulating neuronal growth and elongation
IN Katoh, Susumu, Osaka, JAPAN

Tada, Hiroki, Osaka, JAPAN
Linton, Maria Angelica, San Diego, CA, United States
Kalish, Vincent, Annapolis, MD, United States
Tatlock, John Howard, Vista, CA, United States
Villafranca, Jesus Ernesto, San Diego, CA, United States
Pfizer Inc, New York, NY, United States (U.S. corporation)
PA US 6630472 B1 20031007
PI US 1999-356240 19990716 (9)
AI US 1998-93299P 19980717 (60)
PRAI US 1999-132884P 19990506 (60)

DT Utility
FS GRANTED

LN.CNT 2023

INCL INCLM: 514/249.000
INCLS: 540/520.000; 544/343.000; 544/346.000; 544/349.000

NCL NCLM: 514/249.000

NCLS: 540/520.000; 544/343.000; 544/346.000; 544/349.000

IC [7]
ICM: C07D471-18
ICS: C07D471-08; C07D498-18; A61K031-4995; A61K031-551

EXF 544/349; 544/343; 544/346; 540/520; 514/249

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 107 OF 215 USPATFULL on STN

AN 2003:228339 USPATFULL

TI Heterocyclic compounds as inhibitors of rotomase enzymes

IN Bull, David John, Sandwich, UNITED KINGDOM

Maguire, Robert John, Sandwich, UNITED KINGDOM

Palmer, Michael John, Sandwich, UNITED KINGDOM

Wythes, Martin James, Sandwich, UNITED KINGDOM

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 6610707 B1 20030826

WO 9945006 19990910

AI US 1999-380427 19990901 (9)

WO 1999-IB259 19990215

PRAI GB 1998-4426 19980302

DT Utility

FS GRANTED

LN.CNT 4168

INCL INCLM: 514/326.000

INCLS: 514/316.000; 514/322.000; 514/343.000; 514/442.000; 514/443.000;
514/235.500; 514/255.000; 514/256.000; 544/129.000; 544/242.000;
544/364.000; 546/187.000; 546/199.000; 546/210.000; 548/200.000;
548/201.000; 548/123.000; 548/124.000; 548/125.000; 548/128.000;
548/131.000

NCL NCLM: 514/326.000

NCLS: 514/235.500; 514/253.090; 514/253.100; 514/256.000; 514/316.000;
514/322.000; 514/343.000; 514/442.000; 514/443.000; 544/129.000;
544/242.000; 544/364.000; 546/187.000; 546/199.000; 546/210.000;
548/123.000; 548/124.000; 548/125.000; 548/128.000; 548/131.000;
548/200.000; 548/201.000

IC [7]

ICM: A61K031-445

ICS: C07D413-04; C07D413-14; C07D417-04

EXF 548/200; 548/201; 548/123; 548/124; 548/125; 548/128; 548/131; 546/187;
546/199; 546/210; 544/129; 544/242; 544/364; 514/343; 514/316; 514/442;
514/322; 514/443; 514/326; 514/235.5; 514/255; 514/256

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 108 OF 215 USPATFULL on STN

AN 2003:136920 USPATFULL

TI Materials and methods involving conditional retention domains

IN Rivera, Victor, Arlington, MA, United States

Clackson, Timothy, Cambridge, MA, United States

Rothman, James, New York, NY, United States

PA Ariad Gene Therapeutics, Inc., Cambridge, MA, United States (U.S. corporation)

PI US 6566073 B1 20030520

AI US 1999-420819 19991019 (9)

RLI Continuation of Ser. No. US 1998-174799, filed on 19 Oct 1998, now abandoned

PRAI US 1999-137787P 19990602 (60)

US 1998-104743P 19981019 (60)

DT Utility

FS GRANTED

INCL INCLM: 435/007.100
INCLS: 435/069.700; 435/325.000; 530/350.000
NCL NCLM: 435/007.100
NCLS: 435/069.700; 435/325.000; 530/350.000
IC [7]
ICM: G01N033-53
ICS: C12P021-04; C12N005-02; C07K017-00
EXF 435/7.1; 435/325; 435/375; 435/69.7; 435/69.1; 514/31; 536/6.5; 530/350;
424/93.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 109 OF 215 USPATFULL on STN
AN 2003:130014 USPATFULL
TI Heterocyclic compounds as inhibitors of rotamase enzymes
IN Kemp, Mark Ian, Sandwich, UNITED KINGDOM
Palmer, Michael John, Sandwich, UNITED KINGDOM
Sanner, Mark Allen, Old Saybrook, CT, United States
Wythes, Martin James, New London, CT, United States
Pfizer Inc, New York, NY, United States (U.S. corporation)
PA US 6562964 B1 20030513
PI US 2002-56901 20020123 (10)
AI Division of Ser. No. US 1999-358107, filed on 21 Jul 1999, now patented,
RLI Pat. No. US 6372736, issued on 23 Oct 2002
PRAI GB 1998-15880 19980721
DT Utility
FS GRANTED
LN.CNT 1994
INCL INCLM: 540/603.000
INCLS: 546/064.000; 546/273.400; 548/306.100; 548/309.100; 548/301.700
NCL NCLM: 540/603.000
NCLS: 546/064.000; 546/273.400; 548/301.700; 548/306.100; 548/309.100
IC [7]
ICM: C07D403-00
ICS: C07D471-00; C07D401-04; C07D403-02; C07D235-16
EXF 548/306.1; 548/309.4; 548/301.7; 546/64; 546/273.4; 540/603
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 110 OF 215 USPATFULL on STN
AN 2003:96083 USPATFULL
TI Neurotrophic 2-azetidinecarboxylic acid derivatives, and related
compositions and methods
IN Lanter, James C., Hillsborough, NJ, United States
Zhang, Suying, New Providence, NJ, United States
Zhao, Boyu, Lansdale, PA, United States
PA Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S.
corporation)
PI US 6544976 B1 20030408
AI US 2000-592531 20000612 (9)
PRAI US 1999-143001P 19990709 (60)
DT Utility
FS GRANTED
LN.CNT 1738
INCL INCLM: 514/210.000
INCLS: 540/200.000; 540/354.000
NCL NCLM: 514/210.180
NCLS: 540/200.000; 540/354.000
IC [7]
ICM: A01N043-00
ICS: C07D205-00; C07D205-08
EXF 514/423; 514/422; 514/210; 548/533; 548/536; 548/517; 548/526; 548/527;
540/200; 540/354
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 111 OF 215 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2003:496645 BIOSIS
DN PREV200300491816
TI Expression of ***FKBP12*** after brain ischemia.
AU Kato, Hiroyuki [Reprint Author]
CS Department of Neurology, Tohoku University School of Medicine, 1-1
Seiryomachi, Aoba-ku, Sendai, 980-8574, Japan
kato@mail.cc.tohoku.ac.jp
SO Abe, Koji [Editor, Reprint Author]. Int. Congr. Ser. - Excerpta Med.,
(2003) pp. 123-128. Molecular mechanism and epochal therapeutics of
ischemic stroke and dementia. print.

Box 211, Amsterdam, Netherlands. Series: International Congress Series.
Meeting Info.: International Symposium on Molecular Mechanism and Epochal
Therapeutics for Ischemic Stroke and Dementia. Okayama, Japan. October
18-20, 2002.

CODEN: EXMDA4. ISSN: 0531-5131. ISBN: 0-444-51222-5 (cloth).

DT Book; (Book Chapter)
Conference; (Meeting)
Conference; (Meeting Paper)

LA English

ED Entered STN: 22 Oct 2003

Last Updated on STN: 22 Oct 2003

L3 ANSWER 112 OF 215 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN

AN 2003:504700 SCISEARCH

GA The Genuine Article (R) Number: 687RR

TI ***FKBP12*** mRNA expression is upregulated by intrinsic CNS neurons
regenerating axons into peripheral nerve grafts in the brain

AU Mason M R J (Reprint); Lieberman A R; Latchman D S; Anderson P N

CS Univ Coll London, Dept Anat & Dev Biol, Gower St, London WC1E 6BT, England
(Reprint); Univ Coll London, Dept Anat & Dev Biol, London WC1E 6BT,
England; Univ Coll London, Inst Child Hlth, London WC1N 1EH, England

CYA England

SO EXPERIMENTAL NEUROLOGY, (JUN 2003) Vol. 181, No. 2, pp. 181-189.

Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN
DIEGO, CA 92101-4495 USA.

ISSN: 0014-4886.

DT Article; Journal

LA English

REC Reference Count: 44

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L3 ANSWER 113 OF 215 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2003:739269 CAPLUS

DN 139:336014

TI Expression of ***FKBP12*** after brain ischemia

AU Kato, Hiroyuki

CS Department of Neurology, Tohoku University School of Medicine, Aoba-ku,
Sendai, 980-8574, Japan

SO International Congress Series (2003), 1252(Molecular Mechanism and Epochal
Therapeutics of Ischemic Stroke and Dementia), 123-128

CODEN: EXMDA4; ISSN: 0531-5131

PB Elsevier Science B.V.

DT Journal; General Review

LA English

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 114 OF 215 BIOTECHDS COPYRIGHT 2004 THE THOMSON CORP. on STN
DUPLICATE 6

AN 2002-06198 BIOTECHDS

TI Use of nucleic acid encoding calcineurin for diagnosis and detection of
neuronal stress;

recombinant protein gene production useful in disease gene therapy and
drug screening

AU AIET IKHLEF A; RESINK A; SCHWEIGHOFFER F

PA EXONHIT THERAPEUTICS SA

PI WO 2002000872 3 Jan 2002

AI WO 2000-FR2058 29 Jun 2000

PRAI FR 2000-8407 29 Jun 2000

DT Patent

LA French

OS WPI: 2002-130890 [17]

L3 ANSWER 115 OF 215 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 7

AN 2002:290791 CAPLUS

DN 136:309922

TI Preparation of benzoxazolyl piperidines and analogs as rotamase enzyme
inhibitors

IN Kemp, Mark Ian; Palmer, Michael John; Sanner, Mark Allen; Wythes, Martin
James

PA Pfizer Inc., USA

SO U.S., 43 pp.

CODEN: USXXAM

DT Patent

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6372736	B1	20020416	US 1999-358107	19990721
	US 6562964	B1	20030513	US 2002-56901	20020123
PRAI	GB 1998-15880	A	19980721		
	US 1999-358107	A3	19990721		

OS MARPAT 136:309922

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 116 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 8

AN 10142377 IFIPAT;IFIUDB;IFICDB

TI COMPOSITIONS AND METHODS FOR PROMOTING NERVE REGENERATION; NON-
 FKBP12 -BINDING AGENT THAT BINDS TO A POLYPEPTIDE COMPONENT OF A
 STEROID RECEPTOR COMPLEX OTHER THAN A STEROID HORMONE BINDING PORTION OF
 THE COMPLEX; CAUSES HSP90 DISSOCIATION FROM OR PREVENTS HSP90 ASSOCIATION
 WITH THE COMPLEX.

IN Gold Bruce G

PA Oregon Health Sciences University (25323)

PI US 2002086015 A1 20020704

AI US 2001-825243 20010402

RLI US 1997-956691 19971024 CONTINUATION

GRANTED

US 1999-326728 19990607 CONTINUATION

ABANDONED

FI US 2002086015 20020704

US 6641810 20031104

DT Utility; Patent Application - First Publication

FS CHEMICAL

APPLICATION

CLMN 22

GI 17 Figure(s).

FIG. 1 shows structures of FK506 (left) and a representative FK506 analog,
 V-10,367 (right). The bracketed portion of FK506 represents the
 calcineurin-binding domain, which is absent in V10,367.

FIGS. 2-8 are histograms showing the stimulation of growth of SHSY5Y cells
 by geldanamycin and FK506 in the presence of NGF (10 ng/mL) 168 hours
 after treatment.

FIG. 2: control cells (untreated).

FIG. 3: NGF only (10 ng/mL).

FIG. 4: geldanamycin (1 nM)+NGF (10 ng/mL).

FIG. 5: geldanamycin (10 nM)+NGF (10 ng/mL).

FIG. 6: FK506 (10 nM)+NGF (10 ng/mL).

FIG. 7: geldanamycin (1 nM)+FK506 (10 nM)+NGF (10 ng/mL).

FIG. 8: geldanamycin (10 nM)+FK506 (10 nM)+NGF (10 ng/mL).

FIGS. 9-15 are histograms showing the stimulation of growth of SH-SY5Y
 cells by geldanamycin and FK506 in the presence of NGF (10 ng/ml) 168
 hours after treatment.

FIG. 9: control cells (untreated).

FIG. 10: NGF only (10 ng/mL).

FIG. 11: FK506 (1 nM)+NGF (10 ng/mL).

FIG. 12: FK506 (10 nM)+NGF (10 ng/mL)

FIG. 13: geldanamycin (0.1 nM)+NGF (10 ng/mL).

FIG. 14: geldanamycin (0.1 nM)+FK506 (1 nM)+NGF (10 ng/mL).

FIG. 15: geldanamycin (0.1 nM)+FK506 (10 nM)+NGF (10 ng/mL).

L3 ANSWER 117 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 9

AN 10108775 IFIPAT;IFIUDB;IFICDB

TI INHIBITORS OF ROTAMASE ENZYME ACTIVITY; USING NEUROTROPHIC PIPECOLIC ACID
 DERIVATIVE COMPOUNDS HAVING AN AFFINITY FOR FKBP-TYPE IMMUNOPHILINS AS
 INHIBITORS OF THE ENZYME ACTIVITY ASSOCIATED WITH IMMUNOPHILIN PROTEINS

IN DAWSON TED; HAMILTON GREGORY S; SNYDER SOLOMON; STEINER JOSEPH P

PA Unassigned Or Assigned To Individual (68000)

PPA GPI NIL Holdings Inc (Probable)

PI US 2002052372 A1 20020502

AI US 1999-435323 19991105

RLI US 1996-653905 19960528 CONTINUATION

5696135

US 1997-787162 19970123 CONTINUATION

5843960

US 1998-113330 19980710 CONTINUATION

6022878

US 1995-474072 19950607 CONTINUATION-IN-PART

5798355

FI US 2002052372 20020502

US 5696135

US 5843960

US 6022878

US 5798355

US 6500843

20021231

FIG. 1

FKBP-12 and GAP-43 expression in the facial nucleus after nerve crush. In situ hybridization comparing the time course of expression of mRNA in the facial nucleus for ***FKBP12*** (left) and GAP-43 (right). The right facial nucleus is ipsilateral to the crush, and the left side is an unoperated control (FIG. 1B). In situ hybridization for FKBP-12 on an untreated control (left) and for calcineurin A alpha, beta 7 days following facial nerve crush (right).

Experiments were replicated at least 3 times with similar results.

FIG. 2

Localization of FKBP-12 to facial motor neurons following nerve crush. Bright-field photomicrographs of in situ hybridization for FKBP-12 in motor neurons of the facial nucleus 7 days after crush (FIG. 2A), and in motor neurons of control facial nucleus (FIG. 2B).

FIG. 3

Upregulation of FKBP-12 mRNA in lumbar ***spinal*** ***cord*** motor neurons after sciatic nerve crush. In situ hybridization for FKBP-12 7 days after crush of the right sciatic nerve. Top panel (FIG. 3A) shows the response of motor neurons in the ventral horn of lower lumbar ***spinal*** ***cord*** (indicated by the arrow). Bright field photomicrographs of corresponding motor neuron pools are shown in the bottom panels: (FIG. 3B) left side contralateral to nerve crush, (FIG. 3C) right side ipsilateral to the nerve crush. This experiment was repeated 3 times with similar results.

FIG. 4

Induction of FKBP and FKBP-12 mRNA in the dorsal root ganglion 1 and 6 weeks after sciatic nerve crush. Dark-field photomicrographs of sections through the L4 dorsal root ganglion ipsilateral to sciatic nerve crush processed for FKBP in situ hybridization are shown in the left panels and for (3H) FK506 autoradiography in the right panels. These results were replicated 3 times for each time point.

FIG. 5

Ricin lesion of the right facial nerve. Nissl stain (bottom panel, FIG. 5A) reveals extensive degeneration of motor neurons in the right facial nucleus with an accompanying glial proliferation 7 days following injection of ricin into the facial nerve. In situ hybridization for FKBP mRNA 7 days after ricin lesion of the facial nerve/nucleus is shown in the top panel (FIG. 5B). This experiment was replicated 3 times with similar results.

FIG. 6

(3H)FK506 binding in segments of sciatic nerve 7 days following crush. The diagram illustrates the 3 mm segments of nerve taken: constrictions indicate positions of ligatures applied at day 7 for the 6 hr collection time as described in the methods. The distal ligature site is 10 mm proximal to the original crush site. Anterograde transport of FKBP is 124 mm/day. Data are the means +-S.E.M. (n=3).

FIG. 7

Transport of FKBP in the sciatic nerve. Dark-field photomicrographs of sections through a control (untreated) sciatic nerve and a 7 day sciatic nerve crush site processed for FKBP-12 in situ hybridization (FIG. 7A, FIG. 7B) and for (3H)FK-506 autoradiography (FIG. 7C, FIG. 7D). Arrows indicate the sight of the nerve crush. This experiment was repeated 3 times with similar results.

FIG. 8

Levels of (3H)FK506 binding in PC-12 cells maintained in the presence or absence of NGF (50 ng/ml). n=3 for each time point. Bars represent S.E.M.

FIG. 9

Immunosuppressant mediated enhancement of neurite outgrowth in PC-12 cells. Hoffman contrast photomicrographs (64) of cultures grown for 48 hr in the presence of NGF with or without added FK506 or rapamycin.

FIG. 9A: PC-12 cells grown in 1.0 ng/ml NGF.

FIG. 9B: 50 ng/ml NGF.

FIG. 9C: 1.0 ng/ml NGF and 100 nM FK506.

FIG. 9D: 1.0 ng/ml NGF and 100 nM rapamycin. Magnification 200 x .

FIG. 10

Effects of FK506 on neurite outgrowth in PC-12 cells. Cultures were treated with varying concentrations of NGF in the presence or absence of 100 nM FK506, and neurite sprouting was measured at 48 hr. Outgrowth was quantitated as described in Methods by counting cells with neuritic processes greater than 5 μ m. n=4 separate experiments for each point and error bars represent SEM.

Concentration-response relationship for FK506 potentiation of neurite outgrowth in PC-12 cells. Cells were treated for 48 hr with 1 ng/ml NGF and varying concentrations of FK506. Neurite outgrowth response was measured as described in FIG. 10 and Methods. n=4 separate experiments for each data point *p less than 0.001 Students t test.

FIG. 12

(3H)FK-506 autoradiography on dorsal root ganglion explant cultures. After 26 days of cultures with 100 ng/ml NGF the extensive processes display abundant FKBP associated silver grains. Autoradiographic grains are abolished with 1 μ M unlabeled FK506.

FIG. 13

Phase-contrast micrographs of dorsal root ganglia grown with different substances.

FIG. 13A: NGF 100 ng/ml,

FIG. 13B: FK506 1 μ M,

FIG. 13C: FK506 1 μ M and anti-NGF antibody,

FIG. 13D: No added growth factor,

FIG. 13E: FK506 1 pM,

FIG. 13F: FK506 1 μ M. and rapamycin 1 μ M. Scale bar is 205 μ m. NGF

produces abundant axon outgrowth (FIG. 13A), as does 1 μ M FK506 (FIG. 13B). The effects of FK506 are substantially decreased by reducing the concentration to 1 pM (FIG. 13E). However, neurite outgrowth with 1 pM FK506 is greater than in its absence (FIG. 13D). FK506 effects are also diminished by adding anti-NGF antibody to eliminate the effects of NGF produced by non-neuronal cells in the cultures. The abundant neurites that occur in large fascicles in response to NGF (100 ng/ml) (FIG. 13A) or 1 μ M FK506 (FIG. 13B) appear white, while small fascicles or individual neurites appear black. Nonneuronal cells, Schwann cells and some fibroblasts, are more evident with 1 pM FK506 (FIG. 13E) or anti-NGF antibody (FIG. 13C) than with 1 μ M FK506 (FIG. 13B). NGF produced by nonneuronal cells in the cultures results in the limited axon outgrowth seen in cultures with no added growth factors (FIG. 13D). The large number of refractile non-neuronal cells, appearing white, tend to overshadow the few neurites (FIG. 13D). Rapamycin completely inhibits axon outgrowth in the presence of FK506 (FIG. 13F). Micrographs are representative of 12-30 ganglia from each experimental condition. Differences between all experimental groups were highly reproducible.

FIG. 14

Effects of FK506 and rapamycin on NGF-mediated neurite extension in PC12 cells. PC12 cells (passage 60) were treated with various concentrations of NGF alone or in the presence of 100 nM FK506, 100 nM rapamycin or 100 nM WAY-124,466. Neurite outgrowth was measured after 96 hours with cells bearing processes longer than the diameter of the cells scoring positive. n=3 separate experiments for each point and error bars represent S.E.M.

FIG. 15

Picomolar concentrations of (A) FK506 and (B) rapamycin and WAY124,466 potentiate neurite extension elicited by NGF (0.5 ng/ml) in PC12 cells. Low passage PC12 cells were treated for 4 days with 0.5 ng/ml NGF in the presence of various concentrations of FK506 (*), rapamycin () or WAY-124,466 (). Neurite expression was quantitated as described above in FIG. 14. The levels of neurite production in the presence of 0.5 ng/ml NGF (designated L) and 50 ng/ml NGF (designated H) are indicated for comparative purposes.

FIG. 16

Photomicrographs of PC12 cells treated with immunophilin ligands +0.5 ng/ml NGF itself or 50 ng/ml NGF.

FIG. 17

Immunophilin ligands reduce the amount of NGF required to produce maximal neurite extension in chick sensory ganglia. Whole dorsal root ganglion explants were isolated from day 9-10 chick embryos and cultured in Matrigel-coated 12-well dishes containing L15 medium plus high glucose, with 10% fetal calf serum supplemented with 10 μ M Ara C penicillin and streptomycin) at 37 degrees C. in a 5% CO₂ environment. Sensory ganglia were treated with 1 ng/ml NGF, 1 ng/ml NGF plus 100 nM FK506 or 100 ng/ml NGF for 48 hr, and neuronal processes were counted and photographed.

FIG. 18

FK506, rapamycin, and WAY-124,466 potentiate NGF-dependent neurite production in sensory ganglia. Explants of chick DRG were cultured as described in FIG. 17 above. FK506, rapamycin and WAY-124,466 (100 nM each plus or minus 0.1 ng/ml NGF) were added to the DRG explant cultures. At 48 hrs., neurite outgrowth was quantitated and the cultures were photographed.

FIG. 19

Photomicrograph of Example 111 promoting neurite outgrowth in Chick dorsal root ganglion cultures. The three panels show neurite outgrowth at 1 pM

nM concentration (right panel) of Example 111.

FIG. 20

Photomicrograph of Example 17 promoting neurite outgrowth in dorsal root ganglion cultures. The three panels show neurite outgrowth at 1 pM concentration (left panel), 100 pM concentration (center panel), and 100 nM concentration (right panel) of Example 17.

FIG. 21

Photomicrograph of Example 102 promoting neurite outgrowth in dorsal root ganglion cultures. The three panels show neurite outgrowth at 1 pM concentration (left panel), 100 pM concentration (center panel), and 100 nM concentration (right panel) of Example 102.

L3 ANSWER 118 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 10
AN 10105613 IFIPAT;IFIUDB;IFICDB
TI N-LINKED CARBAMATES AND UREAS OF HETEROCYCLIC THIOESTERS; NEUROTROPHIC LOW MOLECULAR WEIGHT, SMALL MOLECULE N-LINKED UREAS AND CARBAMATES OF HETEROCYCLIC THIOESTERS HAVING AFFINITY FOR FKBP-TYPE IMMUNOPHILINS, USED AS INHIBITORS OF THE ENZYME ACTIVITY ASSOCIATED WITH IMMUNOPHILIN PROTEINS
IN Hamilton Gregory S; Huang Wei; Li Jia-He
PA Unassigned Or Assigned To Individual (68000)
PI US 2002049199 A1 20020425
AI US 2001-885178 20010621
RLI US 1996-775585 19961231 CONTINUATION-IN-PART 5935989
US 1997-997451 19971223 DIVISION 5958949
US 1999-393650 19990910 DIVISION 6274607
FI US 2002049199 20020425
US 5935989
US 5958949
US 6274607
DT Utility; Patent Application - First Publication
FS CHEMICAL APPLICATION
CLMN 41

L3 ANSWER 119 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 11
AN 10105607 IFIPAT;IFIUDB;IFICDB
TI N-LINKED SULFONAMIDES OF HETEROCYCLIC THIOESTERS; INHIBITORS OF THE ENZYME ACTIVITY ASSOCIATED WITH IMMUNOPHILIN PROTEINS, PARTICULARLY PEPTIDYL-PROLYL ISOMERASE, OR ROTAMASE, ENZYME ACTIVITY.
IN Hamilton Gregory S; Huang Wei; Li Jai-He
PA GPI NIL Holdings Inc (43964)
PI US 2002049193 A1 20020425
AI US 2001-925630 20010810
RLI US 1996-775584 19961231 CONTINUATION-IN-PART 5874449
US 1997-996342 19971222 DIVISION 6121273
US 2000-516239 20000301 DIVISION 6294551
FI US 2002049193 20020425
US 5874449
US 6121273
US 6294551
DT Utility; Patent Application - First Publication
FS CHEMICAL APPLICATION
CLMN 47

L3 ANSWER 120 OF 215 USPATFULL on STN DUPLICATE 12
AN 2002:338053 USPATFULL
TI Heterocyclic ketone and thioester compounds and uses
IN Hamilton, Gregory S., Catonsville, MD, UNITED STATES
Li, Jia-He, Cockeysville, MD, UNITED STATES
PA GPI NIL Holdings, Inc., Wilmington, DE, UNITED STATES (U.S. corporation)
PI US 2002193420 A1 20021219
AI US 2002-104242 A1 20020325 (10)
RLI Continuation of Ser. No. US 2000-733037, filed on 11 Dec 2000, GRANTED, Pat. No. US 6417209 Division of Ser. No. US 1999-444200, filed on 22 Nov 1999, GRANTED, Pat. No. US 6218424 Continuation-in-part of Ser. No. US 1997-904461, filed on 1 Aug 1997, GRANTED, Pat. No. US 5990131 Continuation-in-part of Ser. No. US 1996-721765, filed on 25 Sep 1996, GRANTED, Pat. No. US 5786378
DT Utility
FS APPLICATION
LN.CNT 1740
INCL INCLM: 514/438.000
INCLS: 514/513.000; 514/460.000

NCLS: 514/513.000; 514/460.000
IC [7]
ICM: A61K031-38
ICS: A61K031-35; A61K031-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 121 OF 215 USPATFULL on STN DUPLICATE 13
AN 2002:295226 USPATFULL
TI Trisubstituted carbocyclic cyclophilin binding compounds and their use
IN Wu, Yong-Qian, Columbia, MD, UNITED STATES
Belyakov, Sergei, Baltimore, MD, UNITED STATES
Hamilton, Gregory S., Cantonville, MD, UNITED STATES
Limburg, David, Baltimore, MD, UNITED STATES
Steiner, Joseph P., Mt. Airy, MD, UNITED STATES
Vaal, Mark, Baltimore, MD, UNITED STATES
Wei, Ling, Lutherville, MD, UNITED STATES
Wilkinson, Douglas, Baltimore, MD, UNITED STATES
PI US 2002165275 A1 20021107
US 6656971 B2 20031202
AI US 2002-57203 A1 20020125 (10)
PRAI US 2001-263703P 20010125 (60)
US 2001-291365P 20010517 (60)
DT Utility
FS APPLICATION
LN.CNT 3137
INCL INCLM: 514/518.000
INCLS: 514/534.000; 514/601.000; 514/602.000; 514/596.000; 514/597.000;
514/617.000; 558/037.000; 560/012.000; 560/034.000; 560/041.000;
564/048.000; 564/081.000; 564/090.000; 564/152.000
NCL NCLM: 514/599.000
NCLS: 514/617.000; 564/074.000; 564/156.000
IC [7]
ICM: A61K031-255
ICS: A61K031-24; A61K031-18; A61K031-17; A61K031-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 122 OF 215 USPATFULL on STN DUPLICATE 14
AN 2002:228346 USPATFULL
TI Bicyclic derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
PI US 2002123507 A1 20020905
US 6660748 B2 20031209
AI US 2002-39886 A1 20020103 (10)
RLI Continuation of Ser. No. WO 2000-US18355, filed on 5 Jul 2000, UNKNOWN
PRAI US 1999-142509P 19990706 (60)
DT Utility
FS APPLICATION
LN.CNT 736
INCL INCLM: 514/305.000
INCLS: 514/413.000; 546/133.000; 548/453.000
NCL NCLM: 514/305.000
NCLS: 546/133.000
IC [7]
ICM: C07D453-02
ICS: A61K031-49; A61K031-407
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 123 OF 215 USPATFULL on STN DUPLICATE 15
AN 2002:199132 USPATFULL
TI N-heterocyclic derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Ledford, Brian, Hopkinton, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
PI US 2002107241 A1 20020808
US 6747042 B2 20040608
AI US 2002-40931 A1 20020103 (10)
RLI Continuation of Ser. No. WO 2000-US18492, filed on 6 Jul 2000, UNKNOWN
PRAI US 1999-142512P 19990706 (60)
DT Utility
FS APPLICATION
LN.CNT 844
INCL INCLM: 514/217.120
INCLS: 514/227.500; 514/231.200; 514/252.120; 514/317.000; 514/408.000;
540/609.000; 544/059.000; 544/170.000; 544/400.000; 546/233.000;

NCL NCLM: 514/307.000
NCLS: 546/147.000
IC [7]
ICM: A61K031-55
ICS: A61K031-54; A61K031-445; A61K031-535; A61K031-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 124 OF 215 USPATFULL on STN DUPLICATE 16
AN 2002:199131 USPATFULL
TI N-substituted glycine derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Ledford, Brian, Hopkinton, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
PI US 2002107240 A1 20020808
US 6677359 B2 20040113
AI US 2002-39896 A1 20020103 (10)
RLI Continuation of Ser. No. WO 2000-US18564, filed on 6 Jul 2000, UNKNOWN
PRAI US 1999-142568P 19990706 (60)
DT Utility
FS APPLICATION
LN.CNT 850
INCL INCLM: 514/217.120
INCLS: 514/227.500; 514/231.200; 514/252.100; 514/331.000; 514/408.000;
540/609.000; 544/059.000; 544/170.000; 544/399.000; 546/237.000;
548/571.000
NCL NCLM: 514/332.000
NCLS: 514/617.000; 514/625.000; 514/629.000; 546/265.000; 564/155.000;
564/158.000
IC [7]
ICM: C07D295-10
ICS: C07D279-12; A61K031-54; A61K031-535; A61K031-496; A61K031-445;
C07D223-04; A61K031-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 125 OF 215 USPATFULL on STN DUPLICATE 17
AN 2002:199130 USPATFULL
TI Cyclized amide derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
Ledford, Brian, Attleboro, MA, UNITED STATES
PI US 2002107239 A1 20020808
US 6552041 B2 20030422
AI US 2002-39897 A1 20020103 (10)
RLI Continuation of Ser. No. WO 2000-US18418, filed on 5 Jul 2000, UNKNOWN
PRAI US 1999-142515P 19990706 (60)
DT Utility
FS APPLICATION
LN.CNT 841
INCL INCLM: 514/211.150
INCLS: 514/227.800; 514/231.500; 514/253.120; 514/327.000; 514/326.000;
514/422.000; 514/424.000; 514/212.080; 544/060.000; 546/207.000;
546/216.000; 544/360.000; 544/130.000
NCL NCLM: 514/318.000
NCLS: 514/327.000; 514/349.000; 540/509.000; 540/523.000; 540/527.000;
546/193.000; 546/194.000; 546/216.000; 546/297.000; 548/550.000
IC [7]
ICM: A61K031-553
ICS: A61K031-554; A61K031-535; A61K031-55; A61K031-541; A61K031-5377;
A61K031-454; A61K031-4015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 126 OF 215 USPATFULL on STN DUPLICATE 18
AN 2002:192119 USPATFULL
TI Azo amino acids derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
PI US 2002103190 A1 20020801
US 6528533 B2 20030304
AI US 2002-39900 A1 20020103 (10)
RLI Continuation of Ser. No. WO 2000-US18416, filed on 5 Jul 2000, UNKNOWN
PRAI US 1999-142569P 19990706 (60)
DT Utility
FS APPLICATION
LN.CNT 1055
INCL INCLM: 514/227.500

514/385.000; 514/408.000; 514/478.000; 544/059.000; 544/171.000;
544/400.000; 546/231.000; 548/146.000; 548/215.000; 548/338.500;
548/335.500; 514/567.000; 558/232.000; 560/159.000
NCL NCLM: 514/357.000
NCLS: 546/329.000; 546/332.000; 546/340.000
IC [7]
ICM: C07D279-12
ICS: C07D277-08; C07C261-00; C07C271-00; C07D265-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 127 OF 215 USPATFULL on STN DUPLICATE 19
AN 2002:119893 USPATFULL
TI Compounds, compositions, and methods for stimulating neuronal growth and
elongation
IN Guo, Chuangxing, Encinitas, CA, UNITED STATES
Dong, Liming, San Diego, CA, UNITED STATES
Hou, Xinjun J., San Diego, CA, UNITED STATES
Vanderpool, Darin, San Diego, CA, UNITED STATES
Villafranca, Jesus Ernest, San Diego, CA, UNITED STATES
PI US 2002061881 A1 20020523
US 6544987 B2 20030408
AI US 2000-726314 A1 20001201 (9)
PRAI US 1999-168246P 19991201 (60)
DT Utility
FS APPLICATION
LN.CNT 3768
INCL INCLM: 514/227.500
INCLS: 514/317.000; 514/235.500; 546/192.000; 544/130.000; 544/059.000
NCL NCLM: 514/231.500
NCLS: 514/227.500; 514/227.800; 514/231.200; 514/316.000; 514/317.000;
514/318.000; 514/319.000; 544/059.000; 544/060.000; 544/106.000;
544/111.000; 546/192.000; 546/193.000; 546/195.000
IC [7]
ICM: A61K031-54
ICS: C07D279-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 128 OF 215 USPATFULL on STN
AN 2002:235416 USPATFULL
TI Bisubstituted carbocyclic cyclophilin binding compounds and their use
IN Hamilton, Gregory S., Catonsville, MD, UNITED STATES
Belyakov, Sergei, Baltimore, MD, UNITED STATES
Vaal, Mark, Baltimore, MD, UNITED STATES
Wei, Ling, Lutherville, MD, UNITED STATES
Wu, Yong-Qian, Columbia, MD, UNITED STATES
Steiner, Joseph P., Mt. Airy, MD, UNITED STATES
PI US 2002127605 A1 20020912
AI US 2001-994927 A1 20011128 (9)
PRAI US 2000-253074P 20001128 (60)
US 2001-291966P 20010521 (60)
DT Utility
FS APPLICATION
LN.CNT 3481
INCL INCLM: 435/007.100
INCLS: 564/018.000; 564/034.000; 564/048.000; 564/039.000; 564/148.000;
564/082.000; 564/084.000
NCL NCLM: 435/007.100
NCLS: 564/018.000; 564/034.000; 564/048.000; 564/039.000; 564/148.000;
564/082.000; 564/084.000
IC [7]
ICM: G01N033-53
ICS: C07C311-50; C07C311-15; C07C275-28; C07C281-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 129 OF 215 USPATFULL on STN
AN 2002:228332 USPATFULL
TI Cyclic amine derivatives
IN Mullican, Michael, Needham, MA, UNITED STATES
Lauffer, David, Stow, MA, UNITED STATES
PI US 2002123493 A1 20020905
AI US 2002-40033 A1 20020103 (10)
RLI Continuation of Ser. No. WO 2000-US18578, filed on 6 Jul 2000, UNKNOWN
PRAI US 1999-146588P 19990730 (60)
DT Utility
FS APPLICATION

INCL INCLM: 514/227.500
INCLS: 514/231.200; 514/252.120; 514/317.000; 514/365.000; 514/400.000;
514/374.000; 514/538.000; 514/619.000; 544/060.000; 544/162.000;
544/399.000; 544/400.000; 546/233.000; 548/204.000; 548/248.000;
548/338.100; 560/019.000; 564/163.000
NCL NCLM: 514/227.500
NCLS: 514/231.200; 514/252.120; 514/317.000; 514/365.000; 514/400.000;
514/374.000; 514/538.000; 514/619.000; 544/060.000; 544/162.000;
544/399.000; 544/400.000; 546/233.000; 548/204.000; 548/248.000;
548/338.100; 560/019.000; 564/163.000

IC [7]
ICM: A61K031-54
ICS: A61K031-5375; A61K031-495; A61K031-445; A61K031-426; A61K031-421;
A61K031-4164

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 130 OF 215 USPATFULL on STN
AN 2002:228331 USPATFULL
TI Beta-amino acid derivatives
IN Lauffer, David, Stow, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
PI US 2002123492 A1 20020905
AI US 2002-39885 A1 20020103 (10)
RLI Continuation of Ser. No. WO 2000-US18353, filed on 5 Jul 2000, UNKNOWN
PRAI US 1999-142405P 19990706 (60)
DT Utility
FS APPLICATION

LN.CNT 858
INCL INCLM: 514/227.500
INCLS: 514/231.200; 514/255.010; 514/255.020; 514/327.000; 514/329.000;
514/369.000; 514/370.000; 514/380.000; 514/385.000; 514/534.000;
514/619.000; 514/626.000; 544/059.000; 544/162.000; 514/382.000;
544/382.000; 544/383.000; 546/223.000; 546/217.000
NCL NCLM: 514/227.500
NCLS: 514/231.200; 514/255.010; 514/255.020; 514/327.000; 514/329.000;
514/369.000; 514/370.000; 514/380.000; 514/385.000; 514/534.000;
514/619.000; 514/626.000; 544/059.000; 544/162.000; 514/382.000;
544/382.000; 544/383.000; 546/223.000; 546/217.000

IC [7]
ICM: A61K031-54
ICS: A61K031-5375; A61K031-445; A61K031-495; C07D279-12; C07D265-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 131 OF 215 USPATFULL on STN
AN 2002:228296 USPATFULL
TI Methods of identifying agents affecting atrophy and hypertrophy
IN Glass, David J., Cortlandt Manor, NY, UNITED STATES
PI US 2002123456 A1 20020905
AI US 2002-86201 A1 20020228 (10)
PRAI US 2001-273174P 20010302 (60)
DT Utility
FS APPLICATION

LN.CNT 1856
INCL INCLM: 514/001.000
INCLS: 435/007.200
NCL NCLM: 514/001.000
NCLS: 435/007.200

IC [7]
ICM: A61K031-00
ICS: G01N033-53; G01N033-567

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 132 OF 215 USPATFULL on STN
AN 2002:222796 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002120947 A1 20020829
AI US 2001-949143 A1 20010910 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
DT Utility

LN.CNT 3104
INCL INCLM: 800/003.000
INCLS: 435/007.920
NCL NCLM: 800/003.000
NCLS: 435/007.920
IC [7]
ICM: A01K067-00
ICS: G01N033-53

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 133 OF 215 USPATFULL on STN
AN 2002:206649 USPATFULL
TI Amino-alkyl derivatives
IN Harbeson, Scott, Cambridge, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
PI US 2002111347 A1 20020815
AI US 2002-39899 A1 20020103 (10)
RLI Continuation of Ser. No. WO 2000-US18430, filed on 5 Jul 2000, UNKNOWN
PRAI US 1999-142510P 19990706 (60)
DT Utility
FS APPLICATION

LN.CNT 847
INCL INCLM: 514/227.500
INCLS: 514/231.200; 514/252.120; 514/317.000; 514/428.000; 514/649.000;
514/666.000
NCL NCLM: 514/227.500
NCLS: 514/231.200; 514/252.120; 514/317.000; 514/428.000; 514/649.000;
514/666.000

IC [7]
ICM: A61K031-54
ICS: A61K031-535; A61K031-496; A61K031-445; A61K031-40; A61K031-137;
A61K031-13

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 134 OF 215 USPATFULL on STN
AN 2002:191539 USPATFULL
TI Full-length human cDNAs encoding potentially secreted proteins
IN Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
Bougueleret, Lydie, Petit Lancy, SWITZERLAND
Jobert, Severin, Paris, FRANCE
PI US 2002102604 A1 20020801
AI US 2000-731872 A1 20001207 (9)
PRAI US 1999-169629P 19991208 (60)
US 2000-187470P 20000306 (60)

DT Utility
FS APPLICATION

LN.CNT 28061
INCL INCLM: 435/007.100
INCLS: 536/023.100; 530/350.000
NCL NCLM: 435/007.100
NCLS: 536/023.100; 530/350.000

IC [7]
ICM: G01N033-53
ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 135 OF 215 USPATFULL on STN
AN 2002:134563 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PI US 2002069424 A1 20020606
AI US 2001-971677 A1 20011009 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)

DT Utility
FS APPLICATION

LN.CNT 3101
INCL INCLM: 800/018.000
INCLS: 435/007.900; 800/003.000
NCL NCLM: 800/018.000
NCLS: 435/007.900; 800/003.000

IC [7]

ICS: G01N033-00; G01N033-53; G01N033-542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 136 OF 215 USPATFULL on STN
AN 2002:113904 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA MYRIAD GENETICS, INC., Salt Lake City, UT, UNITED STATES, 84108 (U.S. corporation)
PI US 2002059653 A1 20020516
AI US 2001-970666 A1 20011005 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
DT Utility
FS APPLICATION
LN.CNT 3084
INCL INCLM: 800/012.000
INCLS: 424/146.100; 514/012.000
NCL NCLM: 800/012.000
NCLS: 424/146.100; 514/012.000
IC [7]
ICM: A01K067-00
ICS: A61K039-395; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 137 OF 215 USPATFULL on STN
AN 2002:105674 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA MYRIAD GENETICS, INC., Salt Lake City, UT, 84108 (U.S. corporation)
PI US 2002054876 A1 20020509
AI US 2001-971675 A1 20011009 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
DT Utility
FS APPLICATION
LN.CNT 3070
INCL INCLM: 424/146.100
NCL NCLM: 424/146.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 138 OF 215 USPATFULL on STN
AN 2002:92251 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA MYRIAD GENETICS, INC., Salt Lake City, UT (U.S. corporation)
PI US 2002048769 A1 20020425
AI US 2001-970814 A1 20011005 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
DT Utility
FS APPLICATION
LN.CNT 3101
INCL INCLM: 435/006.000
INCLS: 435/007.100; 435/196.000; 530/388.100
NCL NCLM: 435/006.000
NCLS: 435/007.100; 435/196.000; 530/388.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C12N009-16; C07K016-42
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 139 OF 215 USPATFULL on STN
AN 2002:85161 USPATFULL

IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA MYRIAD GENETICS, INC., Salt Lake City, UT, UNITED STATES, 84108 (U.S.
corporation)
PI US 2002045201 A1 20020418
AI US 2001-970898 A1 20011005 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
DT Utility
FS APPLICATION
LN.CNT 3090
INCL INCLM: 435/007.920
NCL NCLM: 435/007.920
IC [7]
ICM: G01N033-53
ICS: G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 140 OF 215 USPATFULL on STN
AN 2002:73343 USPATFULL
TI Protein-protein interactions in neurodegenerative disorders
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002040484 A1 20020404
AI US 2001-948904 A1 20010910 (9)
RLI Division of Ser. No. US 1999-466139, filed on 21 Dec 1999, PENDING
PRAI US 1998-113534P 19981222 (60)
US 1999-124120P 19990312 (60)
US 1999-141243P 19990630 (60)
DT Utility
FS APPLICATION
LN.CNT 3069
INCL INCLM: 800/008.000
INCL: 514/012.000
NCL NCLM: 800/008.000
NCL: 514/012.000
IC [7]
ICM: A01K067-00
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 141 OF 215 USPATFULL on STN
AN 2002:22515 USPATFULL
TI Compounds possessing neuronal activity
IN McCaffrey, Patricia, Auburndale, MA, UNITED STATES
Novak, Perry M., Milford, MA, UNITED STATES
Mullican, Michael, Needham, MA, UNITED STATES
PA VERTEX PHARMACEUTICALS INCORPORATED (U.S. corporation)
PI US 2002013351 A1 20020131
AI US 2001-815193 A1 20010627 (9)
RLI Division of Ser. No. US 1998-85441, filed on 27 May 1998, GRANTED, Pat.
No. US 6268384 Continuation-in-part of Ser. No. US 1997-920838, filed on
29 Aug 1997, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 1845
INCL INCLM: 514/357.000
INCL: 546/334.000; 514/399.000; 514/406.000; 514/365.000; 514/374.000;
514/438.000; 514/461.000; 514/602.000; 514/601.000; 548/203.000;
548/215.000; 548/335.500; 548/375.100; 549/075.000; 549/491.000;
564/084.000; 564/095.000
NCL NCLM: 514/357.000
NCL: 546/334.000; 514/399.000; 514/406.000; 514/365.000; 514/374.000;
514/438.000; 514/461.000; 514/602.000; 514/601.000; 548/203.000;
548/215.000; 548/335.500; 548/375.100; 549/075.000; 549/491.000;
564/084.000; 564/095.000
IC [7]
ICM: A61K031-44
ICS: C07D333-12; C07D333-20; A61K031-42; A61K031-425; A61K031-4164;
A61K031-415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:346994 USPATFULL
TI Pyrrolidine derivatives and processes for preparing same
IN Hamilton, Gregory S., Catonsville, MD, United States
Steiner, Joseph P., Hampstead, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6500959 B1 20021231
AI US 2000-605475 20000628 (9)
RLI Continuation of Ser. No. US 1997-833629, filed on 8 Apr 1997
Continuation of Ser. No. US 1996-650461, filed on 21 May 1996, now
patented, Pat. No. US 5859031 Continuation-in-part of Ser. No. US
1995-479436, filed on 7 Jun 1995, now patented, Pat. No. US 5614547
DT Utility
FS GRANTED
LN.CNT 1230
INCL INCLM: 548/533.000
NCL NCLM: 548/533.000
IC [7]
ICM: C07D207-16
EXF 548/533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 143 OF 215 USPATFULL on STN
AN 2002:297700 USPATFULL
TI Compositions and method for regulation of transcription
IN Natesan, Sridaran, Chestnut Hill, MA, United States
Gilman, Michael Z., Newton, MA, United States
PA ARIAD Gene Therapeutics, Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 6479653 B1 20021112
AI US 2000-615917 20000713 (9)
RLI Continuation of Ser. No. US 1998-140149, filed on 26 Aug 1998, now
patented, Pat. No. US 6117680 Continuation-in-part of Ser. No. US
1998-126009, filed on 29 Jul 1998, now abandoned Continuation-in-part of
Ser. No. US 1997-920610, filed on 27 Aug 1997, now patented, Pat. No. US
6015709 Continuation-in-part of Ser. No. US 1997-918401, filed on 26 Aug
1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 3897
INCL INCLM: 536/023.400
INCLS: 435/320.100; 435/325.000
NCL NCLM: 536/023.400
NCLS: 435/320.100; 435/325.000
IC [7]
ICM: C07H021-04
EXF 435/320.1; 435/325; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 144 OF 215 USPATFULL on STN
AN 2002:262380 USPATFULL
TI Cyclic ester or amide derivatives
IN Hamilton, Gregory S., Catonsville, MD, United States
Limburg, David C., Baltimore, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6462072 B1 20021008
AI US 1998-157566 19980921 (9)
DT Utility
FS GRANTED
LN.CNT 1282
INCL INCLM: 514/423.000
INCLS: 548/533.000; 548/537.000
NCL NCLM: 514/423.000
NCLS: 548/533.000; 548/537.000
IC [7]
ICM: A61K031-401
ICS: C07D207-16
EXF 548/533; 548/537; 514/423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 145 OF 215 USPATFULL on STN
AN 2002:224760 USPATFULL
TI Methods for assessing the role of calcineurin immunosuppression and
neurotoxicity
IN Zhang, Wei, Stanford, CA, United States
Seidman, Jonathan G., Milton, MA, United States

Potter, Huntington, Boston, MA, United States
 PA President and Fellows of Harvard College, Cambridge, MA, United States
 (U.S. corporation)
 PI US 6444870 B1 20020903
 AI US 1998-212868 19981216 (9)
 RLI Continuation of Ser. No. US 1995-433162, filed on 3 May 1995, now
 abandoned
 DT Utility
 FS GRANTED
 LN.CNT 3549
 INCL INCLM: 800/003.000
 INCLS: 800/018.000; 800/025.000; 435/455.000; 435/463.000; 435/320.100;
 435/325.000
 NCL NCLM: 800/003.000
 NCLS: 435/320.100; 435/325.000; 435/455.000; 435/463.000; 800/018.000;
 800/025.000
 IC [7]
 ICM: A01K067-027
 ICS: G01N033-00; C12N015-00; C12N015-63; C12N015-85
 EXF 800/3; 800/14; 800/18; 800/21; 800/22; 800/25; 800/12; 435/455; 435/463;
 435/320.1; 435/325; 435/69.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 146 OF 215 USPATFULL on STN
 AN 2002:168224 USPATFULL
 TI AZA compounds, pharmaceutical compositions and methods of use
 IN Wu, Yong-Qian, Columbia, MD, United States
 Huang, Wei, Wildwood, MD, United States
 Hamilton, Gregory S., Catonsville, MD, United States
 PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
 PI US 6417189 B1 20020709
 AI US 2000-551618 20000417 (9)
 PRAI US 1999-164950P 19991112 (60)
 DT Utility
 FS GRANTED
 LN.CNT 1878
 INCL INCLM: 514/252.010
 INCLS: 514/252.020; 514/252.030; 514/252.040; 514/252.050; 514/252.060;
 514/218.000; 514/406.000; 514/407.000; 540/553.000; 544/238.000;
 548/356.100; 548/364.100; 548/364.200; 548/364.300; 548/364.400;
 548/364.500; 548/364.600; 548/364.700
 NCL NCLM: 514/252.010
 NCLS: 514/218.000; 514/252.020; 514/252.030; 514/252.040; 514/252.050;
 514/252.060; 514/406.000; 514/407.000; 540/553.000; 544/238.000;
 548/356.100; 548/364.100; 548/364.400; 548/364.700
 IC [7]
 ICM: A61K031-495
 ICS: C07D243-00; C07D401-00; C07D231-02
 EXF 514/252.01; 514/252.02; 514/252.03; 514/252.04; 514/252.05; 514/252.06;
 514/218; 514/406; 514/407; 544/238; 540/553; 548/356.1; 548/364.1;
 548/364.2; 548/364.3; 548/364.4; 548/364.5; 548/364.6; 548/364.7
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 147 OF 215 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
 AN 2002-599593 [64] WPIDS
 DNC C2002-169417
 TI Use of tacrolimus derivatives for manufacturing neurotrophic agent useful
 for treating neuronal injury or dysfunction e.g. Alzheimer's disease,
 Huntington's disease, radiculopathy, diabetic neuropathy.
 DC B02
 IN GOLD, B; MATSUOKA, N; YAMAJI, T
 PA (FUJI) FUJISAWA PHARM CO LTD; (GOLD-I) GOLD B; (MATS-I) MATSUOKA N;
 (YAMA-I) YAMAJI T
 CYC 101
 PI WO 2002053159 A1 20020711 (200264)* EN 24 A61K031-44
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ
 NL OA PT SD SE SL SZ TR TZ UG ZM ZW
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK
 DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR
 KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT
 RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM
 ZW
 EP 1353671 A1 20031022 (200370) EN A61K031-44
 R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT
 RO SE SI TR

AU 2002231277 A1 20020716 (200427) A61K031-44
 US 2004077676 A1 20040422 (200428) A61K031-4745
 CZ 2003002060 A3 20040114 (200429) A61K031-44
 KR 2004007431 A 20040124 (200435) A61K031-44
 BR 2001016762 A 20040810 (200455) A61K031-44
 JP 2004527472 W 20040909 (200459) 41 A61K031-70
 ADT WO 2002053159 A1 WO 2001-US50419 20011231; EP 1353671 A1 EP 2001-991558
 20011231, WO 2001-US50419 20011231; HU 2003002521 A2 WO 2001-US50419
 20011231, HU 2003-2521 20011231; AU 2002231277 A1 AU 2002-231277 20011231;
 US 2004077676 A1 WO 2001-US50419 20011231, US 2003-451361 20031114; CZ
 2003002060 A3 WO 2001-US50419 20011231, CZ 2003-2060 20011231; KR
 2004007431 A KR 2003-708787 20030627; BR 2001016762 A BR 2001-16762
 20011231, WO 2001-US50419 20011231; JP 2004527472 W WO 2001-US50419
 20011231, JP 2002-554109 20011231
 FDT EP 1353671 A1 Based on WO 2002053159; HU 2003002521 A2 Based on WO
 2002053159; AU 2002231277 A1 Based on WO 2002053159; CZ 2003002060 A3
 Based on WO 2002053159; BR 2001016762 A Based on WO 2002053159; JP
 2004527472 W Based on WO 2002053159
 PRAI US 2000-258500P 20001229; US 2003-451361 20031114
 IC ICM A61K031-44; A61K031-4745; A61K031-70
 ICS A61P003-10; A61P021-00; A61P021-02; A61P025-00; A61P025-02;
 A61P025-14; A61P025-16; A61P025-18; A61P025-28; B65D077-00;
 B65D077-28

L3 ANSWER 148 OF 215 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:515544 CAPLUS
 DN 137:201562
 TI Synthesis of N-Glyoxyl Prolyl and Pipecolyl Amides and Thioesters and
 Evaluation of Their In Vitro and In Vivo Nerve Regenerative Effects
 AU Hamilton, Gregory S.; Wu, Yong-Qian; Limburg, David C.; Wilkinson, Douglas
 E.; Vaal, Mark J.; Li, Jia-He; Thomas, Christine; Huang, Wei; Sauer,
 Hansjorg; Ross, Douglas T.; Soni, Raj; Chen, Yi; Guo, Hongshi; Howorth,
 Pamela; Valentine, Heather; Liang, Shi; Spicer, Dawn; Fuller, Mike;
 Steiner, Joseph P.
 CS Department of Research, Guilford Pharmaceuticals Inc., Baltimore, MD,
 21224, USA
 SO Journal of Medicinal Chemistry (2002), 45(16), 3549-3557
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 137:201562
 RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 149 OF 215 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 20
 AN 2002:659266 CAPLUS
 DN 138:231622
 TI Genetically engineered analogs of ascomycin for nerve regeneration
 AU Revill, W. P.; Voda, J.; Reeves, C. R.; Chung, L.; Schirmer, A.; Ashley,
 G.; Carney, J. R.; Fardis, M.; Carreras, C. W.; Zhou, Y.; Feng, L.;
 Tucker, E.; Robinson, D.; Gold, B. G.
 CS Kosan Biosciences, Inc., Hayward, CA, USA
 SO Journal of Pharmacology and Experimental Therapeutics (2002), 302(3),
 1278-1285
 CODEN: JPETAB; ISSN: 0022-3565
 PB American Society for Pharmacology and Experimental Therapeutics
 DT Journal
 LA English
 RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 150 OF 215 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
 RESERVED. on STN DUPLICATE 21
 AN 2003053782 EMBASE
 TI ***FKBP12*** immunoreactivity in the human ***spinal***
 cord of motor neuron disease patients.
 AU Kihira T.; Hironishi M.; Utunomiya H.; Kondo T.
 CS T. Kihira, Department of Neurology, Wakayama Medical University, School of
 Medicine, Kimiidera, 811-1, Wakayama City, Japan
 SO Neuropathology, (2002) 22/4 (269-274).
 Refs: 14
 ISSN: 0919-6544 CODEN: NOPAFH
 CY Australia
 DT Journal; Article

008 Neurology and Neurosurgery
LA English
SL English

L3 ANSWER 151 OF 215 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2003:293840 BIOSIS
DN PREV200300293840
TI THE IMMUNOPHILIN FK506-BINDING PROTEIN 12 IS EXPRESSED IN THE HUMAN BRAIN
AND ACCUMULATES IN PATIENTS WITH NEURODEGENERATIVE DISEASES.
AU Avramut, M. [Reprint Author]; Achim, C. L. [Reprint Author]
CS Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA,
USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002)
Vol. 2002, pp. Abstract No. 326.7. <http://sfn.scholarone.com.cd-rom>.
Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience.
Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 25 Jun 2003
Last Updated on STN: 25 Jun 2003

L3 ANSWER 152 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 22
AN 10036925 IFIPAT;IFIUDB;IFICDB
TI N-OXIDES OF HETEROCYCLIC ESTERS, AMIDES, THIOESTERS, AND KETONES; NERVOUS
SYSTEM DISORDERS
IN Burak Eric S; Hamilton Gregory S; Steiner Joseph P
PA Unassigned Or Assigned To Individual (68000)
PPA GPI NIL Holdings Inc (Probable)
PI US 2001036942 A1 20011101
AI US 2001-842174 20010426
RLI US 1997-807406 19970228 CONTINUATION 5846979
US 1998-112319 19980709 CONTINUATION 6054452
US 2000-556482 20000421 CONTINUATION 6251892
FI US 2001036942 20011101
US 5846979
US 6054452
US 6251892
US 6486151 20021126
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 55

L3 ANSWER 153 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 23
AN 03579874 IFIPAT;IFIUDB;IFICDB
TI N-LINKED SULFONAMIDES OF HETEROCYCLIC THIOESTERS; PERIPHERAL NEUROPATHY
CAUSED BY PHYSICAL INJURY OR DISEASE STATE, PHYSICAL DAMAGE TO THE BRAIN,
PHYSICAL DAMAGE TO THE ***SPINAL*** ***CORD***, STROKE ASSOCIATED
WITH BRAIN DAMAGE, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AND
AMYOTROPHIC LATERAL
IN Hamilton Gregory S; Huang Wei; Li Jai-He
PA GPI NIL Holdings Inc (43964)
PI US 6294551 B1 20010925 (CITED IN 001 LATER PATENTS)
AI US 2000-516239 20000301
RLI US 1996-775584 19961231 CONTINUATION-IN-PART 5874449
US 1997-996342 19971222 DIVISION 6121273
FI US 6294551 20010925
US 5874449
US 6121273
DT Utility; REASSIGNED
FS CHEMICAL
GRANTED
MRN 012232 MFN: 0006
012232 0013
CLMN 34

L3 ANSWER 154 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 24
AN 03557903 IFIPAT;IFIUDB;IFICDB
TI N-LINKED UREAS AND CARBAMATES OF HETEROCYCLIC THIOESTERS; INHIBITORS OF
PEPTIDYL-PROLYL ISOMERASE, OR ROTAMASE ENZYME ACTIVITY; DO NOT EXERT ANY
IMMUNOSUPPRESSIVE ACTIVITY IN ADDITION TO THEIR NEUROTROPHIC ACTIVITY;
BIOAVAILABILITY; POTENCY

PA GPI NIL Holdings Inc (43964)
PI US 6274607 B1 20010814
AI US 1999-393650 19990910
RLI US 1996-775585 19961231 CONTINUATION-IN-PART 5935989
US 1997-997451 19971223 DIVISION 5958949
FI US 6274607 20010814
US 5935989
US 5958949
DT Utility; CERTIFICATE OF CORRECTION
CDAT 19 Mar 2002
FS CHEMICAL
GRANTED
CLMN 20

L3 ANSWER 155 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 25
AN 03532659 IFIPAT;IFIUDB;IFICDB
TI N-OXIDES OF HETEROCYCLIC ESTERS, AMIDES, THIOESTERS, AND KETONES;
NEUROTROPHIC LOW MOLECULAR WEIGHT SMALL MOLECULE N-OXIDES OF HETEROCYCLIC
ESTERS, AMIDES, THIOESTERS AND KETONES; INHIBITORS OF ENZYME ACTIVITY
ASSOCIATED WITH IMMUNOPHILIN PROTEINS, PARTICULARLY PEPTIDYL-PROLYL
ISOMERASE OR ROTAMASE
IN Burak Eric S; Hamilton Gregory S; Steiner Joseph P
PA GPI NIL Holdings Inc (43964)
PI US 6251892 B1 20010626 (CITED IN 002 LATER PATENTS)
AI US 2000-556482 20000421
RLI US 1997-807406 19970228 CONTINUATION 5846979
US 1997-112319 19970911 CONTINUATION 6054542
FI US 6251892 20010626
US 5846979
US 6054542
DT Utility; CERTIFICATE OF CORRECTION
CDAT 28 Jan 2003
FS CHEMICAL
GRANTED
CLMN 33
GI 1 Drawing Sheet(s), 1 Figure(s).

L3 ANSWER 156 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 26
AN 03457770 IFIPAT;IFIUDB;IFICDB
TI N-LINKED UREAS AND CARBAMATES OF HETEROCYCLIC THIOESTERS; NEUROLOGICAL
DISORDERS
IN Hamilton Gregory S; Huang Wei; Li Jia-He
PA GPI NIL Holdings Inc (43964)
PI US 6184243 B1 20010206
AI US 1998-165372 19981002
RLI US 1996-775585 19961231 DIVISION 5935989
FI US 6184243 20010206
US 5935989
DT Utility; CERTIFICATE OF CORRECTION
CDAT 23 Oct 2001
FS CHEMICAL
GRANTED
MRN 009612 MFN: 0288
009612 0329
CLMN 10

L3 ANSWER 157 OF 215 USPATFULL on STN DUPLICATE 27
AN 2001:237983 USPATFULL
TI Heterocyclic ketone and thioester compounds and uses
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
PA GPI NIL HOLDINGS, Inc. (U.S. corporation)
PI US 2001056103 A1 20011227
US 6417209 B2 20020709
AI US 2000-733037 A1 20001211 (9)
RLI Division of Ser. No. US 1999-444200, filed on 22 Nov 1999, GRANTED, Pat.
No. US 6218424 Continuation-in-part of Ser. No. US 1997-904461, filed on
1 Aug 1997, GRANTED, Pat. No. US 5990131 Continuation-in-part of Ser.
No. US 1996-721765, filed on 25 Sep 1996, GRANTED, Pat. No. US 5786378
DT Utility
FS APPLICATION
LN.CNT 1737
INCL INCLM: 514/327.000
INCLS: 514/513.000
NCL NCLM: 514/365.000

IC [7]
ICM: A61K031-445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 158 OF 215 USPATFULL on STN
AN 2001:223927 USPATFULL
TI Methods for high level expression of genes in primates
IN Rivera, Victor, Arlington, MA, United States
Zoltick, Philip, Wynnewood, PA, United States
Wilson, James M., Gladwyne, PA, United States
PI US 2001049144 A1 20011206
AI US 2000-733368 A1 20001208 (9)
PRAI US 1999-170019P 19991210 (60)
DT Utility
FS APPLICATION
LN.CNT 2283
INCL INCLM: 435/456.000
INCLS: 424/093.210
NCL NCLM: 435/456.000
NCLS: 424/093.210

IC [7]
ICM: A61K048-00
ICS: C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 159 OF 215 USPATFULL on STN
AN 2001:176357 USPATFULL
TI Bcl-G polypeptides, encoding nucleic acids and methods of use
IN Reed, John C., Rancho Santa Fe, CA, United States
Godzik, Adam, San Diego, CA, United States
PI US 2001029013 A1 20011011
AI US 2000-738396 A1 20001214 (9)
PRAI US 2000-287581P 20000406 (60)
DT Utility
FS APPLICATION
LN.CNT 2392
INCL INCLM: 435/006.000
INCLS: 536/023.200; 800/018.000; 514/044.000; 435/325.000; 435/183.000
NCL NCLM: 435/006.000
NCLS: 536/023.200; 800/018.000; 514/044.000; 435/325.000; 435/183.000

IC [7]
ICM: A01K067-027
ICS: C12Q001-68; C07H021-04; A61K048-00; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 160 OF 215 USPATFULL on STN
AN 2001:221065 USPATFULL
TI Methods and compositions for stimulating neurite growth
IN Armistead, David M., Maynard, MA, United States
PA Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)
PI US 6326387 B1 20011204
AI US 2000-616539 20000714 (9)
RLI Division of Ser. No. US 1997-795956, filed on 28 Feb 1997, now patented, Pat. No. US 6124328 Division of Ser. No. US 1995-486004, filed on 8 Jun 1995, now patented, Pat. No. US 6037370
DT Utility
FS GRANTED
LN.CNT 1465
INCL INCLM: 514/354.000
INCLS: 514/357.000; 514/360.000; 514/365.000; 514/374.000; 514/385.000;
514/192.000
NCL NCLM: 514/354.000
NCLS: 514/192.000; 514/357.000; 514/360.000; 514/365.000; 514/374.000;
514/385.000

IC [7]
ICM: A61K031-44
ICS: A61K031-41; A61K031-425; A61K031-43; A61K031-415
EXF 514/354; 514/357; 514/360; 514/365; 514/374; 514/384; 514/192
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 161 OF 215 USPATFULL on STN
AN 2001:215064 USPATFULL
TI Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods

Sui, Zhihua, Flemington, NJ, United States
Walsh, Shawn, Somerville, NJ, United States
Zhao, Boyo, Lansdale, PA, United States
PA Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ, United States (U.S. corporation)
PI US 6323215 B1 20011127
AI US 2000-592530 20000612 (9)
PRAI US 1999-143098P 19990709 (60)
DT Utility
FS GRANTED
LN.CNT 1410
INCL INCLM: 514/301.000
INCLS: 514/307.000; 546/114.000; 546/145.000; 546/146.000; 546/147.000
NCL NCLM: 514/301.000
NCLS: 514/307.000; 546/114.000; 546/145.000; 546/146.000; 546/147.000
IC [7]
ICM: A61K031-4365
ICS: A61K031-472; A61K031-4725; C07D401-12; C07D217-26; C07D495-04
EXF 546/114; 546/147; 546/146; 546/145; 514/301; 514/307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 162 OF 215 USPATFULL on STN
AN 2001:147986 USPATFULL
TI Heteroaromatic compounds
IN Brumby, Thomas, Berlin, Germany, Federal Republic of
McDonald, Fiona, Berlin, Germany, Federal Republic of
Ottow, Eckhard, Berlin, Germany, Federal Republic of
Schneider, Herbert, Berlin, Germany, Federal Republic of
PA Schering Aktiengesellschaft, Berlin, Germany, Federal Republic of
(non-U.S. corporation)
Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)
PI US 6284779 B1 20010904
AI US 2000-496278 20000201 (9)
PRAI DE 1999-19905256 19990203
US 1999-126007P 19990324 (60)
DT Utility
FS GRANTED
LN.CNT 842
INCL INCLM: 514/340.000
INCLS: 546/269.100; 546/269.400
NCL NCLM: 514/340.000
NCLS: 546/269.100; 546/269.400
IC [7]
ICM: C07D413-14
ICS: A61K031-4439
EXF 546/269.1; 546/269.4; 514/340
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 163 OF 215 USPATFULL on STN
AN 2001:121491 USPATFULL
TI Compounds possessing neuronal activity
IN Novak, Perry M., Milford, MA, United States
Mullican, Michael, Needham, MA, United States
PA Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)
PI US 6268384 B1 20010731
AI US 1998-85441 19980527 (9)
RLI Continuation-in-part of Ser. No. US 1997-920838, filed on 29 Aug 1997, now abandoned
DT Utility
FS GRANTED
LN.CNT 1674
INCL INCLM: 514/332.000
INCLS: 514/357.000; 514/318.000; 546/265.000; 546/337.000; 546/193.000; 546/194.000
NCL NCLM: 514/332.000
NCLS: 514/318.000; 514/357.000; 546/193.000; 546/194.000; 546/265.000; 546/337.000
IC [7]
ICM: A61K031-44
ICS: C07D213-81
EXF 546/265; 546/337; 546/193; 546/194; 514/332; 514/357; 514/318
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:86484 USPATFULL
TI Method of using neurotrophic sulfonamide compounds
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
Steiner, Joseph P., Hampstead, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6245783 B1 20010612
AI US 1999-419801 19991018 (9)
RLI Division of Ser. No. US 1998-28517, filed on 23 Feb 1998, now patented,
Pat. No. US 5968957
DT Utility
FS GRANTED
LN.CNT 1019
INCL INCLM: 514/330.000
INCLS: 514/317.000; 514/318.000; 514/343.000; 514/422.000; 514/423.000
NCL NCLM: 514/330.000
NCLS: 514/317.000; 514/318.000; 514/343.000; 514/422.000; 514/423.000
IC [7]
ICM: A61K031-445
ICS: A61K031-44; A61K031-40
EXF 514/330; 514/317; 514/318; 514/343; 514/422; 514/423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 165 OF 215 USPATFULL on STN
AN 2001:82793 USPATFULL
TI Carbamate and urea compositions and neurotrophic uses
IN Li, Jia-He, 27 Manor Ct., Cockeysville, MD, United States 21030
Steiner, Joseph P., 988 Sugar Maple St., Hampstead, MD, United States
21074
Hamilton, Gregory S., 6501 Frederick Rd., Catonsville, MD, United States
21228
PI US 6242468 B1 20010605
AI US 1998-139672 19980825 (9)
RLI Continuation-in-part of Ser. No. US 1997-805646, filed on 27 Feb 1997
DT Utility
FS Granted
LN.CNT 1363
INCL INCLM: 514/343.000
INCLS: 514/342.000; 514/423.000; 514/330.000; 514/613.000; 514/316.000;
514/317.000
NCL NCLM: 514/343.000
NCLS: 514/316.000; 514/317.000; 514/330.000; 514/342.000; 514/423.000;
514/613.000
IC [7]
ICM: A61K031-44
ICS: A61K031-40; A61K031-445; A61K031-16
EXF 514/316; 514/317; 514/613; 514/330; 514/423; 514/342; 514/343
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 166 OF 215 USPATFULL on STN
AN 2001:56120 USPATFULL
TI Heterocyclic esters and amides
IN Li, Jia-He, Cockeysville, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
PA Gpi Nil Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6218544 B1 20010417
AI US 1999-442628 19991118 (9)
RLI Division of Ser. No. US 1998-27622, filed on 23 Feb 1998 Division of
Ser. No. US 1996-719947, filed on 25 Sep 1996, now patented, Pat. No. US
5801187, issued on 1 Sep 1998
DT Utility
FS Granted
LN.CNT 1052
INCL INCLM: 548/201.000
NCL NCLM: 548/201.000
IC [7]
ICM: C07D277-06
EXF 548/201
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 167 OF 215 USPATFULL on STN
AN 2001:56000 USPATFULL
TI Heterocyclic ketone and thioester compounds and uses
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States

PI US 6218424 B1 20010417
AI US 1999-444200 19991122 (9)
RLI Continuation-in-part of Ser. No. US 1997-904461, filed on 1 Aug 1997,
now patented, Pat. No. US 5990131 Continuation-in-part of Ser. No. US
1996-721765, filed on 25 Sep 1996, now patented, Pat. No. US 5786378
DT Utility
FS Granted
LN.CNT 2115
INCL INCLM: 514/423.000
INCLS: 548/530.000; 548/539.000; 548/540.000; 546/226.000; 546/279.100;
514/315.000; 514/330.000; 514/343.000
NCL NCLM: 514/423.000
NCLS: 514/315.000; 514/330.000; 514/343.000; 546/226.000; 546/279.100;
548/530.000; 548/539.000; 548/540.000
IC [7]
ICM: A61K031-40
ICS: C07D207-04
EXF 514/330; 514/423; 514/343; 514/315; 546/226; 546/279.1; 548/540;
548/539; 548/530; 435/240.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 168 OF 215 USPATFULL on STN
AN 2001:47848 USPATFULL
TI Compositions and methods for promoting nerve regeneration
IN Gold, Bruce G., West Linn, OR, United States
PA Oregon Health Sciences University, Portland, OR, United States (U.S.
corporation)
PI US 6210974 B1 20010403
AI US 1999-288061 19990407 (9)
RLI Division of Ser. No. US 1997-956691, filed on 24 Oct 1997, now patented,
Pat. No. US 5968921
DT Utility
FS Granted
LN.CNT 1227
INCL INCLM: 436/501.000
INCLS: 436/034.000; 436/086.000; 436/091.000; 436/063.000
NCL NCLM: 436/501.000
NCLS: 436/034.000; 436/063.000; 436/086.000; 436/091.000
IC [7]
ICM: G01N033-566
ICS: G01N024-00; G01N033-00; G01N033-48
EXF 436/86; 436/91; 436/34; 436/63; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 169 OF 215 USPATFULL on STN
AN 2001:36832 USPATFULL
TI Rapamycin derivatives
IN Cottens, Sylvain, Witterswil, Switzerland
Sedrani, Richard, Basel, Switzerland
PA Novartis AG, Basel, Switzerland (non-U.S. corporation)
PI US 6200985 B1 20010313
AI US 1999-356587 19990719 (9)
RLI Continuation of Ser. No. US 973604, now patented, Pat. No. US 5985890
PRAI GB 1995-11704 19950609
GB 1995-13754 19950806
DT Utility
FS Granted
LN.CNT 1196
INCL INCLM: 514/291.000
NCL NCLM: 514/291.000
IC [7]
ICM: A61K031-695
ICS: A61P043-00
EXF 514/291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 170 OF 215 USPATFULL on STN
AN 2001:36819 USPATFULL
TI Heterocyclic esters and amides
IN Li, Jia-He, Cockeysville, MD, United States
Hamilton, Gregory S., Catonsville, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 6200972 B1 20010313
AI US 1998-27622 19980223 (9)
RLI Division of Ser. No. US 1996-719947, filed on 25 Sep 1996, now patented,

DT Utility
FS Granted
LN.CNT 1158
INCL INCLM: 514/227.500
INCLS: 514/227.800; 514/237.500; 544/059.000; 544/060.000; 544/061.000;
544/062.000; 544/170.000; 544/171.000; 544/172.000; 544/173.000;
544/175.000; 544/176.000
NCL NCLM: 514/227.500
NCLS: 514/227.800; 514/237.500; 544/059.000; 544/060.000; 544/061.000;
544/062.000; 544/170.000; 544/171.000; 544/172.000; 544/173.000;
544/175.000; 544/176.000
IC [7]
ICM: A61K031-5375
ICS: A61K031-54; C07D265-30; C07D279-12
EXF 544/59; 544/60; 544/61; 544/62; 544/170; 544/171; 544/172; 544/173;
544/175; 544/176; 514/227.5; 514/227.8; 514/237.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 171 OF 215 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2002:22559 BIOSIS
DN PREV200200022559
TI Regeneration failure of new peptidyl-prolyl-isomerase inhibitors following
sciatic nerve crush in rats.
AU Brecht, S. J. [Reprint author]; Kuellertz, G.; Hottenrott, S.; Klinder,
K.; Fischer, G.; Herdegen, T. [Reprint author]; Buerger, E.
CS Institute for Pharmacology, University Kiel, Kiel, Germany
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 2317.
print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San
Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 26 Dec 2001
Last Updated on STN: 25 Feb 2002

L3 ANSWER 172 OF 215 PASCAL COPYRIGHT 2004 INIST-CNRS. ALL RIGHTS
RESERVED. on STN
AN 2001-0234465 PASCAL
CP Copyright .COPYRG. 2001 INIST-CNRS. All rights reserved.
TIEN Failure of GPI compounds to display neurotrophic activity in vitro and in
vivo
AU BOCQUET Arnaud; LORENT Genevieve; FUKS Bruno; GRIMEE Renee; TALAGA
Patrice; DALIERS Jean; KLITGAARD Henrik
CS Preclinical CNS Research, UCB S.A. Pharma Sector, Chemin du Foriest, 1420
Braine-l'Alleud, Belgium
SO European journal of pharmacology, (2001), 415(2-3), 173-180, 29 refs.
ISSN: 0014-2999 CODEN: EJPHAZ
DT Journal
BL Analytic
CY Netherlands
LA English
AV INIST-13322, 354000095065030080

L3 ANSWER 173 OF 215 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN
AN 2002:51127 SCISEARCH
GA The Genuine Article (R) Number: 508ZR
TI The immunosuppressant drug FK506 is a potent trophic agent for human fetal
neurons
AU Avramut M; Zeevi A; Achim C L (Reprint)
CS Univ Pittsburgh, Sch Med, Dept Pathol, Div Neuropathol, S 406 Biomed Sci
Tower, 200 Lothrop St, Pittsburgh, PA 15261 USA (Reprint); Univ
Pittsburgh, Sch Med, Dept Pathol, Div Neuropathol, Pittsburgh, PA 15261
USA; Univ Pittsburgh, Sch Med, TE Starzl Transplantat Inst, Pittsburgh, PA
USA
CYA USA
SO DEVELOPMENTAL BRAIN RESEARCH, (31 DEC 2001) Vol. 132, No. 2, pp. 151-157.
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM,
NETHERLANDS.
ISSN: 0165-3806.
DT Article; Journal
LA English

L3 ANSWER 174 OF 215 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2001:349775 BIOSIS
DN PREV200100349775
TI Regenerative potential of new peptidyl-prolyl-isomerase inhibitors
following sciatic nerve crush in rats.
AU Brecht, S. [Reprint author]; Buerger, E.; Kuellertz, G.; Klinder, K.;
Fischer, G.; Herdegen, T. [Reprint author]
CS Institute for Pharmacology, Christian-Albrechts-University, 24105, Kiel,
Germany
SO Naunyn-Schmiedeberg's Archives of Pharmacology, (2001) Vol. 363, No. 4
Supplement, pp. R91. print.
Meeting Info.: 42nd Spring Meeting of the German Society for Experimental
and Clinical Pharmacology and Toxicology. Mainz, Germany. March 13-15,
2001. German Society for Experimental and Clinical Pharmacology and
Toxicology.
CODEN: NSAPCC. ISSN: 0028-1298.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 25 Jul 2001
Last Updated on STN: 19 Feb 2002

L3 ANSWER 175 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 28
AN 03391242 IFIPAT;IFIUDB;IFICDB
TI METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH; TREATING NERVE
CELLS WITH A NEUROTROPHIC AGENT; PROMOTING REPAIR OF NEURONAL DAMAGE
CAUSED BY DISEASE OR PHYSICAL TRAUMA
IN Armistead David M
PA Vertex Pharmaceuticals Inc (30287)
PI US 6124328 A 20000926 (CITED IN 002 LATER PATENTS)
AI US 1997-795956 19970228
RLI US 1995-486004 19950608 DIVISION 6037370
FI US 6124328 20000926
US 6037370
DT Utility; CERTIFICATE OF CORRECTION
CDAT 1 May 2001
8 Jan 2002
FS CHEMICAL
GRANTED
CLMN 13

L3 ANSWER 176 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 29
AN 03387922 IFIPAT;IFIUDB;IFICDB
TI N-LINKED SULFONAMIDES OF HETEROCYCLIC THIOESTERS; ISOMERASE INHIBITORS
EFFECTIVE AGAINST NEUROLOGICAL DISORDERS, I.E. PARKINSON'S DISEASE,
ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS; SIDE EFFECT REDUCTION
IN Hamilton Gregory S; Huang Wei; Li Jai-He
PA GPI NIL Holdings Inc (43964)
PI US 6121273 A 20000919
AI US 1997-996342 19971222
RLI US 1996-775584 19961231 CONTINUATION-IN-PART 5874449
FI US 6121273 20000919
US 5874449
DT Utility; CERTIFICATE OF CORRECTION
CDAT 1 May 2001
FS CHEMICAL
GRANTED
OS CA 133:237855
MRN 009183 MFN: 0704
010501 0991
CLMN 24

L3 ANSWER 177 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 30
AN 03294092 IFIPAT;IFIUDB;IFICDB
TI METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH; TREATING
ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, PARKINSON'S DISEASE,
AND OTHER NERVOUS SYSTEM DISORDERS WITH PEPTIDE DERIVATIVES
IN Armistead David M
PA Vertex Pharmaceuticals Inc (30287)
PI US 6037370 A 20000314 (CITED IN 011 LATER PATENTS)
AI US 1995-486004 19950608
FI US 6037370 20000314

CDAT 5 Jun 2001
FS CHEMICAL
GRANTED
MRN 007891 MFN: 0912
CLMN 11

L3 ANSWER 178 OF 215 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:84802 CAPLUS
DN 132:137377
TI Preparation of benzoxazolyl piperidines and analogs as rotamase enzyme inhibitors
IN Kemp, Mark Ian; Palmer, Michael John; Sanner, Mark Allen; Wythes, Martin James
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005232	A1	20000203	WO 1999-IB1211	19990628
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2338214	AA	20000203	CA 1999-2338214	19990628
	AU 9942858	A1	20000214	AU 1999-42858	19990628
	AU 765925	B2	20031002		
	BR 9912330	A	20010417	BR 1999-12330	19990628
	EP 1100797	A1	20010523	EP 1999-963123	19990628
	EP 1100797	B1	20030226		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	TR 200100135	T2	20010621	TR 2001-200100135	19990628
	EE 200100044	A	20020617	EE 2001-44	19990628
	JP 2002521382	T2	20020716	JP 2000-561188	19990628
	NZ 508838	A	20021220	NZ 1999-508838	19990628
	AT 233261	E	20030315	AT 1999-963123	19990628
	ES 2191484	T3	20030901	ES 1999-963123	19990628
	NZ 522270	A	20040326	NZ 1999-522270	19990628
	NO 2001000322	A	20010315	NO 2001-322	20010119
	HR 2001000052	A1	20011231	HR 2001-52	20010119
	BG 105254	A	20011031	BG 2001-105254	20010214
	JP 2004002374	A2	20040108	JP 2003-105099	20030409
PRAI	GB 1998-15880	A	19980721		
	JP 2000-561188	A3	19990628		
	NZ 1999-508838	A1	19990628		
	WO 1999-IB1211	W	19990628		

OS MARPAT 132:137377

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 179 OF 215 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:84800 CAPLUS
DN 132:137376
TI Preparation of benzoxazolyl and benzimidazolyl piperidines as FKBP inhibitors
IN Wythes, Martin James; Palmer, Michael John; Kemp, Mark Ian; Mackenny, Malcolm Christian; Maguire, Robert John; Blake, James Francis, Jr.
PA Pfizer Limited, UK; Pfizer Inc.; Blake, James Francis, Jr.
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000005231	A1	20000203	WO 1999-IB1227	19990701
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,				

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
 MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
 TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,
 MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA	2338276	AA	20000203	CA	1999-2338276	19990701
AU	9943855	A1	20000214	AU	1999-43855	19990701
AU	756769	B2	20030123			
BR	9912307	A	20010502	BR	1999-12307	19990701
EP	1098894	A1	20010516	EP	1999-926683	19990701
EP	1098894	B1	20021002			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
TR	200100133	T2	20010621	TR	2001-200100133	19990701
EE	200100043	A	20020617	EE	2001-43	19990701
JP	2002521381	T2	20020716	JP	2000-561187	19990701
JP	3545341	B2	20040721			
AT	225346	E	20021015	AT	1999-926683	19990701
NZ	508839	A	20030131	NZ	1999-508839	19990701
PT	1098894	T	20030228	PT	1999-926683	19990701
ES	2183567	T3	20030316	ES	1999-926683	19990701
US	6166011	A	20001226	US	1999-354193	19990715
US	6495549	B1	20021217	US	2000-699878	20001030
US	6509464	B1	20030121	US	2000-699869	20001030
US	6686357	B1	20040203	US	2000-699752	20001030
ZA	2001000229	A	20020409	ZA	2001-229	20010109
NO	2001000299	A	20010315	NO	2001-299	20010118
HR	2001000053	A1	20011231	HR	2001-53	20010119
BG	105249	A	20011130	BG	2001-105249	20010214
US	2004058905	A1	20040325	US	2003-404524	20030401
PRAI	GB 1998-15696	A	19980720			
	WO 1999-IB1227	W	19990701			
	US 1999-354193	A3	19990715			
	US 2000-699752	A1	20001030			

OS MARPAT 132:137376

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 180 OF 215 USPATFULL on STN
 AN 2000:146403 USPATFULL
 TI Small molecule inhibitors of rotamase enzyme activity
 IN Hamilton, Gregory S., Catonsville, MD, United States
 Steiner, Joseph P., Hampstead, MD, United States
 PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
 PI US 6140357 20001031
 AI US 1997-833629 19970408 (8)
 RLI Continuation of Ser. No. US 1996-650461, filed on 21 May 1996 which is a
 continuation-in-part of Ser. No. US 1995-479436, filed on 7 Jun 1995,
 now patented, Pat. No. US 5614547
 DT Utility
 FS Granted
 LN.CNT 1680
 INCL INCLM: 514/423.000
 NCL NCLM: 514/423.000
 IC [7]
 ICM: A61K031-401
 EXF 514/423
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 181 OF 215 USPATFULL on STN
 AN 2000:121323 USPATFULL
 TI Compositions and methods for regulation of transcription
 IN Natesan, Sridaran, Chestnut Hill, MA, United States
 Gilman, Michael Z., Newton, MA, United States
 PA ARIAD Gene Therapeutics, Inc., Cambridge, MA, United States (U.S.
 corporation)
 PI US 6117680 20000912
 AI US 1998-140149 19980826 (9)
 RLI Continuation-in-part of Ser. No. US 1998-126009, filed on 29 Jul 1998
 which is a continuation-in-part of Ser. No. US 1997-920610, filed on 27
 Aug 1997, now patented, Pat. No. US 6015709 which is a
 continuation-in-part of Ser. No. US 1997-918401, filed on 26 Aug 1997,
 now abandoned

DT Utility
 FS Granted
 LN.CNT 3943
 INCL INCLM: 435/455.000
 INCLS: 435/235.100; 435/320.100; 435/325.000; 435/456.000; 536/023.400
 NCL NCLM: 435/455.000
 NCLS: 435/235.100; 435/320.100; 435/325.000; 435/456.000; 536/023.400
 IC [7]
 ICM: C12N005-10
 ICS: C12N015-63
 EXF 435/235.1; 435/320.1; 435/325; 435/455; 435/456; 536/23.1; 536/23.4
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 182 OF 215 USPATFULL on STN
 AN 2000:50702 USPATFULL
 TI N-oxides of heterocyclic esters, amides, thioesters, and ketones
 IN Hamilton, Gregory S., Catonsville, MD, United States
 Steiner, Joseph P., Hampstead, MD, United States
 Burak, Eric S., Forest Hill, MD, United States
 PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
 PI US 6054452 20000425
 AI US 1998-112319 19980709 (9)
 RLI Continuation of Ser. No. US 1997-807406, filed on 28 Feb 1997, now
 patented, Pat. No. US 8846979
 DT Utility
 FS Granted
 LN.CNT 940
 INCL INCLM: 514/212.000
 INCLS: 514/315.000; 514/423.000; 540/529.000; 546/245.000; 548/530.000
 NCL NCLM: 514/217.110
 NCLS: 514/315.000; 514/423.000; 540/529.000; 546/245.000; 548/530.000
 IC [7]
 ICM: A61K031-40
 ICS: A61K031-44; A61K031-50
 EXF 514/212; 514/315; 514/423; 540/529; 546/245; 548/530
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 183 OF 215 USPATFULL on STN
 AN 2000:15654 USPATFULL
 TI Inhibitors of rotamase enzyme activity
 IN Steiner, Joseph P., Hampstead, MD, United States
 Snyder, Solomon, Baltimore, MD, United States
 Hamilton, Gregory S., Catonsville, MD, United States
 Dawson, Ted, Baltimore, MD, United States
 PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
 John Hopkins University School of Medicine, Baltimore, MD, United States
 (U.S. corporation)
 PI US 6022878 20000208
 AI US 1998-113330 19980710 (9)
 RLI Continuation of Ser. No. US 1997-787162, filed on 23 Jan 1997, now
 patented, Pat. No. US 5843960 which is a continuation of Ser. No. US
 1996-653905, filed on 28 May 1996, now patented, Pat. No. US 5696135
 which is a continuation-in-part of Ser. No. US 1995-474072, filed on 7
 Jun 1995, now patented, Pat. No. US 5798355
 DT Utility
 FS Granted
 LN.CNT 1811
 INCL INCLM: 514/317.000
 INCLS: 514/318.000; 514/330.000; 514/012.000
 NCL NCLM: 514/317.000
 NCLS: 514/012.000; 514/318.000; 514/330.000
 IC [6]
 ICM: A61K031-445
 ICS: A61K038-18
 EXF 514/317; 514/318; 514/330; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 184 OF 215 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:45907 CAPLUS
 DN 137:149525
 TI Pharmacological activities of neurophilin ligands
 AU Cole, Douglas G.; Ogenstad, Stephan; Chaturvedi, Pravin
 CS Vertex Pharmaceuticals, Inc., Cambridge, MA, USA
 SO Immunophilins in the Brain: FKBP Ligands: Novel Strategies for the
 Treatment of Neurodegenerative Disorders, [Proceedings from the Conference

(2000), Meeting Date 1999, 109-116.~ Editor(s): Göld, Bruce G.; Fischer, Gunter; Herdegen, Thomas. Publisher: Prous Science, Barcelona, Spain.
CODEN: 69CEO5; ISBN: 84-8124-165-2

DT Conference; General Review

LA English

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 185 OF 215 MEDLINE on STN

AN 2001118017 MEDLINE

DN PubMed ID: 11113532

TI Postischemic changes in the immunophilin ***FKBP12*** in the rat brain.

AU Kato H; Oikawa T; Otsuka K; Takahashi A; Itoyama Y

CS Department of Neurology, Field of Neuroscience, Tohoku University Graduate School of Medicine, 1-1 Seiryomachi, Aoba-ku, Sendai 980-8574, Japan..
kato@mail.cc.tohoku.ac.jp

SO Brain research. Molecular brain research, (2000 Dec 8) 84 (1-2) 58-66.

Journal code: 8908640. ISSN: 0169-328X.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 200102

ED Entered STN: 20010322

Last Updated on STN: 20010322

Entered Medline: 20010215

L3 ANSWER 186 OF 215 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN DUPLICATE 31

AN 2001:107830 BIOSIS

DN PREV200100107830

TI Structural and biochemical analysis of neurotrophic FKBP ligands.

AU Hamilton, G. S. [Reprint author]; Holmes, A.; Thomas, C.; Ho, T.;
Rothstein, J.; Steiner, J. P.

CS Guilford Pharmaceut Inc, Baltimore, MD, USA

SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
No.-216.1. print.

Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.

ISSN: 0190-5295.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 28 Feb 2001

Last Updated on STN: 15 Feb 2002

L3 ANSWER 187 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 32

AN 03183146 IFIPAT;IFIUDB;IFICDB

TI N-LINKED UREAS AND CARBAMATES OF HETEROCYCLIC THIOESTERS; TREATING
NERVOUS SYSTEM DISORDERS

IN Hamilton Gregory S; Huang Wei; Li Jia-He

PA GPI NIL Holdings Inc (43964)

PI US 5935989 A 19990810 (CITED IN 003 LATER PATENTS)

AI US 1996-775585 19961231

FI US 5935989 19990810

DT Utility; CERTIFICATE OF CORRECTION

CDAT 21 May 2002

23 Jul 2002

FS CHEMICAL

GRANTED

MRN 008585 MFN: 0746

008592 0125

CLMN 21

L3 ANSWER 188 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 33

AN 03114638 IFIPAT;IFIUDB;IFICDB

TI N-LINKED SULFONAMIDES OF HETEROCYCLIC THIOESTERS; INHIBITORS OF
IMMUNOPHILIN

IN Hamilton Gregory S; Huang Wei; Li Jia-He

PA GPI NIL Holdings Inc (43964)

PI US 5874449 A 19990223 (CITED IN 007 LATER PATENTS)

AI US 1996-775584 19961231

FI US 5874449 19990223

DT Utility; CERTIFICATE OF CORRECTION

3 Jun 2003
FS CHEMICAL
GRANTED
MRN 009130 MFN: 0219
009130 0225
CLMN 33

L3 ANSWER 189 OF 215 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:576925 CAPLUS
DN 131:214289
TI Preparation of oxadiazolyl piperidine derivatives as rotamase enzyme
inhibitors
IN Bull, David John; MaGuire, Robert John; Palmer, Michael John; Wythes,
Martin James
PA Pfizer Inc., USA; Pfizer Ltd.
SO PCT Int. Appl., 237 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9945006	A1	19990910	WO 1999-IB259	19990215
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2322442	AA	19990910	CA 1999-2322442	19990215
	AU 9921810	A1	19990920	AU 1999-21810	19990215
	BR 9908480	A	20001205	BR 1999-8480	19990215
	EP 1060178	A1	20001220	EP 1999-901847	19990215
	EP 1060178	B1	20030903		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2002505329	T2	20020219	JP 2000-534548	19990215
	AT 248836	E	20030915	AT 1999-901847	19990215
	PT 1060178	T	20031231	PT 1999-901847	19990215
	ES 2204101	T3	20040416	ES 1999-901847	19990215
	US 6610707	B1	20030826	US 1999-380427	19990901
PRAI	GB 1998-4426	A	19980302		
	WO 1999-IB259	W	19990215		

OS MARPAT 131:214289
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 190 OF 215 USPATFULL on STN
AN 1999:151234 USPATFULL
TI Heterocyclic thioesters and ketones
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
PA Gpi Nil Holdings Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5990131 19991123
AI US 1997-904461 19970801 (8)
RLI Continuation-in-part of Ser. No. US 1996-721765, filed on 25 Sep 1996
DT Utility
FS Granted
LN.CNT 1779
INCL INCLM: 514/330.000
INCLS: 546/226.000; 548/533.000; 548/540.000; 514/422.000; 514/423.000
NCL NCLM: 514/330.000
NCLS: 514/422.000; 514/423.000; 546/226.000; 548/533.000; 548/540.000
IC [6]
ICM: A61K031-445
ICS: C07D211-06
EXF 548/533; 548/540; 514/422; 514/423; 514/330; 546/226
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 191 OF 215 USPATFULL on STN
AN 1999:146589 USPATFULL
TI Rapamycin derivatives
IN Cottens, Sylvain, Witterswil, Switzerland
Sedrani, Richard, Basel, Switzerland

PI US 5985890 19991116
WO 9641807 19961227
AI US 1997-973604 19971208 (8)
WO 1996-EP2441 19960605
19971208 PCT 371 date
19971208 PCT 102(e) date

PRAI GB 1995-11704 19950609
GB 1995-13754 19950706

DT Utility
FS Granted

LN.CNT 1064

INCL INCLM: 514/291.000
INCLS: 540/456.000

NCL NCLM: 514/291.000
NCLS: 540/456.000

IC [6]

ICM: C07D498-18

ICS: A61K031-435; A61K031-695; C07F007-18

EXF 540/456; 514/291

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 192 OF 215 USPATFULL on STN

AN 1999:128573 USPATFULL

TI Method of using neurotrophic sulfonamide compounds

IN Hamilton, Gregory S., Catonsville, MD, United States

Li, Jia-He, Cockeysville, MD, United States

Steiner, Joseph P., Hampstead, MD, United States

PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)

PI US 5968957 19991019

AI US 1998-28517 19980223 (9)

RLI Division of Ser. No. US 1997-799407, filed on 12 Feb 1997, now patented,
Pat. No. US 5721256

DT Utility

FS Granted

LN.CNT 1018

INCL INCLM: 514/330.000

INCLS: 514/317.000; 514/318.000; 514/343.000; 514/422.000; 514/423.000

NCL NCLM: 514/330.000

NCLS: 514/317.000; 514/318.000; 514/343.000; 514/422.000; 514/423.000

IC [6]

ICM: A61K031-445

ICS: A61K031-44; A61K031-40

EXF 514/330; 514/317; 514/318; 514/343; 514/422; 514/423

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 193 OF 215 USPATFULL on STN

AN 1999:128537 USPATFULL

TI Compositions and methods for promoting nerve regeneration

IN Gold, Bruce G., West Linn, OR, United States

PA Oregon Health Sciences University, Portland, OR, United States (U.S. corporation)

PI US 5968921 19991019

AI US 1997-956691 19971024 (8)

DT Utility

FS Granted

LN.CNT 1254

INCL INCLM: 514/183.000

INCLS: 514/330.000; 514/423.000; 514/428.000; 514/465.000; 514/466.000;
514/534.000; 514/547.000; 514/548.000; 514/549.000

NCL NCLM: 514/183.000

NCLS: 514/330.000; 514/423.000; 514/428.000; 514/465.000; 514/466.000;
514/534.000; 514/547.000; 514/548.000; 514/549.000

IC [6]

ICM: A61K031-33

ICS: A61K031-445; A61K031-40; A61K031-36

EXF 514/183; 514/548; 514/330; 514/423; 514/428; 514/534; 514/547; 514/549;
514/551; 514/465; 514/466

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 194 OF 215 USPATFULL on STN

AN 1999:117520 USPATFULL

TI N-linked ureas and carbamates of piperidyl thioesters

IN Hamilton, Gregory S., Catonsville, MD, United States

Li, Jia-He, Cockeysville, MD, United States

Huang, Wei, Chesterfield, MO, United States

PI US 5958949 19990528
 AI US 1997-997451 19971223 (8)
 RLI Continuation-in-part of Ser. No. US 1996-775585, filed on 31 Dec 1996
 DT Utility
 FS Granted
 LN.CNT 1793
 INCL INCLM: 514/318.000
 INCLS: 514/323.000; 546/186.000; 546/193.000; 546/225.000
 NCL NCLM: 514/318.000
 NCLS: 514/323.000; 546/186.000; 546/193.000; 546/225.000
 IC [6]
 ICM: A61K031-445
 ICS: C07D401-12
 EXF 546/186; 546/225; 546/193; 514/318; 514/323; 514/324
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 195 OF 215 USPATFULL on STN
 AN 1999:92670 USPATFULL
 TI Compounds with improved multi-drug resistance activity
 IN Armistead, David M., Maynard, MA, United States
 PA Saunders, Jeffrey O., Acton, MA, United States
 Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S. corporation)
 PI US 5935954 19990810
 AI US 1997-961551 19971030 (8)
 RLI Division of Ser. No. US 1996-626259, filed on 29 Mar 1996, now patented, Pat. No. US 5717092
 DT Utility
 FS Granted
 LN.CNT 2309
 INCL INCLM: 514/235.200
 INCLS: 514/235.500; 514/237.200; 514/343.000; 514/422.000; 514/423.000; 544/124.000; 544/141.000; 544/143.000; 544/059.000; 544/186.000; 544/187.000; 544/193.000; 544/194.000; 544/360.000; 544/372.000; 546/279.100; 548/517.000; 548/518.000; 548/531.000; 548/536.000
 NCL NCLM: 514/235.200
 NCLS: 514/235.500; 514/237.200; 514/343.000; 514/422.000; 514/423.000; 544/059.000; 544/124.000; 544/141.000; 544/143.000; 544/186.000; 544/187.000; 544/193.000; 544/194.000; 544/360.000; 544/372.000; 546/279.100; 548/517.000; 548/518.000; 548/531.000; 548/536.000
 IC [6]
 ICM: C07D211-60
 ICS: C07D401-12; C07D409-12; A61K031-445
 EXF 548/517; 548/518; 548/531; 548/536; 546/279.1; 544/124; 544/141; 544/143; 514/235.2; 514/235.5; 514/237.2; 514/343; 514/422; 514/423
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 196 OF 215 USPATFULL on STN
 AN 1999:4688 USPATFULL
 TI Small molecule inhibitors of rotamase enzyme activity
 IN Hamilton, Gregory S., Catonsville, MD, United States
 Steiner, Joseph P., Hampstead, MD, United States
 PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
 PI US 5859031 19990112
 AI US 1996-650461 19960521 (8)
 RLI Continuation-in-part of Ser. No. US 1995-479436, filed on 7 Jun 1995, now patented, Pat. No. US 5614547
 DT Utility
 FS Granted
 LN.CNT 1761
 INCL INCLM: 514/343.000
 INCLS: 514/365.000; 514/422.000; 514/423.000; 546/281.000; 548/204.000; 548/517.000; 548/526.000; 548/527.000; 548/533.000; 548/538.000
 NCL NCLM: 514/343.000
 NCLS: 514/365.000; 514/422.000; 514/423.000; 546/279.100; 548/204.000; 548/517.000; 548/526.000; 548/527.000; 548/533.000; 548/538.000
 IC [6]
 ICM: A61K031-40
 ICS: C07D207-16
 EXF 514/343; 514/423; 514/365; 514/422; 548/517; 548/204; 548/526; 548/527; 548/533; 548/538; 546/281
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 197 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 34
 AN 03032538 IFIPAT;IFIUDB;IFICDB

IN Hamilton Gregory S; Li Jia-He
 PA GPI NIL Holdings Inc (43964)
 PI US 5801187 A 19980901 (CITED IN 022 LATER PATENTS)
 AI US 1996-719947 19960925
 FI US 5801187 19980901
 DT Utility
 FS CHEMICAL
 GRANTED
 MRN 008151 MFN: 0924
 008281 0238
 008417 0853
 CLMN 12
 GI 2 Drawing Sheet(s), 6 Figure(s).

L3 ANSWER 198 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 35
 AN 03016337 IFIPAT;IFIUDB;IFICDB
 TI HETEROCYCLIC THIOESTERS; FKBP TYPE IMMUNOPHILLINS FOR NERVOUS SYSTEM DISORDERS
 IN Hamilton Gregory S; Li Jia-He
 PA GPI NIL Holdings Inc (43964)
 PI US 5786378 A 19980728 (CITED IN 022 LATER PATENTS)
 AI US 1996-721765 19960925
 FI US 5786378 19980728
 DT Utility; CERTIFICATE OF CORRECTION
 CDAT 15 Dec 1998
 FS CHEMICAL
 GRANTED
 MRN 008161 MFN: 0517
 008281 0291
 CLMN 43
 GI 4 Drawing Sheet(s), 3 Figure(s).

L3 ANSWER 199 OF 215 USPATFULL on STN
 AN 1998:154288 USPATFULL
 TI Inhibitors of rotamase enzyme activity
 IN Steiner, Joseph P., Hampstead, MD, United States
 Snyder, Solomon, Baltimore, MD, United States
 Hamilton, Gregory S., Catonsville, MD, United States
 Dawson, Ted, Baltimore, MD, United States
 PA GPI NIL Holdings Inc., Wilmington, DE, United States (U.S. corporation)
 Johns Hopkins University School of Medicine, Baltimore, MD, United States (U.S. corporation)
 PI US 5846981 19981208
 AI US 1997-787163 19970123 (8)
 RLI Continuation of Ser. No. US 1993-653905, filed on 28 May 1993, now patented, Pat. No. US 5696135 which is a continuation-in-part of Ser. No. US 1995-474072, filed on 7 Jun 1995, now patented, Pat. No. US 5798355
 DT Utility
 FS Granted
 LN.CNT 1681
 INCL INCLM: 514/317.000
 INCLS: 514/318.000; 514/330.000; 514/012.000
 NCL NCLM: 514/317.000
 NCLS: 514/012.000; 514/318.000; 514/330.000
 IC [6]
 ICM: A61K031-445
 ICS: A61K038-18
 EXF 514/317; 514/318; 514/330; 514/12
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 200 OF 215 USPATFULL on STN
 AN 1998:154286 USPATFULL
 TI N-oxides of heterocyclic esters, amides, thioesters, and ketones
 IN Hamilton, Gregory S., Catonsville, MD, United States
 Steiner, Joseph P., Hampstead, MD, United States
 Burak, Eric S., Forest Hill, MD, United States
 PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
 PI US 5846979 19981208
 AI US 1997-807406 19970228 (8)
 DT Utility
 FS Granted
 LN.CNT 1310
 INCL INCLM: 514/311.000
 INCLS: 514/314.000; 514/316.000; 514/318.000; 514/323.000; 514/320.000;

514/336.000; 514/354.000; 514/423.000; 546/186.000; 546/193.000;
546/205.000; 546/168.000; 540/597.000; 540/602.000; 540/603.000;
540/607.000; 540/608.000; 518/527.000; 518/517.000; 518/518.000
NCL NCLM: 514/311.000
NCLS: 514/314.000; 514/316.000; 514/317.000; 514/318.000; 514/320.000;
514/323.000; 514/326.000; 514/332.000; 514/336.000; 514/337.000;
514/339.000; 514/354.000; 514/423.000; 540/597.000; 540/602.000;
540/603.000; 540/607.000; 540/608.000; 546/168.000; 546/186.000;
546/193.000; 546/205.000; 548/517.000; 548/518.000; 548/527.000

IC [6]

ICM: A61K031-47

ICS: A61K031-445; C07D211-02

EXF 540/597; 540/602; 540/603; 540/607; 540/608; 546/186; 546/193; 546/205;
546/168; 548/527; 548/517; 548/518; 514/316; 514/318; 514/323; 514/320;
514/317; 514/326; 514/332; 514/339; 514/337; 514/336; 514/354; 514/423;
514/314; 514/311

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 201 OF 215 USPATFULL on STN

AN 1998:150962 USPATFULL

TI Inhibitors of rotamase enzyme activity

IN Steiner, Joseph P., Hampstead, MD, United States

Snyder, Solomon, Baltimore, MD, United States

Hamilton, Gregory S., Catonsville, MD, United States

Dawson, Ted, Baltimore, MD, United States

PA GPI Nil Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
Johns Hopkins University School of Medicine, Baltimore, MD, United
States (U.S. corporation)

PI US 5843960 19981201

AI US 1997-787162 19970123 (8)

RLI Continuation of Ser. No. US 1996-653905, filed on 28 May 1996, now
patented, Pat. No. US 5696135 which is a continuation-in-part of Ser.
No. US 1995-474072, filed on 7 Jun 1995, now patented, Pat. No. US
5798355

DT Utility

FS Granted

LN.CNT 1785

INCL INCLM: 514/317.000

INCLS: 514/318.000; 514/330.000; 514/012.000

NCL NCLM: 514/317.000

NCLS: 514/012.000; 514/318.000; 514/330.000

IC [6]

ICM: A61K031-445

ICS: A61K038-18

EXF 514/317; 514/318; 514/330; 514/12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 202 OF 215 USPATFULL on STN

AN 1998:101646 USPATFULL

TI Inhibitors of rotamase enzyme activity

IN Steiner, Joseph P., Hampstead, MD, United States

Snyder, Solomon, Baltimore, MD, United States

Hamilton, Gregory S., Catonsville, MD, United States

Dawson, Ted, Baltimore, MD, United States

PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
Johns Hopkins University School of Medicine, Baltimore, MD, United
States (U.S. corporation)

PI US 5798355 19980825

AI US 1995-474072 19950607 (8)

DT Utility

FS Granted

LN.CNT 2249

INCL INCLM: 514/248.000

INCLS: 514/293.000; 514/300.000; 514/302.000; 514/248.000; 514/326.000;
514/330.000

NCL NCLM: 514/248.000

NCLS: 514/293.000; 514/300.000; 514/302.000; 514/318.000; 514/326.000;
514/330.000

IC [6]

ICM: A61K031-50

ICS: A61K031-44; A61K031-445

EXF 514/248; 514/293; 514/300; 514/318; 514/326; 514/330; 514/302

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 203 OF 215 USPATFULL on STN

TI Small molecule inhibitors of rotamase enzyme activity
IN Hamilton, Gregory S., Catonsville, MD, United States
Steiner, Joseph P., Hampstead, MD, United States
PA GPI Nil Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5795908 19980818
AI US 1997-787161 19970123 (8)
RLI Continuation of Ser. No. US 1996-650461, filed on 21 May 1996 which is a
continuation of Ser. No. US 1995-479436, filed on 7 Jun 1995, now
patented, Pat. No. US 5614547
DT Utility
FS Granted
LN.CNT 1576
INCL INCLM: 514/423.000
INCLS: 548/533.000
NCL NCLM: 514/423.000
NCLS: 548/533.000
IC [6]
ICM: C07D207-16
ICS: A01K031-40
EXF 514/423; 548/533
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 204 OF 215 USPATFULL on STN
AN 1998:19723 USPATFULL
TI Method of using neurotrophic sulfonamide compounds
IN Hamilton, Gregory S., Catonsville, MD, United States
Li, Jia-He, Cockeysville, MD, United States
Steiner, Joseph P., Hampstead, MD, United States
PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)
PI US 5721256 19980224
AI US 1997-799407 19970212 (8)
DT Utility
FS Granted
LN.CNT 966
INCL INCLM: 514/330.000
INCLS: 514/317.000; 514/318.000; 514/343.000; 514/422.000; 514/423.000
NCL NCLM: 514/330.000
NCLS: 514/317.000; 514/318.000; 514/343.000; 514/422.000; 514/423.000
IC [6]
ICM: A61K031-445
ICS: A61K031-44; A61K031-40
EXF 514/330; 514/317; 514/318; 514/343; 514/422; 514/423
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 205 OF 215 USPATFULL on STN
AN 1998:14934 USPATFULL
TI Compounds with improved multi-drug resistance activity
IN Armistead, David M., Maynard, MA, United States
Saunders, Jeffrey O., Acton, MA, United States
PA Vertex Pharmaceuticals Inc., Cambridge, MA, United States (U.S.
corporation)
PI US 5717092 19980210
AI US 1996-626259 19960329 (8)
DT Utility
FS Granted
LN.CNT 2110
INCL INCLM: 544/129.000
INCLS: 544/360.000; 546/193.000; 546/194.000; 546/207.000; 546/208.000;
546/213.000; 546/226.000; 546/227.000
NCL NCLM: 544/129.000
NCLS: 544/360.000; 546/193.000; 546/194.000; 546/207.000; 546/208.000;
546/213.000; 546/226.000; 546/227.000
IC [6]
ICM: C07D211-06
ICS: C07D211-36; C07D211-60
EXF 544/129; 546/193; 546/194; 546/207; 546/208; 546/213; 546/226; 546/227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 206 OF 215 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1998-413664 [35] WPIDS
DNC C1998-124764
TI New N-linked urea(s) and carbamate(s) of heterocyclic thio-ester compounds
- have affinity for FKBP-type immunophilin(s) and are used for treating
neurological disorders.
DC B02 B03

PA (GUIL-N) GUILFORD PHARM INC; (HAMI-I) HAMILTON G S; (HUAN-I) HUANG W;
(LIJJ-I) LI J; (GPIN-N) GPI NIL HOLDINGS INC

CYC 81

PI WO 9829117 A1 19980709 (199835)* EN 116 A61K031-40
RW: AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA
PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN

AU 9857241 A 19980731 (199849)
ZA 9711704 A 19981125 (199901) 114 C07C000-00
US 5935989 A 19990810 (199938) A61K031-40
NO 9902751 A 19990804 (199941) C07D000-00
US 5958949 A 19990928 (199947) 19 A61K031-445
EP 959882 A1 19991201 (200001) EN
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
CZ 9901546 A3 19991117 (200002)
CN 1241942 A 20000119 (200023) A61K031-40
BR 9714092 A 20000509 (200033) A61K031-40
SK 9900578 A3 20000516 (200036) A61K031-40
AU 721572 B 20000706 (200038) A61K031-40
MX 9906121 A1 19991001 (200103) A61K031-40
US 6184243 B1 20010206 (200109) A61K031-415
HU 2000002442 A2 20001228 (200111) C07D207-16
KR 2000057488 A 20000915 (200122) A61K031-40
US 6274607 B1 20010814 (200148) A61K031-425
NZ 336386 A 20010928 (200161) A61K031-401
US 2002049199 A1 20020425 (200233) A61K031-55
JP 2002515050 W 20020521 (200236) 113 C07D207-08
TW 485159 A 20020501 (200318) C07D207-18

ADT WO 9829117 A1 WO 1997-US24070 19971223; AU 9857241 A AU 1998-57241
19971223; ZA 9711704 A ZA 1997-11704 19971230; US 5935989 A US 1996-775585
19961231; NO 9902751 A WO 1997-US24070 19971223, NO 1999-2751 19990607; US
5958949 A CIP of US 1996-775585 19961231, US 1997-997451 19971223; EP
959882 A1 EP 1997-953508 19971223, WO 1997-US24070 19971223; CZ 9901546 A3
WO 1997-US24070 19971223, CZ 1999-1546 19971223; CN 1241942 A CN
1997-181059 19971223; BR 9714092 A BR 1997-14092 19971223, WO 1997-US24070
19971223; SK 9900578 A3 WO 1997-US24070 19971223, SK 1999-578 19971223; AU
721572 B AU 1998-57241 19971223; MX 9906121 A1 MX 1999-6121 19990629; US
6184243 B1 Div ex US 1996-775585 19961231, US 1998-165372 19981002; HU
2000002442 A2 WO 1997-US24070 19971223, HU 2000-2442 19971223; KR
2000057488 A WO 1997-US24070 19971223, KR 1999-705162 19990610; US 6274607
B1 CIP of US 1996-775585 19961231, Div ex US 1997-997451 19971223, US
1999-393650 19990910; NZ 336386 A NZ 1997-336386 19971223, WO 1997-US24070
19971223; US 2002049199 A1 CIP of US 1996-775585 19961231, Div ex US
1997-997451 19971223, Div ex US 1999-393650 19990910, US 2001-885178
20010621; JP 2002515050 W WO 1997-US24070 19971223, JP 1998-519760
19971223; TW 485159 A TW 1997-120096 19971231

FDT AU 9857241 A Based on WO 9829117; EP 959882 A1 Based on WO 9829117; CZ
9901546 A3 Based on WO 9829117; BR 9714092 A Based on WO 9829117; AU
721572 B Previous Publ. AU 9857241, Based on WO 9829117; US 6184243 B1 Div
ex US 5935989; HU 2000002442 A2 Based on WO 9829117; KR 2000057488 A Based
on WO 9829117; US 6274607 B1 CIP of US 5935989, Div ex US 5958949; NZ
336386 A Div in NZ 511109, Based on WO 9829117; US 2002049199 A1 CIP of US
5935989, Div ex US 5958949, Div ex US 6274607; JP 2002515050 W Based on WO
9829117

PRAI US 1997-997451 19971223; US 1996-775585 19961231;
US 1998-165372 19981002; US 1999-393650 19990910;
US 2001-885178 20010621

IC ICM A61K031-40; A61K031-401; A61K031-415; A61K031-425; A61K031-445;
A61K031-55; C07C000-00; C07D000-00; C07D207-08; C07D207-16;
C07D207-18

ICS A61K031-4439; A61P025-00; A61P025-16; A61P025-28; A61P043-00;
C01B000-00; C07D207-06; C07D207-12; C07D207-267; C07D211-30;
C07D211-60; C07D223-04; C07D231-06; C07D277-04; C07D401-12;
C07D403-02; C07D413-02

L3 ANSWER 207 OF 215 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN

AN 1998-286409 [25] WPIDS

DNC C1998-088621

TI Heterocyclic compounds useful as neurotrophic agents - are immunophilin
inhibitors, used to treat stroke damage to brain or ***spinal***
cord, neuropathy, and Alzheimer's and Parkinson's diseases.

DC B03

IN HAMILTON, G S; LI, J

HAMILTON G S; (LIJJ-I) LI J

CYC 80
PI WO 9813355 A1 19980402 (199825)* EN 53 C07D267-02
RW: AT BE CH DE DK EA ES FI FR GB GH GR IE IT KE LS LU MC MW NL OA PT
SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX
NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN YU
ZA 9707901 A 19980527 (199827) 50 C07D000-00
AU 9740769 A 19980417 (199834)
US 5801187 A 19980901 (199842) A61K031-425
CZ 9900660 A3 19990616 (199929) C07D267-02
NO 9901433 A 19990525 (199930) C07D000-00
EP 934287 A1 19990811 (199936) EN C07D267-02
R: AL AT BE CH DE DK ES FI FR GB GR IE IT LI LT LU LV MC NL PT RO SE
SI
BR 9712834 A 19991116 (200012) C07D267-02
CN 1234795 A 19991110 (200012) C07D267-02
SK 9900266 A3 20000118 (200018) C07D267-02
NZ 334186 A 20000929 (200060) C07D207-06
HU 2000000969 A2 20001030 (200064) C07D267-02
JP 2001502668 W 20010227 (200115) 39 C07D233-02
KR 2000048589 A 20000725 (200116) C07D261-02
US 6200972 B1 20010313 (200120) A61K031-5375
US 6218544 B1 20010417 (200123) C07D277-06
AU 732194 B 20010412 (200128) C07D267-02
MX 9902814 A1 20000601 (200133) C07D267-02
IL 128675 A 20020814 (200272) C07D277-04
US 2003032635 A1 20030213 (200314) A61K031-554
PH 1199757725 B1 20020416 (200382) A61K031-425
ADT WO 9813355 A1 WO 1997-US14624 19970820; ZA 9707901 A ZA 1997-7901
19970903; AU 9740769 A AU 1997-40769 19970820; US 5801187 A US 1996-719947
19960925; CZ 9900660 A3 WO 1997-US14624 19970820; CZ 1999-660 19970820; NO
9901433 A WO 1997-US14624 19970820; NO 1999-1433 19990324; EP 934287 A1 EP
1997-938449 19970820; WO 1997-US14624 19970820; BR 9712834 A BR 1997-12834
19970820; WO 1997-US14624 19970820; CN 1234795 A CN 1997-198198 19970820;
SK 9900266 A3 WO 1997-US14624 19970820; SK 1999-266 19970820; NZ 334186 A
NZ 1997-334186 19970820; WO 1997-US14624 19970820; HU 2000000969 A2 WO
1997-US14624 19970820; HU 2000-969 19970820; JP 2001502668 W WO
1997-US14624 19970820; JP 1998-515638 19970820; KR 2000048589 A WO
1997-US14624 19970820; KR 1999-702523 19990324; US 6200972 B1 Div ex US
1996-719947 19960925, US 1998-27622 19980223; US 6218544 B1 Div ex US
1996-719947 19960925, Div ex US 1998-27622 19980223, US 1999-442628
19991118; AU 732194 B AU 1997-40769 19970820; MX 9902814 A1 MX 1999-2814
19990324; IL 128675 A IL 1997-128675 19970820; US 2003032635 A1 Cont of US
1996-719947 19960925, Div ex US 1998-27622 19980223, Cont of US
2000-733043 20001211, US 2002-177666 20020624; PH 1199757725 B1 PH
1997-57725 19970827
FDT AU 9740769 A Based on WO 9813355; CZ 9900660 A3 Based on WO 9813355; EP
934287 A1 Based on WO 9813355; BR 9712834 A Based on WO 9813355; NZ 334186
A Div in NZ 505957, Based on WO 9813355; HU 2000000969 A2 Based on WO
9813355; JP 2001502668 W Based on WO 9813355; KR 2000048589 A Based on WO
9813355; US 6200972 B1 Div ex US 5801187; US 6218544 B1 Div ex US 5801187;
AU 732194 B Previous Publ. AU 9740769, Based on WO 9813355; IL 128675 A
Based on WO 9813355; US 2003032635 A1 Cont of US 5801187, Div ex US
6200972
PRAI US 1996-719947 19960925; US 1998-27622 19980223;
US 1999-442628 19991118; US 2000-733043 20001211;
US 2002-177666 20020624
IC ICM A61K031-425; A61K031-5375; A61K031-554; C07D000-00; C07D207-06;
C07D233-02; C07D261-02; C07D267-02; C07D277-04; C07D277-06
ICS A01B000-00; A61K031-40; A61K031-41; A61K031-415; A61K031-4164;
A61K031-4172; A61K031-42; A61K031-426; A61K031-427; A61K031-445;
A61K031-454; A61K031-495; A61K031-496; A61K031-53; A61K031-535;
A61K031-537; A61K031-538; A61K031-54; A61K031-55; A61K031-551;
A61K031-553; A61P025-00; A61P025-16; A61P025-28; C07D211-14;
C07D239-04; C07D241-04; C07D249-04; C07D251-04; C07D257-04;
C07D257-08; C07D263-02; C07D265-06; C07D265-30; C07D273-01;
C07D273-04; C07D279-06; C07D279-12; C07D281-02; C07D285-04;
C07D285-15; C07D291-04; C07D417-02; C07D417-12; C07D521-00

L3 ANSWER 208 OF 215 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1998-40563 DRUGU P
TI Investigations of neurotrophic inhibitors of FK506 binding protein via
Monte Carlo simulations.

CS Univ.Yale
LO New Haven, Conn., USA
SO J.Med.Chem. (41, No. 21, 3928-39, 1998) 11 Fig. 4 Tab. 60 Ref.
CODEN: JMCMAR ISSN: 0022-2623
AV Department of Chemistry, Yale University, New Haven, CT 06520-8107, U.S.A.
(W.L.J.).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L3 ANSWER 209 OF 215 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:66625 CAPLUS

DN 130:306436

TI Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after ***spinal*** ***cord*** injury in rats

AU Madsen, Joseph R.; MacDonald, Paul; Irwin, Nina; Goldberg, David E.; Yao, Gui-Lan; Meiri, Karina F.; Rimm, Ilonna J.; Stieg, Philip E.; Benowitz, Larry I.

CS Department of Neurosurgery, Children's Hospital, Boston, MA, 02115, USA

SO Experimental Neurology (1998), 154(2), 673-683

CODEN: EXNEAC; ISSN: 0014-4886

PB Academic Press

DT Journal

LA English

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 210 OF 215 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 36

AN 02868953 IFIPAT;IFIUDB;IFICDB

TI METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH; PATENT NOT GRANTED PER O.G. ERRATA OF 12-16-97

IN Armistead David M

PA Vertex Pharmaceuticals Inc (30287)

PI US 5654332 A 19970805 (CITED IN 008 LATER PATENTS)

AI US 1995-486004 19950608

FI US 5654332 19970805

DT Utility

FS CHEMICAL

GRANTED

MRN 007891 MFN: 0912

CLMN 6

L3 ANSWER 211 OF 215 USPATFULL on STN

AN 97:115293 USPATFULL

TI Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth

IN Steiner, Joseph P., Hampstead, MD, United States

Snyder, Solomon, Baltimore, MD, United States

Hamilton, Gregory S., Catonsville, MD, United States

PA GPI NIL Holdings, Inc., Wilmington, DE, United States (U.S. corporation)

Johns Hopkins Univ. School of Medicines, Baltimore, MD, United States (U.S. corporation)

PI US 5696135 19971209

AI US 1996-653905 19960528 (8)

RLI Continuation-in-part of Ser. No. US 1995-474072, filed on 7 Jun 1995

DT Utility

FS Granted

LN.CNT 1891

INCL INCLM: 514/317.000

INCLS: 514/318.000; 514/330.000; 514/012.000

NCL NCLM: 514/317.000

NCLS: 514/012.000; 514/318.000; 514/330.000

IC [6]

ICM: A61K031-445

ICS: A61K038-18

EXF 514/318; 514/330; 514/317; 514/12

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 212 OF 215 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 37

AN 1997:307496 CAPLUS

DN 126:272378

TI Methods and compositions for stimulating neurite growth using compds. with affinity for ***FKBP12*** in combination with neurotrophic factors

IN Armistead, David M.

SO S. African, 54 pp.

CODEN: SFXAB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	ZA 9604852	A	19960729	ZA 1996-4852	19960607
	US 6037370	A	20000314	US 1995-486004	19950608
	CA 2222430	AA	19961227	CA 1996-2222430	19960606
	WO 9641609	A2	19961227	WO 1996-US10123	19960606
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	AU 9661119	A1	19970109	AU 1996-61119	19960606
	EP 831812	A2	19980401	EP 1996-918469	19960606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1202104	A	19981216	CN 1996-195690	19960606
	BR 9609333	A	19991013	BR 1996-9333	19960606
	NZ 310339	A	20000327	NZ 1996-310339	19960606
	NZ 501709	A	20001027	NZ 1996-501709	19960606
	JP 2002502355	T2	20020122	JP 1997-503275	19960606
	IL 122346	A1	20020523	IL 1996-122346	19960606
	IL 136118	A1	20021201	IL 1996-136118	19960606
	RU 2197240	C2	20030127	RU 1998-100456	19960606
	PL 185798	B1	20030731	PL 1996-328723	19960606
	US 6124328	A	20000926	US 1997-795956	19970228
	AU 757406	B2	20030220	AU 2000-43801	20000703
	US 6326387	B1	20011204	US 2000-616539	20000714
PRAI	US 1995-486004	A	19950608		
	AU 1996-61119	A3	19960606		
	IL 1996-122346	A3	19960606		
	NZ 1996-310339	A1	19960606		
	WO 1996-US10123	W	19960606		
	US 1997-795956	A3	19970228		
OS	MARPAT 126:272378				

L3 ANSWER 213 OF 215 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information
BV on STN

ACCESSION NUMBER: 2000:1449 ADISINSIGHT

SOURCE: Adis R&D Insight

DOCUMENT NO: 014594

CHANGE DATE: Aug 9, 2002

GENERIC NAME: Research programme: FKBP neuroimmunophilin ligands -
Guilford Pharmaceuticals

SYNONYM: FKBP neuroimmunophilin ligands - Guilford
Pharmaceuticals; Neuroimmunophilin ligands research
programme - Guilford Pharmaceuticals; Research
programme: neuroimmunophilin ligands -Guilford
Pharmaceuticals

MOLECULAR FORMULA: Unspecified

STRUCTURE:

STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMA ATC CODE: N7X All other CNS drugs

WHO ATC CODE: N07X Other Nervous System Drugs

HIGHEST DEV. PHASE: Preclinical

COMPANY INFORMATION

ORIGINATOR: Guilford Pharmaceuticals (United States)

PARENT: Guilford Pharmaceuticals

WORD COUNT: 201

L3 ANSWER 214 OF 215 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information
BV on STN

ACCESSION NUMBER: 1998:9933 ADISINSIGHT

SOURCE: Adis R&D Insight

DOCUMENT NO: 010875

CHANGE DATE: Sep 21, 2004

GENERIC NAME: GPI 1485

NIL-A
MOLECULAR FORMULA:Unspecified
STRUCTURE:

STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMRA ATC CODE: G4B4 Urinary incontinence products; N2 Analgesics; N4A
Anti-Parkinson Drugs; N6D Nootropics
WHO ATC CODE: G04B-E Drugs used in erectile dysfunction; N02
Analgesics; N04 Anti-Parkinson Drugs; N06D Anti-Dementia
Drugs
HIGHEST DEV. PHASE: Phase II

COMPANY INFORMATION

ORIGINATOR: Guilford Pharmaceuticals (United States)
PARENT: Guilford Pharmaceuticals
LICENSEE: Symphony Neuro Development Company

OTHER SOURCES: 809026607; 809031538; 809028224
WORD COUNT: 1119

L3 ANSWER 215 OF 215 IMSRESEARCH COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 95:1336 IMSRESEARCH
SOURCE: R&D Focus, (30 Aug 2004)
GENERIC NAME: neuroimmunophilin ligands, Guilford
STRUCTURE:

STRUCTURE DIAGRAM IS NOT AVAILABLE

CLASSIFICATION: N7X All Other CNS Drugs
HIGHEST DEV. PHASE: Preclinical (20)

COMPANY INFORMATION:

Type	Company	Nationality
=====	=====	=====
Originator	Guilford	United States

LICENSING CONTACT:

Russell Wesdyk, VP, Business Development, Guilford Pharmaceuticals, 6611
Tributary Street, Baltimore, MD 21224, USA; Tel: +1 410 631 6340; Fax: +1 410
631 6819; Email: wesdykr@guilfordpharm.com

=> S benzoquinone ansamycin

47 FILES SEARCHED...

L4 1602 BENZOQUINONE ANSAMYCIN

=> DUP REM 14

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L4

L5 1146 DUP REM L4 (456 DUPLICATES REMOVED)

=> S L5 AND spinal cord

25 FILES SEARCHED...

46 FILES SEARCHED...

69 FILES SEARCHED...

L6 4 L5 AND SPINAL CORD

=> D L6 1-4

L6 ANSWER 1 OF 4 IFIPAT COPYRIGHT 2004 IFI on STN

AN 10556392 IFIPAT;IFIUDB;IFICDB

TI COMPOSITIONS AND METHODS FOR PROMOTING NERVE REGENERATION

IN Gold Bruce G

PA Oregon Health Sciences University (25323)

PI US 2004063610 A1 20040401

AI US 2003-656701 20030904

RLI US 1997-956691 19971024 CONTINUATION 5968921

US 1999-326728 19990607 CONTINUATION

US 2001-825243 20010402 CONTINUATION 6641810

FI US 2004063610 20040401

US 5968921

US 6641810

FS CHEMICAL
APPLICATION

CLMN 22

GI 3 Figure(s).

FIG. 1 shows structures of FK506 (left) and a representative FK506 analog, V-10, 367 (right). The bracketed portion of FK506 represents the calcineurin-binding domain, which is absent in V10, 367.

FIGS. 2-8 are histograms showing the stimulation of growth of SHSY5Y cells by geldanamycin and FK506 in the presence of NGF (10 ng/mL) 168 hours after treatment. FIG. 2: control cells (untreated). FIG. 3: NGF only (10 ng/mL). FIG. 4: geldanamycin (1 nM)+NGF (10 ng/mL). FIG. 5: geldanamycin (10 nM)+NGF (10 ng/mL). FIG. 6: FK506 (10 nM)+NGF (10 ng/mL). FIG. 7: geldanamycin (1 nM)+FK506 (10 nM)+NGF (10 ng/mL). FIG. 8: geldanamycin (10 nM)+FK506 (10 nM)+NGF (10 ng/mL).

FIGS. 9-15 are histograms showing the stimulation of growth of SH-SY5Y cells by geldanamycin and FK506 in the presence of NGF (10 ng/mL) 168 hours after treatment. FIG. 9: control cells (untreated). FIG. 10: NGF only (10 ng/mL). FIG. 11: FK506 (1 nM) +NGF (10 ng/mL). FIG. 12: FK506 (10 nM)+NGF (10 ng/mL). FIG. 13: geldanamycin (0.1 nM)+NGF (10 ng/mL). FIG. 14: geldanamycin (0.1 nM)+FK506 (1 nM)+NGF (10 ng/mL). FIG. 15: geldanamycin (0.1 nM)+FK506 (10 nM)+NGF (10 ng/mL).

L6 ANSWER 2 OF 4 IFIPAT COPYRIGHT 2004 IFI on STN

AN 10142377 IFIPAT;IFIUDB;IFICDB

TI COMPOSITIONS AND METHODS FOR PROMOTING NERVE REGENERATION;
NON-FKBP12-BINDING AGENT THAT BINDS TO A POLYPEPTIDE COMPONENT OF A
STEROID RECEPTOR COMPLEX OTHER THAN A STEROID HORMONE BINDING PORTION OF
THE COMPLEX; CAUSES HSP90 DISSOCIATION FROM OR PREVENTS HSP90 ASSOCIATION
WITH THE COMPLEX.

IN Gold Bruce G

PA Oregon Health Sciences University (25323)

PI US 2002086015 A1 20020704

AI US 2001-825243 20010402

RLI US 1997-956691 19971024 CONTINUATION

GRANTED

US 1999-326728 19990607 CONTINUATION

ABANDONED

FI US 2002086015 20020704

US 6641810 20031104

DT Utility; Patent Application - First Publication

FS CHEMICAL
APPLICATION

CLMN 22

GI 17 Figure(s).

FIG. 1 shows structures of FK506 (left) and a representative FK506 analog, V-10,367 (right). The bracketed portion of FK506 represents the calcineurin-binding domain, which is absent in V10,367.

FIGS. 2-8 are histograms showing the stimulation of growth of SHSY5Y cells by geldanamycin and FK506 in the presence of NGF (10 ng/mL) 168 hours after treatment.

FIG. 2: control cells (untreated).

FIG. 3: NGF only (10 ng/mL).

FIG. 4: geldanamycin (1 nM)+NGF (10 ng/mL).

FIG. 5: geldanamycin (10 nM)+NGF (10 ng/mL).

FIG. 6: FK506 (10 nM)+NGF (10 ng/mL).

FIG. 7: geldanamycin (1 nM)+FK506 (10 nM)+NGF (10 ng/mL).

FIG. 8: geldanamycin (10 nM)+FK506 (10 nM)+NGF (10 ng/mL).

FIGS. 9-15 are histograms showing the stimulation of growth of SH-SY5Y cells by geldanamycin and FK506 in the presence of NGF (10 ng/ml) 168 hours after treatment.

FIG. 9: control cells (untreated).

FIG. 10: NGF only (10 ng/mL).

FIG. 11: FK506 (1 nM)+NGF (10 ng/mL).

FIG. 12: FK506 (10 nM)+NGF (10 ng/mL).

FIG. 13: geldanamycin (0.1 nM)+NGF (10 ng/mL).

FIG. 14: geldanamycin (0.1 nM)+FK506 (1 nM)+NGF (10 ng/mL).

FIG. 15: geldanamycin (0.1 nM)+FK506 (10 nM)+NGF (10 ng/mL).

L6 ANSWER 3 OF 4 USPATFULL on STN

AN 2004:116775 USPATFULL

TI Compositions and methods for promoting nerve regeneration

IN Gold, Bruce G., West Linn, OR, United States

PA Oregon Health & Sciences University, Portland, OR, United States (U.S.
corporation)

PI US 6734211 B1 20040511

WO 2001003692 20010118

AI US 2002-30904 20020429 (10)

PRAI US 1999-143180P 19990709 (60)
DT Utility
FS GRANTED
LN.CNT 2153
INCL INCLM: 514/513.000
NCL NCLM: 514/513.000
IC [7]
ICM: A61K031-21
EXF 514/513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 4 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1999-312859 [26] WPIDS
DNC C1999-092323
TI Stimulation of nerve cell growth to treat neurological conditions
involving neuronal dysfunction.
DC B05 D16
IN GOLD, B G
PA (UYOR-N) UNIV OREGON HEALTH SCI
CYC 83

PI WO 9921552 A1 19990506 (199926)* EN 52 A61K031-395
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
OA PT SD SE SZ UG ZW
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
US UZ VN YU ZW

AU 9896783 A 19990517 (199939)
US 5968921 A 19991019 (199950) A61K031-33
EP 1024806 A1 20000809 (200039) EN A61K031-395
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
US 6210974 B1 20010403 (200120) G01N033-566
JP 2001520995 W 20011106 (200203) 70 A61K031-395
US 2002086015 A1 20020704 (200247) A61K039-395
AU 759011 B 20030403 (200335) A61K031-395
US 6641810 B2 20031104 (200374) A61K039-395
US 2004063610 A1 20040401 (200425) A61K039-395

ADT WO 9921552 A1 WO 1998-US20658 19981002; AU 9896783 A AU 1998-96783
19981002; US 5968921 A US 1997-956691 19971024; EP 1024806 A1 EP
1998-950843 19981002, WO 1998-US20658 19981002; US 6210974 B1 Div ex US
1997-956691 19971024, US 1999-288061 19990407; JP 2001520995 W WO
1998-US20658 19981002, JP 2000-517710 19981002; US 2002086015 A1 Cont of
US 1997-956691 19971024, Cont of US 1999-326728 19990607, US 2001-825243
20010402; AU 759011 B AU 1998-96783 19981002; US 6641810 B2 Cont of US
1997-956691 19971024, Cont of US 1999-326728 19990607, US 2001-825243
20010402; US 2004063610 A1 Cont of US 1997-956691 19971024, Cont of US
1999-326728 19990607, Cont of US 2001-825243 20010402, US 2003-656701
20030904

FDT AU 9896783 A Based on WO 9921552; EP 1024806 A1 Based on WO 9921552; US
6210974 B1 Div ex US 5968921; JP 2001520995 W Based on WO 9921552; AU
759011 B Previous Publ. AU 9896783, Based on WO 9921552; US 6641810 B2
Cont of US 5968921; US 2004063610 A1 Cont of US 5968921, Cont of US
6641810

PRAI US 1997-956691 19971024; US 1999-288061 19990407;
US 1999-326728 19990607; US 2001-825243 20010402;
US 2003-656701 20030904

IC ICM A61K031-33; A61K031-395; A61K039-395; G01N033-566
ICS A01N043-30; A61K031-36; A61K031-40; A61K031-445; A61K031-4745;
A61K031-704; A61K038-18; A61K045-00; A61P025-00; A61P043-00;
G01N024-00; G01N033-00; G01N033-48

=> S geldanamycin
50 FILES SEARCHED...
L7 6466 GELDANAMYCIN

=> S L7 AND spinal cord
37 FILES SEARCHED...
L8 30 L7 AND SPINAL CORD

=> DUP REM L8
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

L9

26 DUP REM L8 (4 DUPLICATES REMOVED)

=> D L9 1-26

L9 ANSWER 1 OF 26 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 1

AN 10556392 IFIPAT;IFIUDB;IFICDB

TI COMPOSITIONS AND METHODS FOR PROMOTING NERVE REGENERATION

IN Gold Bruce G

PA Oregon Health Sciences University (25323)

PI US 2004063610 A1 20040401

AI US 2003-656701 20030904

RLI US 1997-956691 19971024 CONTINUATION 5968921

US 1999-326728 19990607 CONTINUATION

US 2001-825243 20010402 CONTINUATION 6641810

FI US 2004063610 20040401

US 5968921

US 6641810

DT Utility; Patent Application - First Publication

FS CHEMICAL

APPLICATION

CLMN 22

GI 3 Figure(s).

FIG. 1 shows structures of FK506 (left) and a representative FK506 analog, V-10, 367 (right). The bracketed portion of FK506 represents the calcineurin-binding domain, which is absent in V10, 367.

FIGS. 2-8 are histograms showing the stimulation of growth of SHSY5Y cells by ***geldanamycin*** and FK506 in the presence of NGF (10 ng/mL) 168 hours after treatment. FIG. 2: control cells (untreated). FIG. 3: NGF only (10 ng/mL). FIG. 4: ***geldanamycin*** (1 nM)+NGF (10 ng/mL). FIG. 5: ***geldanamycin*** (10 nM)+NGF (10 ng/mL). FIG. 6: FK506 (10 nM)+NGF (10 ng/mL). FIG. 7: ***geldanamycin*** (1 nM)+FK506 (10 nM)+NGF (10 ng/mL). FIG. 8: ***geldanamycin*** (10 nM)+FK506 (10 nM)+NGF (10 ng/mL).

FIGS. 9-15 are histograms showing the stimulation of growth of SH-SY5Y cells by ***geldanamycin*** and FK506 in the presence of NGF (10 ng/mL) 168 hours after treatment. FIG. 9: control cells (untreated). FIG. 10: NGF only (10 ng/mL). FIG. 11: FK506 (1 nM) +NGF (10 ng/mL). FIG. 12: FK506 (10 nM)+NGF (10 ng/mL). FIG. 13: ***geldanamycin*** (0.1 nM)+NGF (10 ng/mL). FIG. 14: ***geldanamycin*** (0.1 nM)+FK506 (1 nM)+NGF (10 ng/mL). FIG. 15: ***geldanamycin*** (0.1 nM)+FK506 (10 nM)+NGF (10 ng/mL).

L9 ANSWER 2 OF 26 USPATFULL on STN

AN 2004:233881 USPATFULL

TI Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy

IN Au, Jessie L.-S., Columbus, OH, UNITED STATES

Wientjes, M. Guillaume, Columbus, OH, UNITED STATES

PI US 2004180955 A1 20040916

AI US 2004-807620 A1 20040324 (10)

RLI Continuation-in-part of Ser. No. WO 2002-US30210, filed on 24 Sep 2002, PENDING

PRAI US 2001-324704P 20010924 (60)

DT Utility

FS APPLICATION

LN.CNT 1688

INCL INCLM: 514/553.000

NCL NCLM: 514/553.000

IC [7]

ICM: A61K031-185

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 26 USPATFULL on STN

AN 2004:215006 USPATFULL

TI Low dose methods for treating disorders in which TNFalpha activity is detrimental

IN Kaymakalan, Zehra, Westborough, MA, UNITED STATES

Kamen, Robert, Sudbury, MA, UNITED STATES

PI US 2004166111 A1 20040826

AI US 2003-693233 A1 20031024 (10)

PRAI US 2002-421262P 20021024 (60)

US 2003-455777P 20030318 (60)

DT Utility

FS APPLICATION

LN.CNT 1416

NCL INCLS: 424/600.000
NCLM: 424/145.100
NCLS: 424/600.000
IC [7]

ICM: A61K039-395

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 26 USPATFULL on STN
AN 2004:127426 USPATFULL
TI Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
IN Holzmayer, Tanya A., Mountain View, CA, UNITED STATES
Dunn, Stephen J., Mountain View, CA, UNITED STATES
PA Subsidiary No. 3, Inc. (U.S. corporation)
PI US 2004097409 A1 20040520
AI US 2003-624947 A1 20030721 (10)
RLI Continuation of Ser. No. US 2000-724916, filed on 28 Nov 2000, GRANTED, Pat. No. US 6613506
PRAI WO 1998-US11452 19980602
DT Utility
FS APPLICATION
LN.CNT 3994
INCL INCLM: 514/002.000
INCLS: 435/005.000
NCL NCLM: 514/002.000
NCLS: 435/005.000
IC [7]
ICM: A61K038-16
ICS: C12Q001-70

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 26 USPATFULL on STN
AN 2004:101806 USPATFULL
TI Neurotrophic tacrolimus analogs
IN Matsuoka, Nobuya, Osaka-shi, JAPAN
Yamaji, Takayuki, Osaka-shi, JAPAN
Gold, Bruce, West Linn, OR, UNITED STATES
PI US 2004077676 A1 20040422
AI US 2003-451361 A1 20031114 (10)
WO 2001-US50419 20011231
DT Utility
FS APPLICATION
LN.CNT 669
INCL INCLM: 514/291.000
NCL NCLM: 514/291.000
IC [7]
ICM: A61K031-4745

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 26 USPATFULL on STN
AN 2004:83218 USPATFULL
TI Tetracycline compounds having target therapeutic activities
IN Levy, Stuart B., Boston, MA, UNITED STATES
Draper, Michael, Plaistow, NH, UNITED STATES
Nelson, Mark L., Wellesley, MA, UNITED STATES
Jones, Graham, Needham, MA, UNITED STATES
PI US 2004063674 A1 20040401
AI US 2002-196010 A1 20020715 (10)
PRAI US 2001-305546P 20010713 (60)
US 2002-395741P 20020712 (60)
DT Utility
FS APPLICATION
LN.CNT 4478
INCL INCLM: 514/152.000
NCL NCLM: 514/152.000
IC [7]
ICM: A61K031-65

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 26 USPATFULL on STN
AN 2004:30732 USPATFULL
TI Methods and compositions for modulating the immune system and uses thereof
IN Chen, Lan Bo, Lexington, MA, UNITED STATES
Kraeft, Stine-Kathrein, Dorchester, MA, UNITED STATES

PI US 2004022869 A1 20040205
AI US 2002-307916 A1 20021202 (10)
PRAI US 2001-334121P 20011130 (60)
DT Utility
FS APPLICATION
LN.CNT 5354
INCL INCLM: 424/623.000
INCLS: 514/012.000; 514/011.000; 514/183.000; 514/573.000; 514/050.000;
514/557.000; 514/559.000; 514/165.000; 514/365.000; 514/449.000;
514/291.000; 514/675.000
NCL NCLM: 424/623.000
NCLS: 514/012.000; 514/011.000; 514/183.000; 514/573.000; 514/050.000;
514/557.000; 514/559.000; 514/165.000; 514/365.000; 514/449.000;
514/291.000; 514/675.000
IC [7]
ICM: A61K038-17
ICS: A61K031-557; A61K031-337; A61K031-426; A61K031-427; A61K031-7072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 26 USPATFULL on STN
AN 2004:116775 USPATFULL
TI Compositions and methods for promoting nerve regeneration
IN Gold, Bruce G., West Linn, OR, United States
PA Oregon Health & Sciences University, Portland, OR, United States (U.S.
corporation)
PI US 6734211 B1 20040511
WO 2001003692 20010118
AI US 2002-30904 20020429 (10)
WO 2000-US18539 20000707
PRAI US 1999-143180P 19990709 (60)
DT Utility
FS GRANTED
LN.CNT 2153
INCL INCLM: 514/513.000
NCL NCLM: 514/513.000
IC [7]
ICM: A61K031-21
EXF 514/513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 26 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 2
AN 10310583 IFIPAT;IFIUDB;IFICDB
TI CHARACTERIZATION OF GRP94-LIGAND INTERACTIONS AND PURIFICATION,
SCREENING, AND THERAPEUTIC METHODS RELATING THERETO; CONTACTING COMPLEX
COMPRISING A GRP94 PROTEIN WITH A BINDING AGENT THAT IS IMMOBILIZED TO A
SOLID PHASE SUPPORT, TO IMMOBILIZE THE COMPLEX TO SOLID PHASE SUPPORT;
COLLECTING THE REMAINING SAMPLE; ELUTING THE COMPLEX FROM SOLID PHASE
SUPPORT
IN Nicchitta Christopher V; Reed Robyn C; Rosser Meredith F N; Wassenberg
James J
PA Unassigned Or Assigned To Individual (68000)
PI US 2003054996 A1 20030320
AI US 2002-210333 20020801
RLI WO 2001-US9512 20010326 CONTINUATION PENDING
PRAI US 2000-192118P 20000324 (Provisional)
FI US 2003054996 20030320
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 133
GI 25 Figure(s).

FIG. 1A is a graph depicting Prodan binding to GRP94 independent of GRP94 structural state. Fluorescence emission wavelength scans of 0.5 μ M native or heat shocked (hs) GRP94 were performed following exposure to 5 μ M Prodan for 30 minutes. Values represent the maximal fluorescence relative to that occurring with an identical concentration of heat shocked GRP94. Experiments were conducted at excitation wavelengths of 360 nm (Prodan). All spectra were background corrected.

FIG. 1B is a graph depicting 8-ANS binding to GRP94, and dependence of such binding on GRP94 structural state. Fluorescence emission wavelength scans of 0.5 μ M native or heat shocked (hs) GRP94 were performed following exposure to 5 μ M 8-ANS for 30 minutes. Values represent the maximal fluorescence relative to that occurring with an identical concentration of heat shocked GRP94. Experiments were conducted at excitation wavelengths of 372 nm (8-ANS). All spectra were background

FIG. 1C is a graph depicting bis-ANS binding to GRP94, and dependence of such binding on GRP94 structural state. Fluorescence emission wavelength scans of 0.5 μ M native or heat shocked (hs) GRP94 were performed following exposure to 5 μ M bis-ANS for 20 hours. Values represent the maximal fluorescence relative to that occurring with an identical concentration of heat shocked GRP94. Experiments were conducted at excitation wavelengths of 393 nm (bis-ANS). All spectra were background corrected.

FIG. 1D is a graph depicting a time course of bis-ANS binding to GRP94. Values represent the maximal fluorescence relative to that occurring with an identical concentration of heat shocked GRP94. Experiments were conducted at excitation wavelengths of 393 nm (bis-ANS). All spectra were background corrected.

FIG. 2A is a graph depicting kinetic analysis of bis-ANS interactions with heat shocked GRP94. The concentration dependence of bis-ANS binding to heat shocked GRP94 was conducted under experimental conditions of fixed bis-ANS concentration (50 nM) and increasing GRP94 concentration, as indicated.

FIG. 2B is a Klotz plot representation of bis-ANS/GRP94 binding data. Half maximal binding occurs at 110 nM GRP94. Excitation wavelength, 393 nm. Emission wavelength, 475 nm.

FIG. 3 is a digital image of a Coomassie Blue stained gel depicting that bis-ANS and heat shock increase GRP94 proteolysis sensitivity. GRP94 (5 μ g, 5 μ M) was incubated with 50 μ M bis-ANS for one hour at 37 degrees C. or heat shocked for 15 minutes at 50 degrees C. Samples were then digested with 0.1% trypsin for 30 minutes at 37 degrees C. and analyzed on 12.5% SDS-PAGE gels. Lane 1, 5 μ g of undigested GRP94; lane 2, control native GRP94 incubated with trypsin; lane 3, bis-ANS treated GRP94 digested with trypsin; lane 4, GRP94 heat shocked then digested with trypsin.

FIG. 4 is a digital image of a Coomassie Blue stained gel depicting that bis-ANS and heat shock induce GRP94 multimerization. GRP94 was heat shocked at 50 degrees C. for 0.15 minutes or incubated with 10-fold molar excess of bis-ANS and the structural state of the protein analyzed on 5-18% native blue polyacrylamide gradient gels. The mobilities of GRP94 dimers, tetramers, hexamers, and octamers are shown. Molecular weight standards are indicated to the right of FIG. 4.

FIG. 5 is a graph depicting that circular dichroism spectra of native, heat shocked, and bis-ANS treated GRP94 are identical. Circular dichroism spectra of 1 μ M GRP94 native (diamonds); heat shocked (dot and dash); and treated 2 hours with 10 μ M bis-ANS (dotted) are shown. Spectra were collected as described in Examples 1-8 below.

FIG. 6A is a digital image of a Coomassie Blue stained gel depicting that radicicol blocks bis-ANS structural transitions. GRP94 (5 μ M) was preincubated for one hour at 37 degrees C. with 0-500 μ M radicicol and subsequently incubated for one hour at 37 degrees C. with 50 μ M bis-ANS, trypsinized, and the trypsin digestion pattern analyzed by SDS-PAGE.

FIG. 6B is a graph depicting that radicicol blocks heat shock and bis-ANS binding. GRP94 (0.5 μ M) was preincubated with 0.10 μ M radicicol for one hour, heat shocked, and subsequently incubated with 1 μ M bis-ANS. Bis-ANS binding was determined by spectrofluorometry with bis-ANS binding to native GRP94 in the absence of radicicol shown for comparison. Excitation 393 nm, emission 410-600 nm.

FIG. 7A is a graph depicting that bis-ANS and heat shock stimulate GRP94 chaperone activity. Citrate synthase enzyme was diluted to 0.15 μ M into buffer containing no GRP94, 1 μ M native GRP94, heat shocked GRP94, or GRP94 which had been preincubated for two hours with 10 μ M bis-ANS, and citrate synthase aggregation at 43 degrees C. was monitored by light scattering at 500 nm in a thermostatted spectrofluorometer.

FIG. 7B is a bar graph depicting that bis-ANS and heat shock stimulate GRP94 peptide binding activity. Native, heat shocked, or bis-ANS treated GRP94 were incubated with a 10-fold molar excess of 125I-VSV8 peptide for 30 minutes at 37 degrees C. Free peptide was removed by spin column chromatography and bound radioactive peptide quantitated by gamma counting.

FIG. 8 is a bar graph depicting that GRP94 and Hsp90 exhibit differential ligand binding. NECA and ATP binding to GRP94 was performed in the presence of 20 nM (3H)-NECA (closed bars) or 50 μ M (32P)ATP (hatched bars) for 1 hour at 4 degrees C. Bound versus free nucleotide were separated by vacuum filtration. PEI treated glass filters (S&S #32, Schleicher and Schuell of Keene, N.H.) were used for the NECA binding assay while nitrocellulose filters (S&S BA85, Schleicher and Schuell of Keene, N.H.) were used to measure ATP binding. The data presented are averages of triplicate points and are corrected for nonspecific ligand

FIG. 9A is a Scatchard plot depicting characterization of NECA binding to GRP94. GRP94 was incubated with increasing concentrations of NECA for 1 hour at 4 degrees C. as described in Materials and Methods. Bound versus free NECA were then separated by vacuum filtration with glass filters pretreated in 0.3% PEI.

FIG. 9B is a saturation curve depicting characterization of NECA binding to GRP94. The curve is plotted with respect to GRP94 dimer concentration. The maximal binding stoichiometry is 1 molecule of NECA per molecule of GRP94 dimer.

FIG. 9C is a graph depicting stoichiometry of GRP94 binding to NECA (solid oval) and radicicol (solid rectangle). NECA and radicicol binding to GRP94 was assayed by isothermal titration calorimetry. GRP94 was present at a concentration of 5 μ M. NECA titrations were performed with a 152 μ M NECA stock whereas radicicol titrations were performed with a 115 μ M stock. ITC data were collected as μ cal/sec versus time and the area under individual injection peaks, determined with the instrument software, was plotted.

FIG. 10A is a graph depicting a competition assay for NECA by the Hsp90 family inhibitors, ***geldanamycin*** (diamond-suit) and radicicol (*). GRP94 was incubated with 20 nM (3H)-NECA and increasing concentrations of competitors for 1 hour at 4 degrees C. Bound NECA was separated from free by vacuum filtration with glass filters pre-treated in 0.3% PEI. All data points represent the average of triplicates points minus background (nonspecific NECA binding in the absence of protein).

FIG. 10B is a graph depicting a competition assay for NECA by ATP (diamond-suit), ADP (*), and AMP (up-triangle-filled). GRP94 was incubated with 20 nM 3H-NECA and increasing concentrations of competitors for 1 hour at 4 degrees C. Bound NECA was separated from free by vacuum filtration with glass filters pre-treated in 0.3% PEI. All data points represent the average of triplicate points minus background (nonspecific NECA binding in the absence of protein).

FIG. 10C is a graph depicting a competition assay for NECA by adenosine (up-triangle-filled), and cAMP (*). GRP94 was incubated with 20 nM (3H)-NECA and increasing concentrations of competitors for 1 hour at 4 degrees C. Bound NECA was separated from free by vacuum filtration with glass filters pre-treated in 0.3% PEI. All data points represent the average of triplicates points minus background (nonspecific NECA binding in the absence of protein).

FIG. 11 is a bar graph depicting that ligand binding specificity of GRP94 to the adenosine base. GRP94 was incubated with 20 nM (3H)-NECA and competitors, all at 50 μ M final concentration for 1 hour at 4 degrees C., and bound vs. free NECA was separated by vacuum filtration with glass filters pretreated in 0.3% PEI.

FIG. 12 is a graph depicting that binding of ATP, ADP, and AMP to GRP94 is sensitive to Mg^{2+} concentration. GRP94 was incubated for 1 hour at 4 degrees C. in 50 mM Tris, 20 nM (3H)NECA and one of the following concentrations of competitor: 3.1×10^{-6} M ATP, 3.1×10^{-5} M ADP, 6×10^{-4} M AMP, or 3.1×10^{-5} M adenosine. Reactions were performed in the presence of 10 mM $Mg(OAc)_2$ (hatched bars) or in the presence of nominal, endogenous magnesium (closed bars). Bound vs. free NECA was separated by vacuum filtration with glass filters pretreated in 0.3% PEI.

FIG. 13A is a bar graph depicting the effects of NECA on GRP94 autophosphorylation. 25 μ l reactions consisting of 1 μ M GRP94 (closed bars), 0.15 mM gamma-32P ATP (6000 cpm/pmol), 10 mM $Mg(OAc)_2$, and 50 mM K-Hepes, pH 7.4) were incubated for 1 hour at 37 degrees C. One (1) unit casein kinase II (hatched bars) was incubated in the above conditions with the addition of 4 μ M casein. Competitors were added to the appropriate samples with a final concentration of 180 μ M NECA in 3.6% DMSO, 180 μ M radicicol in 3.6% DMSO, 5 μ g/ml heparin, 5 mM GTP, or 3.6% DMSO. Phosphorylated species were quantitated on a Fuji MACBAS1000 tm phosphorimaging system, and the average PSL units of three independent experiments are displayed.

FIG. 13B is a bar graph depicting ATP hydrolysis in the presence and absence of GRP94. 100 μ l reactions consisting of 1 μ M GRP94 monomer, various concentrations of $MgATP$ (pH 7.0), and 50 mM K-Hepes, pH 7.4, were incubated for two hours at 37 degrees C. ATP and ADP were separated on a Hewlett Packard HPLC using a Partisil SAX column. Spontaneous ATP hydrolysis was determined in the absence of protein. Hydrolysis in the presence of GRP94 is indicated by closed bars and spontaneous hydrolysis is indicated by the hatched bars.

FIG. 14 is a graph depicting ligand-induced conformational changes of GRP94. GRP94 (50 μ g/ml) was incubated in buffer A supplemented with 10 mM $Mg(OAc)_2$ and the following concentrations of ligands for 1 hour at 37 degrees C.: 50 μ M NECA, 50 μ M ***geldanamycin***, 2.5 mM ATP, or 2.5 mM ADP. Samples were excited at a wavelength of 295 nm and the

were corrected by subtraction of spectra obtained in buffer alone or
buffer+ligand samples. !

L9 ANSWER 10 OF 26 USPATFULL on STN
AN 2003:306879 USPATFULL
TI Modulation of immune response by non-peptide binding stress response
polypeptides
IN Nicchitta, Christopher V., Durham, NC, UNITED STATES
Baker-LePain, Julie C., Durham, NC, UNITED STATES
PA Duke University (U.S. corporation)
PI US 2003216315 A1 20031120
AI US 2003-367093 A1 20030213 (10)
PRAI US 2002-356293P 20020213 (60)
DT Utility
FS APPLICATION
LN.CNT 4852
INCL INCLM: 514/012.000
INCLS: 530/350.000
NCL NCLM: 514/012.000
NCLS: 530/350.000
IC [7]
ICM: A61K038-17
ICS: C07K014-71
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 26 USPATFULL on STN
AN 2003:306440 USPATFULL
TI Isolated GRP94 ligand binding domain polypeptide and nucleic acid
encoding same, crystalline form of same, and screening methods employing
same
IN Gewirth, Daniel T., Durham, NC, UNITED STATES
Nicchitta, Christopher V., Durham, NC, UNITED STATES
PA Duke University (U.S. corporation)
PI US 2003215874 A1 20031120
AI US 2002-260104 A1 20020930 (10)
PRAI US 2001-326291P 20011001 (60)
DT Utility
FS APPLICATION
LN.CNT 12401
INCL INCLM: 435/007.100
INCLS: 435/189.000; 702/019.000
NCL NCLM: 435/007.100
NCLS: 435/189.000; 702/019.000
IC [7]
ICM: G01N033-53
ICS: G06F019-00; G01N033-48; G01N033-50; C12N009-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 26 USPATFULL on STN
AN 2003:234662 USPATFULL
TI Compositions and methods for inhibiting human immunodeficiency virus
infection by down-regulating human cellular genes
IN Holzmayer, Tanya A., Mountain View, CA, United States
Dunn, Stephen J., Mountain View, CA, United States
PA Subsidiary No. 3, Inc., Wilmington, NC, United States (U.S. corporation)
PI US 6613506 B1 20030902
AI US 2000-724916 20001128 (9)
DT Utility
FS GRANTED
LN.CNT 4376
INCL INCLM: 435/005.000
INCLS: 424/208.100; 435/007.100; 435/375.000
NCL NCLM: 435/005.000
NCLS: 424/208.100; 435/007.100; 435/375.000
IC [7]
ICM: C12Q001-70
EXF 424/9.2; 424/208.1; 435/5; 435/7.1; 435/375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 26 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2003:101399 BIOSIS
DN PREV200300101399
TI Neuroimmunophilin ligands accelerate and promote nerve regeneration in the
rat peripheral nerve and ***spinal*** ***cord*** : Role of the

AU Gold, Bruce G. [Reprint Author]
 CS Center for Research on Occupational and Environmental Toxicology (CROET),
 and Department of Cell and Developmental Biology, Oregon Health and
 Science University, Portland, OR, USA
 SO Borlongan, Cesario V. [Editor, Reprint Author]; Isacson, Ole [Editor];
 Sanberg, Paul R. [Editor]. (2003) pp. 317-328. Immunosuppressant analogs
 in neuroprotection. print.
 Publisher: Humana Press Inc., 999 Riverview Drive, Suite 208, Totowa, NJ,
 07512, USA.
 ISBN: 0-89603-944-7 (cloth).
 DT Book; (Book Chapter)
 LA English
 ED Entered STN: 19 Feb 2003
 Last Updated on STN: 4 Apr 2003

L9 ANSWER 14 OF 26 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
 on STN
 AN 2003:690133 SCISEARCH
 GA The Genuine Article (R) Number: 708JF
 TI Neuroimmunophilin ligands: The development of novel
 neuroregenerative/neuroprotective compounds
 AU Gold B G (Reprint); Villafranca J E
 CS Oregon Hlth Sci Univ, CROET, L606, 3181 SW Sam Jackson Pk Rd, Portland, OR
 97201 USA (Reprint); Oregon Hlth Sci Univ, CROET, Portland, OR 97201 USA;
 Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA;
 Blanchette Rockefeller Neurosci Inst, Morgantown, WV 26506 USA
 CYA USA
 SO CURRENT TOPICS IN MEDICINAL CHEMISTRY, (25 JUL 2003) Vol. 3, No. 12, pp.
 1368-1375.
 Publisher: BENTHAM SCIENCE PUBL LTD, PO BOX 1673, 1200 BR HILVERSUM,
 NETHERLANDS.
 ISSN: 1568-0266.
 DT General Review; Journal
 LA English
 REC Reference Count: 98
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L9 ANSWER 15 OF 26 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
 STN
 AN 2004:200782 BIOSIS
 DN PREV200400201340
 TI High threshold for stress - induced expression of heat shock proteins in
 motor neurons is associated with impaired transactivation of hsf1.
 AU Batulan, Z. [Reprint Author]; Minotti, S. [Reprint Author]; Figlewicz, D.
 A.; Nalbantoglu, J. D. [Reprint Author]; Durham, H. D. [Reprint Author]
 CS Montreal Neurological Inst., McGill Univ., Montreal, PQ, Canada
 SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2003)
 Vol. 2003, pp. Abstract No. 528.7. <http://sfn.scholarone.com>. e-file.
 Meeting Info.: 33rd Annual Meeting of the Society of Neuroscience. New
 Orleans, LA, USA. November 08-12, 2003. Society of Neuroscience.
 DT Conference; (Meeting)
 Conference; Abstract; (Meeting Abstract)
 LA English
 ED Entered STN: 14 Apr 2004
 Last Updated on STN: 14 Apr 2004

L9 ANSWER 16 OF 26 IFIPAT COPYRIGHT 2004 IFI on STN DUPLICATE 3
 AN 10142377 IFIPAT;IFIUDB;IFICDB
 TI COMPOSITIONS AND METHODS FOR PROMOTING NERVE REGENERATION;
 NON-FKBP12-BINDING AGENT THAT BINDS TO A POLYPEPTIDE COMPONENT OF A
 STEROID RECEPTOR COMPLEX OTHER THAN A STEROID HORMONE BINDING PORTION OF
 THE COMPLEX; CAUSES HSP90 DISSOCIATION FROM OR PREVENTS HSP90 ASSOCIATION
 WITH THE COMPLEX.
 IN Gold Bruce G
 PA Oregon Health Sciences University (25323)
 PI US 2002086015 A1 20020704
 AI US 2001-825243 20010402
 RLI US 1997-956691 19971024 CONTINUATION GRANTED
 US 1999-326728 19990607 CONTINUATION ABANDONED
 FI US 2002086015 20020704
 US 6641810 20031104
 DT Utility; Patent Application - First Publication
 FS CHEMICAL
 APPLICATION
 CLMN 22

FIG. 1 shows structures of FK506 (left) and a representative FK506 analog, V-10,367 (right). The bracketed portion of FK506 represents the calcineurin-binding domain, which is absent in V10,367.

FIGS. 2-8 are histograms showing the stimulation of growth of SHSY5Y cells by ***geldanamycin*** and FK506 in the presence of NGF (10 ng/mL) 168 hours after treatment.

FIG. 2: control cells (untreated).

FIG. 3: NGF only (10 ng/mL).

FIG. 4: ***geldanamycin*** (1 nM)+NGF (10 ng/mL).

FIG. 5: ***geldanamycin*** (10 nM)+NGF (10 ng/mL).

FIG. 6: FK506 (10 nM)+NGF (10 ng/mL).

FIG. 7: ***geldanamycin*** (1 nM)+FK506 (10 nM)+NGF (10 ng/mL).

FIG. 8: ***geldanamycin*** (10 nM)+FK506 (10 nM)+NGF (10 ng/mL).

FIGS. 9-15 are histograms showing the stimulation of growth of SH-SY5Y cells by ***geldanamycin*** and FK506 in the presence of NGF (10 ng/mL) 168 hours after treatment.

FIG. 9: control cells (untreated).

FIG. 10: NGF only (10 ng/mL).

FIG. 11: FK506 (1 nM)+NGF (10 ng/mL).

FIG. 12: FK506 (10 nM)+NGF (10 ng/mL).

FIG. 13: ***geldanamycin*** (0.1 nM)+NGF (10 ng/mL).

FIG. 14: ***geldanamycin*** (0.1 nM)+FK506 (1 nM)+NGF (10 ng/mL).

FIG. 15: ***geldanamycin*** (0.1 nM)+FK506 (10 nM)+NGF (10 ng/mL).

L9 ANSWER 17 OF 26 USPATFULL on STN

AN 2002:287633 USPATFULL

TI Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same

IN Gewirth, Daniel T., Durham, NC, UNITED STATES

Nicchitta, Christopher V., Durham, NC, UNITED STATES

PI US 2002160496 A1 20021031

AI US 2001-968436 A1 20011001 (9)

RLI Continuation-in-part of Ser. No. WO 2001-US9512, filed on 26 Mar 2001, UNKNOWN

PRAI US 2000-192118P 20000324 (60)

DT Utility

FS APPLICATION

LN.CNT 5917

INCL INCLM: 435/226.000

INCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200

NCL NCLM: 435/226.000

NCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200

IC [7]

ICM: C12N009-64

ICS: C07H021-04; C12P021-02; C12N005-06

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 26 USPATFULL on STN

AN 2002:3655 USPATFULL

TI Compositions and methods relating to prevention of chemotherapy-induced alopecia

IN Voellmy, Richard W., Miami, FL, UNITED STATES

PI US 2002001629 A1 20020103

AI US 2001-939161 A1 20010824 (9)

RLI Continuation-in-part of Ser. No. WO 2001-IB422, filed on 21 Mar 2001, UNKNOWN

PRAI US 2000-191580P 20000323 (60)

DT Utility

FS APPLICATION

LN.CNT 1575

INCL INCLM: 424/620.000

INCLS: 424/650.000; 424/642.000; 514/044.000; 514/002.000; 514/690.000

NCL NCLM: 424/620.000

NCLS: 424/650.000; 424/642.000; 514/044.000; 514/002.000; 514/690.000

IC [7]

ICM: A61K048-00

ICS: A61K009-127; A61K038-17; A61K033-36; A61K033-24; A61K033-32

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 26 PASCAL COPYRIGHT 2004 INIST-CNRS. ALL RIGHTS RESERVED. on STN

AN 2002-0357975 PASCAL

CP Copyright .COPYRG. 2002 INIST-CNRS. All rights reserved.

TIEN HSP90 inhibitors alter capsaicin- and ATP-induced currents in rat dorsal root ganglion neurons

CS Department of Anesthesiology, University of Wisconsin Medical School,
Madison, WI, United States; Pain Research Center, Anesthesia Research,
MRB 611, Department of Anesthesiology, Perioperative and Pain Medicine,
Brigham and Women's Hospital, Harvard Medical School, 75 Francis St.,
Boston, MA 02115, United States
SO Neuroreport : (Oxford), (2002), 13(4), 437-441, 17 refs.
ISSN: 0959-4965
DT Journal
BL Analytic
CY United Kingdom
LA English
AV INIST-22534, 354000107975880140

L9 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:730772 CAPLUS
DN 135:283220
TI Characterization of GRP94-ligand interactions and purification, screening,
and therapeutic methods relating thereto
IN Nicchitta, Christopher V.; Wassenberg, James J.; Rosser, Meredith F. N.;
Reed, Robyn C.
PA Duke University, USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072779	A1	20011004	WO 2001-US9512	20010326
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1265913	A1	20021218	EP 2001-920734	20010326
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003528886	T2	20030930	JP 2001-571710	20010326
	US 2002160496	A1	20021031	US 2001-968436	20011001
	US 2003054996	A1	20030320	US 2002-210333	20020801
PRAI	US 2000-192118P	P	20000324		
	WO 2001-US9512	W	20010326		

OS MARPAT 135:283220
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 21 OF 26 USPATFULL on STN
AN 2001:47848 USPATFULL
TI Compositions and methods for promoting nerve regeneration
IN Gold, Bruce G., West Linn, OR, United States
PA Oregon Health Sciences University, Portland, OR, United States (U.S. corporation)
PI US 6210974 B1 20010403
AI US 1999-288061 19990407 (9)
RLI Division of Ser. No. US 1997-956691, filed on 24 Oct 1997, now patented, Pat. No. US 5968921
DT Utility
FS Granted
LN.CNT 1227
INCL INCLM: 436/501.000
INCLS: 436/034.000; 436/086.000; 436/091.000; 436/063.000
NCL NCLM: 436/501.000
NCLS: 436/034.000; 436/063.000; 436/086.000; 436/091.000
IC [7]
ICM: G01N033-566
ICS: G01N024-00; G01N033-00; G01N033-48
EXF 436/86; 436/91; 436/34; 436/63; 436/501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 22 OF 26 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

TI Neuroimmunophilin ligands: Evaluation of their therapeutic potential for
 the treatment of neurological disorders.
 AU Gold B.G.
 CS B.G. Gold, Ctr. Res. Occup./Environ. Toxicol., Oregon Health Sciences
 University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97201-3098,
 United States. gold@ohsu.edu
 SO Expert Opinion on Investigational Drugs, (2000) 9/10 (2331-2342).
 Refs: 102
 ISSN: 1354-3784 CODEN: EOIDER
 CY United Kingdom
 DT Journal; General Review
 FS 008 Neurology and Neurosurgery
 030 Pharmacology
 037 Drug Literature Index
 038 Adverse Reactions Titles
 052 Toxicology
 LA English
 SL English

L9 ANSWER 23 OF 26 USPATFULL on STN
 AN 1999:128537 USPATFULL
 TI Compositions and methods for promoting nerve regeneration
 IN Gold, Bruce G., West Linn, OR, United States
 PA Oregon Health Sciences University, Portland, OR, United States (U.S.
 corporation)
 PI US 5968921 19991019
 AI US 1997-956691 19971024 (8)
 DT Utility
 FS Granted
 LN.CNT 1254
 INCL INCLM: 514/183.000
 INCLS: 514/330.000; 514/423.000; 514/428.000; 514/465.000; 514/466.000;
 514/534.000; 514/547.000; 514/548.000; 514/549.000
 NCL NCLM: 514/183.000
 NCLS: 514/330.000; 514/423.000; 514/428.000; 514/465.000; 514/466.000;
 514/534.000; 514/547.000; 514/548.000; 514/549.000
 IC [6]
 ICM: A61K031-33
 ICS: A61K031-445; A61K031-40; A61K031-36
 EXF 514/183; 514/548; 514/330; 514/423; 514/428; 514/534; 514/547; 514/549;
 514/551; 514/465; 514/466
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 24 OF 26 WPIDS COPYRIGHT 2004 THE THOMSON CORP on STN
 AN 1999-312859 [26] WPIDS
 DNC C1999-092323
 TI Stimulation of nerve cell growth to treat neurological conditions
 involving neuronal dysfunction.
 DC B05 D16
 IN GOLD, B G
 PA (UYOR-N) UNIV OREGON HEALTH SCI
 CYC 83
 PI WO 9921552 A1 19990506 (199926)* EN 52 A61K031-395
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
 OA PT SD SE SZ UG ZW
 W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
 GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
 MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
 US UZ VN YU ZW
 AU 9896783 A 19990517 (199939)
 US 5968921 A 19991019 (199950) A61K031-33
 EP 1024806 A1 20000809 (200039) EN A61K031-395
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
 US 6210974 B1 20010403 (200120) G01N033-566
 JP 2001520995 W 20011106 (200203) 70 A61K031-395
 US 2002086015 A1 20020704 (200247) A61K039-395
 AU 759011 B 20030403 (200335) A61K031-395
 US 6641810 B2 20031104 (200374) A61K039-395
 US 2004063610 A1 20040401 (200425) A61K039-395

ADT WO 9921552 A1 WO 1998-US20658 19981002; AU 9896783 A AU 1998-96783
 19981002; US 5968921 A US 1997-956691 19971024; EP 1024806 A1 EP
 1998-950843 19981002, WO 1998-US20658 19981002; US 6210974 B1 Div ex US
 1997-956691 19971024, US 1999-288061 19990407; JP 2001520995 W WO
 1998-US20658 19981002, JP 2000-517710 19981002; US 2002086015 A1 Cont of
 US 1997-956691 19971024, Cont of US 1999-326728 19990607, US 2001-825243

1997-956691 19971024, Cont of US 1999-326728 19990607, US 2001-825243
20010402; US 2004063610 A1 Cont of US 1997-956691 19971024, Cont of US
1999-326728 19990607, Cont of US 2001-825243 20010402, US 2003-656701
20030904

FDT AU 9896783 A Based on WO 9921552; EP 1024806 A1 Based on WO 9921552; US
6210974 B1 Div ex US 5968921; JP 2001520995 W Based on WO 9921552; AU
759011 B Previous Publ. AU 9896783, Based on WO 9921552; US 6641810 B2
Cont of US 5968921; US 2004063610 A1 Cont of US 5968921, Cont of US
6641810

PRAI US 1997-956691 19971024; US 1999-288061 19990407;
US 1999-326728 19990607; US 2001-825243 20010402;
US 2003-656701 20030904

IC ICM A61K031-33; A61K031-395; A61K039-395; G01N033-566
ICS A01N043-30; A61K031-36; A61K031-40; A61K031-445; A61K031-4745;
A61K031-704; A61K038-18; A61K045-00; A61P025-00; A61P043-00;
G01N024-00; G01N033-00; G01N033-48

L9 ANSWER 25 OF 26 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAG78554 peptide DGENE
TI Purifying complexes comprising GRP94 proteins, useful for treating a
disorder associated with ischemia/reperfusion -
IN Nicchitta C V; Wassenberg J J; Rosser M F N; Reed R C
PA (UYDU-N) UNIV DUKE.
PI WO 2001072779 A1 20011004 169p
AI WO 2001-US9512 20010326
PRAI US 2000-192118P 20000324
DT Patent
LA English
OS 2002-055133 [07]
DESC Human HSP90 peptide fragment.

L9 ANSWER 26 OF 26 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAG78553 peptide DGENE
TI Purifying complexes comprising GRP94 proteins, useful for treating a
disorder associated with ischemia/reperfusion -
IN Nicchitta C V; Wassenberg J J; Rosser M F N; Reed R C
PA (UYDU-N) UNIV DUKE.
PI WO 2001072779 A1 20011004 169p
AI WO 2001-US9512 20010326
PRAI US 2000-192118P 20000324
DT Patent
LA English
OS 2002-055133 [07]

STN INTERNATIONAL LOGOFF AT 13:12:05 ON 16 NOV 2004